Studies on the effect of cysteinyl leukotrienes on human t cell differentiation and function by Parmentier, Celine
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 













Download date: 06. Nov. 2017
This electronic theses or dissertation has been 









The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk 
providing details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENSE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 
Unported License. http://creativecommons.org/licenses/by-nc-nd/3.0/  
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in 
any way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings 























STUDIES	  ON	  THE	  EFFECT	  OF	  CYSTEINYL	  LEUKOTRIENES	  







A	  THESIS	  SUBMITTED	  FOR	  THE	  DEGREE	  OF	  
DOCTOR	  IN	  PHILOSOPHY	  
	  
	  
KING’S	  COLLEGE	  LONDON	  
MRC	  &	  ASTHMA	  UK	  CENTRE	  




Antigen-­‐specific	  Th2	  cells	  are	  central	  to	  the	  pathogenesis	  of	  asthma	  and	  other	  allergic	  
diseases.	  Th2	  cells	   secrete	   the	  cytokines	   IL-­‐4,	   IL-­‐5	  and	   IL-­‐13,	   responsible	   for	  many	  of	  
the	   features	  of	  allergic	   inflammation	  such	  as	  eosinophilia,	   IgE	  production	  and	  mucus	  
hypersecretion.	  Cysteinyl	   leukotrienes	   (CysLTs)	   are	   known	   potent	   lipid	   mediators	  
involved	   in	  mucus	  production,	   bronchoconstriction	   and	   leukocyte	  migration,	   and	   act	  
via	   the	   receptors	  CysLT1R	  and	  CysLT2R.	  Recently,	  CysLTs	  have	  been	   implicated	   in	  Th2	  
responses	  in	  mouse	  models,	  although	  the	  exact	  mechanisms	  are	  unclear.	  
Preliminary	   microarray	   studies	   on	   polarised	   human	   Th1	   and	   Th2	   cells	   suggested	   a	  
highly	   selective	   expression	   of	   CYSLTR1	   by	   human	   Th2	   cells.	   	  Subsequent	   RT-­‐PCR	  
analysis	   confirmed	   that	   Th2	   cells	   selectively	   express	   CYSLTR1	   mRNA	   at	   high	  
levels.	  Calcium	   signalling	   experiments	   revealed	   that	   Th2	   cells	   respond	   selectively	   to	  
leukotrienes	   compared	   to	   Th1	   cells,	   with	   a	   rank	   order	   of	   potency	   similar	   to	   that	  
reported	  for	  CysLT1R	  (LTD4>LTC4>LTE4).	  This	  profile	  of	  leukotrienes	  responsiveness	  was	  
blocked	   using	   the	   known	   selective	   CysLT1R	   antagonists	   MK571,	   Montelukast	   and	  
Zafirlukast.	   Additionally,	   the	   LTD4-­‐induced	   signalling	   in	   Th2	   cells	   is	   mediated	   via	  
CysLT1R	   coupled	   to	   Gαq	   and	   Gαi	   proteins,	   which	   are	   blocked	   when	   using	   selective	  
CysLT1R	   antagonists.	   Finally,	   LTD4	   is	   a	   potent	   chemoattractant	   for	   Th2	   cells,	   which	  
migrate	   to	   LTD4	   at	   low	   nanomolar	   concentrations	   in	   a	   dose-­‐dependent	   manner.	  
Migration	   of	   human	   Th2	   cells	   towards	   LTD4	   was	   inhibited	   by	   selective	   CysLT1R	  
antagonist	  MK571.	  Interestingly,	  LTD4	  had	  no	  significant	  effect	  on	  the	  proliferation	  or	  
differentiation	  of	  Th2	  cells,	  or	  on	  the	  expression	  of	  Th2-­‐specific	  cytokines.	  Microarray	  
studies	   on	   LTD4-­‐treated	   Th2	   cells	   identified	   key	   immediate	   early	   genes	   that	   were	  
upregulated	   after	   30	   minutes	   of	   treatment,	   and	   that	   were	   differentially	   expressed	  
compared	  to	  untreated	  cells.	  
This	   is	   the	   first	   report	   that	   human	   T	   cell	   subsets	   express	   functional	   CysLT1R	   and	  
important	   implications	   for	   our	   understanding	   of	   the	   anti-­‐inflammatory	   effect	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5-­‐HETE	  	   5(S)-­‐	  hydroxy-­‐8,11,14-­‐cis-­‐6-­‐trans-­‐eicosatetraenoic	  acid	  
5-­‐HPETE	   5(S)-­‐	  hydroperoxy-­‐8,11,14-­‐cis-­‐6-­‐trans-­‐eicosatetraenoic	  acid	  
5-­‐LO	   	   5-­‐Lipoxygenase	  
7TM	   	   Seven	  transmembrane	  
β-­‐gal	   	   β-­‐galactosidase	  
AA	   	   Arachidonic	  acid	  
AHR	   	   Airway	  hyperresponsiveness	  
ANOVA	   Analysis-­‐of-­‐variance	  
AP-­‐1	   	   Activator	  protein-­‐1	  
ATP	   	   Adenosine	  5’	  –triphosphate	  
BAL	   	   Bronchoalveolar	  lavage	  
BALF	   	   Broncho	  Alveolar	  Lavage	  Fluid	  
BAPTA	  	   1,2-­‐bis(o-­‐aminophenoxy)ethane-­‐N,N,N',N'-­‐tetraacetic	  acid	  
BATF	   	   Basic	  leucine	  zipper	  transcription	  factor	  
cAMP	   	   Adenosine	  3’,	  5’	  –cyclic	  monophosphate	  
COPD	   	   Chronic	  obstructive	  pulmonary	  disease	  
COX	  	   	   Cyclo-­‐oxygenase	  
cPLA2	   	   Cytosolic	  phospholipase	  A2	  
CysLT	   	   Cysteinyl	  leukotriene	  
DAG	   	   Diacylglycerol	  
DC	   	   Dendritic	  cell	  
DH2O	   	   Distilled	  water	  
DMEM	  	   Dulbecco's	  modiﬁed	  Eagle's	  medium	  
EC50	   	   The	   molar	   concentration	   of	   an	   agonist	   required	   to	   achieve	   50	   %	   of	  
	   	   maximum	  effect	  
ECL	   	   Enhanced	  chemiluminescence	  
EDTA	   	   Ethylenediaminetetraacetic	  acid	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EGF	  	   	   Epidermal	  growth	  factor	  
EGF-­‐R	   	   Epidermal	  growth	  factor	  receptor	  
EGTA	   	   ethylene	  glycol	  tetra-­‐acetic	  acid	  
EIA	   	   Exercise-­‐induced	  asthma	  
EP1	   	   Prostaglandin	  E	  receptor	  
EPAS1	   	   Endothelial	  PAS	  domain-­‐containing	  protein	  1	  
ERK	   	   Extracellular	  signal-­‐regulated	  kinase	  
FACS	   	   Fluorescent	  activated	  cell	  sorting	  
FCS	   	   Fetal	  calf	  serum	  
FDR	   	   False	  discovery	  rate	  
FLAP	   	   5-­‐Lipoxigenase	  activating	  protein	  
FLIPR	   	   Fluorescence	  Imagine	  Plate	  Reader	  
GAPDH	  	   Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  
GATA	   	   Trans-­‐acting	  T	  cell-­‐specific	  transcription	  factor	  
GDP	  	   	   Guanosine	  Dinucleotide	  phosphate	  
GM-­‐CSF	   Granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  
GPCR	  	   	   G-­‐protein	  coupled	  receptor	  
GTP	  	   	   Guanosine	  triphosphate	  
HBSS	   	   Hank's	  Buffered	  Salt	  Solution	  
HEPES	   	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	  acid	  
HUVEC	  	   Human	  Umbilical	  Vein	  Endothelial	  Cells	  
ICAM-­‐1	   Intercellular	  Adhesion	  Molecule	  1	  
IFN	   	   Interferon	  
Ig	   	   Imunoglobulin	  
IL	   	   Interleukin	  
IP3	   	   Inositol	  triphosphate	  
IP-­‐10	   	   Interferon	  gamma-­‐induced	  protein	  
Jnk	  	   	   c-­‐Jun	  NH2	  terminal	  kinase	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LT	   	   Leukotriene	   	  
LTα	   	   Lymphotoxin-­‐α	  
LTA4	   	   Leukotriene	  A4,	  5,	  6-­‐epoxy-­‐	  7,9-­‐trans-­‐	  11,	  14-­‐cis-­‐eicosatetraenoic	  	  
	   	   acid	  
LTB4	   	   Leukotriene	  B4,	  5(S),12(R)-­‐dihydroxy-­‐	  6,14-­‐cis-­‐8,10-­‐trans-­‐	   	  
	   	   eicosatetraenoic	  acid	  
LTC4	   	   Leukotriene	  C4,	  5(S)-­‐hydroxy-­‐6	  (R)-­‐S-­‐glutathionyl-­‐7,9-­‐trans-­‐	  	  
	   	   11,14-­‐cis-­‐eicosatetraenoic	  acid	  	  
LTD4	   	   Leukotriene	  D4,	  5(S)-­‐hydroxy-­‐6	  (R)-­‐S-­‐cysteinylglycyl-­‐7,9-­‐trans-­‐	  
	   	   11,14-­‐cis-­‐eicosatetraenoic	  acid	  	  
LTE4	   	   Leukotriene	  E4,	  5(S)-­‐hydroxy-­‐6	  (R)-­‐S-­‐cysteinyl-­‐7,9-­‐trans-­‐	   	  
	   	   11,14-­‐cis-­‐eicosatetraenoic	  acid	  	  
LTRA	   	   Leukotriene	  receptor	  antagonist	  
MAPK	   	   Mitogen-­‐activated	  protein	  kinase	  
M-­‐CSF	   	   Macrophage	  colony-­‐stimulating	  factor	  
MIP-­‐2	   	   Macrophage	  inflammatory	  protein	  2	  
MMP	  	   	   Matrix	  metalloproteinase	  
NFAT	   	   Nuclear	  factor	  of	  activated	  T-­‐cells	  
NFκB	  	   	   Nuclear	  factor	  κ	  B	  
PBMC	   	   Peripheral	  blood	  mononuclear	  cells	  
PBS	   	   Phosphate-­‐Buffered	  Saline	  
PCA	   	   Principal	  component	  analysis	  
PGD2	   	   Prostaglandin	  D2	  
PGE2	   	   Prostaglandin	  E2	  
PI-­‐3K	   	   Phosphatidylinositol-­‐3	  kinase	  
PIP2	   	   Phosphatidylinositol	  (4,5)-­‐bisphosphate	  
PKC	   	   Protein	  kinase	  C	  
PMA	   	   Phorbol	  12-­‐myristate	  13-­‐acetate	  
PTX	   	   Bordetella	  pertussis	  toxin	  
RIN	   	   RNA	  integrity	  number	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ROS	   	   Proto-­‐oncogene	  tyrosine-­‐protein	  kinase	  
RUNX1	  	   Runt-­‐related	  transcription	  factor	  1	  
S1P	   	   Sphingosine-­‐1-­‐phosphate	  
SDF-­‐1α	  	   Stromal	  cell-­‐derived	  factor	  1	  (also	  known	  as	  CXCL12)	  
SERCA	   	   Sarcoendoplasmic	  reticulum	  calcium	  transport	  ATPase	  
SLE	   	   Systemic	  lupus	  erythematosus	  
SRS-­‐A	   	   Slow	  reacting	  substance	  of	  anaphylaxis	  
STAT	   	   Signal	  Transducers	  and	  Activators	  of	  Transcription	  
T-­‐bet	   	   T-­‐box	  expressed	  in	  T	  cells	  
TBS	   	   Tris-­‐buffered	  saline	  
TCR	   	   T	  cell	  receptor	  
TFN-­‐α	   	   Tumor	  necrosis	  factor	  –	  α	  
THP	   	   Thapsigargin	  
TLR	   	   Toll-­‐like	  receptor	  
TXA2	  	   	   Thromboxane	  A2	  
UDP	   	   Uridine	  diphosphate	  
VCAM-­‐1	   Vascular	  cell	  adhesion	  protein	  1	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Chapter	  1 Introduction	  
1.1 Asthma	  and	  the	  immune	  response	  
1.1.1 Asthma	  
Asthma	   is	   an	   immunological,	   inflammatory	   and	   chronic	   disorder	   of	   the	   conducting	  
airways,	   which	   contract	   inappropriately,	   spontaneously,	   and	   in	   response	   to	   a	   wide	  
range	  of	  endogenous	  and	  exogenous	  stimuli,	  leading	  to	  variable	  airway	  obstruction	  in	  
association	   with	   airway	   hyper-­‐responsiveness	   (AHR).	   Asthma	   has	   dramatically	  
increased	   in	  prevalence	   in	   the	  past	   two	  decades	  and	   is	   continuing	   to	  do	   so,	  with	  an	  
estimated	  235	  million	  people	  affected	  worldwide	  (WHO),	  including	  5.4	  million	  people	  
in	  the	  UK	  (Asthma	  UK	  estimate,	  15th	  Feb	  2011),	  with	  1.1	  million	  of	  these	  being	  children,	  
amongst	  whom	  asthma	   is	   the	  most	   common	   chronic	   disease	   (Asthma	  UK	   estimate).	  
Asthma	   is	  characterized	  by	   influx	   to	   the	   lung	  of	   lymphocytes	  and	  eosinophils,	  airway	  
hypersensitivity	   to	   irritant	   stimuli,	   and	   mucus	   hypersecretion,	   resulting	   in	   airway	  
obstruction	   (Wills-­‐Karp	   1999)	   and	   symptoms	   of	  wheezing,	   coughing	   and	   difficulty	   in	  
breathing.	   It	   is	   believed	   to	   be	   Th2	   lymphocyte-­‐mediated	   and,	   in	   the	   case	   of	   allergic	  
asthma,	   is	   caused	   by	   dysregulated	   immune	   responses	   in	   the	   respiratory	   mucosa,	  
following	   inhalation	   of	   a	   particular	   irritable	   substance	   known	   as	   an	   allergen.	   These	  
allergens	   vary	   in	   nature;	   they	   can	   be	   indoor	   allergens	   (such	   as	   house	   dust	   mite),	  
outdoor	  allergens	  (pollen),	  but	  also	  tobacco	  smoke	  particles	  or	  even	  chemical	  irritants	  
(Chilmonczyk	  et	  al.	  1993;	  Salter	  1866).	  Cold	  air	  and	  exercise	  have	  also	  been	  reported	  to	  
induce	  asthma	  exacerbations,	  in	  the	  case	  of	  exercise-­‐induced	  asthma	  (Hallstrand	  et	  al.	  
2005a;	   Hallstrand	   et	   al.	   2005b).	   Long-­‐term	   asthma	   results	   in	   hypertrophy	   and	  
hyperplasia	  of	  the	  smooth	  muscles	  and	  deposition	  of	  fibrous	  tissue	  in	  the	  lamina	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propria.	   These	   result	   in	   "airway	   remodelling",	   which	   sometimes	   involve	   irreversible	  
loss	  of	  lung	  function	  (Bousquet	  et	  al.	  2000).	  
Although	  asthma	  development	   is	  multifactorial,	  Th2-­‐type	  cytokines	  such	  as	   IL-­‐4,	   IL-­‐5,	  
IL-­‐13,	   and	   IL-­‐9,	   and	   Th2-­‐promoting	   factors	   including	   chemokine	   receptors	   CCR4	   and	  
CCR8	  and	  the	  transcription	  factor	  GATA-­‐3	  are	  all	  associated	  with	  the	  disease	  (Mowen	  
and	  Glimcher	  2004;	  Panina-­‐Bordignon	  et	  al.	  2001;	  Ray	  and	  Cohn	  1999).	  
	  
1.1.2 Asthma	  phenotypes	  
Airway	   inflammation	   is	   central	   to	   disease	   pathophysiology	   and	   relates	   to	   airway	  
dysfunction	   partly	   through	   the	   release	   of	   potent	   inflammatory	  mediators	   and	   partly	  
through	   remodelling	   of	   the	   airway	   wall.	   As	   the	   disease	   becomes	   more	   severe,	   the	  
airway	  becomes	  more	  susceptible	  to	  a	  wide	  range	  of	  environmental	   irritants	  and	  has	  
an	   altered	   repair	   response	   with	   secretion	   of	   growth	   factors	   that	   induce	   mucus	  
secretion,	   smooth	   muscle	   proliferation,	   angiogenesis,	   and	   fibrosis	   and	   nerve	  
proliferation	   (Holgate	   2012).	   It	   is	   believed	   that	   combinations	   of	   these	   processes	   are	  
what	   shape	   the	   different	   asthma	   phenotypes	   and	   how	   they	   respond	   to	   treatment	  
(Holgate	  2012).	  
Most	   asthma	   begins	   in	   childhood	   in	   association	  with	   sensitization	   of	   the	   airways	   to	  
common	  aeroallergens,	  particularly	  those	  derived	  from	  house	  dust	  mites,	  cockroaches,	  
animal	   dander,	   fungi	   and	   pollens.	   However,	   several	   asthma	   phenotypes	   have	   been	  
identified	   and	   these	   come	   under	   two	  main	   categories:	   Th2-­‐associated	   and	   non-­‐Th2-­‐
associated	  asthma.	  The	  concept	  of	  Th2-­‐associated	  asthma	  has	  been	  around	  for	  many	  
years	   and	   been	   strongly	   linked	   to	   atopy	   or	   allergy,	   type	   I	   hypersensitivity	   reactions,	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eosinophilic	  inflammation	  and	  response	  to	  corticosteroids	  (Holgate	  2012;	  S.	  E.	  Wenzel	  
2012b).	  	  
Three	  phenotypes	  have	  been	  identified	  within	  the	  Th2-­‐associated	  umbrella	  of	  asthma:	  
early-­‐onset	   allergic	   Th2	   asthma,	   late-­‐onset	   persistent	   eosinophilic	   asthma	   and	  
exercise-­‐induced	  asthma	  (S.	  E.	  Wenzel	  2012b).	  
Early-­‐onset	   asthma	   is	   believed	   to	   occur	   in	   early	   childhood	   and	   is	   linked	   to	   atopy	   or	  
allergy.	  In	  particular,	  Th2-­‐allergic	  asthma	  is	  associated	  with	  high	  levels	  of	  eosinophils,	  
mast	  cells,	  total	  and	  specific	  IgE	  and	  Th2	  cytokines.	  The	  main	  therapy	  for	  this	  type	  of	  
asthma	   remains	   corticosteroids,	   with	   Th2	   pathway-­‐targeted	   therapies	   also	   having	  
some	  positive	  effects,	  such	  as	  antibodies	  to	  IgE,	  IL-­‐4Rα	  and	  IL-­‐13	  (S.	  E.	  Wenzel	  2012b).	  	  
Late-­‐onset	   persistent	   eosinophilic	   asthma	   is	   characterized	   by	   the	   presence	  of	   higher	  
levels	  of	  eosinophils	   in	  the	  sputum	  and	  symptoms	  can	  currently	  be	  maintained	  using	  
corticosteroids.	  As	  patients	  suffering	  from	  this	  type	  of	  asthma	  are	  usually	  observed	  to	  
have	  high	  levels	  of	  cysteinyl	  leukotrienes,	  anti-­‐leukotrienes	  agents	  have	  been	  shown	  to	  
be	   beneficial	   to	   lung	   function	   and	   symptoms.	   Recently	   anti-­‐IL-­‐5	   therapy	   has	   been	  
found	   to	   be	   effective	   in	   diminishing	   blood	   and	   lung	   eosinophils,	   and	   decreasing	  
exacerbations	  (Nair	  et	  al.	  2009;	  S.	  E.	  Wenzel	  2012b).	  	  
Finally	   exercise-­‐induced	   asthma	   (EIA)	   refers	   to	   asthma	   whose	   symptoms	   are	  
experienced	   primarily	   after	   exercise.	   These	   symptoms	   involve	   mild	   asthma	   and	  
reactive	  bronchoconstriction	  in	  response	  to	  sustained	  exercise	  and	  frequently	  occur	  in	  
dry	   and	   cold	   weather	   conditions.	   EIA	   has	   been	   associated	   with	   reports	   of	   levels	   of	  
eosinophilia,	  high	  levels	  of	  mast	  cells	  and	  release	  of	  their	  mediators	  but	  these	  reports	  
have	   been	   contradictory	   (Hallstrand	   et	   al.	   2005a;	   Karjalainen	   et	   al.	   2000).	   A	   good	  
treatment	   response	   in	   EIA	   has	   been	   seen	   with	   the	   use	   of	   anti-­‐cysteinyl	   leukotriene	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agents,	  although	  recent	  studies	  have	  suggested	  that	  monoclonal	  antibody	  blockade	  	  IL-­‐
9	  may	  also	  be	  a	  potential	  treatment	  (S.	  E.	  Wenzel	  2012b).	  
Non-­‐Th2-­‐associated	   asthma	   represents	   approximately	   50%	   of	   all	   asthma	   and	   is	   less	  
understood.	  So	  far	  this	  subgroup	  comprises	  of	  obesity-­‐related	  asthma	  and	  neutrophilic	  
asthma.	  	  
As	   the	   name	   suggests,	   obesity-­‐related	   asthma	   is	   mainly	   driven	   by	   obesity	   and	   its	  
symptoms.	  Although	  it	   is	  difficult	  to	  diagnose	  asthmatic	  symptoms	  in	  obese	  patients,	  
high	   expression	   levels	   of	   TNF-­‐α,	   IL-­‐6	   and	   leptins	   have	   been	   identified.	   No	   specific	  
treatment	  or	  biomarkers	  have	  been	  identified	  for	  this	  phenotype.	  	  
In	   neutrophilic	   asthma,	   high	   levels	   of	   neutrophilia	   are	   seen	   in	   the	   lung	   and	   are	  
associated	   with	   lower	   lung	   function,	   more	   trapping	   of	   air	   and	   thicker	   airway	   walls.	  
Specific	  treatments	  remain	  to	  be	  identified	  as	  corticosteroids	  and	  anti-­‐TNF-­‐α	  therapies	  
have	  shown	  limited	  effectiveness	  (Green	  et	  al.	  2002;	  S.	  E.	  Wenzel	  2012b).	  
	  
1.1.3 The	  Th2	  response	  
The	   lung	   inflammatory	   response	   and	   generation	   of	   Th2	   response	   are	   initiated	   in	  
association	   with	   the	   airway	   epithelium	   and	   underlying	   mucosa	   in	   which	   reside	  
professional	  antigen-­‐presenting	  cells	   (APCs)	  called	  dendritic	  cells	   (DCs).	  DCs	  have	   the	  
ability	   to	   take	   up	   allergens,	   process	   them	   into	   small	   peptides	   and	   present	   them	   via	  
MHC	   Class	   II	   for	   recognition	   by	   T	   cell	   receptors	   (Holgate	   2012).	   Following	   antigen	  
uptake,	   antigen-­‐loaded	   DCs	   undergo	   maturation	   and	   migrate	   from	   the	   peripheral	  
tissue	  to	  the	  draining	   lymph	  nodes.	  Once	   in	  the	   lymph	  node,	  the	  antigen-­‐loaded	  DCs	  
prepare	   for	   interaction	  with	   lymph	   node-­‐homing	   T	   cells	   by	   lining	   up	   along	   the	   high	  
endothelial	  venules.	  The	  DCs	  prepare	  for	  the	  priming	  of	  T	  cells	  in	  the	  lymph	  nodes.	  The	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initial	   encounter	   between	   the	   DC	   and	   the	   T	   cell	   leads	   to	   the	   upregulation	   of	   T-­‐cell	  
activation	  markers	  such	  as	  CD44	  and	  CD69	  and	  the	  secretion	  of	  cytokines	  such	  as	  IL-­‐2.	  
The	  third	  step	  of	  the	  interaction	  between	  the	  DC	  and	  T	  cell	  occurring	  within	  the	  lymph	  
node	   results	   in	   increased	   T	   cell	   motility	   as	   well	   as	   rapid	   STAT-­‐independent	  
proliferation.	  DC-­‐activated	  antigen-­‐specific	  CD4+	  T	   cells	   then	  migrate	   to	   the	   infected	  
peripheral	   tissues	   where	   they	   encounter	   IL-­‐4	   and	   differentiate	   into	   antigen-­‐specific	  
Th2	  cells,	  secreting	  high	  levels	  of	  effector	  cytokines	  in	  a	  STAT6-­‐dependent	  manner.	  The	  
source	  of	  IL-­‐4	  has	  been	  the	  subject	  of	  debate	  and	  there	  is	  now	  increasing	  evidence	  that	  
this	  may	  come	  from	  basophils	  (Holgate	  2012),	  as	  discussed	  later	  on.	  These	  Th2-­‐specific	  
cytokines	  such	  as	  IL-­‐4,	  IL-­‐13,	  IL-­‐9	  and	  IL-­‐5	  are	  essential	  players	  in	  the	  lungs	  of	  asthmatic	  
subjects.	  	  
IL-­‐4	  signals	  via	  a	  specific	   IL-­‐4	  cell-­‐surface	  receptor	  composed	  of	   the	   IL-­‐4Rα	  chain	  and	  
the	   γ	   common	   chain,	   and	   has	   been	   shown	   to	   be	   vital	   for	   the	   regulation	   of	   growth,	  
differentiation,	  activation,	  and	   function	  of	  B	   cells	   (Tangye	  et	  al.	   2002).	   IL-­‐4	  has	  been	  
found	   to	   increase	   the	   expression	   of	   the	   antigen-­‐presenting	   proteins,	   MHC	   class	   II	  
molecules,	  on	  B	  cells,	  resulting	  in	  increased	  allergen	  presentation	  capacity	  to	  Th2	  cells	  
(Hamid	  and	  Tulic	   2009;	   Seder	   and	  Paul	   1994).	   IL-­‐4	  has	   also	  been	   shown	   to	  promote	  
expression	   of	   VCAM-­‐1	   on	   endothelium	   (Schleimer	   et	   al.	   1992),	   thereby	   allowing	   for	  
recruitment	   of	   eosinophils	   and	   other	   inflammatory	   cells	   such	   as	   T	   cells,	  monocytes,	  
and	  basophils	  from	  the	  blood	  into	  the	  sites	  of	  inflammation	  (Hamid	  and	  Tulic	  2009).	  IL-­‐
4	   is	   also	   involved	   in	   inducing	   IgE	   isotype	   class	   switching	   by	   B	   cells.	   Following	   class	  
switching,	   IL-­‐4	   is	   known	   to	  potentiate	   IgE	  production	   and	  enhance	   the	   IgE-­‐mediated	  
response	   by	   upregulating	   IgE	   receptors	   on	   inflammatory	   cells	   within	   the	   airway	  
(Vercelli	  et	  al.	  1988).	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IL-­‐13	  shares	  70%	  sequence	  homology	  with	  IL-­‐4,	  and	  binds	  a	  heterodimer	  composed	  of	  
the	  IL-­‐4Rα	  chain	  and	  an	  IL-­‐13Rα	  chain	  (Mitchell	  et	  al.	  2010;	  Oh	  et	  al.	  2010).	  Like	  IL-­‐4,	  IL-­‐
13	   is	  produced	  by	  Th2	  cells	  and	  both	  cytokines	  have	  some	  overlap	   in	  their	  functions.	  
Similarly	  to	  IL-­‐4,	  overexpression	  of	  IL-­‐13	  within	  the	  lungs	  has	  been	  shown	  to	  lead	  to	  IgE	  
production,	   inflammation,	   mucus	   hypersecretion,	   eosinophilia,	   and	   upregulation	   of	  
VCAM-­‐1	  (Wills-­‐Karp	  et	  al.	  1998).	  	  
IL-­‐9	  is	  also	  relevant	  to	  IgE-­‐dependent	  host	  responses	  and	  its	  expression	  is	  regulated	  by	  
several	  mediators,	   in	  particular	   IL-­‐2,	  which	  stimulates	   its	  production.	  Although	   IL-­‐9	   is	  
produced	   by	   several	   cell	   types,	   including	   mast	   cells,	   eosinophils,	   and	   neutrophils	  
(Hultner	  et	  al.	  2000;	  McNamara	  et	  al.	  2004;	  Shimbara	  et	  al.	  2000),	  the	  major	  sources	  of	  
IL-­‐9	  are	  Th	  lymphocytes.	  Two	  independent	  groups	  have	  demonstrated	  that	  naive	  CD4+	  
T	  cells	  primed	  in	  the	  combination	  of	  TGF-­‐β	  and	  IL-­‐4	  or	  Th2	  cells	  additionally	  cultured	  in	  
TGF-­‐β	  can	  produce	  high	  levels	  of	  IL-­‐9	  with	  reduced	  expression	  of	  other	  lineage-­‐specific	  
cytokines	   and	   transcription	   factors	   and	   promote	   the	   development	   of	   a	   CD4+	   T	   cell	  
subset	   that	   preferentially	   produces	   IL-­‐9,	   and	  which	   has	   therefore	   been	   termed	   	   Th9	  
cells	   (Dardalhon	   et	   al.	   2008;	   Veldhoen	   et	   al.	   2008).	   In	   vitro,	   IL-­‐9	   has	   been	   shown	   to	  
enhance	  IL-­‐4-­‐mediated	  IgE	  production	  by	  both	  human	  and	  murine	  B	  cells	  (Dugas	  et	  al.	  
1993).	  
IL-­‐5	   is	   the	   most	   important	   Th2	   cytokine	   associated	   with	   eosinophils,	   and	   has	   been	  
shown	   to	   regulate	  most	   aspects	   of	   eosinophil	   behavior	   including	   eosinophil	   growth,	  
maturation,	  differentiation,	  survival,	  and	  activation.	  IL-­‐5	  is	  known	  to	  play	  a	  central	  role	  
in	  accumulation	  and	  activation	  of	  eosinophils	  in	  the	  lungs.	  Although	  IL-­‐5	  is	  produced	  by	  
T	   helper	   cells,	   cytotoxic	   T	   lymphocytes,	   and	   mast	   cells,	   eosinophils	   are	   the	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predominant	   sources	   of	   this	   cytokine	   and	   it	   has	   been	   shown	   to	   act	   as	   a	   potent	  
eosinophil	   chemoattractant.	   IL-­‐5	   also	   upregulates	   integrin	   receptor	   expression	   on	  
eosinophils,	   thereby	   promoting	   adherence	   of	   eosinophils	   to	   VCAM-­‐expressing	  
endothelial	   cells	   and	   eosinophil	   accumulation	   (Hamid	   and	   Tulic	   2009;	   Larche	   et	   al.	  
2003).	  
IL-­‐4,	   IL-­‐9	   and	   IL-­‐13	   are	   therefore	   particularly	   critical	   for	   their	   role	   in	   enhancing	   IgE	  
production	  from	  B	  cells,	  leading	  to	  IgE	  and	  Fc	  receptor	  cross-­‐linking	  on	  the	  surface	  of	  
mast	   cells,	   resulting	   in	   their	   degranulation,	   and	   the	   subsequent	   release	   of	  
inflammatory	   mediators	   such	   as	   histamine,	   prostaglandin	   D2	   and	   cysteinyl	  
leukotrienes	  (see	  figure	  1.1);	  while	  IL-­‐5	  is	  involved	  in	  the	  recruitment	  and	  activation	  of	  
eosinophils.	  The	  release	  of	  inflammatory	  cytokines	  and	  mediators	  by	  mast	  cells	  results	  
in	  the	  known	  features	  of	  asthma,	  such	  as	  bronchoconstriction,	  eosinophil	  and	  basophil	  
infiltration,	   mucus	   hypersecretion,	   bronchial	   remodelling,	   and	   airway	   hyper-­‐
responsiveness	   (AHR)	   ((Holgate	   2008;	   Kay	   2005;	   Larche	   et	   al.	   2003;	   Umetsu	   and	  
DeKruyff	   2006).	   The	   inflammatory	   process	   is	   then	  maintained	   by	   the	   recruitment	   of	  
more	  inflammatory	  cells	  into	  the	  lungs,	  such	  as	  eosinophils,	  basophils,	  neutrophils	  and	  















	   	  
Figure	   1.1	   Representation	   of	   the	   Th2	   response	   during	   allergic	   inflammation	  
(Hawrylowicz	  and	  O'Garra	  2005).	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1.1.4 Th1	  and	  Th2	  cells	  
The	  Th1/Th2	  cell	  hypothesis	  emerged	  in	  the	  late	  1980s,	  stemming	  from	  observations	  in	  
mice	  of	  two	  subtypes	  of	  T-­‐helper	  cells,	  originally	  characterised	  by	  the	  cytokine	  profile	  
they	   secreted	   and	   the	   functions	   they	   carried	   out	   (Mosmann	   et	   al.	   1986).	   This	  
hypothesis	  was	  adapted	  to	  human	  immunity,	  with	  Th1-­‐	  and	  Th2-­‐helper	  cells	  directing	  
different	   immune	   response	   pathways.	   Since	   the	   original	   findings	   by	   Mosmann	   and	  
Coffman	   in	  1986,	   the	   study	  of	  Th1	  and	  Th2	  CD4+	  T	   cells	  has	  become	  a	  very	  popular	  
field	  of	  research	  and	  its	  progress	  has	  been	  extensively	  reviewed	  over	  the	  last	  few	  years	  
(Koppelman	  and	  Nawijn	  2011;	  Lloyd	  and	  Hessel	  2010;	  Mosmann	  and	  Coffman	  1989a,	  
1989b;	  Oliphant	  et	  al.	  2011).	  
It	  is	  thought	  that,	  upon	  leaving	  the	  thymus,	  all	  αβ	  CD4+	  T	  cells	  have	  a	  naïve	  phenotype.	  
In	  order	  to	  differentiate	  into	  effector	  cells	  and	  carry	  out	  their	  effector	  functions,	  naive	  
cells	   require	   the	   appropriate	   activation	   signals	   and	   cytokine	  milieu.	   Type	   1	   T	   helper	  
cells	   (Th1)	   produce	   interferon-­‐gamma	   (IFN-­‐γ),	   interleukin	   (IL)-­‐2,	   and	   lymphotoxin-­‐α	  
(LTα)	   (also	   known	   as	   tumour	   necrosis	   factor	   (TNF)-­‐β),	   which	   promote	   inflammatory	  
and	  cellular	  immune	  responses.	  By	  contrast,	  type	  2	  Th	  cells	  (Th2)	  produce	  IL-­‐4,	  IL-­‐5,	  IL-­‐
9,	   IL-­‐13,	   IL-­‐6	   and	   IL-­‐10,	   and	   are	  necessary	   for	   inducing	  humoral	   response	   to	   combat	  
parasitic	   helminths	  by	   inducing	   strong	   IgE	   antibody	  production	  by	  B	   cells,	   eosinophil	  
activation,	   and	   activation	   of	   various	   inflammatory	   cells	   such	   as	   mast	   cells	   and	  
basophils	  (Romagnani	  1999).	  
The	   two	   factors	   thought	   to	   be	   the	   most	   potent	   in	   influencing	   Th1	   and	   Th2	  
differentiation	   are	   IL-­‐12	   and	   IL-­‐4,	   respectively	   (Seder	   et	   al.	   1992).	   IL-­‐12	   induces	  
phosphorylation	  of	  STAT4	  in	  differentiating	  Th1	  (Bacon	  et	  al.	  1995;	  Szabo	  et	  al.	  1995),	  
whereas	  IL-­‐4	  activates	  STAT6	  in	  Th2	  cells	  (Hou	  et	  al.	  1994).	  In	  mice	  deficient	  in	  Stat-­‐4	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and	  Stat-­‐6,	  Th1	  and	  Th2	  development,	  respectively,	  were	  impaired	  (Kaplan	  et	  al.	  1996;	  
Thierfelder	   et	   al.	   1996).	   Controlling	   the	   development	   and	   maintaining	   a	   balance	  
between	   Th1	   and	   Th2	   cells	   is	   crucial	   as	   it	   is	   believed	   that	   excessive	   Th1	   cytokine	  
production	   is	   associated	   with	   autoimmune	   diseases	   and	   excessive	   Th2	   cytokine	  
production	  with	  type	  1	  hypersensitivity	  disorders,	  such	  as	  asthma,	  eczema	  and	  allergy	  
(Sallusto	   et	   al.	   1998).	   Indeed,	   in	   addition	   to	   playing	   different	   roles	   in	   protecting	   the	  
immune	   system,	   polarized	   Th1	   and	   Th2	   cells	   responses	   are	   also	   responsible	   for	  
different	  types	  of	  immunopathological	  reactions	  (Romagnani	  1999,	  2000a,	  2000b).	  
	  
1.1.5 Th1	  cell	  differentiation	  
The	  important	  factors	  in	  the	  differentiation	  of	  Th1	  cells	  are	  STAT1	  and	  STAT4,	  as	  STAT1	  
receives	   signals	   from	   IFNs	   and	   STAT4	   from	   IL-­‐12.	   Both	   STAT1	   and	   STAT4	   have	   the	  
ability	   to	   induce	  T-­‐bet,	  which	   in	   turn	   can	  promote	   IFN-­‐γ	  production	  and	   repress	   IL-­‐4	  
transcription	   with	   the	   help	   of	   HLX,	   RUNX3	   and	   ETS	   family	   members	   (Djuretic	   et	   al.	  
2007;	  Hwang	  et	  al.	  2005).	   It	  has	  been	  shown	   IFN-­‐γ	   is	   involved	   in	  a	  positive	   feedback	  
loop	   in	  which	   IFN-­‐γ	   can	   act	   via	   T-­‐bet	   to	   induce	  more	   IFN-­‐γ,	   including	   in	  monocytes,	  
macrophages,	   dendritic	   cells	   and	   B	   cells,	   and	   this	   is	   done	   through	   the	   activation	   of	  
STAT1	  by	  IFN-­‐γ	  (Szabo	  et	  al.	  2000).	  
IFN-­‐γ	  has	  also	  been	  reported	  to	  positively	  regulate	  STAT4,	  in	  contrast	  to	  IL-­‐4	  and	  GATA-­‐
3,	  which	   negatively	   regulate	   STAT4.	  Once	   activated,	   STAT4	   can	   directly	   induce	   IFN-­‐γ	  
production	  and	  expression	  of	  12Rβ2	  and	  T-­‐bet	  during	  Th1	  differentiation.	  The	  role	  of	  
T-­‐bet	   is	   also	   to	   antagonise	   Th2	   differentiation	   by	   inhibiting	   the	   function	   of	   GATA-­‐3.	  
Some	  studies	  have	  however	  shown	  that	   it	   is	  possible	   for	  Th1	  differentiation	  to	  occur	  
without	  T-­‐bet	  or	  STAT4	  (Kanno	  et	  al.	  2012;	  K.	  Zhu	  et	  al.	  2010).	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1.1.6 Th2	  cell	  differentiation	  
CD4+	   T	   cell	   differentiation	   is	   down	   to	   three	   essential	   signals:	   TCR	   engagement,	  
appropriate	  co-­‐stimulation	  and	  cytokine	  receptor	  ligation.	  The	  first	  signals	  thought	  to	  
induce	   CD4+	   T	   cells	   to	   follow	   a	   Th2	   differentiation	   path	   are	   T-­‐cell	   receptor	  
engagement,	  NFAT	  and	  GATA-­‐3.	  Studies	  in	  naïve	  transgenic	  CD4+	  T	  cells	  have	  reported	  
that	   a	   low-­‐strength	   TCR	   signal	   (0.5pg/ml	   of	   peptide)	   is	   preferable	   to	   induce	   IL-­‐4	  
secretion.	   This	   led	   to	   a	  weak	   and	   transient	   ERK	   activation	   and	  GATA-­‐3	   stabilization,	  
triggering	   the	   activation	   of	   il4.	   This	   also	   allowed	   for	   bypassing	   the	   requirement	   for	  
exogenous	   IL-­‐4,	  by	   inducing	   IL-­‐2,	  which	   in	   turn	   fed	  back	   in	  an	  autocrine	  manner	  and	  
activated	  STAT5.	  In	  contrast,	  higher	  doses	  (over	  0.5	  μg/ml)	  have	  been	  shown	  to	  induce	  
IFN-­‐γ	  production	  (Constant	  et	  al.	  1995;	  Hosken	  et	  al.	  1995).	  
In	   order	   to	   provide	   this	   low	   TCR	   signal,	   the	   question	   remains	   as	   to	   which	   cells	   are	  
responsible	  for	  antigen	  presentation	  and	  providing	  the	  signals.	  There	  has	  been	  a	  lot	  of	  
speculation	  on	  the	  role	  of	  dendritic	  cells	  (DCs)	  in	  providing	  that	  signal	  to	  Th2	  cells	  and	  
acting	   as	   both	   the	   primary	   antigen-­‐processing	   and	   antigen-­‐presenting	   cells,	   using	   a	  
separate	   source	   of	   IL-­‐4.	  More	   recently,	   several	   groups	   have	   reported	   that	   basophils	  
could	  have	  the	  ability	   to	  single-­‐handedly	   induce	  Th2	  cell	  differentiation,	  by	  providing	  
antigen-­‐presenting	  and	  antigen-­‐priming	  capacity	  as	  well	  as	  the	  IL-­‐4	  signal.	  There	  have	  
been	   contradicting	   reports	   on	   the	   role	   of	   basophils	   and	   DCs	   as	   the	   prime	   T	   cell	  
differentiation	  inducer	  and	  clear	  roles	  remain	  to	  be	  defined	  (Okoye	  and	  Wilson	  2011).	  
Co-­‐stimulatory	   signals	   are	   also	   important	   for	   T	   cell	   differentiation,	   as	   antigen	  
presentation	  via	  MHC	   II	   alone	   is	  usually	  not	  enough.	  Co-­‐stimulation	  generally	  occurs	  
via	  CD28,	  ICOS,	  CTLA-­‐4	  and	  PD-­‐1	  on	  the	  surface	  of	  the	  T	  cell	  and	  B7	  molecules	  on	  the	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surface	  of	   the	  antigen-­‐presenting	  cell,	   following	  synapse	   formation	  between	  the	   two	  
cells	  (Okoye	  and	  Wilson	  2011).	  
The	  third	  signal	  essential	  for	  differentiation	  to	  occur	  is	  the	  right	  cytokine	  environment.	  
As	  mentioned	  earlier,	  exogenous	  IL-­‐4	  has	  traditionally	  been	  known	  for	  its	  involvement	  
in	   Th2	   cell	   differentiation.	   However	   IL-­‐4-­‐independent	   pathways	   have	   recently	   been	  
identified	  using	  cytokines	  such	  as	  IL-­‐25,	  IL-­‐33	  and	  TSLP	  (Okoye	  and	  Wilson	  2011).	  
The	  differentiation	  of	   Th2	   cells	   usually	   occurs	  when	  a	  naïve	   T	   cell	   is	   activated	  by	   an	  
antigen	  on	  the	  surface	  of	  an	  APC	  in	  the	  presence	  of	  IL-­‐4.	  The	  IL-­‐4	  receptor	  is	  composed	  
of	   the	   common	   cytokine	   receptor	   gamma	   subunit	   and	   the	   IL-­‐4Rα	   chain.	   IL-­‐4R	   is	  
expressed	  at	  low	  levels	  on	  the	  surface	  of	  naïve	  CD4+	  T	  cells,	  but	  its	  levels	  of	  expression	  
increase	   upon	   antigen	   challenge.	   The	   IL-­‐4	   binding	   to	   the	   IL-­‐4R	   results	   in	   the	  
recruitment	  of	  Signal	  Transducer	  and	  Activator	  of	  Transcription	  6	  (STAT6)	  (Ansel	  et	  al.	  
2006;	  Kanno	  et	  al.	  2012).	  STATS	  are	  DNA-­‐binding	  transcription	  factors	  that	  induce	  the	  
transcription	   of	   their	   target	   genes	   by	   recognizing	   specific	   DNA	   consensus	   sequences	  
(O'Shea	   et	   al.	   2011).	   Following	   recruitment,	   STAT6	   becomes	   phosphorylated,	   then	  
dimerizes,	  and	   translocates	   to	   the	  nucleus	  where	   it	   can	  activate	   transcription	  of	  Th2	  
cell	  specific	  genes	  (Nelms	  et	  al.	  1999).	  Genome	  analysis	  studies	  in	  humans	  have	  shown	  
that	  IL-­‐4-­‐induced	  regulation	  of	  gene	  transcription	  is	  highly	  dynamic,	  as	  only	  a	  handful	  
of	   genes	   differentially	   regulated	   within	   the	   first	   few	   hours	   remain	   differentially	  
expressed	  at	  72	  hours	  (Elo	  et	  al.	  2010;	  O'Shea	  et	  al.	  2011).	  
There	   are	   several	   transcription	   factors	   associated	   with	   establishing	   the	   Th2	   cell	  
phenotype.	  STAT6	  is	  a	  major,	  direct	  contributor	  to	  the	  Th2	  transcriptional	  profile	  and	  
induces	  the	  expression	  of	  Th2	  cell	  master	  regulator	  GATA-­‐3	  (Ouyang	  et	  al.	  2000).	  Other	  
transcription	   factors	   induced	   upon	   TCR	   stimulation	   include	   NFAT	   family	   members,	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IRF4,	   Jun	   family	  members,	  and	  c-­‐MAF	   (Ansel	  et	  al.	  2006;	  G.	  R.	  Lee	  et	  al.	  2006;	  K.	  M.	  
Murphy	   and	   Reiner	   2002).	   Of	   the	   newly	   identified	   STAT6	   targets,	   the	   three	  
transcription	   factors	   RUNX1,	   EPAS1	   and	   BATF	   were	   suggested	   to	   play	   a	   role	   in	  
promoting	   the	   Th2	   cell	   phenotype	   by	   regulating	   and	   amplifying	   Th2	   differentiation	  
(O'Shea	  et	  al.	  2011).	  
Though	  particular	  cytokines	  are	  thought	  to	  be	  promoters	  of	  specific	  T	  cell	   lineages,	  a	  
differentiating	   T	   cell	   receives	  multiple	   cytokine	   signals.	   IL-­‐4	   and	   STAT6	   clearly	   play	   a	  
dominant	  role	  in	  Th2	  cell	  differentiation.	  Studies	  in	  transgenic	  mice	  expressing	  IL-­‐4	  or	  
constitutively	   active	   STAT6	   are	   characterized	   by	   the	   development	   of	   spontaneous	  
allergic	   inflammation	  (Sehra	  et	  al.	  2008;	  Tepper	  et	  al.	  1990).	  Development	  of	  allergic	  
disease	  is	  dependent	  on	  IL-­‐4	  since	  allergic	  inflammation	  is	  diminished	  in	  mice	  deficient	  
in	   IL-­‐4	   or	   STAT6	   (Akimoto	   et	   al.	   1998;	   Brusselle	   et	   al.	   1995;	   Kuperman	   et	   al.	   1998;	  
Sehra	  et	  al.	  2008).	  
  





	   	  
Figure	  1.2	  Representation	  of	  pathogenic	  processes	  and	  Th2	  differentiation	  in	  allergic	  
disease.	  Taken	  from	  (Wambre	  et	  al.	  2012).	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1.1.7 Other	  T	  cell	  subsets	  
In	  recent	  years,	  we	  have	  attained	  a	  much	  more	  detailed	  understanding	  of	  CD4+	  T	  cell	  
differentiation,	   functions,	   and	   gene	   expression	   profiles,	   which	   has	   led	   to	   the	  
identification	   of	   additional	   subtypes.	   The	   lineage-­‐specific	   transcription	   factor	   model	  
has	  been	  extended	  and	  new	  transcription	  factors	  have	  been	  identified.	  
As	   described	   earlier	   on,	   CD4+	   T	   cells	   rapidly	   undergo	   programmed	   differentiation	  
following	   the	   engagement	   of	   the	   T-­‐cell	   receptor	   with	   peptide-­‐MHC-­‐II	   complex	  
processed	   by	   the	   antigen-­‐presenting	   cell	   (APC),	   which	   results	   in	   highly	   polarised	  
immune	  responses,	  particularly	  T	  cell-­‐specific	  cytokines	  and	  chemokines	  secretion	  (Z.	  
Li	  et	  al.	  2011b;	  Okoye	  and	  Wilson	  2011).	  
It	  is	  now	  evident	  that	  naïve	  CD4+	  T	  cells	  can	  differentiate	  into	  at	  least	  five	  functionally	  
distinct	  subsets	  including	  Th1,	  Th2,	  Treg,	  Th17	  and	  Tfh	  (Hirahara	  et	  al.	  2011;	  Sakaguchi	  
et	  al.	  2008;	  Szabo	  et	  al.	  2003;	  J.	  Zhu	  and	  Paul	  2008).	  
Differentiation	  of	  naïve	  CD4+	  T	  cells	   into	  a	  particular	   lineage	  depends	  highly	  on	  their	  
exposure	   to	   antigen,	   the	   co-­‐stimulatory	   molecules	   expressed	   and	   the	   cytokine	  
environment	  (Glimcher	  and	  Murphy	  2000).	   	  An	  imbalance	  or	  dysregulation	  in	  specific	  
cytokine	  production	  in	  effector	  T	  cells	  can	  lead	  to	  both	  tissue	  destruction	  and	  chronic	  
inflammation	  for	  Th1,	  and	  asthma	  and	  allergy	  for	  Th2	  (Hirahara	  et	  al.	  2011;	  Mosmann	  
and	  Coffman	  1989a).	  
Briefly,	   Th1	   cells	   regulate	   cell-­‐mediated	   immunity	   against	   pathogen	   and	   protect	   the	  
host	  against	  intracellular	  infections	  including	  viruses.	  Th1	  cells	  produce	  IL-­‐2	  and	  IFN-­‐y	  
under	  the	  transcription	  regulator	  T-­‐bet	  (Mosmann	  and	  Coffman	  1989a).	  On	  the	  other	  
hand,	  Th2	  cells	  mediate	  host	  defence	  against	  parasitic	  infections	  such	  as	  helminths	  and	  
produce	  IL-­‐4,	  IL-­‐5,	  IL-­‐13	  and	  IL-­‐9	  under	  the	  transcription	  regulator	  GATA-­‐3.	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Regulatory	   T	   cells,	   or	   Tregs,	   consist	   of	   another	   CD4+	   T	   cell	   lineage	   and	   comprise	   of	  
nTregs	   (thymic	   natural)	   and	   iTregs	   (peripherally	   induced).	   These	   cells	   have	   essential	  
immunosuppressive	  functions	  and	  express	  IL-­‐10	  and	  TGF-­‐β	  under	  the	  master	  regulator	  
transcription	  factor	  FoxP3	  (Zheng	  and	  Rudensky	  2007).	  Both	  natural	  and	  induced	  Tregs	  
are	   involved	   in	   maintaining	   peripheral	   tolerance,	   preventing	   autoimmunity	   and	  
inflammatory	  immune	  responses.	  
More	   recently,	   the	  discovery	  of	   IL-­‐17-­‐producing	  CD4+	  T	  cells,	  or	  Th17	  cells,	   renewed	  
the	   interest	   in	   T	   cell	   differentiation	   (Weaver	   et	   al.	   2006).	   Th17	   cells	   express	   a	   splice	  
variant	   of	   the	   retinoid	   orphan	   receptor-­‐c,	   designated	   RORyt,	   and	   produce	   distinct	  
effector	   cytokines,	   including	   IL-­‐17	   (or	   IL-­‐17A),	   IL-­‐17F	   and	   IL-­‐6	   (Weaver	   et	   al.	   2006).	  
Th17	  cells	  	  seem	  to	  originate	  from	  a	  pathway	  different	  to	  Th1	  and	  Th2	  cells,	  however,	  
it	   resembles	  Th1	  cells	   in	  some	  ways,	  which	  has	  caused	  confusion,	  particularly	  on	  the	  
role	   of	   Th1	   cells	   in	   autoimmunity.	   Th17	   cells	   contribute	   to	   host	   defence	   against	  
extracellular	   bacteria	   and	   fungi	   and	   have	   also	   been	   implicated	   in	   the	   pathology	   of	  
several	   autoimmune	   and	   inflammatory	   diseases	   such	   as	   experimental	   autoimmune	  
encephalomyelitis	  (EAE)	  (Becher	  and	  Segal	  2011).	  
Following	  Th17	  cells,	  other	  lineages	  have	  also	  been	  identified	  including	  Th9	  and	  Th22,	  
which	   produce	   their	   namesake	   cytokines	   IL-­‐9	   and	   IL-­‐22,	   respectively.	   Th9	   cells	   have	  
been	  characterized	  as	  yet	  another	  novel	  and	  distinct	  population	  amongst	  the	  other	  T	  
helper	   populations.	   Th9	   cells	   were	   first	   identified	   as	   a	   Th2	   sub-­‐population	   which	  
produced	  large	  quantities	  of	  the	  Th2-­‐specific	  cytokine	  IL-­‐9,	  and	  which	  could	  be	  induced	  
by	  TGF-­‐β	  (Neill	  and	  McKenzie	  2010).	  	  Recently,	  a	  distinct	  subset	  of	  human	  skin-­‐homing	  
memory	  T	  cells	  has	  been	  shown	  to	  produce	  IL-­‐22,	  but	  neither	  IL-­‐17	  nor	  IFN-­‐γ	  (Duhen	  et	  
al.	  2009;	  Trifari	  et	  al.	  2009).	  Differentiation	  of	  IL-­‐22	  producing	  T	  cells,	  now	  named	  Th22	  
	   	   INTRODUCTION	  
 
 31	  
cells,	   can	   be	   promoted	   by	   the	   presence	   of	   IL-­‐6	   and	   TNF-­‐α	   or	   by	   the	   presence	   of	  
plasmacytoid	  dendritic	  cells.	  The	  human	  Th22	  cell	  population	  has	  been	  shown	  to	  co-­‐
express	  the	  chemokine	  receptor	  CCR6	  and	  the	  skin-­‐homing	  receptors	  CCR4	  and	  CCR10,	  
suggesting	   a	   potential	   role	   in	   skin	   homeostasis	   and	   pathology	   (Duhen	   et	   al.	   2009;	  
Trifari	  et	  al.	  2009).	  
Follicular	  T	  helper	  (Tfh)	  cells	  have	  also	  been	  identified	  as	  a	  separate	  lineage	  of	  Th	  cells.	  
These	  cells	  are	  defined	  by	  their	  expression	  of	  Bcl6	  and	  production	  of	  IL-­‐21	  and	  surface	  
molecules	   PD-­‐1,	   CXCR5	   and	   ICOS.	   Tfh	   refers	   to	   cells	   residing	   in	   germinal	   centres	   of	  
lymphoid	   centres,	   in	   proximity	   to	   B	   cells.	   Tfh	   cells	   are	   thought	   to	   help	   B	   cells	   by	  
promoting	   B	   cell	   class	   switching	   and	   specialize	   in	   helping	   B	   cells	   make	   antibody	  
responses	  (Wambre	  et	  al.	  2012).	  
	   	  






	   	  
Figure	  1.3	  Representation	  of	  different	  T	  cell	  subsets.	  This	  shows	  the	  T	  cell	  subsets	  as	  
they	   are	   known	   so	   far,	   including	   their	   characteristic	   transcription	   factors,	   surface	  
markers,	  effector	  cytokines,	  and	  other	  markers	  (Wambre	  et	  al.	  2012).	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1.1.8 T	  cell	  plasticity	  
There	   is	   increasing	   evidence	   that	   the	   T-­‐helper	   cell	   subsets	   display	   some	   plasticity	   in	  
their	  phenotypes.	  Many	  factors	  influence	  the	  cell	  fate	  to	  become	  a	  Th1	  or	  a	  Th2	  cells,	  
such	   as	   signal	   transducer	   and	   activator	   of	   transcription	   (STATs),	   antigen	   dose,	   co-­‐
stimulatory	  molecules,	  genetic	  modifiers	  and	  non-­‐cytokine	  agents.	  However	  how	  each	  
signalling	  molecule	  influences	  the	  process	  of	  differentiation	  remains	  controversial.	  
A	   genome-­‐wide	   analysis	   study	   compared	   patterns	   of	   epigenetic	   modifications	   in	   a	  
variety	  of	  CD4+	  T	  cells	  including	  naïve	  T	  cells,	  Th1,	  Th2,	  Th17	  and	  Tregs	  and	  found	  that	  
bivalent	   permissive	   and	   suppressive	   forms	   of	   histone	   modifications	   were	   found	   at	  
Tbx21	  in	  all	  non-­‐Th1	  cells.	  Tbx21	  is	  the	  gene	  locus	  for	  T-­‐bet	  and	  these	  results	  suggested	  
that	   all	   non-­‐Th1	  differentiated	   cells	   retained	   the	   capacity	   to	  express	   T-­‐bet,	   including	  
Th2	   cells.	   These	   observations	  were	   confirmed	   in	   Th17	   and	   nTregs,	  which	   have	   been	  
shown	  to	  express	  T-­‐bet	  and	  IFN-­‐γ	  when	  stimulated	  through	  their	  T	  cell	  receptor	  and	  in	  
the	  presence	  of	  IL-­‐12	  (Y.	  K.	  Lee	  et	  al.	  2009;	  Wei	  et	  al.	  2009).	  
More	  recently,	  Hegazy	  et	  al.	  showed	  that	  Th2	  cells	  were	  capable	  of	  upregulating	  T-­‐bet	  
and	  producing	  IFN-­‐γ	  following	  LCMV	  infection.	  This	  was	  shown	  only	  in	  Th2	  cells	  bearing	  
a	  TCR	  specific	   for	   the	  LCMV	  epitope	  GP61-­‐68	  and	  differentiated	   for	  2-­‐3	  weeks	   in	  vitro.	  
LCMV-­‐induced	   cytokines	   IL-­‐12,	   IFN-­‐γ	   and	   IFN-­‐α	   and	   IFN-­‐β	  were	   also	   essential	   to	   the	  
conversion	  of	  Th2	  to	  Th1	  cells.	   Interestingly,	  GATA-­‐3	  in	  these	  cells	  was	  only	  modestly	  
suppressed,	   creating	   GATA-­‐3+	   T-­‐bet+	   ‘Th2+1’	   cells,	   which	   still	   have	   the	   ability	   to	  
produce	  IL-­‐4	  (Hegazy	  et	  al.	  2010).	  
	  
Several	  studies	  on	  Tregs	  have	  reported	  that	  these	  cells	  are	  able	  to	  use	  CD4+	  effector	  
cell-­‐associated	   transcription	   factors	   in	   order	   to	   restore	   or	   maintain	   immune	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homeostasis	  during	  Th1,	  Th2	  or	  Th17	  immune	  responses	  (Campbell	  and	  Koch	  2011;	  L.	  
Li	   and	   Boussiotis	   2011).	   Indeed,	   in	   response	   to	   IFN-­‐γ,	   FoxP3+	   Tregs	   are	   able	   to	  
upregulate	   Th1-­‐specific	   transcription	   factor	   T-­‐bet.	   In	   turn,	   T-­‐bet	   then	   induces	   the	  
expression	  of	  CXCR3	  on	  Tregs,	  which	   leads	  to	  the	  mobilization	  of	  T-­‐bet+	  Treg	  cells	  at	  
sites	  of	  Th1	  inflammation.	  Similar	  findings	  have	  been	  found	  with	  IRF4,	  a	  transcription	  
factor	   for	   Th2	   cells,	   and	   mice	   in	   which	   Irf4	   has	   been	   deleted	   from	   FoxP3+	   Tregs	  
develop	   lymphoproliferative	   diseases	   associated	   with	   an	   increase	   in	   IL-­‐4	   and	   IL-­‐5-­‐	  
producing	  CD4+	  T	  cells	  (L.	  Li	  and	  Boussiotis	  2011;	  Zheng	  et	  al.	  2009).	  
Additional	   studies	   have	   also	   shown	   that	   Tregs	   can	   convert	   into	   a	   Th17	   phenotype	  
when	  induced	  by	  the	  appropriate	  inflammatory	  stimuli.	  It	  has	  been	  shown	  that	  under	  
certain	  conditions,	  FoxP3	  is	  able	  to	  physically	  bind	  to	  RORγt	  (which	  are	  both	  expressed	  
in	   Treg	   cells)	   and	   inhibit	   the	   transcriptional	   activity	   of	   RORγt,	   thereby	  blocking	   IL-­‐17	  
production.	  However	   it	  has	  recently	  been	  demonstrated	  that	  Tregs	  can	  be	  converted	  
into	   IL-­‐17+	   Tregs	   if	   in	   the	   presence	   of	   antigen-­‐presenting	   cells	   and	   CD4+	   T	   cells.	   In	  
humans,	   antigen-­‐presenting	   cells	   and	   the	   presence	   of	   IL-­‐2	   or	   IL-­‐15	   as	   well	   as	  
enhancement	  by	  IL-­‐1,	  IL-­‐23	  and	  IL-­‐21,	  have	  been	  shown	  to	  be	  the	  right	  conditions	  for	  
IL-­‐17+	  Tregs	  (L.	  Li	  and	  Boussiotis	  2011;	  Voo	  et	  al.	  2009).	  
These	   few	  studies	  represent	  only	  a	  handful	  of	   reports	  on	  the	  plasticity	  of	  T	  cells	  and	  
their	   ability	   to	   change	   their	   phenotype	   depending	   on	   their	   cytokine	  milieu	   and	   TCR	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1.2 Cysteinyl	  Leukotrienes	  
1.2.1 Biosynthesis	  of	  cysteinyl	  leukotrienes	  
Cysteinyl	  leukotrienes	  are	  potent	  lipid	  mediators	  synthesized	  from	  arachidonic	  acid	  in	  
response	  to	  different	  immune	  and	  inflammatory	  stimuli.	  They	  have	  recognised	  roles	  in	  
respiratory	  diseases	  such	  as	  asthma	  and	  allergic	  rhinitis,	  but	  have	  also	  been	  implicated	  
in	  other	  inflammatory	  conditions	  (Funk	  2001;	  Samuelsson	  and	  Hammarstrom	  1982).	  
Although	  cysteinyl	   leukotrienes	  cannot	  be	  stored,	  they	  can	  be	  generated	  very	  rapidly	  
at	  sites	  of	  inflammation	  using	  de	  novo	  synthesis	  (Luster	  and	  Tager	  2004).	  Upon	  cellular	  
activation,	  phospholipase	  A2	  (PLA2)	  translocates	  from	  the	  cellular	  cytosol	  to	  the	  nuclear	  
membrane	   and	   releases	   arachidonic	   acid	   (AA)	   from	   cell-­‐membrane	   phospholipids	  
(Clark	   et	   al.	   1990).	   AA	   is	   required	   for	   the	   biosynthesis	   of	   leukotrienes	   and	   is	   firstly	  
converted	   to	   5-­‐HPETE	   by	   5-­‐lipoxygenase	   (5-­‐LO)	   (see	   figure	   1.4).	   This	   78	   kDa	  
monomeric	   enzyme	   contains	   a	   non-­‐heme	   iron	   atom	   essential	   for	   enzyme	   activity	  
(Percival	   1991;	   Rouzer	   and	   Samuelsson	   1985).	   5-­‐HPETE	   can	   be	   further	   converted,	  
enzymatically	  or	  non-­‐enzymatically,	   to	  5-­‐HETE.	  Alternatively,	  5-­‐HPETE	   is	  converted	  to	  
the	  unstable	  intermediate	  LTA4	  by	  5-­‐LO	  and	  5-­‐LO	  activating	  protein	  (FLAP).	  FLAP	  is	  an	  
18kDa	  membrane-­‐associated	  protein	  that	  does	  not	  have	  any	  enzymatic	  activity	  but	  is	  
thought	  necessary	  for	  the	  interaction	  of	  5-­‐LO	  with	  arachidonic	  acid,	  by	  presenting	  free	  
AA	   to	   5-­‐LO	   (Abramovitz	   et	   al.	   1993;	   Mancini	   et	   al.	   1993).	   Leukotriene	   A4	   can	   be	  
enzymatically	   converted	   to	   LTB4	   by	   LTA4	   hydrolase,	   or	   LTC4	   by	   LTC4	   synthase.	   LTA4	  
hydrolase	   is	   essential	   and	   acts	   by	   hydrolysing	   the	   epoxide	   of	   LTA4	   (Radmark	   et	   al.	  
1984).	  LTC4	  synthase	  acts	  by	  conjugating	  a	  glutathione	  molecule	  to	  LTA4.	  Neutrophils	  
and	   monocytes	   possess	   LTA4	   hydrolase	   and	   therefore	   follow	   the	   LTB4	   synthesis	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pathway;	  other	  cell	  types	  such	  as	  mast	  cells	  and	  eosinophils	  express	  LTC4	  synthase	  and	  
conjugate	   LTA4	   with	   the	   tri-­‐peptide	   glutathione	   to	   form	   the	   first	   of	   the	   cysteinyl	  
leukotrienes	   LTC4.	   Both	   LTB4	   and	   LTC4	   are	   then	   exported	   from	   the	   cell	   to	   the	  
surrounding	   environment,	   where	   LTB4	   binds	   known	   receptors	   BLT1	   and	   BLT2.	   Once	  
transported	   outside	   of	   the	   cell,	   the	   gamma	   glutamyl	   residue	   of	   the	   glutathione	   side	  
chain	   of	   LTC4	   is	   cleaved	   by	   gamma	   glutamyl	   transpeptidase	   to	   form	   LTD4	  
(Hammarstrom	  et	  al.	  1985;	  Orning	  and	  Hammarstrom	  1980).	  And	  LTE4	  results	  from	  the	  
cleavage	  of	  the	  peptide	  bond	  between	  the	  cysteinyl	  and	  glycine	  residues	  of	  LTD4	  by	  a	  
di-­‐peptidase	  (C.	  W.	  Lee	  et	  al.	  1983;	  Lewis	  et	  al.	  1990).	  This	  process	  can	  be	  stopped	  by	  
L-­‐cysteine.	   In	   the	  body,	   LTC4	   is	   rapidly	  metabolized.	   The	   stable	   LTE4	   is	   catabolized	   in	  
the	   liver	   predominantly	   by	   N-­‐acetylation	   and	   excreted	   in	   the	   urine	   and	   bile.	   The	  
concentration	   of	   LTE4	   can	   be	   measured	   in	   urine	   using	   sensitive	   immunoassays	   and	  
reflects	  endogenous	  LTC4	  production	  (Sansom	  et	  al.	  1997).	  
As	   5-­‐LO	   is	   only	   found	   in	   myeloid	   cells	   such	   as	   neutrophils,	   eosinophils,	   basophils,	  
monocytes/macrophages	  and	  mast	  cells,	  other	  non-­‐myeloid	  cells	  that	  lack	  the	  required	  
enzyme	   rely	   on	   LTA4	   transferred	   from	   surrounding	   cells,	   in	   order	   to	   produce	  
leukotrienes.	   This	   process	   is	   called	   transcellular	   biosynthesis	   or	   transcellular	  
metabolism	   (Luster	   and	   Tager	   2004;	   Nicosia	   et	   al.	   2001),	   and	   enables	   the	   cysteinyl	  
leukotriene	  cascade	  to	  be	  initiated.	  Following	  release	  from	  inflammatory	  cells,	  LTA4	  is	  
taken	  up	  by	  nearby	  cells	  or	  platelets,	  which	  metabolize	  it	  into	  LTB4	  or	  LTC4	  (McGee	  and	  
Fitzpatrick	  1986).	  
Whereas	   LTB4	   is	   best	   known	   for	   its	   role	   in	   neutrophil	   chemotaxis	   and	   inflammation,	  
cysteinyl	   leukotrienes	  LTC4,	  LTD4	  and	  LTE4	  promote	  recruitment	  of	   inflammatory	  cells	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into	  tissues,	  such	  as	  eosinophils	  and	  neutrophils	  (Krauss	  et	  al.	  1994;	  Spada	  et	  al.	  1994),	  
and	  cause	  bronchoconstriction.	  However,	  both	  LTB4	  and	  cysteinyl	  leukotrienes	  amplify	  
inflammation	  mediated	  by	  Th2	  cells,	  particularly	  allergic	  responses	  (Peters-­‐Golden	  and	  
Henderson	  2007).	  
	   	  








Figure	   1.4	   Biosynthesis	   of	   cysteinyl	   leukotrienes.	   Arachidonic	   acid	   is	   released	  
from	   membrane	   phospholipids	   with	   the	   help	   of	   phospholipase	   A2	   and	   is	  
converted	   into	   5-­‐(S)-­‐hydroperoxyeicosatetraenoic	   acid	   (5-­‐HPETE)	   and	  
subsequently	  into	  LTA4	  by	  5-­‐LO.	  LTA4	  can	  be	  either	  hydrolyzed	  into	  LTB4	  by	  LTA4	  
hydrolase	   or	   converted	   into	   LTC4	   via	   conjugation	   with	   glutathione	   by	   LTC4	  
synthase.	  Removal	  of	  the	  glutamyl	  group	  of	  LTC4	  by	  γ-­‐glutamyl	  transferase	  forms	  
LTD4,	  which	  can	  be	  cleaved	   further	   into	  LTE4	  by	  a	  dipeptidase	  enzyme	  (adapted	  
from	  (Montuschi	  and	  Peters-­‐Golden	  2010)).	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1.2.2 The	  role	  of	  leukotrienes	  in	  asthma	  
Cysteinyl	   leukotrienes	   have	   long	   been	   implicated	   in	   inflammation	   and	   allergic	  
mechanisms,	   particularly	   asthma,	   for	   being	   active	   components	   of	   the	   ‘slow-­‐reacting	  
substance	  of	  anaphylaxis’	  (SRS-­‐A).	  The	  name	  SRS-­‐A	  was	  given	  to	  a	  substance	  that	  was	  
able	   to	   contract	   smooth	   muscle	   when	   antigen-­‐sensitized	   guinea	   pig	   lungs	   were	  
stimulated	   (Kellaway	  CH	  1940).	   The	  name	   is	   derived	   from	   the	  original	   name	   SRS	   (or	  
slow	  reaction	  smooth	  muscle-­‐stimulating	  substance)	  given	  by	  Feldberg	  and	  colleagues	  
(Feldberg	   1938)	   after	   observations	   of	   contraction	  of	   an	   isolated	   guinea	  pig	   ileum	  by	  
snake	  venom	  perfusion.	  
The	  evidence	   for	   the	   importance	  of	   leukotrienes	   in	  asthma	  stems	   from	   two	  aspects:	  
the	   pathophysiological	   responses	   induced	   by	   leukotrienes	   and	   the	   effectiveness	   of	  
anti-­‐leukotrienes	  agents.	  Leukotrienes	  induce	  constriction,	  increase	  mucus	  production	  
and	  vascular	  leakage	  and	  attract	  eosinophils	  to	  the	  airways	  (Lewis	  et	  al.	  1990).	  When	  
inhaled,	   LTC4	   and	   LTD4	   are	   1000	   times	   more	   potent	   bronchoconstrictors	   than	  
histamine	   (N.	   C.	   Barnes	   et	   al.	   1984).	   Leukotrienes	   have	   also	   been	   measured	   in	  
biological	   fluids	   of	   asthmatic	   patients.	   Reports	   have	   revealed	   the	   presence	   of	   high	  
concentrations	  of	   leukotrienes	   in	  sputum	  from	  asthmatic	   individuals,	  with	  high	   levels	  
correlating	  to	  the	  severity	  of	  asthma	  (Pavord	  et	  al.	  1999).	  Increased	  concentrations	  of	  
leukotrienes	   in	   bronchoalveolar	   lavage	   fluids	   of	   asthmatic	   patients	   have	   also	   been	  
reported,	  including	  those	  with	  nocturnal	  asthma,	  compared	  with	  normal	  subjects	  (S.	  E.	  
Wenzel	   et	   al.	   1995).	   Additionally	   higher	   levels	   of	   LTC4	   and	   LTD4	   have	   been	   found	   in	  
nasal	   secretions	   of	   patients	   with	   symptomatic	   rhinitis	   than	   in	   those	   of	   non-­‐allergic	  
patients	  (Knani	  et	  al.	  1992).	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The	  biological	  relevance	  of	  leukotrienes	  in	  asthma	  is	  further	  confirmed	  by	  the	  presence	  
of	   increased	   levels	   of	   LTE4	   in	   the	   urine	   of	   patients	   following	   allergen	   inhalation	  
(Manning	  et	  al.	  1990b),	  exercise	  challenge	  (Kikawa	  et	  al.	  1992),	  aspirin	  challenge	  (Israel	  
et	  al.	  1993a)	  and	  asthma	  exacerbations	  (Taylor	  et	  al.	  1989).	  Studies	  involving	  LTE4	  have	  
shown	   that	  patients	  with	  asthma	  were	  26	   times	  more	   sensitive	   to	  LTE4	   than	  healthy	  
individuals,	  compared	  with	  7	  times	  more	  sensitive	  to	  histamine.	  Additional	  studies	  of	  
asthmatics	   versus	  healthy	   individuals	   revealed	   that	  airway	  hyper-­‐responsiveness	  was	  
higher	   by	   14-­‐fold	   in	   asthmatic	   patients	   in	   response	   to	   histamine,	   16-­‐fold	   for	  
methacholine,	   6-­‐fold	   for	   LTC4,	   9-­‐fold	   for	   LTD4	   and	   219-­‐fold	   for	   LTE4,	   suggesting	   a	  
possible	   alternative	   bronchoconstriction	  mechanism	   for	   LTE4	   (Arm	   et	   al.	   1990).	   LTE4	  
was	   also	   the	   only	   cysteinyl	   leukotriene	   capable	   of	   enhancing	   airway	   hyper-­‐
responsiveness	   of	   agonist	   histamine.	   Also,	   a	   much	   higher	   dose	   of	   antagonist	   was	  
needed	   to	   inhibit	   LTE4-­‐induced	   increase	   of	   response	   to	   histamine,	   in	   comparison	   to	  
CysLT-­‐induced	   contractions	   (T.	   H.	   Lee	   et	   al.	   1984),	   suggesting	   the	   presence	   of	   other	  
receptors	  by	  which	  LTE4	  might	  operate.	  	  
Cysteinyl	   leukotrienes	   (CysLTs)	   play	   a	   particularly	   important	   role	   in	   exercise-­‐induced	  
asthma	   (EIA),	   a	   condition	   characterised	   by	   bronchoconstriction	   after	   a	   period	   of	  
exercise.	  Increased	  levels	  of	  CysLTs	  were	  found	  in	  induced	  sputum	  and	  exhaled	  breath	  
condensate	   in	   asthmatics	   with	   EIA.	   The	   CysLT1R	   antagonist	   montelukast	   has	   been	  
demonstrated	   to	   be	   efficacious	   in	   the	   prevention	   of	   EIA	   (Hallstrand	   and	   Henderson	  
2010).	  
Further	  supporting	  evidence	  for	  the	  role	  of	   leukotrienes	  in	  asthma	  is	  anti-­‐leukotriene	  
therapy,	   which	   improves	   the	   quality	   of	   life	   of	   asthma	   patients,	   such	   as	   improved	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pulmonary	   function,	   decreased	   daytime/nocturnal	   symptoms,	   and	   reduced	   need	   for	  
short-­‐acting	  β2-­‐agonists	  (Britton	  1992;	  Pearlman	  et	  al.	  1992).	  CysLT1R	  antagonists	  also	  
improve	   lung	   function,	   reduce	   the	   rate	   of	   exacerbation,	   and	   airway	   and	   blood	  
eosinophilia	   (Montuschi	   and	   Peters-­‐Golden	   2010).	   	   Commercially	   available	   anti-­‐
leukotriene	  drugs	  include	  Zileuton,	  which	  inhibits	  5-­‐lipoxygenase,	  and	  which	  has	  been	  
approved	  for	  the	  prevention	  and	  chronic	  treatment	  of	  asthma	  in	  adults	  and	  children	  of	  
12	  years	  of	  age	  and	  older	  in	  the	  UK	  and	  USA.	  Others	  include	  Montelukast,	  Zafirlukast,	  
Pranlukast	   and	   Pobilukast	   and	   block	   the	   CysLT1	   receptor	   (Brink	   et	   al.	   2003).	   In	  
randomized,	   double-­‐blind,	   clinical	   trials,	   these	   drugs	   are	   consistently	   superior	   to	  
placebo	   in	   attenuating	   airway	   responses	   in	   many	   clinical	   models	   of	   asthma.	   For	  
example,	   MK571	   (Manning	   et	   al.	   1990b)	   inhibited	   exercise-­‐induced	  
bronchoconstriction	   by	   50-­‐70%.	   Zileuton	   attenuated	   cold-­‐air	   induced	   (Israel	   et	   al.	  
1990)	  and	  aspirin-­‐induced	  (Israel	  et	  al.	  1993b;	  Israel	  et	  al.	  1993a)	  bronchoconstriction.	  
CysLT1R	   antagonists	   provide	   an	   improvement	   in	   asthma	   control,	   although	   low-­‐dose	  
inhaled	   corticosteroids	   remain	   generally	   more	   effective	   in	   patients	   with	   persistent	  
asthma	   who	   remain	   symptomatic	   using	   short-­‐acting	   β2-­‐agonists	   alone	   (Busse	   et	   al.	  
2001).	  In	  asthmatic	  patients	  who	  are	  not	  sufficiently	  controlled	  with	  a	  dose	  of	  inhaled	  
budesonide	   alone,	   add-­‐on	   therapy	   with	   Montelukast	   improves	   asthma	   control	   to	   a	  
level	   that	   is	   comparable	   to	   the	   one	   achieved	   if	   the	   budesonide	   dose	   was	   doubled	  
(Price	  et	  al.	  2003;	  Vaquerizo	  et	  al.	  2003).	  	  The	  role	  of	  cysteinyl	  leukotrienes	  in	  allergen-­‐
induced	   bronchoconstriction	   is	   clearly	   demonstrated	   by	   the	   ability	   of	   the	   receptor	  
antagonists	  to	  attenuate	  allergen-­‐induced	  early	  and	  late	  asthma	  responses	  (Hamilton	  
et	  al.	  1998;	  O'Byrne	  1998).	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1.3 Leukotriene	  receptors	  
1.3.1 G	  protein-­‐coupled	  receptors	  
G	  protein-­‐coupled	  receptors	  (GPCRs)	  form	  the	  largest	  and	  most	  diverse	  superfamily	  of	  
cell	   surface	   receptors	   and	   proteins	   in	   the	  mammalian	   genome	   (Kroeze	   et	   al.	   2003),	  
characterised	  by	  an	  extracellular	  N	  terminus,	  an	   intracellular	  C	   terminus	  and	  a	  seven	  
trans-­‐membrane	   domain.	   They	   are	   also	   referred	   to	   as	   7TM	   receptors.	   They	   can	   be	  
grouped	   into	   6	   different	   classes	   based	   on	   sequence	   homology	   and	   functions:	  
Rhodopsin,	   Secretin,	   Adhesion,	   Glutamate	   and	   frizzled	   receptor	   families.	   There	   are	  
several	  hundred	  different	  GPCRs	  in	  the	  human	  genome,	  most	  of	  which	  belong	  to	  the	  
rhodopsin	   family.	  The	  primary	   function	  of	  GPCRs	   is	   to	   transduce	  extracellular	   stimuli	  
into	   intracellular	   signals,	  which	   is	   achieved	  via	   interactions	  between	   the	   intracellular	  
domains	   of	   the	   receptor	   and	   a	   heterotrimeric	   G	   protein	   (see	   Figure	   1.5).	   Receptors	  
that	  couple	  to	  G	  proteins	  communicate	  signals	  from	  a	  large	  number	  of	  external	  stimuli,	  
which	   include	   light,	   hormones,	   neurotransmitters,	   odorants,	   biogenic	   amines,	   lipids,	  
proteins,	  amino	  acids,	  chemokines,	  and	  many	  others	  (Marinissen	  and	  Gutkind	  2001).	  
Upon	  ligand	  binding,	  the	  receptor	  associates	  with	  the	  heterotrimeric	  G	  protein,	  which	  
becomes	   activated	   by	   the	   exchange	   of	  GDP	   for	  GTP.	   The	  G	   protein	   then	   dissociates	  
into	  its	  α	  and	  βγ	  subunits.	  The	  βγ	  subunit	  gives	  rise	  to	  the	  activation	  of	  phospholipase	  
C,	   leading	   to	   the	   classical	   leukocyte	   activation	   pathway	   and	   cleaving	  
phosphatidylinositol	   (4,5)-­‐bisphosphate	   (PIP2)	   into	   inositol	   triphosphate	   (IP3)	   and	  
diacylglycerol	   (DAG).	   DAG	   activates	   protein	   kinase	   C	   (PKC),	   while	   IP3	   triggers	   the	  
release	   of	   calcium	   from	   intracellular	   stores.	   Signalling	   cascades	   involve	   mitogen-­‐
activated	   protein	   kinase	   (MAPK),	   which	   generates	   responses	   such	   as	   degranulation	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and/or	   chemotaxis.	  When	   signalling	   is	   over,	   the	   α	   subunit	   re-­‐associates	  with	   the	   βγ	  
subunits	  and	  terminates	  the	  signalling	  process.	  Depending	  on	  the	  type	  of	  G	  protein	  to	  
which	   the	   receptor	   is	   coupled,	   different	   downstream	   signalling	   pathways	   can	   be	  
activated	  (Kroeze	  et	  al.	  2003;	  Marinissen	  and	  Gutkind	  2001;	  Neves	  et	  al.	  2002),	  which	  
can	  lead	  to	  the	  regulation	  of	  cellular	  components,	  and	  further	  effects	  on	  homeostasis,	  
behaviour,	  function	  and	  development.	  There	  are,	  however,	  several	  known	  Gα,	  Gβ	  and	  
Gγ	  subunits,	  which	  all	  have	  different	  functions	  (Neves	  et	  al.	  2002).	  
GPCRs	   have	   the	   ability	   to	   control,	   downregulate	   or	   terminate	   their	   activity,	   and	  
therefore	   attenuate	   downstream	   signalling	   pathways	   by	   processes	   of	   receptor	  
phosphorylation,	   desensitization	   and	   internalization.	   Desensitization	   involves	   the	  
uncoupling	   of	   the	   receptor	   from	   the	   G	   protein	   by	   the	   binding	   of	   arrestins	   to	  
phosphorylated	   receptors	   (Ferguson	   2001),	   but	   this	   can	   also	   occur	   via	   arrestin-­‐
independent	  pathways	  (Gray	  et	  al.	  2003).	  
	   	  





	   	  
Figure	  1.5	  Diversity	  of	  GPCR	  signalling.	  This	  shows	  the	  different	  signalling	  pathways	  
and	  effects	  of	  G	  protein-­‐coupled	  receptors	  on	  downstream	  functions	  (Marinissen	  and	  
Gutkind	  2001). 
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1.3.2 Cysteinyl	  leukotriene	  receptors	  
Leukotrienes	  act	  through	  G	  protein-­‐coupled	  seven	  transmembrane	  receptors	  (GPCRs).	  
The	   four	  known	   leukotriene	  receptors	   (LT-­‐Rs)	  belong	   to	   two	  main	  classes:	  BLT-­‐Rs	   (or	  
LTB4	   receptors),	   which	   bind	   LTB4	   and	   other	   eicosanoids,	   and	   CysLTRs	   (cysteinyl	  
leukotriene	  receptors),	  which	  bind	  LTC4,	  LTD4	  and	  LTE4.	  
As	  described	  earlier,	  it	  is	  thought	  that	  LTD4	  activation	  of	  the	  CysLT1R	  leads	  to	  G	  protein	  
activation	  and	  the	  release	  of	  several	  second	  intracellular	  messengers	  such	  as	  DAG,	  IP	  
and	   Ca2+.	   This	   is	   generally	   followed	   by	   the	   activation	   of	   PKC	   and	   accompanied	   by	  
calcium	  mobilization	  derived	  from	  both	  intracellular	  and	  extracellular	  calcium	  stores.	  	  
Although	   stemming	   from	   similar	   molecules,	   LTB4	   and	   cysteinyl	   leukotrienes	   bind	   to	  
different	  receptors.	  LTB4	  binds	  known	  receptors	  BLT1	  and	  BLT2	  (Yokomizo	  et	  al.	  1997;	  
Yokomizo	   et	   al.	   2000b;	   Yokomizo	   et	   al.	   2000a).	   On	   the	   other	   hand,	   cysteinyl	  
leukotrienes	  bind	  to	  the	  two	  known	  receptors	  CysLT1R	  and	  CysLT2R,	  which	  share	  only	  
38%	  homology.	  Both	  receptors	  are	  seven-­‐transmembrane	  G	  protein-­‐coupled	  receptors	  
and	   belong	   to	   the	   rhodopsin/β2	   agonist	   family,	   specifically	   to	   the	   purine	   receptor	  
cluster	  of	  phylogenetically	  related	  receptors	  (see	  figure	  1.5).	  This	  cluster	  also	  includes	  
the	  receptors	  for	  the	  purinergic	  or	  pyrimidinergic	  nucleotides	  (P2Ys),	  proteases	  (PARs)	  
and	   PAF	   (PAFR),	   in	   addition	   to	   several	   orphan	   receptors	   (Fredriksson	   et	   al.	   2003;	  











	   	  
 
Figure	   1.6	   Phylogenetic	   tree	   of	   G	   protein	   coupled	   receptors	   and	   orphan	  
receptors.	  Taken	  from	  (Shimizu	  2009).	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Both	   receptors	   have	   slightly	   different	   binding	   affinities	   to	   the	   cysteinyl	   leukotrienes	  
(see	   Table	   1.1).	   CysLT1R	  binds	   LTD4>LTC4>>LTE4,	  while	   CysLT2R	  binds	   LTC4=LTD4>LTE4	  
(Evans	   2002).	   The	   two	   receptors	   also	   differ	   in	   their	   role:	   CysLT1R	   has	   a	   more	  
predominant	   role	   in	  bronchoconstriction	   than	  CysLT2R,	  with	  CysLT2	  being	   involved	   in	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Table	  1.1	  Comparison	  between	  CysLT1	  and	  CysLT2	  receptors.	  Adapted	  from	  Rovati	  
and	  Capra,	  2007	  (Rovati	  and	  Capra	  2007).	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1.3.3 Cysteinyl	  leukotriene	  receptor	  1	  
1.3.3.1 Cloning	  of	  CYSLTR1	  
The	   human	   cysteinyl	   leukotriene	   receptor	   1	   or	   hCysLT1R	   was	   first	   cloned	   and	  
characterised	  in	  1999	  by	  two	  independent	  groups	  (Lynch	  et	  al.	  1999;	  Sarau	  et	  al.	  1999).	  
As	  part	  of	  a	  programme	  to	  identify	  ligands	  for	  orphan	  GPCRs,	  Lynch	  et	  al	  identified	  an	  
expressed	   sequence	   tag	   entry,	   re-­‐named	   HG55	   at	   the	   time,	   and	   now	   known	   as	  
CysLTR1,	  that	  had	  32%	  amino	  acid	  homology	  to	  the	  purinoreceptor	  P2Y1	  and	  PAF	  and	  
28%	  homology	   to	   the	   LTB4	   receptor	   (BLT)	  which	  had	  been	   cloned	   the	  previous	   year	  
(Lynch	  et	  al.	  1999).	  HG55,	  or	  the	  human	  CysLTR1,	  was	  identified	  as	  a	  337	  amino	  acid	  
putative	   seven	   trans-­‐membrane	   domain	   receptor	   with	   a	   calculated	   molecular	   mass	  
varying	  between	  38kDa	  and	  42kDa	  as	  a	  monomeric	  form,	  but	  usually	  found	  in	  dimeric	  
or	   oligomeric	   forms.	   The	  human	  CysLT1	   receptor	  was	   located	   to	   the	   X	   chromosome	  
Xq13-­‐Xq21	  and	   is	   composed	  of	  at	   least	  3	  exons	   (Evans	  2002).	   It	  has	  31%	  amino	  acid	  
identity	  to	  the	  P2Y	  purinoceptor	  (Sarau	  et	  al.	  1999).	  
Using	   two	   different	   Xenopus	   laevis	   functional	   systems,	   Lynch	   et	   al	   characterised	  
CysLT1R	  (or	  HG55)	  activation.	  They	  found	  that	  LTD4	  induced	  a	  robust	  dose-­‐dependent	  
calcium	  response	   in	  oocytes	   injected	  with	  CysLTR1	  cRNA,	  and	  that	   this	   response	  was	  
attenuated	  with	  continuous	  administration	  of	  agonist.	  Oocytes	  injected	  with	  saline	  or	  
another	  orphan	  GPCR	  cRNA	  did	  not	  respond	  to	  LTD4.	  When	  pre-­‐treated	  with	  pertussis	  
toxin	   the	   result	   showed	   a	   slight	   inhibition	   and	   a	  much	   lower	   response,	   suggesting	   a	  
partial	   signalling	   via	   the	   Gαi	   pathway	   in	   oocytes.	   When	   treated	   with	   the	   known	  
CysLTR1	  selective	  antagonist	  MK-­‐571,	  the	  calcium	  responses	  to	  LTD4	  were	  inhibited	  in	  
oocytes	   in	  a	  dose-­‐dependent	  manner.	   Similar	   results	  were	  achieved	  when	   the	  group	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added	  LTC4,	  LTD4,	  and	  LTE4	  to	  Xenopus	  laevis	  melanophores	  transfected	  with	  CysLTR1	  
cDNA	   and	   found	   that	   all	   three	   cysteinyl	   leukotrienes	   caused	   activation	   of	   pigment	  
dispersion,	   in	   a	   dose-­‐dependent	  manner.	   In	   this	   system,	   LTD4	   was	   the	  most	   potent	  
agonist,	   while	   LTC4	   was	   slightly	   weaker	   and	   LTE4	   very	   weak.	   When	   transfected	  
melanophores	  were	  pre-­‐treated	  with	   antagonist	  MK-­‐571,	   the	   response	  was	  blocked.	  
Similar	   results	  were	   found	   in	  mammalian	  monkey	   kidney	   COS-­‐7	   cells	   expressing	   the	  
human	  CYSLTR1	  (Lynch	  et	  al.	  1999).	  Using	  aequorin	  luminescence	  and	  calcium	  green	  –	  
1	  fluorescence,	  the	  group	  measured	  the	  intracellular	  calcium	  mobilization	  in	  response	  
to	  LTD4	  in	  COS-­‐7	  monkey	  kidney	  cells	  transiently	  expressing	  CYSLTR1.	  They	  found	  that	  
all	  three	  LTs	  caused	  a	  calcium	  response	  in	  the	  COS-­‐7	  cells,	   in	  contrast	  to	  control	  cells	  
which	  did	  not	  respond.	  Again	  they	  found	  that	  there	  was	  a	  rank	  order	  of	  potency	  with	  
LTD4	  being	  most	  potent	  (LTD4>LTC4>LTE4).	  As	  in	  previous	  experiments,	  MK571	  blocked	  
the	  response.	  Saturation	  analysis	  studies	  of	   [3H]LTD4	  binding	  to	  membranes	  revealed	  
an	  order	  of	  affinity	  of	  LTD4	  ≥	  LTE4	  =	  LTC4	  ≥	  LTB4.	  CysLT1	  receptor	  antagonists	  MK571,	  
montelukast	   (Singulair),	   zafirlukast	   (Accolate)	   and	  pranlukast	   (Onon)	   all	   showed	  high	  
affinity	   for	   the	   CysLT1	   receptor.	   Northern	   blot	   analysis	   studies	   of	   CYSLT1R	  mRNA	   in	  
various	  human	   tissues	   indicated	   the	  highest	   expression	   in	   the	   spleen	   and	  peripheral	  
blood	   leukocytes,	  and	  a	   lower	  expression	   in	  various	   tissues	   including	   the	   lung.	  Given	  
the	   important	   role	   of	   CysLT1R	   in	   asthma,	   the	   group	   decided	   to	   investigate	   CYSLT1R	  
mRNA	   distribution	   in	   the	   lung	   using	   in	   situ	   hybridization,	   using	   an	   oligonucleotide	  
probe,	   and	   found	   it	   to	   be	   present	   in	   peribronchial	   smooth	   muscle	   cells,	   including	  
segmental	   bronchi	   and	   bronchioles,	   in	   smooth	   muscle	   bundles	   and	   in	   lung	  
macrophages	  (Lynch	  et	  al.	  1999).	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At	   the	   same	   time,	   Sarau	   et	   al.	   also	   investigated	   the	   molecular	   cloning,	   expression,	  
localization,	  and	  pharmacological	  characterization	  of	  the	  CysLT1	  receptor	  (Sarau	  et	  al.	  
1999).	  Using	  public	   and	  private	  ESTs	   (Expression	   Sequence	  Tags)	   converted	   into	   full-­‐
length	  cDNAs	  and	  transiently	  or	  stably	  expressed	  in	  human	  embryonic	  kidney	  (HEK293)	  
cells,	   and	   using	   the	   FLIPR	   (Fluorescence	   Imaging	   Plate	   Reader)	   method,	   the	   group	  
identified	  a	  transiently	  transfected	  receptor	  cell	  line	  that	  responded	  specifically	  to	  LTC4	  
and	  LTD4.	  The	  FLIPR	  Assay	  method	  uses	  a	  calcium	  sensitive	  dye	  that	   is	  taken	  into	  the	  
cytoplasm	   of	   the	   cell	   during	   incubation.	  	   The	   particular	  masking	   technology	   remains	  
outside	   the	   cell	   and	   blocks	   background	   fluorescence.	   Upon	   ligand	   binding	   to	   the	  
receptor,	   calcium	   is	   released	   into	   the	   cytoplasm	   of	   the	   cell.	  	   The	   dye	   binds	   to	   the	  
intracellular	   calcium	   and	   becomes	   fluorescent.	   Sequence	   analysis	   revealed	   the	   full	  
length	  of	  this	  cDNA	  sequence	  was	  1579	  bp	  and	  encoded	  a	  protein	  of	  337	  amino	  acids,	  
which	   they	   identified	   as	   CysLT1R.	   The	   group	   found	   that	   in	  mammalian	   HEK293	   cells	  
transfected	   with	   CysLT1R,	   the	   human	   CysLTR1	   responded	   selectively	   to	   cysteinyl	  
leukotrienes	  LTD4>LTC4>LTE4	  in	  that	  rank	  order	  of	  potency,	  and	  with	  EC50	  values	  of	  2.5	  
nM,	   24	   nM	   and	   240	   nM,	   respectively.	   Of	   900	   ligands	   tested,	   the	   group	   found	   that,	  
aside	  from	  cysteinyl	  leukotrienes,	  none	  elicited	  a	  specific	  calcium	  response	  in	  HEK293-­‐
CysLT1R	  transfectants.	  They	  tested	  the	  LTD4	  response	  in	  COS-­‐7-­‐	  and	  CHO-­‐	  transfected	  
cells	  and	  found	  a	  strong	  calcium	  response	  similar	  to	  Lynch	  et	  al.	  All	  calcium	  responses	  
were	  inhibited	  calcium	  mobilization	  induced	  by	  LTD4	  in	  those	  cells	  was	  inhibited	  by	  the	  
structurally	   distinct	   CysLT1	   receptor	   antagonists	   pranlukast,	   zafirlukast,	   montelukast	  
and	   pobilukast.	   The	   rank	   order	   of	   potency	   for	   these	   antagonists	   was	  
pranklukast=zafirlukast>montelukast>pobilukast	  (Sarau	  et	  al.	  1999).	  Interestingly,	  pre-­‐
treatment	   with	   pertussis	   toxin	   did	   not	   affect	   the	   calcium	   response	   and	   the	   calcium	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response	  was	  still	  observed	  after	  removal	  of	  extracellular	  calcium.	  Radio-­‐ligand	  binding	  
studies	  confirmed	  the	  affinity	  results	  observed	  by	  Lynch	  et	  al.	  Similarly,	  northern	  blot	  
analysis	  studies	  of	  human	  tissues	  revealed	  localization	  and	  a	  high	  expression	  of	  human	  
CYSLTR1	  mRNA	  in	  the	  spleen	  and	  peripheral	  blood	  leukocytes,	  less	  so	  in	  the	  lung,	  small	  
intestine,	  pancreas	  and	  placenta,	  with	  little	  or	  no	  expression	  in	  the	  liver,	  colon,	  kidney,	  
skeletal	  muscle,	  thymus,	  ovary,	  testis,	  heart	  and	  brain	  (Lynch	  et	  al.	  1999).	  	  
Human	   CYSLTR1	   has	   been	   reported	   to	   be	   expressed	   by	   a	   variety	   of	   airway	  mucosal	  
inflammatory	   cells	   involved	   in	   asthma,	   including	   bronchial	   mucosal	   eosinophils,	  
neutrophils,	  mast	   cells,	  macrophages,	   B	   lymphocytes	   and	   plasma	   cells.	   Interestingly,	  
CYSLTR1	  expression	  has	  not	  been	  reported	  in	  T	  lymphocytes	  (Figueroa	  et	  al.	  2001).	  
Two	  isoforms	  of	  the	  mouse	  CysLT1	  receptor	  have	  been	  cloned	  (Maekawa	  et	  al.	  2001;	  V.	  
Martin	  et	  al.	  2001;	  Mollerup	  et	  al.	  2001):	  a	  short	  and	  a	  long	  isoform.	  The	  short	  isoform	  
cDNA	   contains	   2	   exons	   and	   encodes	   a	   polypeptide	   of	   339	   amino	   acids	   with	   87.3%	  
amino	  acid	  identity	  to	  the	  human	  CysLT1R.	  The	  long	  isoform	  has	  2	  additional	  exons	  and	  
an	  in-­‐frame	  upstream	  start	  codon,	  which	  results	  in	  a	  13-­‐amino	  acid	  extension	  at	  the	  N-­‐
terminus	  (Lynch	  et	  al.	  1999;	  Maekawa	  et	  al.	  2001;	  Sarau	  et	  al.	  1999).	  The	  long	  isoform	  
resembles	  the	  human	  receptor	  the	  most	  and	  is	  found	  more	  abundantly	  in	  the	  mouse	  
tissues.	  The	  mouse	  Cysltr1	  is	  found	  on	  chromosome	  X	  at	  band	  XD.	  Like	  in	  the	  human	  
system,	  LTD4-­‐induced	  calcium	  mobilisation	  was	  also	  blocked	  by	  MK571.	  The	  receptor	  
binding	  affinities	  to	  cysteinyl	  leukotrienes	  were	  similar	  (Lynch	  et	  al.	  1999;	  Maekawa	  et	  
al.	  2001;	  Sarau	  et	  al.	  1999).	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1.3.3.2 Cellular	  and	  tissue	  distribution	  
The	  expression	  of	  CYSLTR1	  has	  been	  extensively	  studied	  since	  the	  first	  cloning	  reports	  
in	   1999.	   Figueroa	  et	   al.	   have	   examined	   the	   expression	  of	   CYSLTR1	   in	   normal	   human	  
lung	   tissue	   and	   peripheral	   blood	   leukocytes.	   Using	   immunohistochemistry,	   they	  
investigated	  the	  distribution	  of	  the	  receptor	  protein	  in	  smooth	  muscle	  cells	  of	  normal	  
human	   lung	   and	   in	   macrophages,	   as	   well	   as	   peripheral	   blood	   leukocytes.	   Using	   a	  
specific	   oligonucleotide	   probe	   (antisense),	   the	   group	   identified	   CYSLTR1	   mRNA	   and	  
protein	   expression	   in	   smooth	  muscle	   fibres.	  While	   the	   antisense	   probe	   had	   already	  
previously	   been	   used	   to	   recognise	   CYSLTR1	   mRNA	   in	   human	   lung	   muscle	   cells	   and	  
macrophages	   (Lynch	  et	  al.	  1999),	   this	  was	   the	   first	   report	  using	  antisera	  designed	   to	  
recognise	  CysLTR1.	  The	  antisera	  were	  raised	   in	  goat	  and	  recognised	  purified	  CysLTR1	  
specifically	  on	  immunoblot	  analysis.	  However	  they	  were	  unable	  to	  detect	  any	  receptor	  
in	   immunoblot	   analyses	   of	   lung	   tissue	   or	   COS	   cells	   transfected	   with	   CysLTR1	  
membrane	   fractions,	  which	   they	  suggested	  was	  due	   to	   the	   receptor	   levels	  being	   too	  
low	   to	   detect.	   They	   suggested	   that	   much	   larger	   amounts	   of	   dimerized	   and	  
oligomerized	   CysLT1	   receptors	   were	   observed	   than	   the	   monomeric	   recombinant	  
CysLTR1	  of	  molecular	  weight	  42kD,	  however	   the	  blots	  were	  not	  very	   clear.	  However	  
using	   immunohistochemistry	   on	   COS	   cells	   transfected	   with	   CysLT1R,	   they	   found	  
positive	  staining	  for	  CysLTR1	  using	  the	  antiserum,	  in	  contrast	  to	  COS	  cells	  alone.	  Using	  
the	  specific	  antiserum,	  the	  group	  found	  CysLTR1	  protein	  expression	  in	  airway	  smooth	  
muscle	  cells.	  Further	  experiments	  using	  PBMCs	  from	  which	  T	  cells	  had	  been	  removed	  
revealed	   similar	   CYSLTR1	   mRNA	   and	   protein	   expression	   in	   20%	   of	   the	   total	   cell	  
population,	  and	  positive	  cells	  were	  also	  found	  to	  express	  CD14	  monocytic	  and	  CD19	  B-­‐
lymphocytic	   cells	   markers.	   CYSLTR1	   expression	   was	   also	   observed	   in	   CD34+	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granulocytic	  precursor	  cells,	  cells	  expressing	  the	  IL-­‐5β	  receptor,	  eosinophils	  from	  non-­‐
asthmatic	   individuals	   and	   in	   human	   lung	   interstitial	  macrophages.	   	   Interestingly,	   the	  
data	   showed	   no	   evidence	   of	   the	   CYSLTR1	  mRNA	   or	   protein	   expression	   in	   purified	   T	  
cells	   isolated	   from	   PBMCs	   from	   non-­‐asthmatic	   subjects.	   Neither	   CYSLTR1	   mRNA	   or	  
protein	  expression	  was	  observed	  in	  either	  CD4+	  or	  CD8+	  helper	  T	  cells	  (Figueroa	  et	  al.	  
2001).	  
Zhu	  et	  al.	  used	  in	  situ	  hybridization	  and	  immunohistochemistry	  in	  order	  to	  identify	  and	  
quantify	   inflammatory	  cells	  expressing	  CYSLTR1	  mRNA	  and	  protein	  on	  endobronchial	  
biopsy	   tissue	   (J.	   Zhu	  et	  al.	  2005).	  The	   studies	   to	   identify	  CYSLTR1	  mRNA	  and	  protein	  
expression	  involved	  using	  3	  subjects	  groups:	  non-­‐smoking	  control	  subjects	  with	  normal	  
lung	  function,	  stable	  asthmatics	  (non-­‐smoking	  with	  mild	  persistent	  asthma)	  and	  severe	  
asthmatics.	  The	  group	  used	  IHC	  and	  observed	  positive	  staining	  for	  CysLTR1	  protein	  in	  
CysLTR1	   cDNA-­‐	   transfected	   COS	   cells,	   using	   a	   selective,	   affinity	   purified,	   anti-­‐human	  
polyclonal	   antisera	   for	   CysLT1	   receptor.	   The	   group	   then	   used	   double	  
immunohistochemistry	   to	   identify	   the	   specific	   immunophenotypes	   of	   the	   cells	   in	  
biopsy	  samples.	  They	  identified	  CYSLTR1	  mRNA	  and	  protein	  in	  inflammatory	  cells	  from	  
the	  subepithelium,	  which	  were	  more	  abundant	  in	  stable	  and	  severe	  asthmatics	  than	  in	  
control	   subjects.	   Some	  of	   the	  cells	   that	   stained	  positive	  were	  also	   found	   to	   infiltrate	  
the	   surface	   epithelium.	   CYSLTR1	   mRNA	   and	   protein	   were	   found	   in	   vascular	  
endothelium	  from	  all	   subjects.	  Using	  double	   immunostaining	   they	   identified	  CysLT1R	  
receptor	  protein	  co-­‐expression	   in	  bronchial	   inflammatory	  cells,	   including	  eosinophils,	  
neutrophils,	   mast	   cells,	   macrophages,	   B-­‐lymphocytes,	   plasma	   cells	   and	   monocytes.	  
Furthermore,	   expression	   was	   higher	   in	   asthmatics	   subjects,	   with	   significantly	   higher	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numbers	   in	   severe	   asthmatics.	   Interestingly,	   they	   found	  no	   expression	   of	   the	   CysLT1	  
receptor	  in	  bronchial	  CD3+	  T	  cells,	  CD4+	  T	  cells	  and	  CD8+	  T	  cells.	  Strong	  variability	  was	  
seen	  across	  all	  subject	  groups	  for	  CYSLTR1	  mRNA	  and	  protein	  in	  airway	  smooth	  muscle	  
myocytes.	   Quantification	   analyses	   revealed	   a	   strong	   positive	   correlation	   between	  
numbers	  of	  CD45+	   leukocytes	  and	   the	  number	  of	  cells	  expressing	  CysLT1	   receptor	   (J.	  
Zhu	  et	  al.	  2005).	  
Further	   studies	   on	   human	   peripheral	   blood	   cells	   have	   demonstrated	   expression	   of	  
CysLT1R	  on	  various	  cell	  types.	  
Thivierge	  et	   al.	   showed	   that	   CYSLTR1	  mRNA	  was	   constitutively	   expressed	   by	   human	  
monocytes	  and	  treatment	  with	  IL-­‐13	  augmented	  the	  CYSLTR1	  mRNA	  levels	  by	  3-­‐	  to	  5-­‐
fold.	   This	   increase	   was	   time-­‐dependent	   and	   observed	   as	   early	   as	   4	   hours	   post	  
stimulation,	  with	   a	  maximal	   response	   at	   8	   hours.	   This	   effect	  was	  maintained	   for	   24	  
hours.	  The	  group	  also	  showed	  that	   they	  obtained	  similar	   results	  by	   treating	   the	  cells	  
with	  IL-­‐4,	  but	  not	  IFN-­‐y.	  In	  both	  cases,	  protein	  levels	  were	  also	  increased	  (Thivierge	  et	  
al.	  2001).	  
Studies	  on	  human	  platelets	  have	  also	  revealed	  expression	  of	  CYSLTR1.	  CYSLTR1	  mRNA	  
was	   identified	   in	   human	   platelets	   from	   healthy	   individuals.	   Using	   an	   anti-­‐CysLT1R	  
antibody,	  CysLT1R	  expression	  was	   found	  by	   flow	  cytometry	  on	   the	   surface	  of	  human	  
platelets	   and	   positive	   control	   cells.	   Protein	   expression	   was	   also	   detected	   in	   human	  
platelets	  by	  western	  blotting	  (Hasegawa	  et	  al.	  2010).	  
CYSLTR1	   mRNA	   was	   also	   identified	   in	   chronic	   lymphocytic	   leukemia	   (CLL)	   cell	   lines	  
MEC-­‐1	   and	   EHEB,	   and	   in	   CD19+	  B	   cells	   from	  CLL	   patients.	   Additional	   calcium	   studies	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showed	  that	  LTD4	  induced	  calcium	  flux	  in	  both	  MEC-­‐1	  and	  EHED	  cells	  lines	  and	  this	  was	  
measured	   using	   fluorescent	   Ca2+	   indicator	   fluo-­‐3	   AM	   and	   flow	   cytometry.	   Calcium	  
mobilisation	  occurred	   via	  G	  protein	  Gαi,	   as	   indicated	  by	  experiments	  using	  pertussis	  
toxin.	   All	   calcium	   flux	   was	   inhibited	   when	   using	   CysLT1R	   antagonists	   MK571	   and	  
LY171883	  (Drost	  et	  al.	  2012).	  	  
Woszczek	  et	  al.	  investigated	  steady-­‐state	  levels	  of	  mRNA	  for	  2	  known	  CysLT	  receptors	  
in	  human	  monocytes	  and	   found	  that	  CYSLTR1	  mRNA	  was	   the	  most	  highly	  expressed,	  
followed	  by	  16-­‐fold	  lower	  levels	  of	  CYSLTR2	  mRNA.	  Interestingly	  they	  could	  not	  detect	  
GPR17	   mRNA	   (Woszczek	   et	   al.	   2008b).	   The	   group	   also	   stimulated	   monocytes	   with	  
different	  concentrations	  of	  LTC4,	  LTD4	  and	  LTE4	  to	  find	  that	  all	  three	  of	  them	  induced	  
intracellular	  calcium	  mobilization,	  with	  LTD4	  showing	  the	  highest	  potency,	  followed	  by	  
LTC4	  and	  LTE4.	  Pre-­‐treatment	  of	  human	  monocytes	  with	  MK571	  inhibited	  the	  calcium	  
response,	   as	   did	   pre-­‐treatment	   with	   pertussis	   toxin,	   2APB,	   and	   U73122,	   suggesting	  
that	   calcium	   flux	   was	   induced	   by	   CysLT1	   receptor	   coupled	   to	   Gαi,	   followed	   by	  
activation	  of	  phospholipase	  C	  and	   IP3	  signaling.	  Pre-­‐incubation	  with	   the	  extracellular	  
calcium-­‐chelating	   agent	   EGTA	   and	   with	   the	   intracellular	   calcium-­‐chelating	   agent	  
BAPTA/AM	   inhibited	   calcium	   mobilization,	   suggesting	   both	   intracellular	   and	  
extracellular	   calcium	   are	   required.	   Pre-­‐incubation	   with	   thapsigargin	   to	   deplete	  
endoplasmic	   reticular	   calcium	   stores	   blocked	   the	   previously	   observed	   calcium	  
response.	  However	  pre-­‐treatment	  with	  plasma	  membrane	  channels	   inhibitor	   (L-­‐type)	  
verapamil	  did	  not	  have	  any	  effect.	   These	  data	   suggested	   that	   calcium	   flux	   in	  human	  
monocytes	   required	   store-­‐operated	   calcium-­‐channel	   activation	   by	   LTD4	   stimulation	  
(Woszczek	  et	  al.	  2008b).	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In	  a	  separate	  study,	  the	  same	  group	  investigated	  whether	  the	  IL-­‐4-­‐increased	  CYSLTR1	  
promoter	  activity	  observed	  previously	  in	  gene	  reporter	  experiments	  was	  functional	  at	  
mRNA	   and	   protein	   levels.	   Using	   RT-­‐PCR	   and	   flow	   cytometry,	   they	   found	   that	   IL-­‐4	  
stimulation	   of	   THP-­‐1	   (acute	   monocytic	   leukemia)	   cells	   increased	   CYSLTR1	   mRNA	  
expression	  in	  a	  time-­‐dependent	  manner,	  with	  the	  highest	  increase	  observed	  after	  6	  h	  
of	   incubation,	   as	  well	   as	   a	   significant	   time-­‐	   and	   dose-­‐dependent	   increase	   in	   surface	  
receptor	   expression,	  with	   the	  maximum	   response	   observed	   after	   24	   h	   of	   incubation	  
(Woszczek	   et	   al.	   2005).	   Culture	   of	   human	   monocytes	   in	   the	   presence	   of	   IL-­‐10	   was	  
found	   to	  decrease	  CYSLTR1	  mRNA	  expression	   in	  a	  concentration-­‐dependent	  manner,	  
with	   the	  maximum	   effect	   observed	   after	   6	   hours.	   IL-­‐10	  was	   found	   to	   also	   decrease	  
CYSLTR1	   gene	   transcription	   and	   protein	   expression	   in	   a	   time-­‐dependent	   manner	  
(Woszczek	  et	  al.	  2008a).	  
1.3.3.3 Murine	  studies	  
Studies	   in	  mouse	  models	  have	  also	  reported	  the	  expression	  of	  Cysltr1	  in	  murine	  cells	  
and	  calcium	  flux	  caused	  in	  response	  to	  LTD4.	  The	  following	  section	  describes	  some	  of	  
the	  results	  observed	  in	  these	  studies.	  	  
Martin	  et	  al.	  first	  cloned	  the	  murine	  CysLT1	  receptor	  in	  2001,	  and	  found	  87%	  identity	  at	  
the	   amino	   acid	   level	   between	   the	  mouse	   and	   human	   receptor.	   Binding	   experiments	  
revealed	   similar	   results	   to	   the	   human	   studies	   and	   all	   known	   specific	   antagonists	  
competed	  for	  binding	  sites	  in	  mouse	  CysLT1R	  (mCysLT1R).	  Calcium	  flux	  was	  observed	  in	  
response	  to	  LTD4	  in	  COS-­‐7	  cells	  transfected	  with	  mCysLT1R.	  Calcium	  flux	  in	  HEK293	  cells	  
transfected	  with	  mCysLT1R	  was	  LTD4-­‐dose-­‐dependent.	  Finally,	  the	  group	  also	  tested	  X.	  
laevis	   melanophores	   and	   transfected	   them	   with	   mCysLT1R.	   LTD4	   stimulation	   of	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mCysLT1R	   caused	   pigment	   dispersion	   in	   a	   concentration-­‐dependent	  manner	  with	   an	  
EC50	  value	  of	  0.2	  nM	  (V.	  Martin	  et	  al.	  2001).	  
Several	  studies	  have	  involved	  Cysltr1-­‐/-­‐,	  Cysltr2-­‐/-­‐	  knockouts	  or	  Cysltr1/Cysltr2-­‐/-­‐	  double	  
knockout	   mice.	   Maekawa	   et	   al.	   generated	   Cysltr1-­‐deficient	   mice	   by	   targeted	   gene	  
disruption	  and	  mice	  were	  found	  to	  develop	  normally	  and	  to	  be	  fertile.	  Targeted	  gene	  
disruption	   was	   generated	   by	   homologous	   recombination	   using	   a	   targeting	   vector	  
designed	  so	  that	  the	  neo	  gene	  insertion	  interrupts	  the	  coding	  region	  that	  is	  common	  to	  
the	   long	   and	   short	   isoforms	   of	   the	   mouse	   Cysltr1	   gene.	   Using	   an	   intracellular	  
mobilization	  assay	  with	  fura-­‐2	  acetoxymethyl	  ester,	  the	  group	  found	  that	  macrophages	  
from	   Cysltr1-­‐deficient	   mice	   did	   not	   respond	   to	   either	   LTD4	   or	   LTC4,	   compared	   to	  
peritoneal	  macrophages	  from	  wild-­‐type	  littermates	  (which	  expressed	  both	  Cysltr1	  and	  
Cysltr2),	  which	   responded	   to	   LTD4	   and	   slightly	   to	   LTC4.	   They	   also	   found	   that	   plasma	  
protein	   extravasation,	   but	   not	   neutrophil	   infiltration,	   was	   significantly	   reduced	   in	  
cysltr1-­‐deficient	   mice	   subjected	   to	   zymosan	   A-­‐induced	   peritoneal	   inflammation.	  
Plasma	   protein	   extravasation	  was	   also	   significantly	   reduced	   in	   cysltr1-­‐deficient	  mice	  
undergoing	   IgE-­‐mediated	   passive	   cutaneous	   anaphylaxis,	   in	   comparison	   to	   the	  wild-­‐
type	  mice	  (Maekawa	  et	  al.	  2002)	  
Later,	   the	   same	   group	   generated	   Cysltr2-­‐deficient	   mice	   again	   using	   targeted	   gene	  
disruption	  (as	  described	  earlier).	  These	  mice	  developed	  normally	  and	  were	  fertile,	  like	  
in	  previous	  studies	  in	  cysltr1-­‐deficient	  mice.	  Importantly,	  the	  knockout	  did	  not	  induce	  
any	   change	   in	   the	  CysLTR1	  mRNA	  expression.	   They	   found	   that	   in	  Cysltr2-­‐/-­‐	  mice,	   the	  
increased	   vascular	   permeability	   associated	   with	   IgE-­‐dependent	   passive	   cutaneous	  
anaphylaxis	  was	  significantly	  reduced,	  in	  comparison	  to	  wild-­‐type	  mice.	  Plasma	  protein	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extravasation	   in	   response	   to	   zymosan	   A-­‐induced	   peritoneal	   inflammation	   was	   not	  
altered.	   To	   define	   a	   role	   for	   the	   CysLT2	   receptor	   in	   the	   pathobiology	   of	   chronic	  
inflammation	   with	   fibrosis,	   they	   injected	   bleomycin	   into	   the	   tracheas	   of	   Cysltr2-­‐
deficient	   mice	   and	   their	   wild-­‐type	   littermates	   and	   observed	   that	   the	   lung	   tissue	   of	  
bleomycin-­‐treated	   Cysltr2-­‐deficient	   mice	   had	   less	   septal	   thickening,	   with	   less	  
accumulation	  of	  monocyte/macrophages,	  giant	  cells,	   fibroblasts,	  and	  eosinophils	  and	  
less	   extracellular	   matrix	   deposition	   than	   that	   of	   the	   bleomycin-­‐treated	   wild-­‐type	  
littermates.	   This	   suggested	   that	   CysLT2	   receptor	   can	  mediate	   an	   increase	   in	   vascular	  
permeability	   in	   some	   tissues	   or	   promote	   chronic	   pulmonary	   inflammation	   with	  
fibrosis,	   in	   response	   to	   a	   particular	   pathobiologic	   event	   (Beller	   et	   al.	   2004).	  
Interestingly,	   the	  group	   found	   that	  neither	   the	  Cysltr1-­‐/-­‐	  nor	   the	  Cysltr2-­‐/-­‐	  mice	  were	  
protected	   from	   antigen-­‐induced	   pulmonary	   inflammation,	   suggesting	   that	   additional	  
receptor(s)	  might	   account	   for	   the	   protection	   observed	   in	   previous	   studies	   in	   Ltc4s-­‐/-­‐	  
mice.	  
Jiang	  et	  al.	   reported	   that	   LTD4-­‐mediated	  proliferation	  was	  abrogated	   in	  human	  mast	  
cells	   (hMCs)	   following	   short-­‐hairpin	   RNA	   (shRNA)–mediated	   knockdown	   of	   CysLT1	  
receptor	   expression,	   and	   in	   mouse	   bone	   marrow–derived	   MCs	   (mBMMCs)	   from	  
Cysltr1-­‐/-­‐	  mice.	  In	  contrast,	  the	  study	  showed	  that	  knockdown	  of	  CysLT2	  receptor	  led	  to	  
an	  increase	  in	  CysLT1	  receptor	  surface	  expression	  and	  CysLT1-­‐dependent	  proliferation	  
of	  cord	  blood–derived	  human	  MCs	  (hMCs).	  Although	  CysLT–mediated	  responses	  were	  
absent	  in	  MCs	  from	  mice	  lacking	  CysLT1	  receptors,	  they	  were	  enhanced	  by	  the	  absence	  
of	  CysLT2	  receptors.	  Although	  the	  absence	  of	  CysLT2	  receptor	  did	  not	  affect	  the	  total	  
cellular	  level	  of	  CysLTR1	  protein,	  it	  increased	  CysLT1	  expression	  at	  the	  cell	  surface	  and	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enhances	   LTD4-­‐induced	   ERK	   phosphorylation.	   CysLT1	   and	   CysLT2	   receptors	   were	  
found	  to	  colocalize	  at	   the	  plasma	  membrane,	  nucleus,	  and	  nuclear	  envelope	  of	  MCs,	  
and	   form	   heteromeric	   complexes,	   which	   was	   determined	   by	   Ab-­‐based	   fluorescent	  
lifetime	  imaging	  microscopy	  (FLIM)	  to	  measure	  fluorescent	  resonance	  energy	  transfer	  
(FRET)	  (Jiang	  et	  al.	  2007).	  
Following	   previous	   findings	   of	   a	   greater	   potency	   for	   LTE4	   than	   LTC4	   or	   LTD4	   in	  
constricting	  guinea	  pig	  trachea	  in	  vitro	  and	  comparable	  activity	  in	  eliciting	  a	  cutaneous	  
wheal	  and	  flare	  response	  in	  humans;	  and	  following	  on	  from	  their	  findings	  in	  previous	  
models	   of	   Cysltr1-­‐/-­‐	   and	   Cysltr2-­‐/-­‐	   knockout	   mice,	   Maekawa	   et	   al.	   generated	  
cysltr1/Cysltr2	   double-­‐deficient	   (Cysltr1/Cysltr2-­‐/-­‐)	   mice	   in	   order	   to	   check	   for	   any	  
vascular	   permeability	   response	   to	   LTE4	   (Maekawa	   et	   al.	   2008).	   They	   examined	   the	  
agonist	   function	  of	   the	   three	   cysteinyl	   leukotrienes	  by	   intradermal	   injection	   into	   the	  
ear	   and	   found	   that	   the	   Cysltr1/Cysltr2-­‐/-­‐	   mice	   expressed	   a	   previously	   unrecognized	  
receptor	   that	  mediated	   a	   greater	   vascular	   leak	   in	   response	   to	   LTE4	   than	   to	   LTD4	   or	  
LTC4,	  which	  was	   inhibited	  by	  pre-­‐treatment	  of	  the	  mice	  with	  pertussis	  toxin	  or	  a	  Rho	  
kinase	  inhibitor.	  The	  increased	  sensitivity	  of	  the	  Cysltr1/Cysltr2-­‐/-­‐	  mice	  compared	  with	  
WT	   mice	   was	   approximately	   64-­‐fold	   by	   dose-­‐dependent	   analysis,	   and	   revealed	   a	  
negative	   regulation	   of	   the	   novel	   unknown	   receptor	   for	   LTE4	   by	   the	   two	   known	  
receptors,	   with	   a	   preference	   for	   LTD4	   and	   LTC4.	   Additionally,	   they	   found	   that	   pre-­‐
treatment	   of	   Cysltr1/Cysltr2-­‐/-­‐	   mice	   with	   antagonist	   MK-­‐571	   further	   increased	   the	  
permeability	   response	   of	   these	   mice	   to	   each	   of	   the	   three	   cysteinyl	   leukotrienes	  
(Maekawa	  et	  al.	  2008).	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1.3.4 Cysteinyl	  leukotriene	  receptor	  2	  
The	  human	  CysLT2	  receptor	  was	  initially	  cloned	  and	  characterised	  in	  2000	  by	  Heise	  et	  
al.	   (Heise	   et	   al.	   2000),	   followed	   closely	   by	   two	  other	   groups	   (Nothacker	   et	   al.	   2000;	  
Takasaki	  et	  al.	  2000).	  The	  mouse	  cysltr2	  was	  also	   identified	   in	  2001	  (Hui	  et	  al.	  2001).	  
Although	  from	  the	  same	  family,	  human	  CYSLTR2	  only	  shares	  37.5%	  amino	  acid	  identity	  
with	   human	   CYSLTR1	   (Heise	   et	   al.	   2000).	   The	   receptors	   also	   have	   slightly	   different	  
binding	  affinities	   to	   the	   cysteinyl	   leukotrienes.	  CysLT1R	  binds	   LTD4>LTC4>>LTE4,	  while	  
CysLT2R	  binds	  LTC4=LTD4>LTE4	  (Evans	  2002).	  Human	  CYSLTR2	  is	  localised	  in	  the	  13q14.2	  
region	   of	   chromosome	   13.	   The	   open	   reading	   frame	   of	   human	   CYSLTR2	   encodes	   a	  
protein	  of	  347	  amino	  acids.	  Northern	  blot	  analyses	  of	  human	  CYSLTR2	   revealed	  high	  
expression	  in	  the	  human	  heart,	  adrenals,	  peripheral	  blood	  leukocytes,	  airway	  smooth	  
muscle,	  alveolar	  macrophages,	  and	  lower	  expression	  in	  brain	  cells	  (Heise	  et	  al.	  2000).	  
The	  CysLT2	  receptor	   is	  also	  expressed	   in	  human	  peripheral	  basophils	  (Gauvreau	  et	  al.	  
2005),	   endothelial	   cells	   (Di	   Gennaro	   et	   al.	   2004),	   cultured	   mast	   cells	   (Mellor	   et	   al.	  
2003),	   and	   in	   nasal	   eosinophils	   and	   mast	   cells	   from	   patients	   with	   active	   seasonal	  
rhinitis	  (Figueroa	  et	  al.	  2001).	  
Human	   CYSLTR2	   cRNA	   was	   expressed	   in	   Xenopus	   laevis	   oocytes	   and	   both	   LTC4	   and	  
LTD4	  caused	  a	  calcium-­‐dependent	  chloride	   flux	   (Heise	  et	  al.	  2000).	  This	   could	  not	  be	  
blocked	  by	  selective	  antagonist	  MK571,	  however	  was	  inhibited	  by	  dual	  antagonist	  BAY	  
u9773	   (Heise	   et	   al.	   2000).	   In	   HEK	   293	   cells,	   LTC4-­‐	   and	   LTD4-­‐induced	   calcium	  
mobilization	  was	  concentration-­‐dependent	  in	  cells	  expressing	  the	  recombinant	  human	  
CYSLTR2	   and	   was	   blocked	   by	   BAY	   u9773	   but	   not	   significantly	   by	   CysLT1	   receptor	  
antagonists	   MK571,	   montelukast,	   zafirlukast,	   or	   pranklukast	   (Heise	   et	   al.	   2000).	   To	  
date	  a	  selective	  human	  CysLT2	  receptor	  antagonist	  remains	  to	  be	  identified.	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1.3.5 The	  third	  receptor	  
Over	   the	   years,	   several	   data	   in	   the	   literature	   have	   suggested	   the	   existence	   of	   an	  
additional	  CysLTR	  subtype	  in	  human	  tissues.	  This	  proposal	  has	  been	  based	  on	  several	  
findings	  and	  observations.	  Certain	  reported	  actions	  of	  cysteinyl	  leukotrienes	  cannot	  be	  
explained	  by	  their	  ligation	  to	  either	  CysLT1R	  or	  CysLT2R.	  The	  bronchoconstrictor	  activity	  
of	   LTE4	   that	   has	   been	   observed	   by	   several	   studies	   cannot	   be	   explained	   by	   either	  
CysLT1R	  or	  CysLT2R	  given	  its	  low	  affinity	  to	  both	  (Davidson	  et	  al.	  1987).	  	  
Most	   importantly	  LTE4,	   the	  most	  stable	  CysLT,	   is	  only	  a	  weak	  agonist	   for	   the	  defined	  
CysLT1R	  and	  CysLT2R,	  despite	   its	  greater	  potency	   in	  constricting	  guinea	  pig	  trachea	   in	  
vitro	   and	   comparable	   activity	   in	   eliciting	   a	   cutaneous	   wheal	   and	   flare	   response	   in	  
humans.	  With	  this	  in	  mind,	  Maekawa	  et	  al.	  hypothesized	  that	  a	  vascular	  permeability	  
response	   to	   LTE4	   in	   mice	   lacking	   both	   the	   Cysltr1	   and	   Cysltr2	   could	   establish	   the	  
existence	  of	   a	   separate	   LTE4	   receptor.	  Using	  double	   knockout	  mice	  deficient	   in	  both	  
Cysltr1	  and	  Cysltr2,	  they	  administered	  an	  intradermal	  injection	  of	  LTE4	  into	  the	  ear	  of	  
the	   mice.	   This	   elicited	   a	   vascular	   leak	   that	   exceeded	   the	   response	   to	   intradermal	  
injection	  of	  LTC4	  or	  LTD4.	  Pre-­‐treatment	  of	  the	  mice	  with	  pertussis	  toxin	  or	  a	  Rho	  kinase	  
inhibitor	  inhibited	  the	  response.	  Interestingly,	  it	  was	  found	  that	  LTE4	  was	  64-­‐fold	  more	  
potent	   in	   the	  Cysltr1/Cysltr2	  double-­‐deficient	  mice	  than	   in	  genetically	  sufficient	  mice	  
(Maekawa	  et	  al.	  2008).	  	  
These	  studies	  suggest	  and	  provide	  evidence	  for	  the	  existence	  of	  one	  or	  more	  unknown	  
additional	   receptors,	   including	  one	  specific	   to	  LTE4.	  So	   far	   two	  candidates	  have	  been	  
proposed:	  GPR17	  and	  P2Y12.	  
Recently,	  the	  orphan	  G	  protein-­‐coupled	  receptor	  GPR17	  has	  been	  identified	  as	  a	  third	  
putative	  cysteinyl	   leukotriene	  receptor	  capable	  of	  binding	  LTC4	  and	  LTD4	   (Ciana	  et	  al.	  
	   	   INTRODUCTION	  
 
 63	  
2006).	   GPR17	   has	   been	   characterized	   as	   a	   dual	   receptor	   for	   uracil	   nucleotides	   and	  
cysteinyl	  leukotrienes.	  Its	  expression	  has	  been	  detected	  in	  the	  brain,	  kidney,	  heart	  and	  
human	  umbilical	  cord	  endothelial	  cells	  (Ciana	  et	  al.	  2006)	  using	  semi-­‐quantitative	  PCR.	  
Although	   its	   biological	   role	   still	   remains	   unclear,	   studies	   using	   transfected	   cells	   have	  
shown	  that	  GPR17	  responds	  to	  cysteinyl	  leukotrienes	  in	  the	  same	  concentration	  range	  
as	   CysLT1R	   and	   CysLT2R,	   however	   with	   slightly	   different	   ligand	   binding	   affinity:	  
LTC4>>LTD4.	   Montelukast	   and	   Pranlukast	   were	   both	   found	   to	   block	   the	   receptor.	  
GPR17	  was	  also	  found	  to	  negatively	  regulate	  CysLT1R-­‐mediated	  allergic	  responses	  in	  a	  
mouse	  model	  of	  asthma	  (Maekawa	  et	  al.	  2010).	  
P2Y12,	  a	  target	  of	  clinically	  well-­‐accepted	  anti-­‐platelet	  thienopyridine	  derivatives	  such	  
as	  clopidogrel	  and	  ticlopidine,	  has	  been	  recently	  proposed	  as	  the	  receptor	  for	  LTE4.	  In	  
studies	   using	   P2Y12	   knockout	   mice,	   P2Y12	   antagonist	   clopidogrel	   was	   found	   to	  
suppress	  in	  vivo	  enhancement	  of	  eosinophilic	  lung	  inflammation	  by	  LTE4	  inhalation,	  but	  
not	   in	   Cysltr1/Cysltr2	   double	   knockout	   mice	   (Paruchuri	   et	   al.	   2009).	   However,	   the	  
group	  was	  unable	  to	  confirm	  direct	  binding	  of	  LTE4	  to	  P2Y12.	  
	  
1.3.6 Cysteinyl	  leukotriene	  receptor	  antagonists	  
Currently,	   four	   selective	   CysLT1	   receptor	   antagonists	   are	   clinically	   available,	  
Montelukast,	  Zafirlukast,	  Pranlukast	  and	  Pobilukast,	  with	  Montelukast	  being	  the	  most	  
widely	  available	  and	  actively	  marketed	  (Okunishi	  and	  Peters-­‐Golden	  2011).	  As	  these	  all	  
selectively	  antagonize	  the	  CysLT1	  receptor	  subtype	  and	  all	  have	  very	  similar	  in	  vitro	  and	  
in	   vivo	   preclinical	   profiles,	   they	   mainly	   differ	   in	   terms	   of	   relative	   potency	   and	   oral	  
bioavailability	  (Aharony	  1998).	  The	  potency	  and	  oral	  activity	  of	  Montelukast	  are	  similar	  
to	   those	   of	   Zafirlukast,	   whereas	   Pobilukast	   is	   less	   potent	   in	   binding	   to	   the	   human	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receptor,	   less	   effective	   orally	   and	   is	   delivered	   by	   aerosol	   to	   achieve	   effective	  
antagonism	  (Aharony	  1998).	  Pranlukast	  also	  appears	  to	  be	  less	  potent	  but	  is	  effective	  
when	   administered	   orally	   (Aharony	   1998).	   Although	   clearly	   superior	   to	   placebo	  
controls,	  these	  drugs	  have	  limited	  efficacy,	  which	  include	  their	  inferiority	  to	  ICS	  in	  anti-­‐
inflammatory	   and	   clinical	   effects	   and	   their	   non-­‐responsiveness	   on	   a	   considerable	  
subset	  of	  patients,	  approximately	  50%	  (P.	  J.	  Barnes	  and	  Stockley	  2005;	  Terashima	  et	  al.	  
2002).	   Hypotheses	   for	   their	   limitations	   include	   that	   the	   asthmatic	   patient	   may	   not	  
produce	  or	  produce	  enough	  CysLTs	  for	  them	  to	  become	  therapeutic	  targets,	  but	  also	  
that	   anti-­‐leukotrienes	   may	   target	   CysLT1	   or	   CysLT2	   receptors	   instead	   of	   a	   potential	  
additional	   receptor.	   Other	   leukotriene	   antagonists	   include	   selective	   CysLT1	   receptor	  
antagonists	   Pobilukast	   and	   ICI	   198615,	   and	  non-­‐selective	   antagonists	   FPL	   55712	   and	  
dual	  receptors	  antagonist	  BAY	  u9773	  (Brink	  et	  al.	  2003).	  
However	  these	  drugs	  have	  also	  been	  shown	  to	  be	  useful	  for	  certain	  clinical	  situations.	  
Indeed,	   LTRAs	   (leukotriene	   receptor	   antagonists)	   are	   clinically	   efficacious	   in	   patients	  
with	   aspirin-­‐induced	   asthma	  and	   exercise-­‐induced	   asthma	   (EIA).	   In	   EIA	   patients	  who	  
show	  an	  increase	  in	  airway	  cysteinyl	  leukotrienes	  levels	  following	  exercise,	  LTRAs	  have	  
been	  found	  to	  be	  superior	  to	  ICS	  in	  children	  and	  superior	  to	  long-­‐acting	  beta	  agonists	  
in	   adults.	   Anti-­‐leukotriene	   agents	   also	   have	   the	   additive	   benefit	   in	   patients	   whose	  
disease	  cannot	  be	  adequately	  controlled	  by	  inhaled	  corticosteroids.	  Additionally,	  anti-­‐
leukotriene	  agents	  can	  be	  taken	  orally,	  instead	  of	  inhalation	  (Brink	  et	  al.	  2003).	  

















Figure	   1.7	   Chemical	   structures	   of	   selective	   and	   non-­‐selective	   CysLT1	   receptor	  
antagonists	  (Taken	  from	  (Brink	  et	  al.	  2003).	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1.3.7 Functional	  studies	  on	  cysteinyl	  leukotrienes	  
Several	   functional	   studies	  on	  cysteinyl	   leukotrienes	   support	   the	  hypothesis	   that	   they	  
might	   serve	   as	   chemotactic	   mediators	   and/or	   activating	   ligands	   for	   human	   effector	  
leukocytes.	   Studies	   have	   also	   shown	   that	   some	   cytokines	   and	   other	   environmental	  
factors	   in	   inflammation	  may	  affect	  the	  CYSLTR1	  receptor	  expression	  profile	   in	  certain	  
leukocytes	  (Kanaoka	  and	  Boyce	  2004).	  
In	  addition	  to	  bronchoconstriction,	   inhalation	  of	  LTE4	  by	  asthmatic	  patients	  has	  been	  
shown	  to	   result	   in	   the	  subsequent	   influx	  of	  eosinophils	  and	  neutrophils	   into	   the	  BAL	  
fluid	   (Laitinen	   et	   al.	   1993),	   suggesting	   a	   role	   for	   cysteinyl	   leukotrienes	   in	   direct	   or	  
indirect	  recruitment	  of	  leukocytes	  to	  sites	  of	  inflammation.	  
In	   a	   study	  using	  human	  CD34+	  peripheral	  blood-­‐derived	  progenitor	   cells,	   they	   found	  
the	   expression	   of	   CYSLTR1	   but	   not	   CYSLTR2	   on	   these	   cells.	   Cysteinyl	   leukotrienes	  
induced	   transendothelial	   migration	   of	   these	   cells	   in	   vitro,	   suggesting	   a	   role	   in	   the	  
regulation	  of	  cell	  trafficking.	  Pre-­‐treatment	  of	  these	  cells	  with	  antagonist	  Montelukast	  
completely	  blocked	  CysLT-­‐mediated	  calcium	  flux	  (Bautz	  et	  al.	  2001).	  	  
Additional	   studies	   in	  peripheral	  blood	  monocytes,	  eosinophils	  and	   lung	  macrophages	  
all	  revealed	  expression	  of	  both	  CYSLTR1	  and	  CYSLTR2	  mRNA	  and	  protein	  (Figueroa	  et	  
al.	  2001;	  Lynch	  et	  al.	  1999;	  Mita	  et	  al.	  2001).	  
Thivierge	  et	  al.	  also	  showed	  that	  priming	  of	  either	  human	  peripheral	  blood	  monocytes	  
or	  monocyte-­‐derived	  macrophages	  with	  IL-­‐13	  or	  IL-­‐4	  increased	  their	  levels	  of	  CYSLTR1	  
mRNA	  and	  protein	  expression,	  as	  well	  as	  enhanced	  their	  chemotactic	  response	  to	  LTD4	  
in	  vitro	  (Thivierge	  et	  al.	  2001).	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Cysteinyl	   leukotrienes	   have	   also	   been	   observed	   to	   induce	   cytokine	   generation	   by	  
eosinophils	   and	   mast	   cells.	   Human	   placental	   cord	   eosinophils	   have	   been	   found	   to	  
secrete	   IL-­‐4	   in	   response	   to	   cysteinyl	   leukotrienes	   and	   via	  CysLT1R.	  However	   this	  was	  
not	   found	   in	   freshly	   isolated	   peripheral	   blood	   eosinophils	   unless	   cells	   were	  
permeabilized.	  The	  expression	  of	   IL-­‐4	  by	  permeabilized	  eosinophils	  was	   shown	   to	  be	  
PTX-­‐sensitive	   and	  was	   stronger	   using	   smaller	   doses	   of	   LTC4	   than	   LTD4.	   Interestingly,	  
pre-­‐treatment	  of	  eosinophils	  with	  MK886	   (FLAP	  and	  LTC4S	   inhibitor)	  or	  AA861	   (5-­‐LO	  
inhibitor)	   blocked	   the	   release	  of	   IL-­‐4	   in	   response	   to	   IL-­‐16,	  RANTES	  or	   eotaxin,	  which	  
suggests	  an	  intracrine	  role	  for	  cysteinyl	  leukotrienes	  (Bandeira-­‐Melo	  and	  Weller	  2003;	  
Figueroa	  et	  al.	  2003).	  
Expression	  of	  both	  CYSLTR1	  and	  CYSLTR2	  has	  been	   identified	   in	   resident	   tissue	  mast	  
cells	   from	   nasal	   biopsies	   and	   human	   cord	   blood.	   Mast	   cells	   have	   been	   shown	   to	  
respond	   to	   ex	   vivo	   stimulation	   of	   low	   concentrations	   of	   LTC4	   and	   LTD4	   by	   strong	  
calcium	  flux.	  Calcium	  flux	  was	  pertussis	  toxin-­‐sensitive	  and	  inhibited	  by	  CysLT1	  receptor	  
antagonist	  MK571.	  When	  primed	  with	  IL-­‐4,	  human	  mast	  cells	  responded	  better	  to	  LTC4	  
than	   LTD4,	   as	   observed	   by	   the	   greater	   extent	   of	   the	   LTC4	   dose-­‐response	   curve.	  
However	  the	  IL-­‐4	  priming	  did	  not	  alter	  the	  CYSLTR1	  mRNA	  or	  protein	  expression	  levels.	  
Similar	  calcium	  results	  were	  observed	  using	  UDP,	  which	  were	  also	  inhibited	  by	  MK571.	  
Mast	   cells	   were	   also	   found	   to	   secrete	   cytokines	   IL-­‐5,	   TNF-­‐α,	  MIP-­‐1β	   and	   IL-­‐8	   when	  
stimulated	  with	  LTC4,	  LTD4	  or	  UDP.	   Interestingly,	  of	  all	   cytokines	  produced,	   IL-­‐8	  was	  
the	  only	  one	  resistant	  to	  MK571.	  Interestingly,	   it	  was	  suggested	  that	  the	  induction	  of	  
IL-­‐5	  by	  mast	   cells	   could	  be	  an	  additional	  mechanism	  by	  which	   cysteinyl	   leukotrienes	  
could	  promote	  eosinophilia	  (Mellor	  et	  al.	  2001;	  Mellor	  et	  al.	  2002;	  Mellor	  et	  al.	  2003).	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The	   role	   of	   cysteinyl	   leukotrienes	   and	   their	   receptors	   in	   immune	   responses	   has	   also	  
been	  assessed	  in	  mice.	  In	  a	  study	  by	  Henderson,	  BALB/c	  mice	  were	  sensitized	  with	  an	  
i.p.	   injection	   of	   OVA	   precipitated	   with	   alum	   then	   challenged	   with	   intranasal	  
administration	   of	   OVA.	   Levels	   of	   LTC4	   and	   LTB4	   were	  measured	   in	   the	   BAL	   fluid	   24	  
hours	   after	   challenge	   and	   found	   to	   have	   increased	   5-­‐fold	   and	   3.4-­‐fold,	   respectively,	  
compared	   to	   saline	   controls.	   Increased	   levels	   of	   LTC4	   and	   LTB4	  were	   associated	  with	  
widespread	  mucus	  obstruction	  of	  the	  airways,	  an	  influx	  of	  eosinophils	  in	  airway	  tissues	  
and	   BAL	   fluid,	   and	   airway	   hyperresponsiveness	   to	   intravenous	   infusions	   of	  
methacholine.	   Administration	   of	   inhibitors	   Zileuton	   or	   MK886	   before	   nasal	   antigen	  
challenge	  reduced	  eosinophil	  infiltration	  in	  tissues	  and	  BAL	  fluid	  by	  approximately	  85%	  
and	   significantly	   blocked	   airway	   mucus	   release	   (Henderson	   et	   al.	   1996).	   The	   group	  
reported	  a	   similar	   study	  but	  with	  a	  period	  of	   intranasal	   administration	  of	  OVA	  of	  75	  
days	   this	   time	   in	   order	   to	   induce	   the	   known	   features	   of	   airway	   remodelling	   such	   as	  
smooth	  muscle	  hyperplasia	  and	  sub-­‐epithelial	  fibrosis.	  Results	  showed	  that	  treatment	  
with	  montelukast	  on	  day	  26	  significantly	  reduced	  the	  infiltration	  of	  eosinophils	  in	  the	  
airways,	   mucus	   obstruction,	   collagen	   deposition,	   and	   smooth	   muscle	   hyperplasia.	  
Compared	  to	  placebo-­‐treated	  challenged	  controls,	  montelukast-­‐treated	  mice	  showed	  
reduced	   levels	   of	   IL-­‐13,	   IL-­‐4,	   IL-­‐10	   an	   IL-­‐5	   mRNA,	   which	   suggested	   that	   cysteinyl	  
leukotrienes	   may	   play	   a	   role	   in	   stimulating	   cytokine	   generation	   by	   resident	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1.4 Rationale	  and	  aim	  
Asthma	  has	  been	  described	  as	  a	  Th2-­‐specific	   inflammatory	  disorder,	  characterised	  by	  
symptoms	   of	  wheezing	   and	   breathing	   difficulties,	   and	   at	   the	   cellular	   level	   by	  mucus	  
production,	   airway	   hyperresponsiveness	   and	   bronchoconstriction.	   Cysteinyl	  
leukotrienes	   are	   lipid	   mediators	   known	   for	   their	   potent	   bronchoconstrictive	  
properties,	   and	   have	   been	   associated	   with	   asthma	   and	   inflammation.	   Despite	   this	  
association,	  there	  have	  been	  no	  report	  on	  the	  expression	  of	  cysteinyl	   leukotrienes	  or	  
their	  receptors	  in	  human	  T	  cells	  and	  little	  knowledge	  on	  the	  exact	  role	  of	  leukotrienes.	  
In	   the	   data	   we	   obtained	   from	   microarray	   studies	   using	   human	   T	   cells,	   we	   have	  
identified	  the	  expression	  of	  CYSLTR1	  in	  T	  cell	  subsets.	  
The	   aim	   of	   this	   study	   was	   to	   examine	   the	   expression	   of	   CYSLTR1	   in	   T	   cell	   subsets	  
observed	  in	  microarray	  studies	  and	  characterise	  the	  function	  of	  CYSLTR1	  in	  human	   in	  
vitro-­‐differentiated	   Th2	   cells.	   To	   achieve	   this,	   we	   performed	   a	   series	   of	   functional	  
assays	   such	   as	   calcium,	   cyclic	   AMP	   and	   chemotaxis	   assays,	   but	   also	   microarrays	   to	  










Based	  upon	  preliminary	  observations	  that	  CysLTR1	  mRNA	  may	  be	  selectively	  expressed	  
by	  human	  Th2	  cells,	  we	  hypothesise	  that:	  
Human	   Th2	   cells	   are	   a	   target	   of	   cysteinyl	   leukotrienes	   via	   selective	   expression	   of	  
functional	  CysLTR1.	  	  
To	  test	  this	  hypothesis,	  we	  have	  performed	  several	  experimental	  tests:	  
1. Measurement	  of	  CysLTR1	  mRNA	  levels	  in	  human	  Th1	  and	  Th2	  cells	  
2. Measurement	   of	   calcium	   flux	   in	   Th1	   and	   Th2	   cells	   in	   response	   to	   cysteinyl	  
leukotrienes	  
3. Measurement	   of	   cyclic	   AMP	   signalling	   in	   Th1	   and	   Th2	   cells	   in	   response	   to	  
cysteinyl	  leukotrienes	  
4. Measurement	  of	  chemotaxis	  in	  response	  to	  cysteinyl	  leukotrienes	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Chapter	  2 Materials	  &	  methods	  
2.1 Materials	  
General	  laboratory	  chemicals	  were	  purchased	  from	  Invitrogen	  unless	  otherwise	  noted.	  
Antibodies	  were	  purchased	  as	  described	  in	  tables	  2.1	  and	  2.2.	  
2.1.1.	  Reagents	  
All	   cysteinyl	   leukotrienes,	   their	   antagonists	   (MK-­‐571,	   Montelukast,	   Pranlukast)	   and	  
PGD2	  were	  purchased	  from	  Cayman	  Chemicals.	  SDF1α	  and	  L-­‐cysteine	  were	  purchased	  
from	  Sigma.	  
2.1.2.	  Kits	  
miRNeasy	  mini	   Kit	   was	   purchased	   from	  Qiagen.	   	   RNA	   6000	   Nano	   and	   Pico	   Kits	   was	  
purchased	   from	  Agilent	   Technologies.	   HitHunter	   Assay	   cAMP	   XS+	   and	   FLIPR	   calcium	  
assay	   kit	   were	   purchased	   from	   Molecular	   Devices.	   Ambion	   WT	   Expression	   Kit	   was	  
purchased	  from	  Invitrogen.	  
2.2 Methods	  
2.2.1 Cell	  culture	  
2.2.1.1 	  HEK	  293	  cells	  
HEK	   (Human	  Embryonic	  Kidney)	  293T	  adherent	  cells	  were	  obtained	   from	  Susan	   John	  
(King’s	  College	  London)	  and	  were	  maintained	  at	  1	  to	  2	  x	  105	  cells/ml	  and	  cultured	   in	  
pre-­‐heated	  Dulbecco's	  Modified	  Eagle	  Medium	  (DMEM)	  containing	  2mM	  L-­‐Glutamine	  
supplemented	   with	   10%	   Fetal	   Bovine	   Serum	   (FBS,	   Sigma)	   and	   10%	   PSG	   (penicillin,	  
streptomycin,	   glutamine)	   at	   37°C,	   5%	   CO2	   in	   humidified	   air.	   Cells	   were	   routinely	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passaged	   at	   1:8	   to	   1:10	   dilution	   when	   reaching	   confluence.	   The	   approximate	   cell	  
number	  for	  100%	  confluence	  for	  this	  cell	  line	  in	  a	  T75	  flask	  is	  1	  ×	  107	  cells.	  
2.2.1.2 	  Primary	  human	  T	  cells	  
The	  studies	  described	  in	  this	  thesis	  were	  approved	  by	  the	  Research	  Ethics	  Committee	  
of	   Guy’s	   Hospital	   with	   informed	   consent.	   The	   donors	   used	   in	   this	   study	   were	   non-­‐
atopic,	   non-­‐asthmatic	  male	   individuals	   (25-­‐40	   years)	  with	   no	   other	   chronic	   or	   acute	  
illness	  at	  the	  time	  of	  venepuncture.	  
Primary	   human	   naïve	   T	   cells	   were	   cultured	   in	   RPMI/10%FCS/PSG	   medium	   and	  
expanded	  in	  fresh	  medium	  approximately	  every	  2	  days.	  Cells	  were	  re-­‐stimulated	  every	  
7	  days	  with	  anti-­‐CD3/anti-­‐CD28	  under	  the	  same	  conditions.	  	  
For	  Th1	  differentiation,	  rIL-­‐2	  (50	  units/ml;	  Novartis,	  Horsham,	  U.K.),	  rIL-­‐12	  (2.5	  ng/ml;	  
R&D	   Systems,	   Abingdon,	   Oxfordshire,	   U.K.),	   anti-­‐IL-­‐4	   (5	   µg/ml;	   clone	  MP4-­‐25D2;	   BD	  
Biosciences),	  and	  anti-­‐IL-­‐10	  (5	  µg/ml;	  clone	  JES3-­‐9D7;	  Invitrogen)	  were	  added.	  	  
For	  Th2	  differentiation,	  rIL-­‐2	  (50	  units/ml;	  Novartis,	  Horsham,	  U.K.),	  rIL-­‐4	  (12.5	  ng/ml;	  
R&D	   Systems),	   anti-­‐IFNγ	   (5	   µg/ml;	   clone	   B-­‐B1;	   Invitrogen)	   and	   anti-­‐IL-­‐10	   (5	   µg/ml;	  
clone	   JES3-­‐9D7;	   Invitrogen)	   were	   added.	   Cells	   were	   incubated	   at	   37°C,	   5%	   CO2.	   A	  
schematic	  diagram	  of	  these	  conditions	  is	  shown	  below	  on	  Figure	  2.1.	  After	  4	  days,	  cells	  
were	   removed	   from	   the	   coated	   plate	   and	   expanded	   under	   the	   same	   conditions	   as	  
above	  in	  the	  absence	  of	  anti-­‐CD3	  and	  anti-­‐CD28.	  Cells	  were	  then	  re-­‐stimulated	  every	  7	  
days	  with	  anti-­‐CD3/anti-­‐CD28	  under	  the	  same	  conditions.	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For	  time-­‐courses	  with	  LTD4,	  cells	  were	  cultured	  as	  described	  with	  100	  nM	  LTD4	  added	  
to	  the	  cells.	  	  For	  Day	  21	  time-­‐courses	  prior	  to	  microarrays,	  all	  cells	  were	  incubated	  with	  
and	   without	   100	   nM	   LTD4	   with	   3	   nM	   L-­‐cysteine,	   an	   inhibitor	   of	   dipeptidase	   (the	  
enzyme	   responsible	   for	   converting	   LTD4	   to	   LTE4),	   for	   a	   period	   of	   24	   hours.	   Samples	  
with	  and	  without	  LTD4	  were	  taken	  at	  30	  minutes,	  4	  hours,	  and	  24	  hours.	  Samples	  were	  
spun	  down	  using	  a	  micro	  centrifuge	  for	  10	  min	  at	  13000	  g,	  the	  supernatant	  removed	  
and	  the	  pellets	  frozen	  at	  -­‐80°C.	  	  
	   	  

















	   	  
Figure	  2.1.	  Human	  Th1/Th2	  in	  vitro	  culture	  system	  (Cousins	  et	  al.	  2002a).	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Antibody	   Company	   Cat	  No	  
CD3	   ECACC	   Grown	  in	  house	  
CD28	   Sanquin	   M1650	  
CD45	  RO	   BD	  Pharmingen	   555491	  
IFN-­‐γ	   ECACC	   Grown	  in	  house	  
IL-­‐4	   ECACC	   Grown	  in	  house	  







	   	  
Table	  2.1	  Antibodies	  used	  for	  the	  culture	  and	  differentiation	  of	  primary	  human	  T	  
cell	  in	  vitro.	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2.2.2 Human	  T	  cell	  isolation	  
Human	   naïve	   T	   cells	   were	   isolated	   from	   120	   ml	   of	   human	   blood	   from	   healthy	  
volunteers,	   which	  was	   anti-­‐coagulated	  with	   heparin	   (1000U/ml),	   and	  mixed	  with	   an	  
equal	  volume	  of	  PBS	  before	  being	   layered	  onto	  Lymphoprep	   (Axis-­‐shield,	  Kimbolton,	  
U.K.)	  to	  isolate	  peripheral	  blood	  mononuclear	  cells	  (PBMCs).	  PBMCs	  were	  counted	  and	  
resuspended	   in	   5	   ml	   of	   PBS/2%FCS.	   To	   isolate	   CD4	   positive	   (CD4+)	   T-­‐cells	   a	   CD4	  
Positive	   isolation	   Kit	   (Invitrogen)	   was	   used	   according	   to	   the	   manufacturer’s	  
instructions.	  Briefly,	  CD4	  Dynabeads	  were	  added	   to	  PBMCs	  at	  a	   ratio	  of	  4	  beads	  per	  
cell	  and	  incubated	  in	  the	  cold	  room	  (4°C)	  for	  20	  min	  on	  a	  shaker.	  CD4+	  cells	  were	  then	  
selected	  using	  the	  magnetic	  particle	  concentrator	  (MPC)	  and	  washed	  three	  times	  with	  
ice	   cold	   PBS/2%FCS.	   The	   Dynabeads	  were	   removed	   using	   DETACHaBEADS	  with	   a	   45	  
min	   incubation	   at	   room	   temperature	   followed	   by	   magnetic	   selection	   on	   the	   MPC.	  
Naïve	  CD45RA+	  T	  cells	  were	  purified	  from	  CD4+	  T	  cells	  by	  depletion	  of	  CD45RO+	  cells,	  
using	   mouse	   anti-­‐human	   CD45RO	   at	   10µl/1x107	   cells	   amount/cell	   (UCHL1;	   BD	  
Biosciences,	  San	  Jose,	  CA).	  Cells	  were	  then	  washed	  twice	  in	  PBS/2%FCS	  and	  incubated	  
for	   20	   min	   in	   the	   cold	   room	   with	   pre-­‐washed	   rat	   anti-­‐mouse	   pan	   IgG	   Dynabeads	  
(Invitrogen)	   according	   to	   manufacturer’s	   instructions.	   After	   magnetic	   depletion	   of	  
CD45RO+	   cells,	   unbound	   cells	   (CD45RA+)	  were	   removed,	   centrifuged	   at	   200	   g	   for	   10	  
min	   at	   4°C	   and	   resuspended	   at	   1x106/ml	   in	   sterile	   RPMI/10%FCS/PSG,	   before	   being	  
plated	  on	   tissue	   culture	   plates	   pre-­‐coated	  with	   anti-­‐CD3	   and	   anti-­‐CD28.	   Plates	  were	  
coated	   with	   anti-­‐CD3	   (1	   µg/ml;	   clone	   OKT3)	   and	   anti-­‐CD28	   (2	   µg/ml;	   clone	   15E8;	  
Sanquin	  Reagents,	  Amsterdam,	  The	  Netherlands)	  in	  HBSS	  for	  1.5	  hrs	  at	  37°C	  depending	  
on	  cell	  number	  on	  either	  24-­‐	  or	  48-­‐	  well	  plates,	  prior	  to	  plating.	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2.2.3 Flow	  cytometry	  
Human	  T	  cells	  were	  assessed	  for	  surface	  and	  intracellular	  cytokine	  expression	  prior	  to	  
their	   use	   in	   calcium	   assays,	   cyclic	   AMP	   assays,	   chemotaxis	   assays	   and	   their	   re-­‐
stimulation.	   Approximately	   2	   x	   106	   cells	  were	   harvested,	  washed	  with	   fluorescence-­‐
activated	  cell	  sorting	  (FACS)	  buffer	  (phosphate	  buffered	  saline	  (PBS)	  containing	  0.25%	  
Bovine	   Serum	  Albumin	   (BSA)	   and	  10%	   sodium	  azide)	   and	   centrifuged	   at	   200	  g	   for	   5	  
minutes	  before	  being	  incubated	  with	  different	  antibodies	  at	  different	  concentrations.	  
Cells	   were	   subsequently	   washed	   in	   FACS	   buffer,	   spun	   down	   for	   5	   minutes	   and	  
resuspended	  in	  500	  μl	  of	  FACS	  buffer	  prior	  to	  flow	  cytometry	  analysis.	  Flow	  cytometry	  
was	  performed	  using	  a	  FACScalibur	  (BD	  Biosciences,	  Oxford,	  UK).	  For	  analysis,	  a	  total	  
of	  10,000	   live	  cell	  events	  were	  collected	  and	  gated	  based	  on	  cell	  size	  and	  granularity	  
using	  forward	  and	  side	  scatter	  parameters.	  FITC-­‐	  or	  AlexaFluor	  488-­‐	  labelled	  antibody	  
staining	  was	  read	  on	  the	  FLH-­‐1	  channel,	  PE-­‐labelled	  antibody	  on	  the	  FLH-­‐2	  channel	  and	  
AlexaFluor	  647-­‐	  or	  APC-­‐labelled	  samples	  on	  the	  FLH-­‐4	  channel.	  Results	  were	  analysed	  
using	  BD	  Biosciences	  CellQuestTM	  Pro	  software,	  version	  5.2	  and	  FlowJo	  Flow	  Cytometry	  
Analysis	   Software	   for	  Macintosh	   version	   9.3.2.	  Dead	   cells	  were	   excluded	  by	   forward	  
and	  side	  scatter.	  A	  list	  of	  antibodies	  can	  be	  seen	  in	  Table	  2.2.	  
2.2.4 Surface	  and	  intracellular	  staining	  of	  Th1	  and	  Th2	  cells	  
Th1/Th2	  cells	   from	   in	  vitro	  culture	  were	  stained	  on	  the	  surface	  and	   intracellularly	  on	  
Day	  7,	  14,	  21	  and	  28.	  Between	  500	  μl	  and	  1	  ml	  of	  each	  T	  cell	  population	  was	  stimulated	  
for	   4	   hours	   with	   PMA	   (5	   ng/ml;	   Sigma-­‐Aldrich,	   St.Louis,	   WO)	   and	   ionomycin	   (500	  
ng/ml;	   Calbiochem,	   San	   Jose,	   CA)	   at	   37°C.	   After	   2	   hours	   of	   the	   4-­‐hour	   incubation,	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monensin	   (2	  µM;	   Sigma)	  was	   added	   to	   the	   stimulated	   and	   unstimulated	   T	   cells	   and	  
incubated	   at	   37°C.	   Following	   the	   4	   hours	   incubation,	   cells	   were	   harvested	   and	   7-­‐
amino-­‐actinomycin	   D	   (7-­‐AAD;	   4	   mg/ml;	   Sigma)	   was	   added	   to	   unstimulated	   and	  
stimulated	  cells,	  which	  were	  then	  transferred	  to	  FACS	  tubes	  and	  incubated	  on	  ice	  for	  
10	   min.	   Cells	   were	   washed	   with	   FACSFlow	   (BD	   Biosciences)	   and	   processed	   for	  
intracellular	   cytokine	   staining	   with	   the	   BD	   Cytofix/Cytoperm	   kit	   (BD	   Biosciences)	  
according	   to	   manufacturer’s	   instructions.	   500	   μl	   BD	   Cytofix/Cytoperm	   (Cat.	   No.	  
554722)	  were	  added	  to	  each	  tube,	  and	  each	  tube	  was	  vortexed	  and	  left	  to	  incubate	  for	  
20	   min	   on	   ice.	   Cells	   were	   then	   washed	   twice	   in	   FacsFlow	   and	   the	   pellet	   was	   re-­‐
suspended	  in	  BD	  Perm/Wash	  Buffer	  (Cat.	  No.	  554723),	  and	  left	  on	  ice	  while	  preparing	  
the	  antibodies	  for	  staining	  for	  approximately	  30-­‐45	  min.	  Antibodies	  were	  then	  added	  
to	  the	  tubes,	  followed	  by	  the	  cells,	  and	  incubated	  on	  ice	  for	  30	  min	  in	  the	  dark.	  Cells	  
were	  washed	  once	  in	  Perm/Wash	  and	  once	  in	  FACS	  Flow	  and	  re-­‐suspended	  in	  250	  µl	  of	  
FACS	   Flow	   for	   FACS	   analysis.	   All	   antibodies	   dilutions	   were	   prepared	   in	   Perm/Wash	  
buffer.	  A	  list	  of	  antibodies	  can	  be	  seen	  in	  Table	  2.2.	  
The	   remaining	   cells	   from	   the	   culture	   were	   counted	   using	   50	   µl	   of	   cells	   and	   10	   µl	  
propidium	  iodide	  (10	  µl/ml)	  and	  stained	  extracellularly	  with	  different	  antibodies.	  Cells	  
were	  then	  centrifuged	  and	  re-­‐suspended	  in	  fresh	  RPMI/10%FCS/1%PSG	  medium	  at	  a	  1	  
million	   cells/ml	   concentration,	   before	   being	   plated	   on	   a	   freshly	   coated	   plate	   with	  
HBSS,	   anti-­‐CD3	   (1	  µg/ml;	   clone	  OKT3)	   and	   anti-­‐CD28	   (2	  µg/ml;	   clone	   15E8;	   Sanquin	  
Reagents,	   Amsterdam,	   The	   Netherlands)	   and	   suitable	   cytokines	   and	   placed	   at	   37ºC	  
until	  Day	  3,	  12,	  24.	  A	  list	  of	  antibodies	  can	  be	  seen	  in	  Table	  2.2.	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Antibody Fluorochrome Species Company Cat6No
CD4 FITC Mouse,anti1human,monoclonal BD,Pharmingen 555346
APC Mouse,anti1human,monoclonal BD,Pharmingen 555349
CD8 PE Mouse,anti1human,monoclonal BD,Pharmingen 555367
CD45RA FITC Mouse,anti1human,monoclonal BD,Pharmingen 555488
CD45RO PE Mouse,anti1human,monoclonal BD,Pharmingen 555493
IFNγ Alexa,Fluor,488 Mouse,anti1human,monoclonal In1house
IL14 PE Mouse,anti1human,monoclonal BD,FastImmune 340451
APC Rat,anti1human,monoclonal BD,Pharmingen 554486
IL15 APC Rat,anti1human,monoclonal BD,Pharmingen 554396
IL113 PE Rat,anti1human,monoclonal BD,Pharmingen 554571
CysLTR1 Rabbit,anti1human,polyclonal Novus,Biologicals NLS1317
Rabbit,anti1human,polyclonal Cayman,Chemicals 120500
Table	   2.2	   Antibodies	   used	   for	   surface	   and	   intracellular	   staining	   using	   flow	  
cytometry.	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2.2.5 Measurement	  of	  calcium	  
Cultured	  human	  Th1	  and	  Th2	  cells	  were	  tested	  for	  their	  calcium	  signalling	  when	  fully	  
differentiated	  at	  Day	  21	  and	  28	   in	   response	   to	   cysteinyl	   leukotrienes	   LTC4,	   LTD4	   and	  
LTE4.	   Cells	   were	   re-­‐suspended	   at	   200,000	   cells/well	   in	   100	   µl	   RPMI/2%HEPES	   and	  
plated	  on	  to	  a	  96-­‐well	  black-­‐wall,	  clear	  flat-­‐bottom	  assay	  plate	  (Costar),	  and	  an	  equal	  
volume	  of	   loading	  buffer	   (Component	  A	  with	  1X	  HBSS	  Buffer;	   FLIPR	  Calcium	  4	  Assay	  
Kit;	  Molecular	  Devices)	  was	  added.	  	  The	  plate	  was	  incubated	  for	  1	  hour	  at	  37°C	  and	  5%	  
CO2.	   	   After	   incubation,	   the	   plate	  was	   centrifuged	   at	   200g	   for	   5	  min	   and	   transferred	  
directly	   to	   a	   FlexStation	   3	  Microplate	   Reader.	   Controls	   included	   a	   negative	  medium	  
control	   of	   RPMI/2%	  HEPES,	   and	   a	   positive	   control	   SDF-­‐1/CXCL12,	   and	   all	  wells	  were	  
done	   in	   triplicates.	   Cysteinyl	   leukotrienes	   LTC4,	   LTD4	   and	   LTE4	   were	   used	   at	   various	  
doses	  ranging	  from	  0.1,	  1,	  10	  and	  100	  nM.	  Concentrations	  for	  positive	  controls	  PGD2	  
and	   SDF1α	  were	   used	   at	   various	   doses	   ranging	   from	   0.1,	   1	   and	   10nM,	   and	   10	   nM,	  
respectively.	  Where	  indicated,	  the	  selective	  CysLTR1	  inhibitor	  MK571	  was	  used	  at	  100	  
nM,	  montelukast	  and	  zafirlukast	  were	  used	  at	  10	  nM	  concentrations,	  and	  added	  prior	  
to	   adding	   the	   ligand.	   Pertussis	   toxin	   (PTX),	   a	   toxin	   produced	   by	   the	   bacterium	  
Bordetella	   pertussis	   which	   we	   used	   to	   identify	   the	   CysLTR1	   G	   protein	   signalling	  
pathway,	  was	  used	  in	  some	  of	  our	  experiments	  at	  a	  concentration	  of	  0.1	  mg/ml	  (PTX,	  
Sigma)	  for	  a	  16	  to	  24-­‐hour	  incubation	  period	  to	  inhibit	  Gαi.	  Where	  indicated,	  EDTA	  and	  
thapsigargin	   (THP)	   were	   used	   to	   determine	   the	   origin	   of	   calcium	   in	   our	   assays,	   at	  
concentrations	  of	  2.5	  mM	  and	  1μM,	  respectively,	  and	  added	  prior	  to	  adding	  the	  ligand.	  
Results	  were	  analysed	  using	  SoftMax	  Pro	  Software	  (Molecular	  Devices),	  and	  data	  are	  
	   	   MATERIALS	  &	  METHODS	  
 
 82	  
shown	  as	  a	  percentage	  of	  maximal	  response.	  All	  experiments	  were	  replicated	  at	  least	  
three	  times	  and	  performed	  in	  triplicate.	  
2.2.6 Measurement	  of	  cyclic	  AMP	  
Intracellular	   cyclic	   AMP	   (cAMP)	   levels	   were	   measured	   by	   luminescence	   with	   the	  
HitHunter	  cAMP	  XS+	  assay	  (DiscoverRX,	  Birmingham,	  United	  Kingdom).	  The	  assay	  was	  
carried	  out	  according	  to	  the	  manufacturer’s	  protocol	  for	  a	  3-­‐reagent	  addition.	  	  Human	  
Th2	  cells	  were	  tested	  for	  their	  cAMP	  signalling	  when	  fully	  differentiated	  at	  Day	  21	  and	  
28	  (on	  the	  same	  day	  as	  the	  calcium	  and	  migration	  assays).	  Th2	  cells	  were	  suspended	  in	  
PBS	   at	   a	   concentration	   of	   10	   x	   106/ml	   and	  warmed	   to	   37°C,	   and	   1	   nM	  3-­‐isobutyl-­‐1-­‐
methylxanthine	   (IBMX,	   Sigma)	   was	   added	   to	   inhibit	   cAMP	   phosphodiesterases.	   The	  
Th2	   cell	   suspension	   (2	   x	   105	   cells/well)	  was	   loaded	   into	   a	   96-­‐well	   plate,	   and	   20	   μM	  
forskolin	  were	  added	  to	  stimulate	  cAMP	   induction	  along	  with	  varying	  concentrations	  
of	   LTD4	   ranging	   from	   0.1	   to	   100	   nM,	   as	   indicated	   in	   the	   results	   section.	   Where	  
indicated,	  100	  nM	  MK571	  was	  added	  5	  minutes	  prior	  to	  adding	  the	  ligand.	  Plates	  were	  
incubated	   at	   37°C	   for	   15	  minutes	   before	   cells	  were	   processed	   according	   to	   the	   kit’s	  
instructions,	   and	   cAMP	   signal	   was	   detected	   by	  means	   of	   luminescence	  measured	   4	  
hours	  after	  cell	   lysis.	  Luminescence	  was	  detected	  by	  using	  a	  Flexstation	  3	   (Molecular	  
Devices),	   and	   analysis	   of	   cAMP	   concentrations	   was	   performed	   with	   SoftMax	   Pro	  
software	   (Molecular	  Devices).	  Data	  are	  shown	  as	  a	  percentage	  of	  maximal	   response.	  
All	  experiments	  were	  replicated	  at	  least	  three	  times	  and	  performed	  in	  triplicate.	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2.2.7 Migration	  assay	  
Chemotaxis	   assays	   were	   carried	   out	   using	   24	   well	   6.5mm	   Transwell®	   plates	   with	   a	  
polycarbonate	  membrane	  insert	  filter	  with	  pore	  size	  of	  5.0	  µm	  (Corning,	  3421).	  
In	   vitro	   cultured	  human	  Th2	  cells	  were	   resuspended	  at	  1x106/ml	   in	  RPMI	  buffer	  and	  
rested	  for	  4	  hours	  in	  a	  low	  rIL-­‐2	  concentration	  (25	  units/ml;	  Novartis,	  Horsham,	  U.K.),	  
then	  harvested,	  washed	  in	  PBS	  and	  resuspended	  at	  500,000	  cells/100	  µl	  in	  chemotaxis	  
buffer	  (RPMI	  +	  20	  nM	  Hepes	  +	  0.5%	  ultrapure	  BSA	  (Sigma.	  A7638).	  600	  µl	  chemotaxis	  
buffer	   with	   or	   without	   chemokine	   or	   leukotriene	   of	   interest	   were	   loaded	   on	   the	  
bottom	   of	   the	   transwell.	   Each	   leukotriene	   (LTD4,	   LTE4,	   positive	   control	   SDF1)	  
concentration	  (at	  0.01,	  0.03,	  0.1,	  0.3,	  1,	  3,	  10,	  30,	  100	  nM)	  or	  buffer	  alone	  control	  was	  
tested	  in	  duplicate.	  Using	  tweezers,	  the	  top	  of	  transwell	  was	  placed	  in	  the	  bottom	  well	  
and	  cells	  were	   left	   to	  chemotax	   for	  2	  hours	   in	  a	  37ºC	  and	  5%	  CO2	   incubator.	  After	  2	  
hours,	  the	  plate	  was	  placed	  in	  the	  refrigerator	  for	  15	  minutes.	  The	  top	  of	  the	  transwell	  
was	   then	   removed	  and	  20,000/20	  µl	   beads	   (polystyrene	  15	  µm	  beads,	   Polysciences,	  
18328)	  were	  added	  per	  well	  and	  the	  mixture	  of	  cells	  and	  beads	  was	  transferred	  to	  a	  
FACS	   tube.	   The	  number	   of	   cells	   that	  migrated	   through	   the	   filter	  was	   determined	  by	  
flow	  cytometry	  by	  setting	  SSC	  to	  log	  scale	  to	  visualise	  the	  beads	  on	  scale,	  then	  setting	  
a	   gate	   around	   beads	   and	   acquiring	   10,000	   beads	   per	   tube.	   Cell	   numbers	   were	  
processed	  and	  plotted	  using	  Prism	  software.	  A	  Chemotactic	   Index	  (CI)	  was	  calculated	  
as	  the	  ratio	  of	  migration	  in	  any	  given	  sample	  to	  the	  basal	  migration	  to	  buffer	  alone.	  A	  
CI	   value	   of	   1	   therefore	   represents	   no	   chemotaxis	   above	   basal	   migration	   to	   buffer	  
alone.	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2.2.8 Proliferation	  assay	  
200,000/200μl	   Th1	   and	   Th2	   cells	   were	   seeded	   per	   well	   on	   a	   24-­‐well	   plate	   in	   RPMI	  
complete	  medium.	  Some	  of	  the	  cells	  were	  plated	  with	  100	  nM	  LTD4	  and	  some	  without.	  
After	  24	  hours,	  10	  μl/well	  (1:2)	  3H-­‐Thymidine	  were	  added	  to	  the	  cells.	  Cells	  were	  then	  
incubated	  for	  18	  hours	  at	  37°C.	  The	  more	  cell	  divisions	  (or	  the	  higher	  the	  proliferation	  
rate)	  the	  more	  radioactivity	  will	  be	  incorporated	  into	  DNA.	  Following	  incubation,	  filter	  
paper	  was	  used	  over	  the	  plate	  and	  the	  cells	  were	  harvested	  by	  washing	  the	  cells	  with	  
distilled	  water	  several	  times.	  The	  cell	  fragments	  and	  DNA	  were	  passed	  through	  a	  filter	  
membrane	   (glass	   fibre).	   The	   filter	   membrane	   was	   dried	   and	   transferred	   to	   a	   white	  
plate	   containing	   25	   μl	   microsin	   (scintillation	   fluid),	   before	   being	   analysed	   on	   a	  
scintillation	  counter	  to	  measure	  the	  amount	  of	  radioactivity.	  
	  
2.2.9 	  RNA	  extraction	  
For	  RNA	  extraction	  of	  fully	  differentiated	  Th1	  and	  Th2	  resting	  and	  activated	  cells,	  cells	  
were	  harvested	  at	  Day	  21	  or	  Day	  28,	  washed	  in	  FACS	  flow	  and	  PBS	  and	  spun	  down	  at	  
1200	  rpm	  to	  obtain	  a	  pellet.	  Cells	  for	  RNA	  isolation	  were	  snap-­‐frozen	  in	  liquid	  nitrogen	  
and	  stored	  at	  -­‐80°C.	  Total	  cellular	  RNA	  was	  isolated	  from	  resting	  and	  activated	  T	  cells	  
using	   the	  miRNeasy	  mini	   kit	   (Qiagen,	   Crawley,	   UK)	   according	   to	   the	  manufacturer’s	  
protocol.	   Briefly,	   cells	   were	   thawed	   out	   and	   lysed	   using	   700	   μl	   Trizol	   (Invitrogen)	  
before	  being	  vortexed	  to	  homogenize.	  140	  μl	  of	  chloroform	  were	  added	  to	  each	  lysate	  
and	  phases	  were	  mixed	  by	  vigorous	  shaking	  for	  15	  seconds	  before	  placing	  the	  tube	  at	  
room	  temperature	  for	  2-­‐3	  minutes.	  Phases	  were	  separated	  by	  centrifugation	  at	  12,000	  
g	  for	  15	  min.	  The	  upper	  aqueous	  phase	  containing	  the	  RNA	  was	  pipetted	  out,	  placed	  in	  
a	   new	   tube	   and	   mixed	   vigorously	   with	   1.5	   volumes	   of	   100%	   ethanol,	   before	   being	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transferred	  onto	  an	  RNeasy	  Mini	  column.	  Further	  steps	  were	  carried	  out	  according	  to	  
the	  manufacturer’s	  manual.	  RNA	  was	  eluted	  in	  80	  μl	  and	  mixed	  with	  10	  μl	  10x	  buffer	  
and	  10	  μl	  TurboDNase	  (TURBO	  DNase	  Kit,	  Ambion),	  and	  incubated	  for	  an	  hour	  at	  37°C.	  
100	  μl	  phenol:chloroform:isoamyl	  alcohol	  (25:24:1)	  (pH	  5.2,	  Invitrogen)	  were	  added	  to	  
the	  samples.	  The	  samples	  were	  vortexed	  for	  20	  seconds	  before	  centrifuging	  at	  12,000	  
g	   for	   15	   min	   at	   room	   temperature	   to	   allow	   phase	   separation.	   The	   upper	   aqueous	  
phase	  was	  carefully	  removed	  without	  disturbing	  the	  interface,	  or	  phenol	  phase,	  before	  
adding	  1.5	  volumes	  100%	  ethanol	  (approximately	  150	  μl)	  and	  transferring	  the	  samples	  
to	   RNeasy	   Mini	   column.	   The	   samples	   were	   then	   washed	   according	   to	   the	  
manufacturer’s	  manual.	   The	   samples	  were	   eluted	   in	   30	   μl	   RNase-­‐free	  water	   (1	  min,	  
10,000	   g,	   20°C).	   RNA	   concentration	   was	   measured	   at	   260	   nm	   with	   a	   NanoDrop	  
spectrophotometer	  (Thermo	  Scientific).	  RNA	  integrity	  was	  determined	  on	  a	  RNA	  6000	  
Nano	  LabChip	  (RNA	  6000	  Nano	  Kit,	  Agilent	  Technologies)	  using	  the	  Agilent	  Bioanalyser	  
2100	  machine	  (Agilent	  Technologies),	  according	  to	  the	  manufacturer’s	  instructions.	  
2.2.9.1 Reverse	  transcription	  
Briefly,	  RNA	  samples	  were	  adjusted	  to	  250	  ng	  and	  4	  μl	  of	  random	  hexamer	  (0.1µg/µl	  
pd(N)6;	  Amersham)	  was	  added	  to	  each	  sample	  in	  a	  22	  μl	  final	  volume	  of	  water.	  Using	  
the	  RevertAid	  First	  Strand	  cDNA	  Synthesis	  Kit,	   samples	  were	   incubated	  at	  70°C	   for	  5	  
min	  before	  being	  placed	  on	  ice.	  16	  μl	  of	  reaction	  mix	  (see	  below)	  were	  then	  added	  to	  
each	  sample	  before	  an	  incubation	  of	  5	  min	  at	  25°C.	  
	  
	  




	   8	  μl	  5x	  reaction	  buffer	  (Fermentas)	  
	   4	  μl	  10	  nM	  dNTPs	  (Fermentas)	  
	   1	  μl	  RiboLock	  (Fermentas)	  
	   2	  μl	  dH2O	  
	  
2	  μl	  Revert-­‐Aid	  Reverse	  Transcriptase	  (Fermentas	  Life	  Sciences;	  400	  U/reaction)	  were	  
added	   to	   each	   sample	   and	   the	   reaction	   incubated	   at	   room	   temperature	   for	   10	  min,	  
before	  42°C	  for	  1	  hour;	  followed	  by	  70°C	  for	  10	  min,	  using	  a	  PTC-­‐100	  Thermal	  cycler.	  
260	   μl	   dH2O	  were	   then	   added	   to	   each	   sample.	   cDNA	   samples	  were	   stored	   at	   -­‐80°C	  
before	  use	  in	  real-­‐time	  RT-­‐PCR.	  
2.2.10 Microarrays	  
Following	   extraction	   of	   total	   cellular	   RNA	   and	   determination	   of	   RNA	   quality,	   as	  
described	   earlier,	   RNA	   was	   reverse	   transcribed	   into	   cDNA,	   which	   was	   then	   in	   vitro	  
transcribed	   into	   cRNA.	   For	  GeneChip	  U133	  plus	   2	   arrays	   (Affymetrix),	   cRNA	   samples	  
were	   prepared	   for	   microarray	   hybridization,	   according	   to	   the	   manufacturer’s	  
instructions	   using	   the	   Ambion	   MessageAmp	   Premier	   RNA	   amplification	   kit	   (Life	  
Technologies).	   For	   GeneChip	   Human	  Gene	   1.0	   ST	   arrays	   (Affymetrix),	   cRNA	   samples	  
were	   prepared	   for	   microarray	   hybridization	   according	   to	   the	   manufacturers	  
instructions	  using	  the	  Ambion	  WT	  Expression	  Kit	  (Life	  Technologies).	  Fragmented	  cRNA	  
was	   hybridized	   to	   GeneChip	   arrays	   at	   45°C	   for	   18	   hours.	   Arrays	   were	   washed	   and	  
stained	  with	  streptavidin-­‐phycoerythrin,	  according	  to	  the	  manufacturer’s	  instructions,	  
on	   the	  GeneChip	   fluidics	   station	  450	   (Affymetrix).	   Fluorescent	   signals	  were	  detected	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with	  the	  GeneChip	  scanner	  3000.	  Images	  were	  analysed	  with	  the	  GeneChip	  Command	  
Console	  Software	  (Affymetrix)	  to	  generate	  raw	  data	  as	   .cel	   files.	  Further	  analysis	  was	  
performed	  with	   the	   Partek	  Genomics	   Suite	   (Partek,	   St	   Louis,	  Mo)	   by	   using	   the	   gene	  
expression	   workflow	   to	   identify	   differentially	   expressed	   genes.	   Briefly,	   robust	  
multichip	   average	   (RMA)	   pre-­‐processing	   was	   performed,	   along	   with	   quantile	  
normalization,	  and	  genes	  differentially	  expressed	  samples	  were	  identified	  by	  using	  the	  
Partek	  ANOVA	  model.	  Statisical	  significance	  including	  false	  discovery	  rate	  analysis	  was	  
performed	  using	  Partek	  and	  the	  Benjamini-­‐Hochberg	  Step	  up	  procedure	  to	  correct	  for	  
multiple	  comparisons.	  	  
2.2.11 Reverse	  Transcription	  Polymerase	  Chain	  Reaction	  (RT-­‐PCR)	  
In	  order	   to	  confirm	  the	  results	  obtained	  by	  microarray	  analysis	  and	   to	  quantify	  gene	  
expression,	   RT-­‐PCR	   analysis	  was	   performed.	   Primer	   sets	   used	   for	   these	   experiments	  
can	  be	  seen	  in	  Table	  2.3.	  All	  primers	  and	  probe	  sets	  were	  tested	  for	  multiplexing	  with	  
the	  endogenous	  control	  18s	  rRNA	  primer	  set.	  Real-­‐time	  PCR	  was	  carried	  out	  using	  2X	  
Master	  mix	  (Applied	  Biosystems),	  18s	  rRNA	  (Applied	  Biosystems)	  50	  nM	  Primer,	  83	  nM	  
Probe/reaction	  and	  2.5	  μl	  cDNA	  in	  a	  15	  µl	  reaction	  volume	  per	  well	  in	  384	  well	  plates.	  
RT-­‐PCR	  was	  carried	  out	  at	  50°C	  for	  2	  min,	  95°C	  for	  10	  min,	  95ºC	  for	  15	  sec,	  and	  60ºC	  
for	  1	  min	  for	  50	  cycles	  using	  an	  ABI	  Prism	  7900HT	  Thermal	  Cycler	  (Applied	  Biosystems).	  
Results	   were	   analysed	   using	   SDS	   2.4	   Software	   (Applied	   Biosystems).	   Relative	  
quantification	   was	   performed	   using	   the	   2-­‐∆∆ct	   method	   (Livak	   and	   Schmittgen	   2001).	  
Statistical	   analyses	  were	   performed	   by	   comparing	   gene	   expression	   levels	   relative	   to	  
18s	   rRNA	   levels	   by	   using	   a	   2-­‐way	   repeated-­‐measures	   ANOVA	   with	   Bonferroni	   post	  
tests	  in	  GraphPad	  Prism	  version	  5.0a	  software	  (GraphPad,	  Inc,	  La	  Jolla,	  CA).	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Real-­‐time	  RT-­‐PCR	  Reaction	  Mix	  
	   7.5	  μl	  2x	  Mastermix	  
	   0.5	  μl	  FAM	  primer	  set	  
	   0.5	  μl	  18s	  VIC	  primer	  set	  
	   4.0	  μl	  dH2O	  
	   2.5	  μl	  cDNA	  
	  
2.2.12 Statistical	  Analysis	  
Statistical	  analyses	  were	  performed	  using	  GraphPad	  Prism	  or	  Partek	  GS.	  The	  statistical	  

































HEK293	  cells	  were	  seeded	  at	  3	  x	  106	  cells/10cm	  plate	  with	  warm	  Dulbecco's	  Modified	  
Eagle	  Medium	   (DMEM)	   supplemented	  with	   L-­‐Glutamine,	   10%	   FBS	   and	   10%	   PSG,	   on	  
Day	  0	  and	  incubated	  for	  24	  hours	  at	  37°C.	  On	  Day	  1,	  10	  to	  20	  μg	  of	  construct	  DNA	  was	  
used	   and	   the	   volume	   adjusted	   to	   250	   μl	   with	   sterile	   H2O.	   250	   μl	   of	   0.5	  M	   Calcium	  
Chloride	  solution	  (CaCl2,	  Fluka)	  were	  mixed	  with	  the	  DNA	  and	  this	  was	  added	  dropwise	  
on	  to	  500	  μl	  of	  2x	  concentrated	  HEPES	  buffered	  saline	  (HBS,	  Fluka)	  while	  bubbling	  with	  
a	   thin-­‐tipped	   pastette.	   Tubes	   were	   left	   to	   stand	   for	   30	   min	   at	   room	   temperature,	  
before	  being	  added	  dropwise	  to	  the	  plated	  HEK293	  cells.	  Cells	  were	  incubated	  for	  24	  
hours	   at	   37°C.	  On	  Day	   2,	  media	  was	   removed	   and	   replaced	   by	   10ml	   of	  DMEM,	   and	  
incubated	  for	  24	  hours.	  On	  Day	  3,	  cells	  were	  harvested	  and	  stained	  with	  antibodies	  for	  
FACS	  analysis	  or	  frozen	  for	  protein	  extraction	  and	  western	  blotting.	  
2.2.14 SDS-­‐PAGE	  and	  Western	  blotting	  
2.2.14.1 Cell	  lysis	  
HEK293	   transfectants	   were	   grown	   in	   10	   cm	   plates	   at	   3	   x	   106	   cells/10cm.	   DMEM	  
medium	  was	  removed	  and	  cells	  were	  rinsed	  twice	  in	  ice-­‐cold	  PBS.	  Cells	  were	  lysed	  in	  
150	  μl	   lysis	  buffer	  (details	  below).	  The	   lysates	  were	  collected	  and	  boiled	  for	  5	  min	  at	  
100°C.	  To	   fragment	  genomic	  DNA,	   the	   lysates	  were	  sonicated	  on	   ice	  and	  centrifuged	  
for	  2	  min	  at	  10,000	  g.	  The	  supernatants	  were	  aliquoted	  and	  stored	  at	  -­‐20°C.	  
	  
	  




	   Tris.HCl	  50	  mM	  pH7.5	  
	   EDTA	  1mM	  
	   1%	  TritonX-­‐100	  
	   In	  10	  ml	  1	  tablet	  protease	  inhibitors	  (Roche	  11	  836	  170	  001)	  
	   In	  10	  ml	  1	  tablet	  phosphatase	  inhibitors	  (Roche	  04906845001)	  
	  
2.2.14.2 Protein	  denaturation	  
Proteins	   were	   denatured	   according	   to	   manufacturer’s	   instructions.	   Briefly,	   20	   µg	  
protein	  were	  made	  up	   to	  a	   final	   volume	  of	  19.5µl	   using	   lysis	  buffer.	   3µl	   of	   reducing	  
agent	  (NuPage®	  Sample	  Reducing	  Agent	  (10x),	   Invitrogen)	  and	  7.5µl	  of	  sample	  buffer	  
(NuPage®	  Sample	  Buffer	  (4x),	  Invitrogen)	  were	  added	  to	  the	  protein	  mix	  and	  samples	  
were	   incubated	  at	  95ºC	  for	  10	  min.	  Samples	  were	   loaded	  on	  to	  a	  NuPage	  ®	  10%	  Bis-­‐
Tris	  Gel	   1.0mm	   (Invitrogen)	   next	   to	   3µl	   of	  MagicMark	   protein	   standard	   (Invitrogen).	  
The	  gel	  was	  run	  in	  a	  gel	  tank	  filled	  with	  running	  buffer	  (50ml	  20x	  running	  buffer	  in	  1L	  
water	  with	  500µl	  NuPage	  ®	  antioxidants,	  all	  Invitrogen)	  at	  180V	  for	  1h30.	  
	  
2.2.14.3 Western	  blotting	  
Protein	  was	  then	  transferred	  onto	  a	  membrane	  (Nitrocellulose	  Membrane	  Filter	  Paper	  
Sandwich,	   0.2µM	   pore	   size,	   Invitrogen)	   using	   an	   XCell	   II	   Blot	   Module	   (Invitrogen)	  
containing	   two	  blotting	  pads,	   two	   filter	  papers,	   the	  gel,	   the	   transfer	  membrane,	   two	  
filter	  papers	  and	   two	  blotting	  pads	   in	   that	  order.	  The	   transfer	  module	  was	  placed	   in	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the	   chamber	   and	   the	   chamber	   filled	   with	   transfer	   buffer	   (50ml	   transfer	   buffer	   and	  
100ml	  methanol	  in	  1L	  water	  with	  1ml	  antioxidants,	  all	  Invitrogen),	  run	  at	  30V	  for	  1h.	  
The	  membrane	  was	   blocked	   in	   5%	  milk	   in	   TBS-­‐Tween	   (1	   sachet	   Tris	   Buffered	   Saline	  
with	  Tween	  ®	  20,	  pH8.0,	  Sigma,	  in	  1L	  of	  water)	  for	  1h30	  placed	  at	  room	  temperature	  
on	  a	  plate	  rocker.	  
Membranes	   were	   then	   incubated	   with	   primary	   antibody	   anti-­‐CysLT1R	   (polyclonal,	  
Cayman	  Chemical	  Company)	  at	  1:100,	  1:1000	  and	  1:5000	  dilutions	   in	  5%	  milk	   in	  TBS-­‐
Tween,	  at	  4°C	  overnight	  on	  a	  plate	  rocker.	  Membranes	  were	  washed	  three	  times	  for	  
10	   min	   with	   TBS-­‐Tween	   then	   incubated	   with	   a	   secondary	   goat	   anti-­‐rabbit	   antibody	  
(Southern	  Biotech)	  at	  a	  1:5000	  dilution	  in	  5%	  milk	  in	  TBS-­‐Tween,	  on	  a	  plate	  rocker	  at	  
room	  temperature	  for	  1h30.	  Membranes	  were	  then	  washed	  again	  three	  times	  for	  10	  
min	  with	  TBS-­‐Tween,	  developed	  for	  5	  min	  using	  the	  ECL	  Western	  Blotting	  Detection	  Kit	  
(GE	   Healthcare),	   and	   developed	   using	   a	   COMPACT	   X2	   developer	   (X-­‐OGRAPH	   LTD)	  
following	  30	  sec,	  1	  min,	  5	  min,	  30	  min	  exposures.	  
Membranes	   were	   then	   washed	   three	   times	   for	   10	   min	   in	   TBS-­‐Tween	   and	   stripped	  
using	   Restore	   ™	   PLUS	  Western	   Blot	   Stripping	   Buffer	   (Thermo	   Scientific)	   for	   15	  min.	  
They	  were	  washed	  again	   three	   times	   for	  10	  min	   in	  TBS-­‐Tween	  and	  blocked	   for	  1h30	  
with	  5%	  milk	  in	  TBS-­‐Tween,	  followed	  by	  an	  overnight	  incubation	  with	  primary	  antibody	  
anti-­‐GAPDH	   (GTX28245,	   GeneTex)	   at	   1:25000	   dilution	   in	   5%	   milk	   in	   TBS-­‐Tween.	  
Membranes	  were	  washed	  again	  three	  times	  for	  10	  min	  then	  incubated	  1h30	  min	  with	  
a	   secondary	   goat	   anti-­‐mouse	   (IgG-­‐HRP,	   Santa	   Cruz	   Biotechnology),	   followed	   by	   an	  
additional	   three	  washes	  and	   then	  developed.	  Membranes	  were	  developed	  using	   the	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Chapter	  3 Results	  –	  Expression	  &	  signalling	  of	  CYSLTR1	  
3.1 Introduction	  
Although	  a	   large	  amount	  of	   studies	  have	  searched	   to	  define	   the	   role	  of	   leukotrienes	  
and	   their	   receptors	   in	   asthma,	   there	   is	   still	   limited	   knowledge	   about	   the	   effect	   of	  
leukotrienes	   on	   cells	   in	   the	   human	   lung	   or	   their	   exact	   mode	   of	   action.	   Numerous	  
studies	   have	   attempted	   to	   characterise	   the	   CysLT1	   receptor	   and	   determine	   its	  
expression	  profile,	  as	  well	  as	  try	  and	  define	  its	  role	  in	  the	  immune	  system	  and	  its	  effect	  
on	  its	  surrounding	  cells.	  We	  have	  previously	  described	  the	  initial	  cloning	  studies	  of	  the	  
CYSLTR1	  gene	  and	  the	  experiments	  performed	  to	  date	  examining	  CysLTR1	  expression.	  
The	   following	   section	   provides	   an	   overview	   of	   the	   experiments	   investigating	   the	  
function	  of	  CYSLTR1	  in	  humans	  and	  mice.	  
There	  have	  been	  extensive	  studies	  on	  the	  signalling	  pathway	  used	  by	  CysLT1R.	  CysLT1R	  
is	   a	   known	   G	   protein-­‐coupled	   receptor,	   characterised	   by	   the	   seven-­‐transmembrane	  
topology	  and	  its	  pathway	  of	  activation	  is	  therefore	  well	  illustrated.	  
When	  CYSLTR1	  was	  cloned	  by	  two	  groups	  in	  1999	  (Lynch	  et	  al.	  1999;	  Sarau	  et	  al.	  1999)	  
using	   a	   cognate	   ligand	   strategy	   for	   fishing	   for	   orphan	   GPCRs,	   the	   biochemical	   and	  
pharmacological	   findings	   confirmed	   the	   receptor	   belonged	   to	   the	  G	   protein-­‐coupled	  
receptors	  family	  characterised	  by	  seven	  transmembranes	  spanning	  the	  surface	  of	  the	  
cell.	   Both	   cysteinyl	   leukotriene	   receptors	   belong	   to	   the	   class	   A	   rhodopsin	   family,	  
particularly	   to	   the	   purine	   receptor	   cluster	   of	   phylogenetically	   related	   receptors,	  
including	  P2Ys,	  F2Rs	  and	  PAFRs	  (Fredriksson	  et	  al.	  2003;	  Kroeze	  et	  al.	  2003).	  
	  










Figure	   3.1	   Phylogenetic	   trees	   of	   G	   protein-­‐coupled	   receptors	   and	   discovered	  
structures.	   Highlighted	   receptors	   indicate	   that	   the	   chemical	   structure	   of	   the	  
GPCR	  has	  been	  solved.	  This	  map	  was	  taken	  from	  The	  Scripps	  Research	  Institute	  
GPCR	  Network	  website	  http://gpcr.scripps.edu/(GPCR	  Network)	  
2
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Several	  groups	  have	  therefore	  attempted	  to	  shed	  some	  light	  on	  the	  G	  protein-­‐coupled	  
receptor	  and	  its	  signalling	  G	  protein	  of	  choice,	  in	  various	  systems.	  
Monocytes	   and	   macrophages	   have	   been	   reported	   to	   respond	   to	   LTD4	   by	   calcium	  
mobilisation.	  As	  mentioned	  previously,	   Thivierge	  et	  al.	   investigated	   the	  effect	  of	   IL-­‐4	  
and	   IL-­‐13	   on	   calcium	  mobilization	   and	   the	   functional	   responsiveness	   of	   the	   cells	   to	  
LTD4.	  Treatment	  of	  monocytes	  with	   IL-­‐13	  or	   IL-­‐4	   lead	   to	  an	   increased	  calcium	  flux	   in	  
response	  to	  LTD4,	  but	  not	  LTB4.	  A	  similar	  treatment	  of	  monocyte-­‐derived	  macrophages	  
led	  to	  an	  even	  larger	  increase	  than	  in	  monocytes.	  These	  responses	  were	  fully	  inhibited	  
by	  antagonist	  MK571.	  Thivierge	  et	  al	  also	   investigated	  the	  effect	  of	   IL-­‐13	  and	   IL-­‐4	  on	  
the	   migration	   of	   monocytes	   towards	   LTD4,	   which	   we	   will	   get	   back	   to	   in	   the	   next	  
chapter	  (Thivierge	  et	  al.	  2001).	  	  
Cysteinyl	   leukotrienes	  also	  cause	  calcium	  flux	   in	  mast	  cells,	  which	  have	   the	  ability	   to	  
induce	  calcium	  desensitisation	  in	  neighbouring	  resting	  mast	  cells	  via	  a	  CysLT	  paracrine	  
signalling	  pathway	  (Di	  Capite	  and	  Parekh	  2009).	  Strong	  calcium	  mobilization	  caused	  by	  
LTD4	  was	  also	  found	  in	  bone	  marrow	  and	  peripheral	  blood	  CD34+	  progenitor	  cells,	  with	  
weaker	   effects	   observed	   using	   LTC4	   and	   LTD4.	   This	   effect	   was	   blocked	   using	   CysLT1	  
receptor	  antagonist	  MK571	  (Bautz	  et	  al.	  2001).	  Similar	  observations	  have	  been	  made	  in	  
human	   basophils,	   and	   the	   effect	   blocked	   by	   antagonist	   zafirlukast	   (Gauvreau	   et	   al.	  
2005).	   In	  T	   cells,	   LTD4	   induces	  a	   robust	   calcium	  signal	   in	  LatY136F	   CD4+	  T	   cells	   from	  
mice	  but	  this	  was	  not	  reported	  in	  wild-­‐type	  CD4+	  T	  cells	  (Prinz	  et	  al.	  2005).	  
It	   is	   known	   that	   both	   CysLT1	   and	   CysLT2	   receptors	   can	   couple	   to	   distinct	   types	   of	   G	  
proteins.	   In	   recombinant	   systems,	  CysLT1	   receptor	   couples	  preferably	   to	   the	  Gαq/11	  
pathway,	   modulating	   inositol	   phospholipids	   hydrolysis	   and	   calcium	   mobilization,	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whereas	   in	   native	   systems	   it	   has	   been	   found	   that	   the	   receptor	   generally	   activates	   a	  
Gαi/o	  protein,	  sensitive	  to	  pertussis	  toxin,	  or	  both	  a	  Gαi/o	  and	  Gαq/11	  pathway	  (Capra	  
et	  al.	  2005).	  
According	   to	   Lynch	  et	   al.	   (Lynch	   et	   al.	   1999),	   treatment	   of	   HEK293	   cells	   transfected	  
with	  CysLT1R	  with	  pertussis	  toxin	  did	  not	  affect	  the	  Ca2+	  responses	  produced	  by	  LTC4,	  
LTD4,	  or	  LTE4.	  Conversely	  in	  human	  cells,	   it	  was	  firstly	  reported	  using	  the	  human	  pro-­‐
monocytic	   differentiated	   U937	   cell	   line,	   in	   which	   the	   receptor	   modulates	   calcium	  
responses	  via	  Gαi/o	  and	  Gαq/11	   (Capra	  et	  al.	  2003;	  Saussy	  et	  al.	  1989)	  but	  with	   the	  
activation	  of	  the	  Ras-­‐MAPK	  cascade	  entirely	  dependent	  on	  Gαi/o	  (Capra	  et	  al.	  2004).	  
Similarly	   in	  human	  acute	  monocytic	   leukaemia	  THP-­‐1	  cells,	  Hoshino	  et	  al	   (Hoshino	  et	  
al,	  1998)	   reported	  both	  a	  pertussis	   toxin-­‐insensitive	  MAPK	  activation	  and	  a	  pertussis	  
toxin-­‐sensitive	   chemotactic	   response.	  More	   data	   confirmed	   these	   findings	   in	   airway	  
smooth	  muscle	  cells	  (Ravasi	  et	  al.	  2006)	  and	  mast	  cells	  (Mellor	  et	  al.	  2001).	  	  
In	   human	   airway	   smooth	  muscle	   cells,	   Ravasi	   et	   al.	   found	   that	   LTD4	  was	   capable	   of	  
inducing	   thymidine	   incorporation	   and	   potentiate	   EGF	   (epidermal	   growth	   factor)-­‐
induced	  proliferation.	  They	  showed	  that	  this	  proliferative	  effect	  of	  LTD4	  requires	  EGF-­‐R	  
phosphorylation	  via	  CysLT1R	  activation,	  PI3K	  and	  ROS	  production.	  They	  confirmed	  that	  
the	   previously	   shown	   LTD4-­‐induced	   DNA	   synthesis	   is	   dependent	   on	   Gαi	   protein.	  
Additionally,	  LTD4	  was	  also	  found	  to	  induce	  signalling	  pathways	  downstream	  of	  EGF-­‐R,	  
including	  the	  activation	  of	  Src-­‐Ras-­‐ERK1/2	  signalling	  pathway	  (Ravasi	  et	  al.	  2006).	  
In	  mast	  cells,	  Mellor	  et	  al.	  determined	  the	  functional	  expression	  of	  CysLT1	  receptor	  by	  
stimulating	   the	   human	   mast	   cells	   with	   exogenous	   LTC4	   and	   LTD4	   with	   or	   without	  
priming	  by	  IL-­‐4.	  They	  found	  that	  both	  LTC4	  and	  LTD4	  elicited	  rapid,	  sustained	  elevations	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in	   the	   levels	   of	   intracellular	   calcium	   with	   LTD4	   at	   lower	   concentrations	   than	   LTC4.	  
Priming	  with	  IL-­‐4	  had	  no	  significant	  effect	  on	  LTD4-­‐induced	  calcium	  but	  a	  2-­‐log	  increase	  
in	   LTC4-­‐induced	   calcium	   flux,	   resulting	   in	   equal	   agonist	   effect	   of	   LTC4	   and	   LTD4	  
following	   IL-­‐4	  priming.	   The	  addition	  of	   serine	  borate,	  which	   inhibits	   the	  extracellular	  
conversion	   of	   LTC4	   to	   LTD4,	   had	   no	   effect	   on	   the	   LTC4-­‐induced	   response;	   while	   the	  
addition	   of	   chelating	   agent	   EGTA	   completely	   inhibited	   the	   sustained	   phase	   of	   the	  
calcium	  response,	  suggesting	  that	  this	  phase	  was	  dependent	  on	  extracellular	  calcium.	  
The	   group	   observed	   a	   response	   when	   using	   LTE4	   but	   the	   data	   was	   not	   shown.	   All	  
calcium	  responses	  were	  inhibited	  by	  MK571,	  with	  or	  without	  priming	  with	  IL-­‐4.	  Using	  
BAY-­‐u9773,	  a	  dual	  CysLT1R	  and	  CysLT2R	  antagonist,	   they	  found	  a	  weak	  calcium	  signal	  
which	  was	  resistant	  to	  MK571	  and	  which	  blocked	  subsequent	  reactivity	  to	  LTC4	  but	  not	  
to	   LTD4.	   The	   group	   also	   found	   that	   there	  was	   complete	   cross-­‐desensitization	   of	   the	  
hMCs	  by	  UDP	  to	  LTC4,	  but	  not	  to	  LTD4,	  which	   indicated	  that	  LTC4	  and	  UDP	  shared	  an	  
MK571-­‐	   sensitive	   receptor	   on	   human	   mast	   cells,	   the	   function	   of	   which	   was	   up-­‐
regulated	  by	  IL-­‐4	  (Mellor	  et	  al.	  2002).	  
Despite	  extensive	  study,	  at	   the	  beginning	  of	  this	  project	  there	  was	  scant	  evidence	  to	  
suggest	   that	   T	   cells	  were	   a	   target	   for	   CysLTs.	   The	   results	   below	  describe	  our	   finding	  
that	  functional	  CYSLTR1	  is	  expressed	  on	  human	  Th2.	  	  
	   	  




3.2.1 Microarray	  analysis	  reveals	  CYSLTR1	  expression	  in	  human	  Th2	  cells	  
We	  have	  previously	   reported	  a	  method	   to	  generate	  highly	  polarized	  human	  Th1	  and	  
Th2	   cells	   from	   naïve	   precursors	   following	   in	   vitro	   differentiation	   and	   have	   used	   this	  
model	  extensively	  to	  investigate	  the	  lineage	  specific	  functions	  of	  these	  cells	  	  (Cousins	  
et	  al.	  2002b;	  Sandig	  et	  al.	  2007,	  2009).	  To	  investigate	  novel	  lineage	  specific	  genes	  we	  
performed	   a	   transcriptomic	   study	   comparing	   highly	   polarized	   human	   Th1	   and	   Th2	  
cells.	  
Naïve	   CD4+	   T	   cells	   were	   isolated	   from	   120	   ml	   of	   fresh	   whole	   human	   blood	   from	  
healthy	  volunteers.	  PBMCs	  were	  firstly	  isolated	  using	  Lymphoprep,	  followed	  by	  a	  CD4+	  
isolation	  and	  memory	  CD45RO+	  T	  cell	  depletion	  using	  anti-­‐human	  CD45RO	  to	  obtain	  
the	  naïve	  CD4RA+	  T	  cells.	  Naïve	  CD4+	  T	  cells	  were	  then	  cultured	  in	  plates	  pre-­‐coated	  
with	  anti-­‐CD3	  and	  anti-­‐CD28	  and	  a	  mix	  of	  cytokines.	  To	  induce	  Th1	  cell	  differentiation,	  
cells	   were	   cultured	   with	   rIL-­‐2,	   rIL-­‐12,	   anti-­‐IL-­‐4	   and	   anti-­‐IL-­‐10.	   To	   induce	   Th2	   cell	  
differentiation,	   naïve	   cells	   were	   cultured	   with	   rIL-­‐2,	   rIL-­‐4,	   anti-­‐IFN-­‐γ	   and	   anti-­‐IL-­‐10.	  
Cells	  were	  incubated	  at	  37°C,	  5%	  CO2	  and	  after	  4	  days	  were	  expanded	  under	  the	  same	  
conditions	  without	  anti-­‐CD3	  and	  anti-­‐CD28.	  Cells	  were	  then	  re-­‐stimulated	  every	  7	  days	  
and	  stained	  for	  extra-­‐	  and	  intra-­‐cellular	  cytokine	  expression.	  To	  identify	  novel	  specific	  
molecules	   that	   may	   play	   a	   selective	   role	   in	   Th2	   cell	   function,	   we	   have	   previously	  
performed	  a	  microarray-­‐based	  study,	  comparing	  Th1	  and	  Th2	  cells	  (Joanne	  McDonald,	  
PhD	  thesis).	  Using	  3	  biological	  replicates	  of	  in	  vitro-­‐differentiated	  human	  Th1	  and	  Th2	  
cells,	   both	   in	   resting	   (R)	   and	   activated	   (A)	   states,	   a	   series	   of	   Affymetrix	  U133	  plus	   2	  
microarrays	  were	  performed	  to	  compare	  the	  gene	  expression	  profiles	  of	  Th1	  R,	  Th1	  A,	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Th2	  R	  and	  Th2	  A	  cells	  and	  identify	  genes	  which	  were	  differentially	  expressed	  in	  those	  
cell	  types.	  Differential	  gene	  expression	  analysis	  using	  ANOVA	  in	  Partek	  Genomics	  Suite	  
identified	  1627	  genes	  (probe	  sets)	  that	  were	  differentially	  expressed	  between	  Th1	  and	  
Th2	   cells	   (Figure	   3.2).	   Examination	   of	   the	   gene	   list	   for	   differentially	   expressed	   cell	  
surface	  molecules,	  which	  could	  potentially	  serve	  as	  lineage	  markers,	  identified	  CysLT1R	  
as	   being	   highly	   and	   selectively	   expressed	   by	   Th2	   cells.	   The	   Affymetrix	   U133	   plus	   2	  
microarray	  contains	  three	  probe	  sets	  that	  recognise	  CysLT1R.	  All	  three	  probe	  sets	  were	  
reported	  as	  differentially	  expressed	  with	  higher	  expression	   in	  Th2	  cells.	  As	  discussed	  
earlier	   T-­‐cells	   are	   not	   a	   recognised	   target	   cell	   type	   for	   CysLTs	   and	   therefore	  
identification	  of	  CysLT1R	  expression	  by	  Th2	  cells	  was	  somewhat	  surprising.	  
	   	  





Gene	  Name Probe	  set	  ID Th1	  Resting Th1	  Activated Th2	  Resting 
Th2	  
Activated 
CYSLT1R 230866_at 115.5 48.6 430.8 336.2 
CYSLT2R 220813_at 14.4 14.8 18.1 17.2 
GPR17 215225_s_at 17.2 16.6 14.5 14.4 



















































































































Th1 Resting Th1 Activated Th2 Resting Th2 Activated
Hierarchical clustering of genes differentially expressed between human Th1 and Th2 cells. 1627 probes were differentially expressed between Th1 and Th2 cells
with a 2 fold change and p-value <0.05 with FDR (ANOVA). CysLTR1 is shown on the close up (right panel, p-value= 0.000587).
Figure	  3.2	  Hierarchical	   clustering	  of	   genes	  differentially	   expressed	  between	  human	  
Th1	  and	  Th2	  cells.	  1627	  were	  differentially	  expressed	  between	  Th1	  and	  Th2	  cells	  with	  
a	  2-­‐fold	  change	  and	  p-­‐value	  <0.05	  with	  FDR	  (ANOVA).	  CYSLTR1	  is	  shown	  on	  the	  close	  
up	  (right	  panel,	  p-­‐value	  =	  0.000587).	  3	  biological	  replicates	  of	   in	  vitro-­‐differentiated	  
Th1	  and	  Th2	  cells	  at	  Day	  28	  were	  used	   for	  gene	  expression	  microarrays	   to	   identify	  
differential	  gene	  expression.	  	  
 
Table	  3.1	  Expression	  of	  selected	  genes	  in	  preliminary	  microarray	  analysis.	  CYSLT1R	  is	  
highly	  expressed	  in	  Th2	  resting	  cells	   in	  comparison	  to	  Th1	  cells.	  Expression	  of	  other	  
potential	  CysLT	  receptors	  such	  as	  CYSLT2R,	  GPCR17	  and	  P2Y12	  was	  undetectable	  by	  
microarray	  analysis.	  
 




Expression	   of	   other	   potential	   cysteinyl	   leukotriene	   receptors	   CYSLTR2,	   GPR17	   and	  
P2YR12	  was	  undetectable	  by	  microarray	  in	  both	  human	  Th1	  and	  Th2	  cell	  populations	  
(Table	  3.1).	  	  
To	   confirm	   the	  expression	  of	  CYSLTR1	  by	  human	  Th2	   cells,	   in	   vitro	   differentiation	  of	  
Th1	  and	  Th2	  cells	  was	  performed	  using	  the	  model	  described	  earlier.	  Naïve	  CD4+	  T	  cells	  
were	  isolated	  from	  fresh	  whole	  blood	  and	  differentiated	  in	  vitro	  for	  28	  days	  using	  the	  
cytokines	  and	  antibodies	  described	  above	  to	  induce	  Th1	  or	  Th2	  polarization.	  Figure	  3.3	  
shows	  the	  flow	  cytometry	  analysis	  of	  these	  in	  vitro-­‐differentiated	  human	  Th1	  and	  Th2	  
cells	   at	   Day	   28	   of	   polarization,	   in	   both	   resting	   and	   activated	   states.	   Intracellular	  
cytokine	  staining	  of	  resting	  and	  activated	  Th1	  and	  Th2	  cells	  demonstrated	  that	  highly	  
polarized	  Th1/Th2	  populations	  were	  generated	   (Figure	  3.3).	  Upon	  activation,	  at	   least	  
99%	   of	   the	   Th1	   cells	   expressed	   IFN-­‐ɣ	   with	   minimal	   Th2	   cytokine	   expression.	   In	  
contrast,	   the	  Th2	  cells	  expressed	  negligible	   IFN-­‐ɣ	  and	  a	  very	  high	  proportion	  express	  
Th2-­‐specific	  cytokines	  (IL-­‐4,	  42%,	  IL-­‐5,	  46%,	  IL-­‐13,	  85%).	  	  
	  
	   	  













Figure	  3.3	  Intracellular	  cytokine	  staining	  of	  differentiated	  human	  Th1	  and	  Th2	  
cells.	   Cells	   were	   either	   resting	   (R)	   or	   activated	   (A)	   for	   4	   hours	   with	   PMA	  
(5ng/ml)	   and	   ionomycin	   (500ng/ml).	   Following	   the	   Th1/Th2	   expression	  
profile,	  Th1	  express	  high	  levels	  of	  IFNɣ	  while	  Th2	  cells	  express	  cytokines	  IL-­‐4,	  
IL-­‐5	  and	  IL-­‐13,	  but	  no	  IFNɣ.	  Data	  shown	  are	  representative	  of	  5	  experiments	  
with	  different	  donors.	  
	  
 
	   	   RESULTS	  
 
 104	  
Quantitative	  real-­‐time	  RT-­‐PCR	  of	  highly	  differentiated	  Th1	  and	  Th2	  samples	  confirmed	  
that	   the	   Th1	   and	   Th2	   cells	   expressed	   high	   levels	   of	   transcripts	   for	   the	   hallmark	  
cytokines	  IFN-­‐ɣ	  (Th1)	  and	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  (Th2)	  upon	  acute	  activation	  (Figure	  3.4).	  
Examination	   of	   CYSLTR1	   mRNA	   expression	   by	   real-­‐time	   RT-­‐PCR	   confirmed	   that	   it	   is	  
selectively	  expressed	  by	   resting	  Th2	  cells	  with	  6.5	   fold	  higher	   levels	   than	  resting	  Th1	  
cells	  (Figure	  3.5).	  The	  selective	  expression	  of	  CYSLTR1	  was	  predominantly	  observed	  in	  
cells	   prior	   to	   activation,	  with	   a	   substantial	   decrease	   in	  mRNA	  expression	   after	   acute	  
activation	   of	   Th2	   cells,	   suggesting	   a	   downregulation	   of	   the	   CysLT1	   receptor	   upon	  
activation	  (Figure	  3.5).	  Real-­‐time	  PCR	  analysis	  also	  confirmed	  that	  CYSLTR2	  mRNA	  was	  
not	   expressed	   at	   high	   levels	   in	   either	   Th1	   or	   Th2	   cells	   (Figure	   3.5).	   Interestingly,	  
examination	   of	   CYSLTR1	  mRNA	   expression	   during	   the	   time-­‐course	   of	   differentiation	  
revealed	  that	  expression	  increased	  substantially	  during	  Th2	  differentiation	  (Figure	  3.6).	  
This	   data	   suggests	   that	   CYSLTR1	   expression	   is	   acquired	   during	   Th2	   differentiation	  
rather	   than	   being	   expressed	   on	   naïve	   T	   cells	   and	   selectively	   lost	   during	   Th1	  
differentiation.	   This	   also	   indicated	   that	   expression	   of	   CYSLTR1	   by	   Th2	   cells	   is	   not	  
merely	   caused	   by	   exposure	   to	   IL-­‐4	   since	   it	   requires	   at	   least	   three	  weeks	   of	   in	   vitro	  
culture	  before	  observing	  high	  levels	  of	  expression	  (Figure	  3.6).	  The	  genes	  adjacent	  to	  
CYSLTR1,	  PGK1,	  TAF9B	  and	  ZCCHC5	  were	  not	  differentially	  expressed	  between	  Th1	  and	  
Th2	  cells	  suggesting	  that	  the	  Th2	  selective	  expression	  of	  CYSLTR1	  is	  not	  merely	  due	  to	  
the	  gene	  being	  located	  in	  close	  proximity	  to	  other	  Th2	  specific	  genes	  (Table	  1).	  
	   	  








	   	  





















































































































Figure	  3.4	  Real-­‐time	  RT-­‐PCR	  analysis	  of	  Th1	  and	  Th2	  cells	  for	  IFN-­‐ɣ,	  IL-­‐5,	  IL-­‐13	  
and	   IL-­‐4.	   IFNɣ	   is	   highly	   expressed	   by	   Th1A	   cells	   and	   IL-­‐5,	   IL-­‐4	   and	   IL-­‐14	   by	  
Th2A	  cells.	  These	  data	  show	  means	  ±	  SEMs	  of	  5	  experiments.	  *P	  <	  0.05,	  **P	  <	  
0.01,	  and	  ***P	  <	  0.001,	  2-­‐way	  ANOVA	  with	  Bonferroni	  post	  test.	  
	  
 





Figure	   3.5	   Real-­‐time	   RT-­‐PCR	   analysis	   of	   Th1	   and	   Th2	   cells	   for	   CYSLTR1	   and	  
CYSLTR2.	  CYSLTR1	  is	  highly	  expressed	  by	  Th2R	  cells	  and	  downregulated	  upon	  Th2	  
cell	   activation.	   CYSLTR2	   shows	   a	   low	   expression	   by	   Th1R/A	   and	   Th2R/A	   cells.	  
These	  data	  show	  means	  ±	  SEMs	  of	  5	  experiments.	  *P	  <	  0.05,	  **P	  <	  0.01,	  and	  ***P	  
<	  0.001,	  2-­‐way	  ANOVA	  with	  Bonferroni	  post	  test.	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3.2.2 Detection	  of	  CYSLT1R	  protein	  in	  human	  cells	  
The	   results	   presented	   above	   confirm	   the	   initial	   microarray	   studies	   and	   show	   that	  
mRNA	  for	  CYSLTR1	  is	  selectively	  expressed	  in	  human	  Th2	  cells	  when	  compared	  to	  Th1	  
cells.	   To	   demonstrate	   that	   the	   selective	   expression	   of	   CYSLTR1	   mRNA	   results	   in	  
CysLTR1	   protein	   production	   in	   Th2	   cells	   we	   attempted	   to	   examine	   CysLTR1	   protein	  
levels	  using	  both	  western	  blotting	  and	  flow	  cytometry.	  
Several	  groups	  have	  used	  these	  techniques	  to	  examine	  CysLTR1	  expression	  in	  the	  past.	  
Thivierge	   et	   al.	   showed	   expression	   of	   CysLTR1	   protein	   by	   western	   blotting,	   using	   a	  
rabbit	   polyclonal	   anti-­‐human	   CysLTR1	   antibody	   developed	   and	   characterised	   by	  
Cayman	   Chemical	   (Thivierge	   et	   al.	   2001).	   Expression	   was	   shown	   in	   monocytes	   and	  
monocyte-­‐derived	   macrophages	   after	   incubation	   with	   and	   without	   IL-­‐13	   and	   IL-­‐4	  
(Thivierge	  et	  al.	  2001).	  
Meliton	  et	  al.	  also	  used	  the	  CysLTR1	  polyclonal	  antibody	   from	  Cayman	  Chemical	  and	  
showed	   CysLTR1	   protein	   expression	   in	   eosinophils	   and	   human	   polymorphonuclear	  
leukocytes	   (PMNs)	  by	  western	  blotting.	  They	   found	   that	  eosinophils	  had	  significantly	  
greater	  expression	  of	  38	  kDa	  CysLTR1	   than	  PMNs.	   In	   their	   experiments,	   the	  western	  
blotting	  membrane	   was	   probed	  with	   2	   μg/ml	   anti-­‐CysLTR1	   pAb	   and	   incubated	   with	  
1:3000	   dilutions	   of	   goat	   anti-­‐rabbit	   IgG	   conjugated	   with	   horseradish	   peroxidase.	   To	  
detect	   the	  expression,	   the	  group	  used	  an	  enhanced	  chemiluminescence	  system	  (ECL,	  
Amersham)	   (Meliton	   et	   al.	   2010).	   Using	   two	   different	   antibody	   concentrations	   we	  
were	   unable	   to	   detect	   CysLTR1	   protein	   (Figure	   3.7)	   in	   cell	   extracts	   isolated	   from	  
HEK293	   cells	   transfected	   with	   pCDNA3	   overexpressing	   the	   human	   CYSLTR1	   gene.	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Examination	  of	  GAPDH	  expression	  on	  the	  same	  membranes	  indicated	  that	  the	  western	  
blotting	  protocol	  was	  working	  satisfactorily.	  	  
Using	  the	  same	  rabbit	  polyclonal	  anti-­‐human	  CysLTR1-­‐antibody	  from	  Cayman	  Chemical	  
we	  used	  for	  western	  blotting,	  we	  examined	  CysLTR1	  protein	  expression	  in	  our	  samples.	  
Cultured	   Th2	   cells	   were	   tested	   for	   CysLTR1	   expression	   and	   GAPDH	   was	   used	   as	   a	  
positive	   control.	   CysLTR1	   antibody	   (Cayman	   Chemical)	   was	   used	   at	   different	  
concentrations	  such	  as	  1:100	  (data	  not	  shown),	  1:1000	  and	  1:5000.	  Membranes	  were	  
then	   incubated	   with	   a	   secondary	   goat	   anti-­‐rabbit	   antibody	   (SouthernBiotech)	   at	   a	  
1:5000	   dilution.	   Positive	   control	   anti-­‐GAPDH	   (GTX28245,	   GeneTex)	   was	   used	   at	  
1:25000	  dilution.	  Using	   the	  GE	  Healthcare	  ECL	  plus	  detection	  kit,	  we	  were	  unable	   to	  
detect	  CysLTR1	  expression	   in	  our	  samples	  at	  10	  min	  and	  30	  min	  exposure.	  However,	  
positive	  control	  GAPDH	  was	  detected	  at	  10	  min	  exposure	  (Figure	  3.7).	  
Using	  different	  anti-­‐CysLTR1	  antibodies,	  we	  also	  attempted	  to	  detect	  CysLTR1	  by	  flow	  
cytometry.	   Using	   Novus	   Biologicals	   rabbit	   polyclonal	   antibody	   (NLS1317)	   (Figure	  
3.8(A)),	   we	   were	   unable	   to	   detect	   surface	   CysLTR1	   expression	   in	   Th1	   or	   Th2	  
differentiated	   cells.	   Using	   Cayman	   Chemical	   rabbit	   polyclonal	   antibody	   (120500)	  
(Figure	  3.8(B)),	  we	  found	  similar	  results	  and	  failed	  to	  observe	  any	  intracellular	  CysLTR1	  













































Figure	   3.7	  CysLTR1	  detection	  by	  Western	  Blotting.	  No	  detection	  of	   CysLTR1	  
expression	   in	   CysLTR1-­‐transfectants	   or	   empty	   vector	   using	   anti-­‐CysLTR1	  
antibody	  (Cayman	  Chemical)	  at	  1:1000	  and	  1:5000	  and	  a	  goat	  anti-­‐rabbit	   Ig-­‐
HRP	  secondary	  antibody	  at	  1:5000.	  Positive	  control	  GAPDH	  could	  be	  detected	  
in	  both	  samples.	  Data	  is	  representative	  of	  three	  experiments.	  







	   	  
























Flow cytometric analysis of human Th1 and Th2 cell expression of CysLT1R.
Cells were di!erentiated in vitro for 28 days and were stained for CysLT1R
expression using protocols as described in the materials and methods.
(A) Extracellular staining using Novus Biologicals rabbit polycolonal antibody
(NLS1317). (B) Intracellular staining using Cayman Chemical rabbit polyclonal
antibody (120500). Both were detected using chicken anti-rabbit Alexa Fluor 647.
Figure	   3.8	   Flow	   cytometric	   analysis	   of	   human	   Th1	   and	   Th2	   cell	   expression	   of	  
CysLTR1.	   Cells	   were	   differentiated	   in	   vitro	   for	   28	   days	   and	   were	   stained	   for	  
CysLTR1	  expression	  using	  protocols	   as	  described	   in	   the	  materials	   and	  methods.	  
(A)	   Extracellular	   staining	   using	   Novus	   Biologicals	   rabbit	   polyclonal	   antibody	  
(NLS1317).	   (B)	   Intracellular	   staining	   using	   Cayman	   Chemical	   rabbit	   polyclonal	  
antibody	  (120500).	  Both	  were	  detected	  using	  chicken	  anti-­‐rabbit	  Alexa	  Fluor	  647.	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Collectively	  our	  efforts	  to	  demonstrate	  CysLTR1	  protein	  expression	  were	  unsuccessful	  
no	   matter	   which	   approach	   we	   took.	   Given	   the	   recognised	   difficulty	   in	   detecting	  
CysLT1R	   protein	   we	   decided	   to	   determine	   whether	   we	   could	   observe	   functional	  
expression	  of	  CysLT1R	  in	  human	  Th2	  cells.	  	  
3.2.3 Ca2+	  mobilization	  through	  CysLT1	  receptor	  in	  resting	  Th2	  cells	  
Following	  our	  finding	  of	  CYSLTR1	  mRNA	  expression	  by	  human	  Th2	  cells,	  we	  decided	  to	  
assess	   whether	   CYSLTR1	   mRNA	   gave	   rise	   to	   functional	   proteins	   via	   monitoring	   the	  
intracellular	   Ca2+	   mobilization	   through	   CysLT1	   receptor.	   Cysteinyl	   leukotrienes	  
signalling	   through	   CysLT1	   receptor	   induce	   calcium	   flux	   in	   other	   cell	   types	   known	   to	  
express	   the	   receptor.	   We	   determined	   whether	   the	   selective	   expression	   of	   CYSLTR1	  
mRNA	  observed	  in	  Th2	  cells	  resulted	  in	  functional	  expression	  of	  CysLTR1	  in	  these	  cells	  
and	   whether	   in	   vitro	   differentiated	   human	   Th1	   and	   Th2	   cells	   were	   capable	   of	   Ca2+	  
mobilization	   in	   response	   to	   the	   known	  high	   affinity	   ligand	   for	   CysLT1	   receptor,	   LTD4.	  	  
The	  purpose	  of	   the	  experiment	  was	   to	   treat	   in	  vitro-­‐differentiated	  Th1	  and	  Th2	  cells	  
with	  LTD4	  and	  measure	  the	  intracellular	  calcium	  responses.	  For	  this	  we	  decided	  to	  use	  
the	   FLIPR	   (Fluorescence	   Imaging	   Plate	   Reader)	   assay	   and	   optimise	   the	   assay	  
conditions.	  	  
As	   per	   previous	   experiments,	  we	   used	   naïve	   CD4+	   T	   cells	   isolated	   from	   fresh	  whole	  
blood	   and	   cultured	   and	   differentiated	   them	   for	   28	   days	   using	   a	   combination	   of	  
cytokines	  and	  antibodies	  to	   induce	  Th1	  or	  Th2	  polarization.	  Cultured	  human	  Th1	  and	  
Th2	  cells	  were	  tested	  for	  calcium	  signalling	  when	  fully	  differentiated	  at	  Day	  21	  and	  28	  
(when	   CysLT1R	  mRNA	   levels	   were	   maximal)	   in	   response	   to	   leukotrienes	   LTB4,	   LTC4,	  
LTD4	  and	  LTE4.	  Cells	  were	  resuspended	  in	  100	  µl	  RPMI/2%HEPES	  and	  plated	  on	  to	  a	  96-­‐
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well	  black-­‐wall,	  clear	  flat-­‐bottom	  assay	  plate	  (Costar;	  Sigma),	  and	  an	  equal	  volume	  of	  
loading	   buffer	   (Component	   A	   with	   1X	   HBSS	   Buffer;	   FLIPR	   Calcium	   4	   Assay	   Kit;	  
Molecular	  Devices)	  was	   added.	   	   The	  plate	  was	   incubated	   for	   1	  hour	   at	   37°C	  and	  5%	  
CO2.	   	   After	   incubation,	   the	   plate	  was	   centrifuged	   at	   200g	   for	   5	  min	   and	   transferred	  
directly	  to	  a	  FlexStation	  3	  Microplate	  Reader.	  Results	  were	  analysed	  using	  SoftMax	  Pro	  
Software	   (Molecular	   Devices).	   Controls	   included	   a	   negative	   medium	   control	   of	  
RPMI/2%	  HEPES,	  and	  a	  positive	  control	  SDF-­‐1α,	  and	  all	  treatments	  were	  performed	  in	  
triplicate.	  SDF-­‐1α	  was	  used	  as	  a	  positive	  control	  as	  it	  is	  a	  chemokine	  known	  to	  attract	  
and	  have	  an	  effect	  on	  both	  Th1	  and	  Th2	  cells	  (Siveke	  and	  Hamann	  1998).	  Its	  receptor	  
CXCR4	  is	  also	  known	  to	  be	  preferentially	  expressed	  on	  naïve	  T	  cells	  (Bleul	  et	  al.	  1997).	  
Similar	  calcium	  flux	  results	  to	  the	  ones	  observed	  in	  our	  study	  were	  seen	  in	  a	  study	  by	  
Drost	  et	  al.,	  using	  SDF-­‐1α	  (Drost	  et	  al.	  2012).	  
During	  optimisation	  experiments,	  we	  determined	  the	  optimum	  cell	  number	  by	  testing	  
50,000,	  100,000	  and	  200,000	  resting	  Th2	  cells	  per	  well	  per	  assay.	  Simultaneously	  we	  
tested	   increasing	   doses	   of	   LTD4	   such	   as	   1	   nM,	   10	   nM	   and	   100	   nM	   to	   determine	  
whether	  calcium	  responsiveness	  was	  observed.	  As	  pictured	  in	  Figure	  3.9	  A,	  B	  and	  C,	  all	  
cell	   numbers	   showed	   positive	   calcium	   responses	   to	   various	   doses	   of	   LTD4,	   with	  
optimum	  results	  seen	  when	  using	  200,000	  cells	  per	  well	  at	  10	  nM	  LTD4	  (Figures	  3.9).	  
While	  optimising	  the	  FLIPR	  assay,	  we	  also	  tested	  the	  same	  cell	  numbers	  and	  doses	  of	  
LTD4	   on	   in	   vitro-­‐differentiated	   Th1	   resting	   cells,	   in	   order	   to	   compare	   the	   calcium	  
responses	  on	   the	   two	   types	  of	   cells	   (Figure	  3.10).	   Based	  on	  previous	  experiments	   in	  
which	  CYSLTR1	  RNA	  levels	  were	  lower	  in	  Th1	  cells	  than	  Th2	  cells,	  we	  expected	  a	  much	  
lower	  calcium	  flux	  response	  in	  Th1	  cells.	  As	  seen	  in	  Figure	  3.10	  A,	  B	  and	  C,	  200,000	  Th1	  
	   	   RESULTS	  
 
 114	  
cells	   and	   an	   LTD4	   dose	   of	   10	   nM	   also	   were	   the	   optimum	   conditions	   for	   the	   assay.	  
However	  the	  calcium	  response	  in	  Th1	  resting	  cells	  was	  considerably	  lower	  than	  in	  Th2	  
resting	  cells.	  
	  




















Well C1 C2 C3 G1 G2 G3
Peak  19.134 48.236 106.31 13.827 54.608 111.50
Time (secs)
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Fig.% 3.% Op#misa#on*of*FLIPR*assay.* Raw*data*showing*50,000,* 100,000* and*
200,000* in#vitro=diﬀeren#ated*Th2*res#ng*cells*and*calcium*ﬂux*in*response *to*
1* (A),* 10*(B)*and*100nM*(C)*LTD4.*Using*1,*10*and*100nM* LTD4*resulted*in*a*






Figure	   3.9	   Optimisation	   of	   the	   FLIPR	   assay	   in	   Th2R	   cells.	   Raw	   data	   showing	  
50,000,	  100,000	  and	  200,000	  in	  vitro-­‐differentiated	  Th2	  resting	  cells	  and	  calcium	  
flux	  in	  response	  to	  1	  (A),	  10	  (B)	  and	  100nM	  (C)	  LTD4.	  Using	  1,	  10	  and	  100nM	  LTD4	  
resulted	  in	  a	  dose-­‐dependent	  calcium	  response	  of	  approximately	  100,	  110	  and	  55	  
luminescence	   units,	   respectively.	   Data	   are	   representative	   of	   three	   experiments	  
using	  at	  least	  2	  technical	  replicates.	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Figure	   3.10	   Optimisation	   of	   the	   FLIPR	   assay	   in	   Th1R	   cells.	   Raw	   data	   showing	  
50,000,	  100,000	  and	  200,000	  in	  vitro-­‐differentiated	  Th1	  resting	  cells	  and	  calcium	  
flux	  in	  response	  to	  1	  (A),	  10	  (B)	  and	  100nM	  (C)	  LTD4.	  Using	  1,	  10	  and	  100nM	  LTD4	  
on	  Th1	  cells	   resulted	   in	  a	  dose-­‐dependent	   calcium	   flux	  of	  approximately	  65,	  80	  
and	   55	   luminescence	   units,	   respectively.	   Data	   are	   representative	   of	   three	  
experiments	  using	  at	  least	  2	  technical	  replicates.	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Following	  the	  optimum	  results	  obtained	  using	  200,000	  Th2	  resting	  cells	  per	  well	  with	  
10nM	  LTD4,	  we	  tested	  the	  same	  conditions	  using	   the	  positive	  control	  SDF1α	  and	  the	  
known	  CysLT1R	  antagonist	  MK571.	  We	  chose	  to	  use	  SDF1α	  as	  a	  positive	  control	  as	  it	  is	  
a	  chemokine	  known	  to	  attract	  both	  Th1	  and	  Th2	  cells	   (Siveke	  and	  Hamann	  1998),	  as	  
well	  as	  spleen	  lymphocytes	  (Bleul	  et	  al.	  1996),	  as	  mentioned	  earlier.	  	  
As	  observed	  in	  previous	  experiments,	  the	  calcium	  flux	  response	  to	  10	  nM	  LTD4	  in	  Th2	  
cells	  was	  very	  high	  with	  a	  calcium	  peak	  of	  approximately	  110	  fluorescence	  units,	  while	  
SDF1α	   led	   to	   a	   moderate	   calcium	   response.	   The	   pre-­‐incubation	   of	   Th2	   cells	   with	  
MK571	   blocked	   the	   response	   to	   LTD4	   and	   the	   high	   calcium	   flux	   previously	   observed	  
was	   fully	   inhibited.	   As	   a	   negative	   control,	   medium	   was	   added	   to	   Th2	   cells	   and	   no	  
calcium	  response	  was	  observed	  (Figure	  3.11).	  
Finally,	  we	  also	  ran	  the	  FLIPR	  assay	  using	  activated	  Th1	  and	  Th2	  cells.	  These	  cells	  had	  
been	  activated	  using	  PMA	  and	  ionomycin	  for	  4	  hours	  prior	  to	  the	  assay.	  We	  tested	  the	  
same	  conditions	  as	  for	  previous	  experiments	  on	  resting	  cells.	  As	  seen	  in	  Figures	  6A	  and	  
6B,	  Th1-­‐	  (A)	  and	  Th2-­‐(B)	  activated	  cells	  were	  tested	  at	  50,000,	  100,000	  and	  200,000	  in	  
cell	   numbers	   to	   check	   their	   response	   to	   10	   nM	   LTD4,	   positive	   control	   SDF1α,	   and	  
medium	   as	   negative	   control.	   Some	   wells	   were	   also	   pre-­‐incubated	   with	   antagonist	  
MK571	   to	   inhibit	   the	   calcium	   response.	   Interestingly,	   the	   results	   observed	   using	  
activated	   T	   cells	   peaked	   downwards	   and	   showed	   no	   calcium	   flux.	   A	   reason	   for	   this	  
effect	  may	  be	   that	  as	  cells	  were	  activated,	  all	   receptors	  may	  have	  been	   internalised,	  
leaving	  no	  receptor	  to	  respond	  to	  LTD4	  or	  SDF-­‐1α	  and	  showing	  no	  calcium	  response.	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Figure	  3.11	  Optimisation	  of	  the	  FLIPR	  assay	  with	  positive	  control	  and	  inhibitor.	  
Raw	  data	   showing	  200,000	   in	   vitro-­‐differentiated	   Th2	   cells	   and	   their	   calcium	  
flux	   in	   response	   to	   10	   nM	   LTD4,	   positive	   control	   SDF-­‐1α	   and	   medium.	   Pre-­‐
incubation	  of	  Th2	  cells	  with	  CysLT1R	  antagonist	  MK571	   inhibited	   the	  calcium	  
response	   completely.	   Data	   are	   representative	   of	   three	   experiments	   using	   at	  
least	  2	  technical	  replicates.	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Well A10 A11 A12 C10 C11 C12 E10 E11 E12 G10 G11 G12
Peak  0.909 2.473 0.358 3.098 0.117 0.099 1.172 0.189 1.465 0.333 0.563 0.295
Time (secs)








Well A4 A5 A6 C4 C5 C6 E4 E5 E6 G4 G5 G6
Peak  2.928 1.847 1.060 4.828 0.317 0.546 0.154 0.551 0.370 2.730 0.803 0.696
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Figure	  3.12	  Calcium	  flux	  in	  activated	  in	  vitro-­‐differentiated	  Th1A	  (A)	  and	  Th2A	  (B)	  
cell.	  The	  graphs	  show	  a	  negative	  calcium	  flux	  in	  response	  to	  10nM	  LTD4,	  positive	  
control	   SDF1α,	   and	   medium,	   using	   50,000,	   100,000	   and	   200,000	   cells.	   Some	  
samples	   were	   also	   pre-­‐treatment	   with	  MK571	   to	   inhibit	   the	   calcium	   response.	  
Data	  are	  representative	  of	  three	  experiments	  using	  2	  technical	  replicates. 
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The	  results	  from	  the	  optimisation	  experiments	   lead	  us	  to	  conclude	  that	  200,000	  cells	  
per	  well	  was	  optimal	  and	  all	  following	  experiments	  were	  performed	  with	  that	  amount	  
of	  cells.	  We	  also	  decided	  that	  resting	  T	  cells	  were	  best	   for	   the	  assay.	  Once	  the	  FLIPR	  
assay	  was	  optimised,	  we	  proceeded	  with	  experiments	  using	  200,000	  cells	  per	  well	  and	  
using	   resting	   T	   cells.	  We	   first	   compared	   the	   calcium	   flux	   response	   in	   Th1-­‐	   and	   Th2-­‐	  
resting	   cells	   using	   various	   doses	   of	   LTD4.	   Consistent	   with	   the	   pattern	   of	   mRNA	  
expression	   (see	   Figure	   3.6),	   LTD4	   induced	   a	   very	   strong	   calcium	  mobilization	   in	   Th2	  
resting	  cells	  at	  concentrations	  similar	  to	  those	  reported	  for	  CysLTR1	  in	  other	  systems	  
with	  an	  EC50	  of	  ~	  1nM	  (see	  Figure	  3.13).	  A	  much	  weaker	  response	  was	  observed	  in	  Th1	  
resting	  cells	  (Figure	  3.13),	  but	  not	  in	  activated	  Th1	  or	  activated	  Th2	  cells.	  The	  Ca2+	  flux	  
observed	   in	  both	  Th1	  and	  Th2	  cells	  was	  dose-­‐dependent.	  This	  confirmed	  that	  human	  
Th2	  cells	  selectively	  express	  a	  functional	  receptor	  for	  LTD4.	  	  
Treatment	  of	  Th2	  cells	  with	  cysteinyl	  leukotrienes	  LTC4,	  LTD4	  and	  LTE4	  showed	  that	  all	  
three	  CysLTs	  induced	  calcium	  mobilization,	  with	  LTD4	  being	  the	  most	  potent,	  followed	  
by	   LTC4	   and	   LTE4	   (Figure	  3.14).	   This	   rank	  order	  of	   potency	   (LTD4>LTC4>LTE4)	   strongly	  
resembles	   previous	   studies	   on	   CysLTR1	   in	   other	   cell	   types,	   suggesting	   that	   Th2	   cells	  
express	  functional	  CysLTR1.	  
	   	  




	   	   	  
	  
Figure	  3.13	   Th2	  cells	  express	   functional	  CysLTR1	  at	  higher	   levels	   than	  Th1	  cells.	  
Calcium	  flux	  in	  in	  vitro-­‐differentiated	  Th1	  and	  Th2	  cells	  in	  response	  to	  increasing	  
concentrations	   of	   LTD4.	   A	   stronger	   calcium	   response	   is	   shown	   in	   Th2	   cells	  
compared	   to	   Th1	   cells.	   Data	   are	   presented	   as	   mean	   ±	   SEM	   percentage	   of	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Figure	   3.14	   Th2	   cells	   express	   functional	   CysLTR1	   in	   LTD4>LTC4>LTE4	   rank	  
order	   of	   potency.	   Calcium	   flux	   in	   Th2	   cells	   in	   response	   to	   increasing	  
concentrations	   of	   all	   three	   cysteinyl	   leukotrienes	   LTC4,	   LTD4	   and	   LTE4,	  
showing	  rank	  of	  potency	  as	  LTD4>LTC4>LTE4.	  Data	  are	  presented	  as	  mean	  ±	  
SEM	   percentage	   of	   maximum	   response	   to	   LTD4	   from	   3	   experiments	   with	  
different	  donors.	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3.2.4 Ca2+	  flux	  via	  CysLT1R	  is	  inhibited	  by	  known	  CysLT1R	  antagonists	  
To	  confirm	  the	  identity	  of	  the	  cysteinyl	   leukotriene-­‐responsive	  receptor	  expressed	  by	  
Th2	  cells	  and	  inhibit	  the	  calcium	  response,	  the	  selective	  antagonists	  MK571	  (100	  nM)	  
and	  marketed	  antagonists	  Montelukast	  (10	  nM)	  and	  Zafirlukast	  (10	  nM)	  were	  used	  to	  
treat	  Th2	  cells	  prior	  to	  treatment	  with	  100	  nM	  LTD4.	  Calcium	  flux	  previously	  observed	  
in	  Th2	  cells	  was	  almost	  completely	  inhibited	  when	  using	  any	  of	  the	  three	  known	  CysLT1	  
receptor	   antagonists	   (Figure	   3.15).	   The	   results	   confirmed	   that	   the	   calcium	   flux	   in	  
response	   to	   LTD4	   by	   human	   Th2	   cells	   is	   dependent	   upon	   selective	   expression	   of	  
functional	  CysLTR1.	  
	   	  




























































































	   	  
Figure	  3.15	   Inhibition	  of	  CysLTR1	   functional	  expression	   in	  Th2	  cells.	  Complete	  
inhibition	  of	  calcium	  flux	  in	  Th2	  cells	  in	  response	  to	  100nM	  LTD4	  by	  3	  different	  
cysteinyl	  leukotrienes	  antagonists	  MK571,	  montelukast	  and	  zafirlukast	  (100	  nM	  
and	   10	   nM).	   Data	   are	   presented	   as	   mean	   ±	   SEM	   percentage	   of	   maximum	  
response	   to	   LTD4	   from	  3	   experiments	  with	  different	   donors.	   ***P	   <	   0.001,	   1-­‐
way	  ANOVA	  with	  Tukey	  post	  test.	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3.2.5 CysLT1R	  is	  partially	  coupled	  to	  Gαi/o	  	  
From	   previous	   calcium	   signalling	   experiments,	   we	   found	   that	   intracellular	   calcium	  
mobilization	   occurred	   in	   response	   to	   various	   doses	   of	   LTD4	   binding	   to	   the	   receptor,	  
suggesting	   signalling	   via	   a	   Gαq	   pathway.	   To	   further	   characterise	   the	   signalling	  
mechanisms	   involved	   in	   CysLT-­‐induced	   calcium	   flux,	   we	   used	   the	   FLIPR	   method	   to	  
investigate	  which	  G	  protein	  CysLT1R	  was	  coupled	  to	  (Schematic	  figure	  3.16).	  Th2	  cells	  
were	  pre-­‐incubated	  overnight	  with	  the	  Gαi/o	  inhibitor	  pertussis	  toxin	  and	  treated	  with	  
increasing	  concentrations	  of	  LTD4	  (Figure	  3.17).	  We	  found	  that,	  compared	  to	  Th2	  cells	  
with	   no	   pertussis	   toxin,	   pre-­‐incubated	   Th2	   cells	   showed	   a	   partial	   inhibition	   of	  
intracellular	  calcium	  release	  of	  about	  50-­‐60%	  at	  the	  highest	  LTD4	  concentration	  since	  
signalling	  was	  not	  completely	  inhibited.	  This	  suggested	  that	  CysLT1	  receptor	  is	  partially	  
coupled	  to	  both	  Gαi	  and	  Gαq	  subunits.	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Figure	  3.16	  GPCR	  signalling	  via	  G	  protein.	  G	  protein-­‐coupled	  signalling	  can	  occur	  
via	  Gαi/o,	  Gαs,	  Gαq/11	  or	  G12/13	  and	  this	  can	  be	  confirmed	  by	  testing	  for	  cAMP,	  
pertussis	   toxin	   sensitivity	   and	   calcium	   flux.	   Pertussis	   toxin	   can	   be	   used	   to	  
determine	   whether	   the	   signalling	   is	   occurring	   via	   Gαi/o.	   Figures	   taken	   and	  
adapted	  from	  (Marinissen	  and	  Gutkind	  2001).	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Figure	   3.17	   Pertussis	   toxin	   (PTX)	   partially	   inhibits	   calcium	   flux.	   The	   calcium	  
response	   to	   LTD4	   in	   Th2	   cells	   was	   inhibited	   by	   50%	   when	   Th2	   cells	   were	  
incubated	  overnight	  with	  PTX.	   ***P	   <	   0.001,	   2-­‐way	  ANOVA	  with	  Bonferroni	  
post	  test.	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3.2.6 	  CysLT1R	  is	  partially	  coupled	  to	  Gαq/11 
To	  confirm	  the	  results	  obtained	  previously	  and	  the	  role	  of	  Gαi	  in	  CysLTR1	  signalling,	  we	  
looked	  at	  the	  cyclic	  AMP	  pathway	  using	  the	  competitive	  immunoassay	  HitHunter	  cAMP	  
XS+	   Assay	   (DiscoveRx).	   The	   DiscoveRx	   EFC	   (Enzyme	   Fragment	   Complementation,	  
DiscoveRx	  technology)	  technology	  is	  based	  on	  two	  fragments	  of	  E.	  coli	  ß-­‐galactosidase	  
(ß-­‐gal),	  a	  large	  protein	  fragment	  (enzyme	  acceptor,	  EA)	  and	  a	  small	  peptide	  fragment	  
(enzyme	   donor,	   ED).	   Separately	   these	   fragments	   are	   inactive,	   but	   in	   solution	   they	  
rapidly	  complement	  and	  recombine	  to	  form	  active	  ß-­‐gal	  enzyme,	  which	  can	  hydrolyse	  
substrate	  to	  produce	  luminescence.	  In	  this	  assay,	  free	  cAMP	  from	  cell	  lysates	  compete	  
for	  antibody	  binding	  against	  labelled	  cAMP	  (ED-­‐cAMP	  conjugate	  is	  free	  to	  complement	  
EA	  to	  form	  active	  enzyme	  by	  EFC,	  which	  subsequently	  hydrolyses	  substrate	  to	  produce	  
a	  luminescent	  signal.	  A	  positive	  signal	  generated	  is	  directly	  proportional	  to	  the	  amount	  
of	   free	   cAMP	   bound	   by	   the	   binding	   protein	   (as	   seen	   in	   figure	   3.18,	  
www.discoverx.com).	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Figure	   3.18	   HitHunter	   EFC	   Assay	   Principle.	   In	   the	   assay,	   ED	   is	  
conjugated	  to	  the	  ligand	  of	  interest	  (cAMP)	  which	  competes	  against	  
free	  ligand	  for	  binding	  to	  a	  binding	  protein.	  Depending	  on	  the	  ligand	  
of	  interest,	  the	  binding	  protein	  can	  be	  an	  antibody,	  an	  enzyme,	  or	  a	  
receptor.	  Taken	  from	  www.discoverx.com	  (DiscoveRx).	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As	   previously	  mentioned,	   signalling	   via	   the	   Gαi/o	   subunit	   is	   also	   characterised	   by	   a	  
decrease	   in	   intracellular	   cyclic	   AMP.	   In	   this	   experiment,	  we	   examined	  whether	   LTD4	  
could	  inhibit	  cAMP	  signalling	  in	  Th2	  cells.	  	  
In	   order	   to	   optimise	   the	   assay,	  we	   first	   tested	   cysteinyl	   leukotrienes	   alone	   to	   check	  
whether	  there	  was	  a	  measurable	  cAMP	  signal	  or	  if	  we	  should	  amplify	  the	  signal	  using	  
forskolin.	   Forskolin	   is	   known	   to	   resensitize	   cell	   receptors	   by	   activating	   the	   enzyme	  
adenylyl	  cyclase	  and	  increasing	  the	  intracellular	  levels	  of	  cAMP.	  As	  seen	  in	  Figure	  3.19,	  
none	  of	  the	  cysteinyl	   leukotrienes	  LTD4,	  LTC4,	  LTE4	  induced	  any	  change	  in	  cyclic	  AMP,	  
even	  at	  100	  nM,	  compared	  to	  the	  signal	  detected	  by	  100nM	  forskolin	  alone.	  
Following	  the	  results	  in	  figure	  3.19,	  we	  decided	  to	  use	  forskolin	  to	  induce	  cAMP	  before	  
adding	  LTD4,	  LTC4	  and	  LTE4	  to	  check	  the	  effect	  of	  cysteinyl	  leukotrienes	  on	  cyclic	  AMP.	  
Initially	  we	  optimised	  the	  cyclic	  AMP	  assay	  testing	  various	  doses	  of	  forskolin	  alone	  and	  
decided	   that	   20	   μM	   forskolin	   would	   induce	   a	   robust	   increase	   in	   cAMP	   levels	   and	  
appeared	   to	  be	   the	  optimal	  dose	   to	  use	   for	   the	  assay.	  We	  proceeded	   to	  use	  20	  μM	  
forskolin	   alone	   at	   various	   doses,	   compared	   in	   both	   Th1	   and	   Th2	   cells	   (Figure	   3.20).	  
Figure	  3.20	  shows	  a	  dose	  response	  for	  forskolin	  alone	  in	  Th1	  and	  Th2	  cells.	  We	  decided	  
to	  use	  a	  concentration	  between	  100	  μM	  and	  10	  μM	  and	  followed	  on	  our	  experiments	  
using	  20	  μM.	  
	   	  






Figure	  3.19	   cAMP	  detection	   in	  Th2	  cells	  using	  LTD4,	   LTC4	  and	  LTE4.	   cAMP	  was	  
measure	  when	  using	  100nM	  forskolin	  alone,	  compared	  to	  100	  nM	  LTD4,	  100	  nM	  
LTC4	  and	  100	  nM	  LTE4	  alone.	  LTD4,	  LTC4	  and	  LTE4	  did	  not	  induce	  cyclic	  AMP	  on	  
their	  own.	  Data	  are	  representative	  of	  3	  biological	  replicates.	  










	   	  
! !Figure	  3.20	  Comparison	  of	  cAMP	  detection	  in	  Th1	  and	  Th2	  cells.	  Dose	  response	  
for	  forskolin	  using	  various	  doses	  of	  forskolin	  alone,	  S1P	  alone	  and	  forskolin	  with	  
S1P.	  Data	  are	  representative	  of	  3	  biological	  replicates.	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The	   optimum	   results	   were	   seen	   when	   using	   20nM	   forskolin	   and	   we	   therefore	  
proceeded	   with	   additional	   experiments.	   We	   went	   on	   to	   test	   some	   known	   positive	  
controls	  such	  as	  S1P	  and	  PGD2,	  as	  seen	  in	  figures	  3.21	  and	  3.22,	  respectively.	  S1P	  has	  
been	  shown	  to	  induce	  cAMP	  via	  its	  S1P	  receptors	  lymphocytes	  in	  smooth	  muscle	  cell	  	  
(Damirin	   et	   al.	   2005;	   Spiegel	   and	  Milstien	   2003b,	   2003a),	   and	   its	   receptor	   has	   been	  
shown	  play	  an	  important	  role	  in	  lymphocyte	  entry,	  via	  G	  protein	  signaling	  (Graler	  2010;	  
Lo	   et	   al.	   2005).	   As	   expected,	   S1P	   inhibited	   cAMP	   levels	   by	   50%	   in	   Th2	   cells.	  
Interestingly,	  PGD2	  only	  inhibited	  cAMP	  by	  approximately	  10%.	  
	   	  












Figure	   3.21	   S1P-­‐mediated	   50%	   inhibition	   of	   cAMP	   signaling	   in	   Th2	   cells.	   Cells	  
were	   treated	   with	   20nM	   forskolin	   to	   induce	   cAMP,	   and	   S1P.	   All	   data	   are	  
expressed	  as	  mean	  ±	  SEM	  percentages	  of	  maximum	  response	  to	  S1P	  or	  forskolin	  
from	  3	  experiments	  with	  different	  donors.	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Figure	   3.22	   PGD2	  does	   not	   inhibit	   cAMP	   signaling	   in	   Th2	   cells.	   Cells	  were	  
treated	  with	  20nM	  forskolin	  to	  induce	  cAMP,	  and	  100nM	  PGD2.	  All	  data	  are	  
expressed	   as	   mean	   ±	   SEM	   percentages	   of	   maximum	   response	   to	   S1P	   or	  
forskolin	  from	  3	  experiments	  with	  different	  donors.	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Following	  the	  testing	  of	  known	  positive	  controls	  S1P	  and	  PGD2,	  we	  continued	  using	  20	  
nM	  forskolin	  but	  this	  time	  with	  various	  doses	  of	  LTD4	  using	  Th2	  cells	  as	  shown	  in	  figure	  
14.	  As	   seen	   in	  previous	   experiments,	   100	  nM	  LTD4	   alone	  did	  not	   induce	   cyclic	  AMP.	  
Adding	  various	  doses	  of	  LTD4	  to	  20	  nM	  forskolin	  resulted	  in	  a	  concentration-­‐dependent	  
decrease	  in	  cyclic	  AMP	  signalling.	  Adding	  0.1nM	  and	  1nM	  LTD4	  to	  Th2	  cells	  showed	  a	  
25%	  decrease	  in	  cyclic	  AMP,	  10	  nM	  LTD4	  showed	  a	  45%	  decrease	  and	  100	  nM	  showed	  
a	  50%	  decrease	  in	  cyclic	  AMP	  (Figure	  3.23).	  
	   	  











	   	  
Figure	  3.23	  LTD4-­‐mediated	  inhibition	  of	  cAMP	  signaling	  in	  Th2	  cells.	  Cells	  were	  
treated	  with	   forskolin	   to	   induce	  cAMP,	  and	   increasing	  concentrations	  of	   LTD4	  
inhibited	  cAMP	  generation.	  All	  data	  are	  expressed	  as	  mean	  ±	  SEM	  percentages	  
of	  maximum	   response	   to	   LTD4	  or	   forskolin	   from	  3	  experiments	  with	  different	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Additional	  experiments	  using	  CysLT1	  receptor	  antagonists	  showed	  that	  pre-­‐treatment	  
of	  the	  Th2	  cells	  with	  the	  CysLT1R	  selective	  antagonist	  MK571	  completely	  blocked	  the	  
LTD4	  dose-­‐dependent	   inhibition	  of	   cAMP	  signalling	   (Figure	  3.24),	   confirming	   that	   the	  
receptor	  is	  partially	  coupled	  to	  Gαq/11	  and	  Gαi/o,	  corresponding	  to	  our	  previous	  data	  
and	  data	  in	  the	  literature	  and	  confirming	  that	  the	  LTD4-­‐induced	  decrease	  in	  cyclic	  AMP	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Figure	  3.24	  Blocking	  of	   the	  LTD4-­‐mediated	   inhibition	  of	  cAMP	  response	  by	  
MK571.	  100nM	  LTD4	  was	  used	  in	  these	  experiments.	  All	  data	  are	  expressed	  
as	  mean	  ±	  SEM	  percentages	  of	  maximum	  response	  to	  LTD4	  or	  forskolin	  from	  
3	  experiments	  with	  different	  donors.	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Similar	  experiments	  were	  performed	  using	  a	  range	  of	  LTC4	  and	  LTE4	  doses,	  as	  seen	  in	  
figure	   3.25	   and	   figure	   3.26.	   Interestingly	   when	   using	   LTC4,	   the	   levels	   of	   cyclic	   AMP	  
increased	   in	  a	  concentration-­‐dependent	  manner,	   instead	  of	  decreasing,	  as	   seen	  with	  
LTD4.	  0.1nM	  LTC4	  induced	  a	  70%	  reduction	  in	  cAMP,	  1nM	  a	  65%	  reduction,	  10nM	  45%	  
and	  100nM	  50%.	  The	  dose	  response	  observed	  when	  using	  LTE4	  was	  similar	  to	  results	  
seen	  using	   LTD4,	  with	  a	  maximum	  reduction	  of	  60%	   in	   cyclic	  AMP	   levels	  when	  using	  
100	  nM	  and	  1	  nM	  LTE4,	  40%	  reduction	  with	  10nM	  LTE4	  and	  30%	  reduction	  when	  using	  
0.1	  nM	  LTE4.	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Figure	  3.25	  LTC4-­‐mediated	  inhibition	  of	  cAMP	  signaling	  in	  Th2	  cells.	  Cells	  were	  
treated	  with	  20nM	   forskolin	   to	   induce	   cAMP,	  and	   increasing	   concentrations	  
of	   LTC4	   decreased	   the	   cAMP	   generation.	   All	   data	   are	   expressed	   as	  mean	   ±	  
SEM	   percentages	   of	   maximum	   response	   to	   LTC4	   or	   forskolin	   from	   3	  
experiments	  with	  different	  donors.	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Figure	  3.26	  LTE4-­‐mediated	  inhibition	  of	  cAMP	  signaling	  in	  Th2	  cells.	  Cells	  were	  
treated	  with	  20	  nM	  forskolin	  to	  induce	  cAMP,	  and	  increasing	  concentrations	  
of	   LTE4	   increased	   the	   cAMP	   generation	   similarly	   to	   LTD4.	   All	   data	   are	  
expressed	   as	   mean	   ±	   SEM	   percentages	   of	   maximum	   response	   to	   LTE4	   or	  
forskolin	  from	  3	  experiments	  with	  different	  donors.	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Following	  the	  cyclic	  AMP	  experiments,	  we	  decided	  to	  investigate	  the	  origin	  of	  calcium	  
observed	  in	  the	  previous	  calcium	  assays.	  
3.2.7 Calcium	  signalling	  in	  Th2	  cells	  
Additionally,	  we	  identified	  the	  source	  of	  calcium	  measured	  in	  the	  calcium	  assays.	  Pre-­‐
incubation	   of	   Th2	   cells	   with	   thapsigargin	   to	   deplete	   calcium	   from	   intracellular	  
endoplasmic	   reticular	   calcium	   stores	   completely	   inhibited	   calcium	   mobilization	   in	  
response	   to	   LTD4.	   Thapsigargin	   (THP)	   is	   a	   non-­‐competitive	   SERCA	   inhibitor,	   which	  
blocks	  the	  calcium	  pump	  on	  the	  surface	  of	  the	  endoplasmic	  reticulum.	  By	  blocking	  the	  
receptors,	  it	  stops	  calcium	  being	  pumped	  back	  into	  the	  sarcoplasmic	  and	  endoplasmic	  
reticulum,	  which	   raises	   cytosolic	   calcium	   levels	   and	   eventually	   depletes	   intracellular	  
calcium	   stores.	   Store	   depletion	   as	   we	   performed	   generally	   induces	   secondary	  
activation	   of	   plasma	   membrane	   calcium	   channels,	   particularly	   calcium-­‐release	  
activated	  calcium	  channels	   (or	  CRAC	  channels),	  whereby	  the	  cell	   sends	  signals	   to	  the	  
cell	   surface	   calcium	   channels	   to	   be	   opened	   and	   allow	   an	   influx	   of	   calcium	   into	   the	  
cytosol.	  To	  confirm	  this	  occurrence	  in	  our	  system,	  we	  used	  EDTA	  to	  block	  extracellular	  
calcium	   which	   may	   be	   pumped	   into	   the	   cell	   following	   intracellular	   store	   depletion.	  
Chelation	   of	   extracellular	   calcium	   by	   pre-­‐incubation	   of	   Th2	   cells	   with	   EDTA	   partially	  
inhibited	  calcium	  flux	  by	  approximately	  40-­‐50%	  (Figure	  3.27).	  This	  data	  suggests	  that	  
LTD4	  signalling	  through	  CysLTR1	  activates	  store-­‐operated	  calcium	  channels	  in	  Th2	  cells,	  
with	   the	   primary	   source	   of	   calcium	   originating	   from	   intracellular	   stores,	   and	   the	  
secondary	  source	  extracellular	  calcium	  being	  pumped	  into	  the	  cell.	  
	   	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  








































Figure	  3.27	  Source	  of	  calcium	  in	  LTD4-­‐driven	  calcium	  flux.	  Thapsigargin	  (THP)-­‐
mediated	   inhibition	   and	   EDTA-­‐mediated	   partial	   inhibition	   of	   calcium	   flux	  
responses	   to	   LTD4	   in	   Th2	   cells.	   Data	   are	   expressed	   as	   mean	   ±	   SEM	  
percentages	  of	  maximum	  response	  to	  LTD4	  from	  3	  experiments	  with	  different	  
donors.	  ***P	  <	  0.001,	  1-­‐way	  ANOVA	  with	  Tukey	  post	  test.	  


















Figure	   3.28	   Representation	   of	   intracellular	   calcium	   stores.	   The	   origin	   of	  
calcium	   can	   be	   tested	   by	   using	   the	   extracellular	   calcium-­‐chelating	   agent	  
EDTA	   and/or	   THP	   (thapsigargin)	   to	   deplete	   endoplasmic	   reticular	   calcium	  
stores.	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3.2.8 Summary	   	  
Using	   in-­‐vitro	   differentiated	   human	   Th1	   and	   Th2	   cells,	   we	   have	   demonstrated	   that	  
CYSLTR1	  is	  expressed	  on	  both	  Th1	  and	  Th2	  cells.	  LTD4,	  the	  known	  physiological	  ligand	  
with	  highest	  affinity	  for	  CysLT1R,	  caused	  calcium	  mobilisation	  in	  both	  Th1	  and	  Th2	  cells	  
with	  much	  higher	  levels	  of	  calcium	  flux	  in	  Th2	  cells.	  The	  other	  two	  known	  ligands	  LTC4	  
and	   LTE4	   also	   caused	   calcium	   signalling	   in	   Th2	   cells	   and	   the	   response	   was	   dose-­‐
dependent	   and	   ligand	   affinity-­‐dependent.	   The	   calcium	   response	   was	   completely	  
inhibited	  by	  known	  CysLT1	  receptor	  antagonists	  MK571,	  Montelukast	  and	  Zafirlukast.	  
In	   these	   experiments,	   we	   have	   shown	   that	   the	   human	   CysLT1R	   is	   coupled	   to	   both	  
Gαi/o	   and	   Gαq/11	   in	   our	   in	   vitro-­‐differentiated	   human	   Th2	   cells	   system.	   This	  
corresponds	   to	   previous	   findings	   that	   the	   receptor	   is	   partially	   coupled	   in	   native	  
systems	  but	  only	  coupled	  to	  Gαq/11	  in	  recombinant	  systems.	  We	  showed	  this	  via	  two	  
different	   measurements:	   one	   measured	   calcium	   flux	   following	   pertussis	   toxin	  
incubation,	  the	  other	  measured	  cyclic	  AMP	  levels	  after	  adding	  LTD4.	  This	  confirms	  that	  
CysLTR1	  is	  pertussis	  toxin-­‐sensitive	  in	  Th2	  cells.	  Furthermore,	  we	  have	  shown	  that	  the	  
calcium	   flux	   measured	   in	   our	   experiments	   is	   sourced	   in	   the	   endoplasmic	   reticulum	  
calcium	   stores	   and	   that,	   following	  depletion	  of	   these	   stores,	   the	   cell	   signals	   to	  open	  
membrane	  calcium	  channels	  to	  allow	  influx	  of	  extracellular	  calcium	  into	  the	  cytosol.	  
Although	  other	   studies	   have	   reported	   the	   expression	   of	   CYSLTR1	   in	   various	   types	   of	  
cells,	   this	  data	  consist	  of	   the	   first	   report	   that	  CYSLTR1	   is	  expressed	   in	  human	  T	  cells.	  	  
We	   show	   for	   the	   first	   time	   that	   human	   Th2	   cells	   selectively	   express	   CYSLTR1	  mRNA	  
with	  6.5	   fold	  higher	  expression	   than	  human	  Th1	   cells	   (Figure	  1C).	  We	  also	   found	  no	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evidence	   for	   expression	   of	   the	   other	   known	   CysLT	   receptors,	   CYSLTR2,	   GPR17	   or	  
P2YR12	  in	  T	  cells.	  
During	  the	  course	  of	  these	  studies	  other	  evidence	  emerged	  supporting	  out	  finding	  that	  
T	  cells	  may	  be	  a	  CysLT	  target	  cell	  type.	  The	  first	  evidence	  we	  have	  found	  was	  a	  study	  by	  
Chtanova	  et	  al.	  where	  transcriptional	  profiling	  of	  human	  T-­‐cell	  subsets	  was	  performed	  
(Chtanova	   et	   al.	   2004).	   They	   investigated	   the	   function,	   identity	   and	   molecular	  
interactions	  of	  another	  subset	  of	  human	  effector	  T	  cells,	  T	  follicular	  helper	  cells	  (Tfh).	  
For	  this,	  CD57+CXCR5+CD4+	  and	  CD57-­‐CXCR5+CD4+	  T	  cells	  were	  isolated	  from	  human	  
tonsils	  and	  assessed	  by	  Affymetrix	  microarrays	  for	  gene	  expression	  in	  a	  similar	  manner	  
to	  our	  study.	  Alongside	  TFH,	   they	  also	  made	  a	  comparison	  between	  Tfh	  cells	  and	  Th1	  
and	  Th2	  cells,	  as	  well	  as	  comparing	  to	  TEM	  (effector	  memory)	  and	  TCM	  (central	  memory)	  
cells	   isolated	   from	   peripheral	   blood.	   In	   their	   analysis	   CysLT1R	   was	   listed	   as	   being	  
upregulated	  in	  human	  Th2	  cells.	  Unfortunately	  no	  additional	  comments	  were	  made	  on	  
this	   finding	   and	   no	   further	   investigations	   were	   performed	   to	   examine	   CysLT	  
responsiveness.	  
Prinz	  et	  al.	  found	  further	  evidence	  for	  a	  role	  Cysltr1	  in	  T-­‐cells	  in	  a	  study	  examining	  mice	  
with	  mutations	  in	  the	  adaptor	  molecule	  linker	  for	  activation	  of	  T	  cells	  (LAT),	  LatY136F	  
αβ	   and	   Lat3YF	   γδ	   T	   cells	   expressed	   high	   levels	   of	   Cysltr1.	   Binding	   of	   LTD4	   to	   the	  
receptor	  caused	  Ca2+	   flux	  and	  chemotaxis	   in	  both	  LatY136F	  αβ	  and	  Lat3YF	  γδ	  T	  cells.	  
Wild-­‐type	   in	  vitro-­‐activated	  mice	  T	  cells,	  but	  not	  resting	  T	  cells,	  also	  migrated	  toward	  
LTD4	  however	  with	  a	  lower	  magnitude	  than	  T	  cells	  freshly	  isolated	  from	  LatY136F	  and	  
Lat3YF	  mice.	   These	  mice	  with	  mutations	   of	   distinct	   LAT	   tyrosine	   residues	   (LatY136F	  
and	  Lat3YF)	  develop	  lymphoproliferative	  disorders	   involving	  TCR	  αβ	  or	  γδ	  T	  cells	  that	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trigger	   symptoms	   resembling	   allergic	   inflammation.	   LatY136F	   (mutation	   of	   tyrosine	  
136	   in	   LAT	   into	   phenylalanine)	   caused	   a	   fatal	   lymphoproliferative	   disorder	   involving	  
polyclonal	   CD4+	  T	   cells	   that	   chronically	   produced	   type	  2	   cytokines	   such	  as	   IL-­‐4,	   IL-­‐5,	  
and	  IL-­‐13.	  Lat3YF	  (mutation	  in	  tyrosine	  175,	  195	  and	  235	  into	  phenylalanine)	  resulted	  
in	   the	   selective	   development	   and	   expansion	   of	   γδ	   T	   cells,	   which	   spontaneously	  
deployed	   a	   Th2-­‐like	   effector	   program.	   Both	  mutated	   cell	   types	   behaved	   similarly	   to	  
effector	  T	  cells,	  particularly	  following	  activation	  with	  ionomycin	  and	  their	  subsequent	  
activation	   of	   effector	   functions	   and	   ability	   to	   produce	   Th2-­‐specific	   cytokines.	   Given	  
that	   the	  T-­‐cells	   they	  were	   investigating	  appear	   to	  have	  Th2-­‐like	  properties	   this	   study	  
strongly	  supports	  our	  findings	  that	  Th2	  cells	  respond	  to	  CysLTs	  even	  though	  they	  were	  
examining	  mutant	  murine	  T	  cells	  (Prinz	  et	  al.	  2005).	  
One	  final	  piece	  of	  evidence	  for	  Cysltr1	  expression	  on	  T	  cells	  was	  found	  in	  a	  study	  using	  
knock-­‐in	   mice	   expressing	   a	   GFP-­‐Foxp3	   fusion	   protein,	   in	   which	   a	   population	   of	  
CD4+CD25+Foxp3-­‐	  T	  cells	  were	  identified	  as	  effector	  T	  cells.	  Transcriptional	  profiling	  of	  
these	   cells	   revealed	   Cysltr1	   expression,	   which	   was	   not	   present	   in	   naïve	   CD4+CD25-­‐
Foxp3-­‐	  T	  cells	  and	  CD4+CD25+Foxp3+	  regulatory	  T	  cells	  (Fontenot	  et	  al.	  2005).	  
Collectively	  our	  data	  and	  the	   literature	  strongly	  suggest	  that	  T	  cells,	   in	  particular	  Th2	  
cells,	   should	  be	  considered	  a	   legitimate	   target	   cell	   type	   for	  CysLTs.	  The	  next	   chapter	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Chapter	  4 Results	  –	  Functional	  effect	  of	  LTD4	  on	  Th2	  cells	  
4.1 Introduction	  
4.1.1 Characterisation	  of	  CysLTR1	  functions	  in	  human	  T	  cells 
In	   the	   previous	   chapter	   we	   demonstrated	   that	   human	   Th2	   cells	   selectively	   express	  
CYSLTR1	   mRNA	   and	   that	   this	   results	   in	   functional	   expression	   of	   the	   receptor	   as	  
evidenced	   by	   responsiveness	   to	   CysLTs	   via	   calcium	   mobilisation.	   Additional	  
experiments	   indicated	   that	   the	   CysLT1R	   receptor	   was	   partially	   coupling	   via	   Gαi	   and	  
Gαq	   and	   these	   results	  were	   confirmed	   both	   via	   calcium	   assays	   using	   pertussis	   toxin	  
and	  cyclic	  AMP	  assays.	   In	  all	  assays,	   the	  known	  CysLT1	  receptor	  antagonists	   inhibited	  
the	   LTD4	   response.	   Finally,	   we	   also	   reported	   that	   calcium	   appeared	   to	   originate	  
primarily	  from	  intracellular	  calcium	  stores.	  To	  examine	  the	  functional	  consequences	  of	  
CysLTR1	   signalling	   in	   Th2	   cells	   we	   wished	   to	   study	   several	   facets	   of	   T	   cell	   biology,	  
specifically	  migration	  (chemotaxis),	  cytokine	  expression	  and	  gene	  transcription.	  These	  
studies	  were	   to	  some	  extent	  guided	  by	   the	  known	  functions	  of	  CysLTs	   in	  vivo	  and	   in	  
other	  cell	  types.	  
4.1.2 CysLTR1	  involvement	  in	  chemotaxis 
G	  protein-­‐coupled	   receptors	   (GPCRs)	  have	  been	  widely	   studied	   in	   chemotaxis	   assays	  
since	   many	   of	   them	   are	   the	   key	   receptors	   to	   which	   leukotrienes,	   chemokines	   and	  
other	  mediators	  bind	  to	  in	  order	  to	  effect	  cellular	  migration.	  GPCRs	  are	  found	  on	  the	  
surface	   of	   target	   cells	   and	   interact	  with	  mediators	   typically	   of	   nanomolar	   affinity	   to	  
subsequently	   transduce	   intracellular	   signalling	   events.	   Immunological	   processes	   such	  
as	   antigen	   recognition,	   lymphocyte	   priming	   and	   effector	   responses	   to	   inflammation	  
are	  executed	  by	   leukocytes	  and	  their	  ability	   to	  circulate	  around	  and	  migrate	  through	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body	   tissues	   is	   critical	   for	   these	   functions.	   Leukocyte	   trafficking	   is	   regulated	   by	   a	  
complex	  interaction	  of	  molecules,	  such	  as	  leukotrienes,	  cytokines	  and	  chemokines,	  all	  
with	   roles	   in	   the	   chemotactic	   response.	   Chemotaxis	   can	   be	   defined	   as	   a	   directed	  
movement	   of	   a	   cell	   towards	   a	   chemical	   signal	   or	   chemotactic	   stimuli,	   in	   the	   case	  of	  
leukocytes	  usually	  mediated	  via	  cell	  surface	  receptors.	  
The	  major	   role	   of	   these	  mediators	   such	   as	   leukotrienes	   and	   chemokines	   is	   to	   guide	  
cells	   for	  migration	   by	   providing	   them	  with	   directional	   cues.	  Migrating	   cells	   follow	   a	  
signal	  of	   increasing	  mediator	  concentration	  towards	  the	  source	  of	  the	  mediator,	  very	  
often	  to	  migrate	  to	  a	  site	  of	  inflammation	  (D'Ambrosio	  et	  al.	  2001).	  	  
LTD4	  has	  been	   reported	  as	  being	  able	   to	   induce	   chemotactic	   responses	   from	  several	  
cell	   types,	   including	   eosinophils,	   neutrophils,	   basophils,	   monocytes	   and	  
haematopoietic	   stem	  cells.	  One	   study	  used	   the	   chemotaxis	  under-­‐agarose	   technique	  
to	   demonstrate	   that	   LTD4	   was	   a	   potent	   chemoattractant	   for	   eosinophils	   at	   various	  
doses	  and	  this	  migration	  was	  inhibited	  using	  the	  SK&F	  104353	  antagonist	  (Spada	  et	  al.	  
1994).	   However,	   LTD4	   had	   little	   effect	   on	   the	   eosinophil	   chemokinesis.	   LTB4	   also	  
induced	   chemotaxis	   of	   eosinophils.	   Both	   LTB4	   and	   LTD4	   induced	   chemotaxis	   and	  
chemokinesis	  in	  neutrophils	  (Krauss	  et	  al.	  1994;	  Spada	  et	  al.	  1994).	  
In	   a	   randomized	   controlled	   trial,	   another	   study	   reported	   that	   four	   weeks	   of	  
Montelukast	   treatment	   reduced	   airway	   eosinophilic	   inflammation	   in	   asthmatic	  
subjects	  suggesting	  an	  effect	  on	  eosinophil	  migration	  (Pizzichini	  et	  al.	  1999).	  Following	  
reports	  that	  LTE4	  can	  increase	  numbers	  of	  eosinophils	  (10-­‐fold	  higher	  than	  neutrophils)	  
and	   neutrophils	   in	   the	   human	   airway	   mucosa	   4	   hours	   after	   inhalation	   in	   subjects	  
(Laitinen	  et	  al.	  1993),	  additional	   studies	   found	   that	   LTD4	  also	   induced	  eosinophilia	   in	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sputum	   of	   asthmatic	   subjects	   4	   hours	   after	   inhalation	   (Diamant	   et	   al.	   1997).	  
Interestingly,	   reports	   indicated	   no	   significant	   change	   in	   numbers	   of	   lymphocytes,	  
plasma	  cells,	  mast	   cells	  or	  macrophages	   in	   response	   to	  LTD4	   (Laitinen	  et	  al.	  1993).	   It	  
was	  also	  shown	  that	  eosinophils	   isolated	  from	  non-­‐	  atopic	  venous	  blood	  migrated	  to	  
LTD4,	  and	  this	  was	  inhibited	  using	  pranlukast	  in	  a	  dose-­‐dependent	  fashion	  (Ohshima	  et	  
al.	   2002).	   This	  was	   also	   reproduced	   by	   another	   group,	  who	   demonstrated	   using	   the	  
Boyden	  chamber	  system	  that	  human	  eosinophils	  migrated	  to	  LTD4,	  LTC4	  and	  LTE4	  and	  
this	   was	   inhibited	   by	   Montelukast	   (Fregonese	   et	   al.	   2002).	   Conversely,	   it	   was	   also	  
reported	  in	  a	  comparison	  between	  inhaled	  LTD4	  and	  LTE4	  that	  LTE4	  causes	  an	  increase	  
in	  sputum	  eosinophils	  but	  LTD4	  did	  not	  (Gauvreau	  et	  al.	  2001).	  
In	   guinea	   pig	   tracheal	   explant	   preparations,	   it	   was	   found	   that	   both	   LTB4	   and	   LTD4	  
facilitated	   eosinophil	   migration	   from	   the	   lamina	   propria	   to	   the	   lumen	   caused	   by	  
formyl-­‐met-­‐leu-­‐phe	   (FMLP)	   (Munoz	   et	   al.	   1997).	   Using	   radio-­‐labelled	   guinea-­‐pig	  
conjuctiva	  eosinophils	  injected	  into	  recipient	  animals,	  Chan	  et	  al.	  found	  that	  LTD4	  and	  
PAF	   induced	  a	  significant	  2.5	  fold	   increase	   in	  chemotaxis	   in	  vivo,	  which	  was	   inhibited	  
using	   MK571,	   a	   known	   CysLT1	   receptor	   antagonist	   (Chan	   et	   al.	   1990).	   Similarly,	  
inhalation	  of	  aerosolized	  LTD4	  elicited	  eosinophil	  migration	  into	  guinea	  pig	  lungs,	  which	  
was	   maintained	   up	   to	   4	   weeks	   post	   challenge	   (Underwood	   et	   al.	   1996)	   again	  
implicating	  LTD4	  in	  the	  migration	  of	  eosinophils.	  
In	   2005	   basophils	   were	   analysed	   for	   their	   expression	   and	   function	   of	   CYSLTR1,	  
(Gauvreau	   et	   al.	   2005)	   following	   previous	   studies	   by	   the	   group	   reporting	   basophil	  
accumulation	   in	   asthmatic	   airways	   after	   inhalation	   of	   LTE4	   (Gauvreau	   et	   al.	   2001).	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Although	   it	   seems	   to	   report	   migration	   of	   basophils	   to	   LTD4,	   the	   assays	   were	  
problematic	  and	  the	  evidence	  for	  the	  chemotaxis	  of	  basophils	  is	  unclear.	  
Cysteinyl	   leukotrienes	   have	   also	   been	   shown	   to	   be	   chemotactic	   to	   hematopoietic	  
progenitor	  cells.	  CD34+	  hematopoietic	  progenitor	  cells	  isolated	  from	  peripheral	  blood	  
mononuclear	   cells	   from	  normal	  patients	  were	   found	   to	  express	  CYSLTR1	  and	  also	   to	  
migrate	   to	   LTD4	   (Bautz	   et	   al.	   2001).	   RT-­‐PCR	  was	   used	   to	   examine	   the	   expression	   of	  
CYSLTR1	   mRNA	   in	   CD34+	   cells,	   mature	   leukocytes	   and	   in	   monocytic	   cell	   line	   THP-­‐1	  
used	  as	  a	  positive	  control,	  CD34+	  hematopoietic	  cell	  line	  KG1a	  and	  CD34-­‐	  myeloid	  cell	  
line	  HL-­‐60.	   Calcium	  experiments	   revealed	   that	   LTD4	   induced	   a	   significant	   increase	   in	  
intracellular	   calcium	   in	   peripheral	   blood	   CD34+	   cells.	   Incubation	  with	   pertussis	   toxin	  
resulted	   in	   partial	   inhibition	   of	   the	   calcium	   response.	   Using	   a	   modified	   Boyden	  
chamber	   system	   for	   the	   chemotaxis	   assay,	   LTD4	   was	   seen	   to	   cause	   migration	   of	  
peripheral	  blood	  CD34+	  cells	  at	  various	  concentrations	  (Bautz	  et	  al.	  2001).	  
In	  a	  study	  described	   in	   the	  previous	  chapter,	  using	  αβ	  and	  γδ	  T	  cells	   from	  mice	  with	  
knock-­‐in	   mutations	   (Lat3YF	   and	   LatY136F,	   respectively)	   strongly	   migrated	   to	   LTD4.	  
Wild-­‐type	  comparison	  revealed	   that	   in	  vitro-­‐stimulated	  CD4+	  T	  cells	  also	  migrated	  to	  
LTD4	   but	   with	   a	   lower	   magnitude	   and	   unstimulated	   CD4+	   T	   cells	   did	   not	   migrate	  
towards	  LTD4	  at	  all.	  Interestingly	  these	  mutant	  cells	  caused	  a	  fatal	  lymphoproliferative	  
disorder	   involving	  polyclonal	  CD4+	  T	  cells	   that	   chronically	  produced	   type	  2	  cytokines	  
such	   as	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   and	   which	   spontaneously	   deployed	   a	   Th2-­‐like	   effector	  
program,	  characterized	  by	  lymphocytic	  infiltration	  of	  the	  lungs	  and	  tissue	  eosinophilia,	  
symptoms	  reminiscent	  of	  allergic	   inflammation.	  This	   latter	  study	  is	  the	  only	  report	  of	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chemotaxis	  observed	   in	  CD4+	  T	  cells,	  however	  these	  were	  from	  LatY136F	  and	  Lat3YF	  
mutant	  mice	  that	  had	  LAT-­‐mutated	  T	  cells	  (Prinz	  et	  al.	  2005).	  
Several	   studies	   have	   investigated	   the	   role	   of	   CYSLTR1	   expression	   in	   monocytes.	  
Thivierge	   et	   al.	   investigated	   the	   potential	   for	   cytokines	   such	   as	   IL-­‐13	   and	   IL-­‐4	   to	  
modulate	   the	   expression	   and	   function	   of	   CysLT1R.	   The	   group	   found	   that	   CysLT1R	  
mRNA	  was	  constitutively	  expressed	  by	  human	  monocytes	  and	  that	  treatment	  of	  cells	  
with	  IL-­‐13	  augmented	  the	  CysLT1R	  mRNA	  levels	  by	  3-­‐	  to	  5-­‐fold.	  This	  increase	  was	  time-­‐
dependent	  and	  observed	  as	  early	  as	  4	  hours	  post	  stimulation,	  with	  a	  maximal	  response	  
at	  8	  hours	  and	  sustained	   for	  24	  hours.	   Similar	   results	  were	  observed	  by	   treating	   the	  
cells	   with	   IL-­‐4,	   but	   not	   IFN-­‐y.	   In	   both	   cases,	   protein	   levels	   were	   also	   increased.	  
Thivierge	  et	  al.	  investigated	  the	  effect	  of	  IL-­‐4	  and	  IL-­‐13	  on	  calcium	  mobilization	  and	  the	  
functional	   responsiveness	  of	   the	  cells	   to	  LTD4.	  Treatment	  of	  monocytes	  with	   IL-­‐13	  or	  
IL-­‐4	   led	   to	  an	   increased	   calcium	   flux	   in	   response	   to	   LTD4	  but	  not	   LTB4.	   Treatment	  of	  
monocyte-­‐derived	   macrophages	   led	   to	   an	   even	   larger	   increase	   than	   in	   monocytes.	  
These	   responses	   were	   fully	   inhibited	   by	   antagonist	   MK571.	   Thivierge	   et	   al.	   also	  
investigated	  the	  effect	  of	  IL-­‐13	  and	  IL-­‐4	  on	  the	  migration	  of	  monocytes	  towards	  LTD4.	  
Resting	   monocytes	   did	   not	   show	   much	   chemotactic	   response	   to	   LTD4.	   However	  
monocytes	  that	  had	  been	  incubated	  with	  IL-­‐13	  or	  IL-­‐4	  showed	  a	  significant	  increase	  in	  
chemotaxis	   (Thivierge	   et	   al.	   2001).	   In	   a	   further	   study	   by	   Thivierge	   (Thivierge	   et	   al.	  
2006),	  monocyte-­‐derived	  dendritic	  cells	  stimulated	  and	  matured	  with	  LPS	  (which	  binds	  
TLR4)	   showed	   a	   near	   total	   loss	   of	   their	   CysLTR1	   expression.	   This	  was	   also	   observed	  
when	  stimulating	  the	  cells	  with	  zymosan,	  which	  is	  known	  to	  bind	  to	  TLR2.	  Interestingly,	  
results	   showed	   that	   maturation	   with	   polyI:C	   had	   no	   effect	   on	   CYSLTR1	   expression.	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Inhibition	   of	   LPS-­‐induced	   COX-­‐2	   by	   COX-­‐2	   inhibitor	   NS-­‐398	   reversed	   the	  
downregulation	   of	   CysLTR1	   in	   LPS-­‐stimulated	   DCs.	   PGE2	   and	   TNF-­‐α	   combined	   also	  
reduced	  the	  CYSLTR1	  expression	  to	  very	   low	  levels.	  These	  results	  were	  also	  observed	  
at	   the	   mRNA	   level,	   which	   was	   decreased	   by	   70%	   to	   80%	   in	   LPS-­‐	   and	   PGE2/TNF-­‐α-­‐
matured	  DCs,	  respectively.	  In	  contrast	  to	  the	  MoDCs,	  human	  monocytes	  were	  resistant	  
to	  CysLT1R	  downregulation	  and	  this	  suggested	  the	  differentiation	  process	   in	  DCs	  was	  
the	  key	  to	  rendering	  the	  cells	  sensitive	  to	  LPS	  and	  PGE2/	  TNF-­‐α.	  Cells	  matured	  with	  LPS	  
showed	   no	   calcium	   response	   to	   LTD4	   in	   contrast	   to	   polyI:C-­‐matured	   DCs.	   The	   same	  
effect	  was	  noted	  on	  chemotaxis	  (Thivierge	  et	  al.	  2006).	  
Woszczek	  et	  al.	  showed	  that	  LTD4	  induced	  signalling,	  gene	  expression	  and	  migration	  of	  
monocytes	   and	   monocyte-­‐derived	   immature	   dendritic	   cells	   (iDCs)	   and	   that	   these	  
effects	   could	   be	   inhibited	   by	   IL-­‐10	   (Woszczek	   et	   al.	   2008a).	   They	   also	   found	   that	  
CysLT2R	  and	  GPR17	  were	  also	  expressed	  on	  iDCs.	   In	  their	  experiments,	  they	  cultured	  
monocytes	  in	  the	  presence	  of	  IL-­‐10	  for	  up	  to	  24	  hours	  and	  measured	  mRNA	  levels	  of	  
CYSLTR1	   to	   find	   that	   IL-­‐10	   reduced	  mRNA	   expression	   in	   a	   dose-­‐dependent	  manner,	  
with	  an	  optimal	  result	  after	  6	  hours.	  Similar	  results	  were	  observed	  in	  iDCs,	  which	  were	  
cultured	  without	  IL-­‐4	  prior	  to	  the	  experiment,	  as	  IL-­‐4	  is	  known	  to	  upregulate	  CYSLTR1	  
expression	   in	   these	   cells.	   In	   iDCs,	   the	   response	   was	   time-­‐dependent.	   Calcium	   flux	  
experiments	  revealed	  that	  LTD4	  induced	  a	  strong	  calcium	  response	  in	  both	  monocytes	  
and	  iDCs	  and	  this	  was	  significantly	   inhibited	  when	  both	  types	  of	  cells	  were	  incubated	  
overnight	  with	  IL-­‐10.	  Additional	  tests	  revealed	  that	  IL-­‐10	  was	  also	  capable	  of	  inhibiting	  
LTD4-­‐induced	  immediate-­‐early	  genes	  FOSB	  and	  EGR2	  in	  monocytes	  but	  also	  in	  iDCs,	  in	  
a	  way	   similar	   to	  MK571.	   siRNA	   of	   the	   receptor	   confirmed	   that	   the	   results	   observed	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previously	   were	   all	   CysLT1R-­‐mediated,	   including	   intracellular	   calcium	   and	   gene	  
expression.	  IL-­‐10	  also	  inhibited	  the	  migration	  of	  monocytes	  and	  iDCs	  towards	  LTD4.	  In	  
additional	  experiments,	  IL-­‐10	  was	  also	  found	  to	  enhance	  the	  LTD4-­‐induced	  chemotaxis	  
of	   iDCs	   to	   CCL5	   and	   CCL3	   (Woszczek	   et	   al.	   2008a).	   Monocytes	   were	   also	   found	   to	  
chemotax	   to	   both	   LTB4	   and	   LTD4	   with	   an	   increase	   in	   migration	   towards	   both	  
leukotrienes	  together	  (Chen	  et	  al.	  2011).	  	  
Kato	   et	   al.	   showed	   that	   LTD4	   had	   an	   enhancing	   effect	   on	   the	   migration	   of	   normal	  
human	   lung	   fibroblasts	   to	   human	   plasma	   fibronectin.	   Despite	   claiming	   that	   LTD4	  
potentiated	   the	   chemotaxis,	   the	   results	   showed	   a	   one-­‐fold	   increase	   in	   the	  migrated	  
cells	  when	  LTD4	  was	  added	  to	  the	  normal	  lung	  fibroblasts	  before	  incubation	  (Kato	  et	  al.	  
2005).	  
A	   study	   by	   Espinosa	   et	   al.	   showed	   that	   exposure	   of	   bronchial	   smooth	   muscle	   cells	  
(BSMCs)	  to	  TGF-­‐β,	  IL-­‐13	  or	  IFN-­‐γ	  increased	  the	  protein	  expression	  of	  CysLTR1	  on	  these	  
cells	  (Espinosa	  et	  al.	  2003).	  Surprisingly,	  IL-­‐4	  had	  no	  effect	  on	  the	  protein	  expression	  of	  
CysLT1R	   in	   human	   BSMCs.	   mRNA	   levels	   studies	   revealed	   that	   IL-­‐13	   and	   IFN-­‐γ	   both	  
increased	  mRNA	  levels	  but	  not	  TGF-­‐β,	  and	  this	  after	  a	  long	  exposure	  of	  24	  hours.	  The	  
study	   then	   investigated	   the	   effect	   of	   LTD4	   on	   the	   proliferation	   of	   the	   cells	   on	   both	  
control	  cells	  and	  TGF-­‐β,	  IL-­‐13-­‐	  and	  IFN-­‐γ-­‐stimulated	  cells.	  Results	  showed	  no	  significant	  
proliferation	   in	   control	   BSMCs.	   However,	   a	   24-­‐hour	   stimulation	   with	   IL-­‐13	   or	   TGF-­‐β	  
induced	  a	  significant	  proliferation	  in	  BSMCs	  (Espinosa	  et	  al.	  2003).	  	  
Since	  CysLTs,	  acting	  through	  CysLT1	  receptor,	  are	  chemotactic	  for	  several	  immune	  cell	  
types	  we	  hypothesized	  that	  they	  may	  also	  be	  chemotactic	  for	  human	  Th2	  cells.	  In	  our	  
experiments,	  we	  investigated	  the	  chemotactic	  effect	  of	  LTD4	  on	  Th2	  cells	  and	  this	  was	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tested	  at	  various	  doses	  of	  LTD4.	  We	  also	  tested	  known	  positive	  controls	  such	  as	  SDF-­‐1α	  
and	   PGD2.	   Additionally	   we	   examined	   whether	   chemotaxis	   could	   be	   inhibited	   by	  
antagonist	  MK571.	  
In	   further	   experiments,	   we	   looked	   at	   the	   effect	   of	   LTD4	   on	   Th1	   and	   Th2	   cells	  
proliferation,	  differentiation	  and	  cytokine	  expression.	  
	   	  




4.2.1 Human	  Th2	  cells	  migrate	  to	  LTD4	  in	  a	  dose-­‐dependent	  manner	  
We	   next	   aimed	   at	   determining	   the	   functional	   consequence	   of	   CysLTR1	   signaling	   on	  
human	  Th2	  cells.	  The	  mechanism	  of	  recruitment	  of	  T	  cells	  and	  other	  inflammatory	  cells	  
to	  the	  lung	  during	  inflammation	  has	  been	  the	  focus	  of	  research	  for	  a	  long	  time	  and	  is	  
of	   high	   interest	   since	   blocking	   T	   cell	   recruitment	   to	   the	   lung	   would	   be	   a	   potential	  
therapeutic	  strategy	  for	  asthma	  and	  other	  inflammatory	  lung	  diseases.	  	  
Cysteinyl	   leukotrienes	   have	   previously	   been	   shown	   to	   be	   chemotactic	   agents	   for	  
haematopoietic	   progenitor	   cells	   and	   monocytes	   (Bautz	   et	   al.	   2001;	   Thivierge	   et	   al.	  
2001;	  Woszczek	   et	   al.	   2008a).	  We	   thus	   determined	  whether	   LTD4	   treatment	   caused	  
CysLTR1-­‐mediated	   chemotaxis	   in	   human	   Th2	   cells	   by	   using	   a	   chemotaxis	   assay.	   This	  
technique	   required	   considerable	   optimisation;	   we	   originally	   started	   testing	   for	  
chemotaxis	  using	  the	  96-­‐well	  ChemoTX	  plate	  system	  from	  NeuroProbe	  and	  a	  Boyden	  
chamber	  using	  protocols	  developed	  by	  James	  Pease	  (Imperial	  College).	  
With	   this	   technique,	   fully	   differentiated	   in	   vitro-­‐cultured	   human	   Th2	   cells	   were	  
collected	  and	  counted.	  Cells	  were	  spun	  down	  at	  1200	  rpm	  for	  5	  minutes	  and	  were	  re-­‐
suspended	   in	   0.1%	  BSA	   (Bovine	   Serum	  Albumin)	   in	  RPMI	  medium	   to	  obtain	   200,000	  
cells	  per	  20	  μl.	  Wells	  were	  pre-­‐incubated	  with	  30	  μl	  1%	  BSA	   in	  RPMI	  medium	  for	  30	  
minutes	   in	  order	  to	  avoid	  chemokines	  and	   leukotrienes	  binding	  to	  the	  plasticware	  of	  
the	   plate.	   Following	   incubation,	   30	   μl	   were	   aspirated	   and	   wells	   were	   left	   to	   dry.	  
Chemokines	   and	   leukotrienes	   were	   prepared	   in	   dilution	   series	   from	   100	   mM	   stock	  
solution,	   in	  0.1%	  BSA	  in	  RPMI	  medium	  and	  31	  μl	  were	  used	  per	  well.	  The	  membrane	  
layer	   was	   then	   carefully	   laid	   down	   and	   20	   μl	   containing	   200,000	   cells	   were	   placed	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above	  each	  well	  as	  a	  drop	  on	  the	  membrane.	  The	  lid	  of	  the	  chamber	  was	  then	  placed	  
on	  the	  plate	  and	  the	  chamber	  was	  incubated	  in	  a	  damp	  container	  for	  5	  hours	  at	  37°C.	  
Following	  incubation,	  drops	  of	  cells	  on	  top	  of	  the	  membrane	  were	  scraped	  off	  using	  a	  
cell	  scraper	  and	  the	  membrane	  removed	  carefully.	  Each	  sample	  in	  each	  well	  was	  then	  
counted	  for	  migrated	  cell	  numbers	  using	  a	  haemocytometer.	  Alternatively,	  cells	  were	  
counted	  using	  luminescence.	  Cells	  were	  scraped	  off	  and	  the	  membrane	  was	  removed	  
before	  transferring	  migrated	  cells/chemokine	  mix	  from	  each	  well	  into	  a	  white	  96-­‐well	  
plate	   by	   centrifuging	   5	   minutes	   at	   1200	   rpm.	   30	   μl	   cell	   glow	   were	   added	   per	   well	  
before	  covering	  the	  white	  plate	  with	  a	  plastic	  film	  and	  rotating	  it	  for	  5	  minutes	  before	  
reading	  cell	   counts	  using	  a	   luminescence	  plate	   reader.	  Luminescence	  of	  each	  sample	  
was	   determined	   by	   subtracting	   luminescence	   counts	   from	  wells	   containing	   no	   cells.	  
Although	   the	   assay	   was	   successful	   and	   migrated	   cells	   were	   visible	   under	   the	  
microscope,	  we	  could	  not	   fully	  determine	  whether	   the	  cells	  had	  dropped	  due	   to	   the	  
membrane	  pore	   size	  being	   too	   large	  or	  whether	   they	  had	  actually	  migrated	   towards	  
leukotrienes.	   Additionally	   it	   was	   very	   difficult	   to	   quantify	   the	  migrated	   cells	   as	   they	  
stuck	   to	   the	   plastic.	   The	   luminescence	   reading	   technique	   did	   not	   give	   us	   accurate	  
enough	  data	  and	  we	  proceeded	  to	  optimize	  the	  chemotaxis	  assay	  for	  better	  results.	  
While	   researching	   a	   way	   to	   optimise	   our	   chemotaxis	   assay	   and	   studies	   which	   used	  
human	  T	  cells	  in	  migration	  assays,	  we	  found	  a	  range	  of	  methods	  with	  a	  lot	  of	  variation	  
in	   techniques	   and	   equipment.	   Variations	   included	   assay	   type	   and	   assay	   system,	  
resuspension	  buffer	   for	   cell	   preparation,	   cell	   numbers	   in	   the	  assay,	   incubation	   times	  
and	  cell	  counting	  and	  analysis	  methods.	  A	  study	  by	  Zhou	  et	  al,	  looking	  at	  the	  migration	  
of	  Th17	  cells,	  used	  a	  Transwell	  assay	  with	  a	  membrane	  of	  3	  μm	  pore	  size	  and	  an	  assay	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incubation	  time	  of	  24	  hours	  (Zhou	  et	  al.	  2011)	  .	  Another	  by	  Vijayanand	  (Vijayanand	  et	  
al.	  2010)	  prepared	  CD45RO+CD4+	  memory	  T	  cells	  overnight,	  before	  using	  500,000	  cells	  
resuspended	   in	   HBSS	   with	   BSA	   and	   HEPES	   for	   four	   hours	   in	   a	   96-­‐well	   chemotaxis	  
chamber	  with	  a	  membrane	  of	  3	  µm	  pore	  size,	  before	  counting	  migrated	  cells	  using	  a	  
haemocytometer	  (Vijayanand	  et	  al.	  2010).	  Perez-­‐Novo	  et	  al.	  used	  a	  96-­‐well	  ChemoTx	  
plate	  with	   a	  membrane	  of	   5	  μm	  pore	   size	   for	   their	   Th2	   cells	   resuspended	   in	  X-­‐VIVO	  
media.	  The	  group	  incubated	  the	  Th2	  cells	  for	  an	  hour	  before	  centrifuging	  the	  plate	  to	  
collect	   any	   cells	   underside	   of	   the	   filter	   and	   analysing	   the	   data	   using	   flow	   cytometry	  
(Perez-­‐Novo	  et	  al.	  2010).	  Using	  in	  vitro-­‐cultured	  T	  cells	  isolated	  from	  mice,	  Mira	  et	  al.	  
used	  a	  transwell	  assay	  with	  a	  membrane	  of	  5	  μm	  pore	  size,	  using	  T	  cells	  resuspended	  
in	  RPMI	  1640	  with	  FCS	  and	  anti-­‐CD3/CD28	  and	  incubated	  overnight.	  Following	  a	  2-­‐hour	  
transwell	  incubation,	  cells	  were	  analysed	  by	  flow	  cytometry	  (Mira	  et	  al.	  2008).	  
We	   found	   that	   there	  was	   very	   limited	   data	   available	   in	   the	   literature	   regarding	   the	  
optimisation	  of	  chemotaxis	  assays	  for	  human	  lymphocytes	  until	  a	  study	  by	  Islam	  et	  al.	  
in	   2011,	   looking	   at	   mouse	   CCL8	   and	   its	   chemotactic	   effect	   on	   CCR8-­‐expressing	  
inflammatory	   Th2	   cells	   enriched	   for	   IL-­‐5	   expression.	   Since	   the	   chemotaxis	   assay	  
technique	   was	   not	   clearly	   explained	   in	   the	   methods,	   we	   requested	   additional	  
information	  from	  the	  author	  Sabina	   Islam.	   In	  their	  study,	  the	  group	   identified	  mouse	  
CCL8	   as	   a	   second	  mammalian	   agonist	   for	   the	   known	   chemokine	   receptor	   CCR8.	   The	  
chemokine	  was	   found	   to	   specifically	   induce	  migration	   of	   a	   recently	   activated,	   highly	  
differentiated	   Th2	   cell	   population	   enriched	   in	   IL-­‐5	   and	   IL-­‐25R,	   TNF	   and	   OX40.	  	  
Interestingly	   this	   was	   only	   specific	   to	   the	   mouse	   system,	   as	   human	   CCL8	   did	   not	  
activate	  CCR8.	  The	  group	  also	  suggested	  a	  role	   for	  mouse	  CCR8	   in	  mediating	  chronic	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cutaneous	   allergic	   inflammation.	   For	   their	   migration	   experiments,	   the	   group	   used	  
Transwell	   plates	   with	   a	   polycarbonate	  membrane	   for	   filter	   of	   5	   µm	   pore	   size.	   Cells	  
were	   resuspended	   in	   RPMI	   buffer	   and	   rested	   for	   4	   hours	   in	   low	   rIL-­‐2	   concentration	  
prior	   to	   running	   the	  assay.	  Cells	  were	   then	  harvested,	  washed	   in	  PBS	   then	  used	  at	  a	  
concentration	  of	  500,000	  cells	  per	  100	  µl	   in	  a	  buffer	  made	  of	  RPMI,	  HEPES	  and	  BSA.	  
The	  amount	  of	  chemokines	  or	  leukotrienes	  loaded	  in	  the	  well	  was	  600	  µl	  and	  the	  assay	  
was	  incubated	  for	  2	  hours	  at	  37°C	  and	  5%	  CO2.	  The	  counting	  method	  was	  also	  different	  
than	  those	  seen	  in	  other	  studies.	  Here,	  15	  µm	  beads	  were	  added	  to	  the	  migrated	  cells	  
and	  acted	  as	  a	  standard	  for	  counting	  cells	  by	  flow	  cytometry	  (Islam	  et	  al.	  2011).	  
Using	  this	  method	  we	  managed	  to	  optimise	  the	  chemotaxis	  assay	  using	  Th2	  cells	  and	  
proceeded	   with	   testing	   various	   leukotrienes	   and	   chemokines	   with	   varying	  
concentrations.	  
Firstly	   we	   performed	   the	   chemotaxis	   assay	   using	   LTD4	   at	   a	   wide	   range	   of	  
concentrations	  using	  the	  exact	  method	  described	  above.	  The	  results	  for	  this	  are	  shown	  
in	  figure	  4.1,	   in	  which	  Th2	  cells	  migrated	  towards	  LTD4	  in	  a	  concentration-­‐dependent	  
manner.	  The	  optimum	  concentrations	  observed	  for	  Th2	  cell	  migration	  were	  between	  3	  
nM	   and	   10	   nM	   LTD4,	   which	   strongly	   resembles	   the	   EC50	   for	   LTD4	   in	   the	   calcium	  
mobilization	   studies.	   Additionally,	   the	   migration	   observed	   was	   inhibited	   when	  
incubating	   the	   Th2	   cells	   with	   specific	   CysLT1	   receptor	   antagonist	   MK571	   prior	   to	  
running	  the	  assay.	  
Further	  experiments	  comparing	  LTD4	  with	  known	  chemoattractants	  revealed	  that	  the	  
chemokine	  SDF-­‐1α,	  which	  has	  been	  shown	  to	  induce	  migration	  in	  human	  lymphocytes,	  
particularly	   both	   Th1	   and	   Th2	   cells	   (Siveke	   and	   Hamann	   1998),	   caused	   a	   robust	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chemotactic	   response	   in	   human	   Th2	   cells	   (Figure	   4.2).	   In	   contrast	   CCL18,	  which	   has	  
been	   reported	   to	   be	   selectively	   chemotactic	   for	   human	   Th2	   cells,	   did	   not	   cause	  
chemotaxis	  (Figure	  4.2).	  LTD4	  was	  found	  to	  be	  a	  potent	  chemoattracting	  mediator	  to	  
fully	  polarized	  Th2	  cells	   and	   induced	  concentration-­‐dependent	   chemotaxis	  of	  human	  
Th2	  cells	  with	  a	  classical	  bell-­‐shaped	  curve	  (Figure	  4.2).	  	  
Additional	   experiments	  were	   performed	   to	   compare	   the	  migration	   effect	   of	   LTD4	   in	  
comparison	   to	  LTE4.	  As	   shown	   in	   figure	  4.3,	   LTD4	  was	  more	  chemotactic	   to	  Th2	  cells	  
than	  LTE4.	  	  
	  
	  
	   	  





	   	  
	  
	   	  
Figure	  4.1	  LTD4	  is	  chemotactic	  for	  Th2	  cells	  in	  a	  concentration-­‐dependent	  
manner.	  Chemotactic	  agents	  were	  assessed	  in	  a	  Transwell-­‐based	  system.	  
and	  cells	  were	  allowed	  to	  migrate	  for	  2	  hours.	  Different	  concentrations	  of	  
LTD4	  were	  used	  as	  shown.	  CysLT1R	  antagonist	  MK571	  was	  used	  at	  100nM	  
concentration	  and	  inhibited	  chemotaxis.	  Data	  shown	  are	  means	  ±	  SEM	  of	  
3	  independent	  experiments	  with	  different	  donors.	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Figure	   4.2	   Comparison	   of	   LTD4	   and	   controls	   on	   the	   migration	   of	   Th2	   cells.	  
Chemotactic	   agents	   were	   assessed	   in	   a	   Transwell-­‐based	   system.	   Cells	   were	  
allowed	  to	  migrate	  for	  2	  hours.	  Different	  concentrations	  of	  LTD4	  were	  used	  as	  
shown.	   Control	   chemokines	   CXCL12	   and	   CCL18	   were	   used	   at	   10nM	  
concentration.	   Data	   shown	   are	  means	   ±	   SEMs	   of	   3	   independent	   experiments	  
with	   different	   donors.	   ***P	   <	   0.001	   and	   *P	   <	   0.05,	   2-­‐way	   ANOVA	   with	  












































































	   	  
Figure	  4.3	  LTD4	  is	  more	  chemotactic	  for	  Th2	  cells	  than	  LTE4.	  Chemotactic	  
agents	  were	  assessed	  in	  a	  Transwell-­‐based	  system.	  Cells	  were	  allowed	  to	  
migrate	   for	   2	   hours.	   Different	   concentrations	   of	   cysteinyl	   leukotrienes	  
were	   used	   as	   shown.	   Data	   shown	   are	  means	   ±	   SEMs	   of	   3	   independent	  
experiments	  with	  different	  donors.	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Based	  on	  evidence	  that	  PGD2	  binds	  to	  Th2-­‐specific	  CRTh2	  receptor,	  we	  decided	  to	  test	  
PGD2	  in	  our	  chemotaxis	  assay	  and	  compared	  its	  effect	  to	  that	  of	  LTD4	  at	  various	  doses.	  
PGD2	  has	  previously	  been	  reported	  to	  bind	  to	  receptor	  CRTH2,	  a	  Th2-­‐specific	  marker	  
also	  expressed	  in	  basophils	  and	  eosinophils	  	  (Nagata	  et	  al.	  1999a;	  Nagata	  et	  al.	  1999b).	  
In	  a	  study	  by	  Hirai	  et	  al.,	  they	  showed	  that	  PGD2	  induced	  chemotaxis.	  Chemotaxis	  was	  
shown	   to	   be	   specific	   to	   Th2	   cells	   and	  not	   Th1	   cells	   and	  was	   shown	   to	   occur	   via	   the	  
CRTH2	  receptor	  and	  not	  the	  known	  PGD2	  receptor	  DP	  (Hirai	  et	  al.	  2001).	  	  
In	   their	   experiments,	   human	   Th1	   and	   Th2	   lines	   were	   generated	   from	   PBMCs	   from	  
healthy	   adults	   and	   stimulated	   with	   a	   purified	   protein	   derivative	   of	   Mycobacterium	  
tuberculosis	   in	   the	   presence	   of	   IL-­‐12	   and	   IFN-­‐y	   for	   Th1	   cells,	   and	  with	   an	   extract	   of	  
Dermatophagoides	  in	  the	  presence	  of	  IL-­‐4,	  anti-­‐IFN-­‐y	  and	  anti-­‐IL-­‐12	  antibodies	  for	  Th2	  
cells.	   Both	   cell	   lines	   were	   expanded	   by	   IL-­‐2	   and	   used	   after	   7-­‐14	   days.	   Some	   of	   the	  
chemotaxis	   experiments	  used	  Th2	   cells	   enriched	  by	   sorting	  with	  an	  anti-­‐CRTH2	  mAb	  
(BM16)	   prior	   to	   the	   assay.	   The	   assay	   was	   performed	   on	   a	   96-­‐well	  microchemotaxis	  
chamber,	   using	   a	   5	   μm	   pore	   filter.	   Cells	  were	   prepared	   in	   RPMI	   1640	  with	   FCS	   and	  
HEPES	  and	  incubated	  with	  chemoattractants	  for	  an	  hour,	  before	  being	  counted	  by	  flow	  
cytometry	  (Hirai	  et	  al.	  2001).	  
Similarly,	   Th2	   cells	   have	   been	   reported	   to	   respond	   to	   PGD2	   produced	   in	  mast	   cells	  
supernatants	   (Gyles	   et	   al.	   2006).	   Gyles	   et	   al.	   investigated	   the	   role	   of	   PGD2	   and	   its	  
receptor	   CRTH2	   in	   the	   chemotactic	   response	   of	   Th2	   cells	   to	   supernatants	   collected	  
from	   immunologically	   activated	   human	  mast	   cells.	   In	   this	   in	   vitro	   setting,	   the	   group	  
found	   Th2	   cells	   to	   chemotax	   to	   PGD2.	   Treatment	   of	  mast	   cells	  with	   cyclooxygenase	  
inhibitor	  diclofenac	  substantially	  inhibited	  the	  production	  of	  PGD2	  by	  mast	  cells,	  which	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therefore	   inhibited	   the	   production	   of	   CRTH2+	   CD4+	   Th2	   cell	   stimulatory	   activity.	  
Addition	   of	   PGD2	   to	   the	   conditioned	   media	   restored	   the	   ability	   of	   the	   mast	   cell	  
supernatants	   to	   induce	  chemotaxis	   in	  Th2	  cells.	  Experiments	  using	  CRTH2	  antagonist	  
ramatroban	   in	   the	   supernatants	   inhibited	   the	   chemotactic	   response.	   The	   use	   of	  
selective	  thromboxane-­‐like	  prostanoid	  (TP)	  antagonist	  SQ29548	  showed	  no	  significant	  
inhibitory	  effect	  on	  the	  migration	  of	  CRTH2+	  CD4+	  Th2	  cells,	  which	  confirmed	  CRTH2	  
to	  be	  the	  receptor	  mediating	  the	  chemotactic	  response	  (Gyles	  et	  al.	  2006).	  
In	  our	   study,	  we	  used	   three	  different	  doses	  of	  PGD2,	  0.1	  nM,	  1	  nM	  and	  10	  nM,	  and	  
tested	  these	  in	  a	  similar	  way	  to	  the	  various	  doses	  of	  LTD4.	  Figure	  4.4	  shows	  that,	  in	  our	  
system,	  we	  were	  unable	  to	  reproduce	  the	  results	  reported	  by	  Gyles	  et	  al.	  and	  Hirai	  et	  
al.	  In	  our	  experiment,	  PGD2	  had	  very	  little	  effect	  on	  Th2	  cells.	  This	  lack	  of	  chemotactic	  
response	   was	   observed	   with	   all	   three	   tested	   concentrations.	   This	   could	   be	   due	   to	  
differences	   in	   the	   in	   vitro	   human	   Th2	   cell	   differentiation	   system	  or	   variations	   in	   the	  
chemotaxis	  assay.	  	  
	   	  




	   	  
	   	  
Figure	   4.4	   Th2	   cells	   do	   not	   migrate	   to	   PGD2.	   Chemotactic	   agents	   were	  
assessed	  in	  a	  Transwell-­‐based	  system.	  Cells	  were	  allowed	  to	  migrate	  for	  2	  
hours.	   Different	   concentrations	   of	   LTD4	   and	   PGD2	  were	   used	   as	   shown.	  
Data	   shown	   are	   means	   ±	   SEMs	   of	   3	   independent	   experiments	   with	  
different	  donors.	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Following	  functional	  studies	  and	  migration	  assays,	  we	  investigated	  the	  role	  of	  LTD4	  on	  
the	  proliferation	  of	  Th2	  cells.	  Other	  groups	  such	  as	  Yuan	  et	  al.	  have	  also	  investigated	  
the	  role	  of	  LTD4	  on	  proliferation.	  Indeed,	  Yuan	  et	  al.	  showed	  that	  LTD4	  had	  no	  effect	  on	  
the	  proliferation	  of	  endothelial	  cells,	  in	  contrast	  to	  vascular	  endothelial	  growth	  factor	  
VEGF,	  which	  significantly	  increased	  the	  number	  of	  proliferated	  cells.	  The	  methods	  used	  
(Trypan	   blue	   exclusion	   assay	   and	   BrdU	   incorporation	   assay)	  were	   different	   than	   the	  
technique	  we	  used.	  In	  this	  study,	  the	  group	  showed	  that,	  although	  no	  effect	  was	  found	  
on	   proliferation,	   LTD4	   was	   found	   to	   induce	   migration	   of	   endothelial	   cells	   in	   wound	  
healing,	  as	  effectively	  as	  VEGF	  (Yuan	  et	  al.	  2009).	  
Using	  a	  thymidine	  incorporation	  assay,	  we	  sought	  to	  determine	  whether	  LTD4	  had	  any	  
effect	   on	   T	   cell	   proliferation.	   The	   assay	   functions	   by	   utilizing	   a	   strategy	   wherein	   a	  
radioactive	   nucleoside,	   3H-­‐thymidine,	   is	   incorporated	   into	   new	   strands	   of	  
chromosomal	   DNA	   during	   mitotic	   cell	   division.	   A	   Microplate	   Scintillation	   and	  
Luminescence	  Counter	  (top	  count	  NXT)	  was	  used	  to	  measure	  the	  radioactivity	  in	  DNA	  
recovered	   from	   the	   cells	   in	   order	   to	   determine	   the	   extent	   of	   cell	   division	   that	   has	  
occurred	   in	   response	   to	   a	   test	   agent,	   in	   our	   case	   LTD4.	   This	   assay	   allowed	   for	   direct	  
measurement	  of	  proliferation.	  
Both	   fully	  differentiated	  Th1	  and	  Th2	  cells	  were	   tested	  and	   thymidine	  was	  added	  18	  
hours	   prior	   to	   running	   the	   assay	   on	   both	   CD3/CD28-­‐coated	   and	   uncoated	   wells.	  
Unfortunately,	  we	  could	  no	  detect	  any	  change	  between	  Th1	  and	  Th2	  control	  cells	  and	  
cells	  with	  LTD4.	  Additionally,	  Th2	  cells	  appeared	  to	  still	  be	  activated	  at	  the	  time	  of	  the	  
assay,	  which	  made	   it	   difficult	   to	   obtain	   accurate	   results.	  Unfortunately	  we	  observed	  
similar	   results	   when	   we	   repeated	   the	   assay	   (data	   inaccurate	   and	   not	   shown).	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We	  also	   tested	   the	  effect	  of	   LTD4	   on	  Th1	  and	  Th2	   in	   vitro	   differentiation	   cultures	   to	  
examine	  whether	   LTD4	  had	  any	  direct	   effect	   on	   the	  Th1	  and	  Th2	  differentiation	   and	  
cytokines	  expression.	  Following	  21	  days	  of	  culture	  with	  and	  without	  LTD4,	  Th1	  and	  Th2	  
cells	   with	   and	   without	   LTD4	   were	   stained	   intracellularly	   for	   various	   Th1-­‐	   and	   Th2-­‐
specific	  cytokines.	  No	  significant	  effect	  was	  observed	  on	  cytokine	  productions	  in	  either	  
Th1	  or	  Th2	  cells	  that	  had	  been	  cultured	  with	  LTD4,	  as	  seen	  in	  figure	  4.5.	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Following	  the	  results	  obtained	  by	  flow	  cytometry	  using	  Th1	  and	  Th2	  cells	  cultured	  with	  
LTD4	  and	  the	  lack	  of	  detection	  of	  any	  change	  in	  cytokine	  expression,	  we	  used	  RT-­‐PCR	  to	  
check	   for	   any	   cytokine	   expression	   changes	   at	  mRNA	   level.	   Using	   fully	   differentiated	  
Th1	  and	  Th2	  cells	  at	  Day	  21,	  we	  set	  up	  a	  time-­‐course	  at	  time	  30	  min,	  1	  hour,	  4	  hours	  
and	  24	  hours,	  with	  and	  without	  LTD4.	  Samples	  were	  harvested	  at	  each	  time	  point	  and	  
mRNA	  was	  isolated.	  With	  these	  samples,	  we	  looked	  at	  mRNA	  expression	  for	  Th1-­‐	  and	  
Th2-­‐specific	   cytokines,	   such	   as	   IFN-­‐γ,	   IL-­‐4,	   IL-­‐5	   and	   IL-­‐13	   to	   identify	   potential	  
immediate	  changes	  in	  cytokine	  production.	  We	  found	  that	  the	  addition	  of	  LTD4	  in	  our	  
Th1	  and	  Th2	  cultures	  had	  no	  immediate	  or	  later	  effect	  on	  the	  mRNA	  expression	  of	  Th1-­‐	  
and	  Th2-­‐specific	  cytokines,	  as	  seen	  in	  figure	  4.6.	   IFN-­‐γ	  was	  found	  mainly	  on	  Th1	  cells	  
and	  the	  expression	  was	  higher	  at	  30	  min	  and	  1	  hour,	  and	  then	  decreased	  at	  4	  and	  24	  
hours.	  LTD4	  had	  no	  effect	  on	  the	  expression.	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  each	  showed	  a	  similar	  
pattern	  of	  expression,	  with	  a	  high	  expression	  at	  30	  min	  and	  a	  progressive	  decrease	  in	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Figure	  4.6	  mRNA	  expression	  following	  Th2	  cell	  culture	  with	  LTD4.	  No	  LTD4	  or	  LTD4	  
was	  added	   to	  Th1	  and	  Th2	  cells,	  which	  were	  harvested	  after	  an	   incubation	  of	  30	  
min,	   1	   hour,	   4	   hours	   and	   24	   hours	   to	   identify	   whether	   LTD4	   had	   any	   effect	   on	  
cytokine	  mRNA	  expression.	  Data	  are	  representative	  of	  three	  experiments,	  using	  at	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In	  previous	  experiments,	  we	  have	  shown	  that	  the	  human	  CysLT1	  receptor	  is	  coupled	  to	  
both	   Gαi/o	   and	   Gαq/11	   in	   our	   in	   vitro-­‐differentiated	   human	   Th2	   cells	   system.	   This	  
corresponds	   to	   previous	   findings	   that	   the	   receptor	   is	   partially	   coupled	   in	   native	  
systems	  but	  only	  coupled	  to	  Gαq/11	  in	  recombinant	  systems.	  	  
In	   these	   experiments	   we	   have	   shown	   that	   Th2	   cells	   migrate	   to	   LTD4	   in	   a	   dose-­‐
dependent	  manner	   and	   this	   is	   the	   first	   report	   that	   human	   Th2	   cells	   can	  migrate	   to	  
cysteinyl	   leukotrienes.	   We	   also	   showed	   that	   antagonist	   MK571	   inhibited	   the	  
chemotactic	  response.	  We	  have	  also	  shown	  that	  the	  addition	  of	  LTD4	  to	  Th1	  and	  Th2	  
cells	   during	   proliferation	   and	   differentiation	   did	   not	   have	   any	   significant	   effect	   on	  
cytokine	   expression	   (at	   least	   for	   those	   cytokines	   that	  we	   examined).	  We	   also	   found	  
that	  LTD4	  had	  no	  significant	  effect	  on	  proliferation	  using	  proliferation	  assays,	  however	  
this	  assay	  was	  not	  fully	  accurate.	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Chapter	  5 Results	  –	  Effect	  of	  LTD4	  on	  gene	  expression	  in	  human	  Th2	  cells	  
5.1 Introduction	  
5.1.1 Comprehensive	  analysis	  of	  gene	  expression	  changes	  in	  response	  to	  CysLTs	  
The	   studies	  performed	   in	   the	  previous	   chapter	   showed	   that	  CysLTs	  acting	   via	  CysLT1	  
receptor	   function	   to	   cause	   migration	   of	   human	   Th2	   cells	   in	   chemotaxis	   assays.	  
However	   we	   failed	   to	   detect	   any	   noticeable	   effects	   on	   Th2	   cell	   proliferation,	  
differentiation	  or	  cytokine	  secretion	  (at	  least	  for	  the	  Th1/Th2	  cytokines	  examined).	  To	  
comprehensively	  examine	   the	  effect	  of	  CysLT	   treatment	  on	   transcription	   in	  Th2	  cells	  
we	  decided	  to	  investigate	  the	  effect	  of	  LTD4	  treatment	  on	  gene	  expression	  levels	  using	  
microarrays.	   The	   rationale	   for	   the	   use	   of	  microarrays	  was	   that	   it	   would	   allow	   us	   to	  
examine	   the	   vast	  majority	  of	   genes	   in	   the	   genome	   in	   an	  unbiased	  manner.	   Previous	  
studies	   have	   investigated	   the	   function	   of	   CysLTs	   on	   other	   cell	   types	   using	   a	  
transcriptomic	  approach	  (Uzonyi	  et	  al.	  2006;	  Woszczek	  et	  al.	  2008b).	  
Woszczek	  et	  al.	  have	  undertaken	  a	  similar	  study	   in	  human	  monocytes,	   in	  which	  they	  
sought	   to	   determine	   the	   gene	   expression	   signature	   response	   of	   human	   monocytes	  
exposed	  to	  CysLTs,	  in	  order	  to	  elucidate	  the	  signalling	  pathways	  involved	  in	  monocyte	  
activation.	  Using	  human	  elutriated	  monocytes	  that	  had	  been	  stimulated	  with	  100	  nM	  
LTD4	  for	  30	  minutes,	  they	  performed	  a	  microarray	  using	  the	  Affymetrix	  HG	  U133	  plus	  
2.0	  arrays.	  The	  group	  found	  that,	  at	  30	  minutes,	  LTD4	  induced	  seven	  genes	  belonging	  
to	   families	  of	   transcription	   factors	  and	  signalling	  molecules.	  Of	   the	   seven	  genes,	   five	  
were	   further	   analysed	   by	   RT-­‐PCR.	   The	   expression	   of	   mRNA	   for	   transcriptional	  
regulators,	  such	  as	  FOSB,	  EGR2,	  EGR3,	  NR4A2,	  and	  TSC22D3,	  was	  quickly	  induced.	  The	  
two	  most	  highly	  upregulated	  genes	  induced	  by	  LTD4	  and	  confirmed	  by	  RT-­‐PCR	  were	  FBJ	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murine	   osteosarcoma	   viral	   oncogene	   homolog	   B	   (FOSB)	   and	   Egr2,	   with	   the	   highest	  
increase	  observed	  between	  30	  and	  60	  minutes	  and	  returning	  to	  baseline	  after	  2	  hours.	  
These	   data	   therefore	   showed	   that	   LTD4	   activates	   the	   expression	   of	   immediate-­‐early	  
genes	  in	  human	  monocytes	  (Woszczek	  et	  al.	  2008b).	  
To	  our	  knowledge,	  the	  only	  other	  comparable	  microarray	  data	  come	  from	  a	  study	  by	  
Uzonyi	  et	   al.,	   in	  which	   they	  determined	   the	   gene	   signature	   of	   human	  umbilical	   vein	  
endothelial	  cells	  (HUVEC)	  in	  response	  to	  LTD4.	  Using	  thrombin	  signalling	  through	  PAR1	  
as	  a	  positive	  control,	  they	  found	  that	  CysLT2R	  activation	  induces	  early	  gene	  signatures	  
that	  resemble	  those	  after	  PAR1	  activation	  and	  that	  the	  combined	  actions	  of	  LTD4	  and	  
thrombin	  further	  stimulate	  gene	  expression.	  The	  group	  identified	  37	  genes	  that	  were	  
significantly	  induced	  after	  60	  minutes	  of	  stimulation	  with	  LTD4,	  and	  most	  of	  these	  were	  
also	   found	   to	   be	   upregulated	   by	   thrombin.	   Interestingly,	   the	   same	   families	   of	  
transcription	   factors	   (EGR,	   activating	   transcription	   factor)	  were	   upregulated,	   such	   as	  
COX2,	  EGR1,	  EGR2	  and	  NR4A2.	  Some	  of	  the	  genes	  found	  in	  HUVECs	  also	  compared	  to	  
the	   ones	   identified	   in	   human	   monocytes.	   However,	   LTD4-­‐induced	   genes	   in	   HUVECs	  
were	  the	  result	  of	  CysLT2	  receptor	  activation	  and	  signalling,	  as	  these	  cells	  only	  express	  
CysLTR2.	   Induction	   of	   several	   of	   the	   genes	   was	   found	   to	   be	   resistant	   to	   specific	  
CysLTR1	  antagonists	  (Uzonyi	  et	  al.	  2006).	  	  
We	  therefore	  investigated	  the	  effect	  of	  LTD4	  on	  various	  time-­‐points	  by	  microarrays	  (30	  
min,	  4	  hours,	  24	  hours)	   and	   found	   several	  upregulated	  genes,	  which	  were	   similar	   to	  
those	  found	  by	  Woszczek	  and	  Uzonyi.	  
	  




5.2.1 Experimental	  design	  and	  exploratory	  analyses	  
To	   examine	   the	   effect	   of	   CysLTs	   on	   gene	   expression	  we	   aimed	   to	   analyse	   Th2	   cells	  
treated	  with	  and	  without	  100	  nM	  LTD4	  at	  various	  time	  points.	  LTD4	  was	  chosen	  as	  the	  
agonist	   since	   it	  was	   the	  most	   potent	   in	   the	   other	   assays	   examined	   such	   as	   calcium,	  
cAMP	  and	  chemotaxis.	  For	  this	  study,	  we	  decided	  to	  focus	  on	  fully	  differentiated	  Th2	  
cells	   21	   days	   after	   naïve	   cell	   isolation.	   	   Prior	   to	   the	   experiments,	   Th2	   cells	   were	  
incubated	   with	   L-­‐cysteine,	   a	   known	   inhibitor	   of	   the	   LTD4	   to	   LTE4	   conversion	  
dipeptidase,	   in	   order	   to	   sustain	   the	   effect	   of	   LTD4	   during	   treatment.	   The	   cells	   were	  
then	  incubated	  with	  or	  without	  100	  nM	  LTD4	  and	  harvested	  at	  various	  time	  points	  –	  30	  
min,	  1	  hour,	  4	  hours	  and	  24	  hours	  -­‐	  for	  RNA	  extraction.	  This	  allowed	  us	  to	  explore	  the	  
effect	  that	  LTD4	  had	  on	  Th2	  cells	  when	  present	  for	  different	  time	  periods,	  from	  early	  
effects	   to	   late	  effects.	  Two	  biological	   replicates	  were	  performed	  on	  different	  donors.	  
RNA	   extraction	   was	   performed	   using	   the	   Qiagen	   miRNeasy	   protocol	   and	   the	   RNA	  
samples	  were	  processed	  for	  microarray	  experiments	  as	  described	  in	  the	  Materials	  and	  
Methods	  section.	  
The	  microarray	  platform	  used	   in	   these	  experiments	  was	  the	  Affymetrix	  Human	  Gene	  
1.0	   ST	   GeneChip,	   which	   examines	   36,079	   RefSeq	   transcripts	   including	   21,014	   well-­‐
annotated	   genes.	   The	   RNA	   isolated	  was	   of	   high	   quality	   as	  measured	   by	   bioanalyser	  
RNA	   integrity	   number	   (RIN)	   and	   the	   labelled	   cRNA	   samples	   met	   all	   of	   the	  
recommended	  Affymetrix	  quality	  control	  criteria	  prior	  to	   loading	  onto	  the	  GeneChips	  
(data	   not	   shown).	   After	   array	   processing	   and	   scanning,	   the	   data	   was	   imported	   into	  
Partek	  Genomics	   Suite	   as	   CEL	   files	   (Partek	   Inc.)	   for	   further	   data	   analysis.	   Partek	   is	   a	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statistical	   software	   package	   that	   performs	  multi-­‐way	   ANOVA	   analyses	   of	  microarray	  
data.	   The	   data	   was	   pre-­‐processed	   using	   Robust	   Multi-­‐array	   Average	   (RMA)	   and	  
quantile	   normalisation	   using	   the	   standard	   Partek	  workflow.	  Quality	   control	   analyses	  
are	  shown	  in	  figure	  5.1.	  Panel	  A	  shows	  that	  the	   intensity	  signals	   for	  the	  positive	  and	  
negative	   controls	  were	   similar	   across	   all	   arrays	  with	   no	   substantial	   outliers.	   Panel	  B	  
shows	  that	  the	  signal	  intensity	  distribution	  of	  all	  probes	  was	  similar	  in	  each	  microarray.	  
Collectively	   these	   quality	   control	   data	   suggest	   that	   all	   of	   the	   samples	  were	   of	   good	  
quality	   and	   that	   the	  microarrays	   have	   all	   functioned	   correctly.	   Since	   the	  microarray	  
data	  passed	  the	  quality	  control	  steps,	   the	  normalised	  data	  containing	  multiple	  probe	  
sets	   for	   each	   transcript	  was	   summarised	   to	   a	   gene	   level	   analysis	   using	   the	   standard	  
Partek	   workflow.	   After	   the	   gene-­‐level	   summarisation,	   principal	   component	   analysis	  
(PCA)	  was	  performed	  in	  Partek	  as	  an	  exploratory	  step	  in	  the	  data	  analysis	  (Figure	  5.2).	  
PCA	   allows	   visualisation	   of	   high-­‐dimensional	   data	   to	   examine	   the	   major	   sources	   of	  
variation	   in	   the	  data.	   The	   first	   three	  principal	   sources	   of	   variation	   (components)	   are	  
represented	  by	   the	  axes,	   and	  each	   spot	  on	   the	  graph	   represents	  a	   single	  microarray	  
sample	  (Figure	  5.2).	  It	  is	  clear	  from	  the	  PCA	  analysis	  that	  the	  major	  source	  of	  variation	  
relates	   closely	   to	   the	   time-­‐point	   of	   sampling	   (PC1:	   36.4%).	   The	   next	   most	   obvious	  
source	   of	   variation	   is	   a	   donor	   effect	   (PC2:	   13.8%).	   There	   is	   no	   obvious	   effect	  
attributable	  to	  LTD4	  treatment	  at	  this	  level	  of	  analysis.	  The	  nature	  of	  the	  experimental	  
design	   means	   that	   we	   cannot	   discriminate	   between	   a	   true	   donor	   effect	   or	   an	  
artifactual	   batch	  effect	   since	   the	  biological	   replicate	   experiments	   and	  RNA	   isolations	  
were	  performed	  on	  different	  dates.	  Using	  the	  multi-­‐way	  ANOVA	  model	   in	  Partek	  it	   is	  
possible	  to	  remove	  the	  effect	  of	  batch/donor	  to	  allow	  for	  better	  interpretation	  of	  the	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dataset.	  Batch	  effect	   removal	  was	  performed	   in	  Partek	  and	  exploratory	  PCA	  analysis	  
performed	  on	  the	  transformed	  data	  (Figure	  5.3).	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Figure	   5.1	   Quality	   control	   of	  microarray	   data.	   (A)	   Intensity	   of	   positive	  
and	   negative	   control	   signals	   across	   all	   arrays.	   (B)	   Signal	   intensity	  
distribution	  of	  each	  array.	  
 





	   	  
Figure	  5.2	  Principal	  component	  analysis	  of	  gene	  summarised	  data.	  The	  three	  
panels	   show	   the	   same	   PCA	   analysis	   coloured	   using	   different	   criteria	   as	  
indicated	  in	  each	  legend.	  
 





	   	  
Figure	   5.3	   Principal	   component	   analysis	   of	   gene	   summarised	   data	   after	  
batch	   effect	   removal.	   The	   three	   panels	   show	   the	   same	   PCA	   analysis	  
coloured	  using	  different	  criteria	  as	  indicated	  in	  each	  legend.	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Figure	  5.3	   clearly	  shows	  that	  batch	  effect	   removal	  causes	  a	  change	   in	   the	  sources	  of	  
variation	  detected	  by	  the	  PCA.	  Importantly	  it	  causes	  the	  samples	  discriminated	  by	  time	  
to	  cluster	  together	  more	  than	  in	  Figure	  5.2.	  The	  major	  source	  of	  variation	  is	  still	  closely	  
related	  to	  the	  time	  point	  of	  the	  sample	  (PC1:	  38.6%).	  However	  there	  is	  still	  no	  obvious	  
effect	  attributable	  to	  LTD4	  treatment.	  Even	  at	  this	  early	  stage	  of	  exploratory	  analysis	  it	  
suggests	   that	   treatment	   with	   LTD4	   does	   not	   have	   a	   profound	   effect	   on	   the	   gene	  
expression	  profile	  of	  Th2	  cells.	  
5.2.2 Detection	  of	  differentially	  expressed	  genes	  upon	  LTD4	  treatment 
Although	   the	   preliminary	   analyses	   suggest	   that	   LTD4	   treatment	   does	   not	   have	   a	  
profound	  effect	  of	  global	  gene	  expression	  patterns	  in	  human	  Th2	  cells,	  it	  does	  not	  rule	  
out	  the	  possibility	  that	  a	  subset	  of	  genes	  are	  regulated	  by	  LTD4	  signalling.	  To	   identify	  
genes	  that	  are	  differentially	  expressed	  due	  to	  LTD4	   treatment	  we	  performed	  a	  three-­‐
way	   ANOVA	   in	   Partek	   using	   time,	   LTD4	   treatment	   and	   donor/batch	   as	   factors	   (see	  
Methods	  for	  further	  details).	  Donor/batch	  was	  considered	  a	  random	  effect	  and	  we	  also	  
included	   in	   the	  ANOVA	  model	   an	   interaction	  between	   time	  and	   LTD4	   treatment	   (i.e.	  
LTD4	   treatment	   may	   cause	   different	   changes	   in	   gene	   expression	   depending	   on	   the	  
time-­‐point	   investigated).	   Figure	   5.4	   shows	   the	   sources	   of	   variation	   detected	   in	   the	  
ANOVA	   analysis.	   The	   figure	   clearly	   shows	   that	   the	   major	   source	   of	   variation	   in	   the	  
dataset	   is	   the	   time	  of	  sampling	  as	  expected	   from	  the	  PCA	  analysis.	  The	  second	  most	  
important	   source	   of	   variation	   is	   donor/batch.	   The	   role	   of	   LTD4	   treatment	   and	   the	  
interaction	  between	   time	  and	   treatment	  both	  provide	  very	   small	   components	  of	   the	  
overall	  variation	  seen	  in	  the	  data.	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Analysis	  of	  the	  ANOVA	  results	  shows	  that	  9057	  genes	  change	  due	  to	  the	  time-­‐point	  of	  
sampling	  (p<0.05)	  including	  false	  discovery	  rate	  (FDR)).	  Hierarchical	  clustering	  analysis	  
of	  this	  subset	  of	  genes	  identifies	  blocks	  of	  genes	  with	  similar	  expression	  patterns	  at	  the	  



























	   	  
Figure	  5.4	  ANOVA	  sources	  of	  variation.	  The	  relative	  role	  of	  each	  factor	   in	  
the	  variation	  in	  the	  data	  is	  shown.	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Whilst	  the	  effect	  of	  time	  in	  culture	  is	  interesting	  in	  the	  context	  of	  T	  cell	  biology	  it	  is	  not	  
the	   focus	   of	   this	   thesis	   and	   therefore	   we	   did	   not	   investigate	   these	   data	   further.	  
However	   it	   is	   important	   to	   point	   out	   that	   these	   results	   have	   implications	   for	   the	  
experimental	   design	   of	   future	   experiments	   examining	   global	   analysis	   of	   gene	  
expression	   in	   T	   cells	   in	   culture.	   These	   cells	   were	   essentially	   ‘resting’	   and	   yet	   many	  
genes	   were	   altered	   during	   the	   time-­‐course	   of	   24	   hours.	   This	   means	   that	   for	   future	  
studies	  examining	   the	  effect	  of	   a	   stimulus	  over	   time,	  paired	   samples	   (untreated	  and	  
treated	  with	   the	   stimulus),	  must	   be	   used	   in	   order	   to	   discriminate	   between	   changes	  
due	  to	  stimulus	  and	  changes	  due	  to	  time.	  
Examination	  of	  the	  data	  relating	  to	  LTD4	  treatment	  showed	  that	  while	  7	  genes	  changed	  
more	   than	   two-­‐fold	   due	   to	   treatment,	   none	   of	   these	   genes	   reached	   statistical	  
significance	   when	   including	   FDR	   (data	   not	   shown).	   It	   is	   possible	   that	   if	   we	   had	  
performed	   more	   biological	   replicates,	   some	   of	   these	   changes	   may	   have	   reached	  
statistical	  significance,	  but	  due	  to	  time	  and	  cost	  limitations	  such	  experiments	  were	  not	  
performed.	   However,	   examination	   of	   genes	   that	   changed	   due	   to	   the	   interaction	  
between	   LTD4	   treatment	   and	   time	   revealed	   20	   genes	   that	   were	   different	   between	  
untreated	   and	   LTD4-­‐treated	   samples	   at	   30	  min	   (Table	   5.1).	  Hierarchical	   clustering	  of	  
these	  genes	  showed	  a	  clear	  pattern	  of	  differential	  expression	  at	  the	  30	  min	  time-­‐point	  
with	  the	  expression	  of	  these	  genes	  returning	  to	  similar	  levels	  in	  both	  LTD4-­‐treated	  and	  
untreated	   samples	   at	   later	   time-­‐points	   (Figure	   5.6,	   2	   fold;	   p<0.05	   including	   FDR).	  
Examination	  of	  changes	  in	  gene	  expression	  due	  to	  LTD4	  treatment	  at	  later	  time-­‐points	  
did	  not	  identify	  any	  statistically	  significant	  differences	  (data	  not	  shown).	  The	  gene	  list	  
identified	  as	  differentially	  expressed	  after	  30	  min	  of	  LTD4	   treatment	  contains	   several	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well-­‐known	  immediate	  early	  genes	  (FOS,	  FOSB,	  EGR	  family)	  as	  well	  as	  T	  cell	  activation	  
marker	  CD69	  and	  the	  cytokine	  TNF-­‐α.	  
	   	  


























8034694 MIR24-2 NR_029497 5.17856 6.52956 3.76E-05 2.55088
7975779 FOS NM_005252 6.55434 9.37456 0.0028718 7.06269
7961075 CD69 NM_001781 10.0861 11.7475 0.0043981 3.16337
7933872 EGR2 NM_000399 7.86675 10.1069 0.00766 4.72451
7892567 --- 7.26128 6.17626 0.0087855 -2.1214
8055952 NR4A2 NM_006186 6.52855 7.88342 0.0094496 2.55774
8029693 FOSB NM_006732 6.45904 8.14831 0.0128386 3.22494
8034698 MIR23A NR_029495 7.16025 8.33351 0.0156821 2.2552
8108370 EGR1 NM_001964 7.72308 10.2386 0.0209553 5.71808
7896526 --- 5.10842 6.14126 0.0223156 2.04604
8115831 DUSP1 NM_004417 7.20377 8.74646 0.0258755 2.91336
8118142 TNF NM_000594 7.73964 8.92597 0.0282552 2.27574
8177983 TNF NM_000594 7.73964 8.92597 0.0282552 2.27574
8179263 TNF NM_000594 7.73964 8.92597 0.0282552 2.27574
7896505 --- 4.70279 5.73665 0.0293128 2.0475
7922976 PTGS2 NM_000963 7.95715 9.51441 0.0371869 2.94294
8149720 EGR3 NM_004430 5.80703 7.25699 0.0415114 2.732
7896181 --- 6.65715 7.66732 0.0435528 2.01414
7895146 --- 5.79725 4.74951 0.0437285 -2.06728
8034696 MIR27A NR_029501 5.59401 6.70597 0.0481581 2.16139
Table	  5.1.	  Genes	  that	  are	  statistically	  significantly	  differentially	  expressed	  in	  Th2	  cells	  
after	  30	  mins	  of	  LTD4	  treatment.	  Samples	  were	  processed	  on	  Affymetrix	  Gene	  1.0	  ST	  
arrays	   and	   data	   was	   normalised	   and	   ANOVA	   performed	   in	   Partek	   as	   described	   in	  
Methods.	  Mean	  columns	  show	  the	  log2	  of	  mean	  array	  signal	  for	  each	  gene.	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While	   hierarchical	   clustering	   and	   heatmap	   analysis	   are	   useful	   visualisation	   tools	   for	  
microarray	   studies,	   other	   visualisation	  methods	   can	   provide	   different	   information	   in	  
respect	  to	  the	  same	  data.	  Figure	  5.7	  shows	  a	  volcano	  plot	  of	  the	  data	  from	  the	  30	  min	  
time-­‐point.	   The	   X-­‐axis	   shows	   the	   fold-­‐change	   between	   untreated	   and	   LTD4-­‐treated	  
samples,	   the	   Y-­‐axis	   shows	   the	   -­‐log10p-­‐value	   from	   the	   ANOVA,	   and	   each	   gene	   is	  
represented	  by	  a	  dot.	  It	  can	  be	  clearly	  seen	  from	  this	  analysis	  that	  the	  genes	  listed	  in	  
table	  5.1	  show	  both	  a	  significant	  p-­‐value	  and	  a	  high	  fold	  change	  compared	  to	  the	  vast	  
majority	  of	  genes	  that	  do	  not	  change	  in	  response	  to	  treatment	  with	  LTD4.	  Interestingly	  
it	  is	  also	  clear	  from	  this	  representation	  that	  all	  of	  the	  statistically	  significantly	  different	  
genes	   are	   upregulated	   in	   response	   to	   LTD4	   with	   very	   little	   evidence	   for	   gene	  
downregulation.	  
While	   the	   Volcano	   plot	   is	   a	   useful	   visualisation	   tool	   it	   does	   not	   provide	   information	  
regarding	  the	  level	  of	  expression	  of	  genes	  of	  interest	  (i.e.	  a	  gene	  could	  have	  a	  high	  fold	  
change	   and	   significant	   p-­‐value	   and	   still	   be	   expressed	   at	   very	   low	   levels).	   Figure	   5.8	  
shows	  a	   scatter	  plot	  of	   the	  data	   from	   the	  30	  min	   time-­‐point	  where	   the	  X-­‐axis	   is	   the	  
mean	  gene	  expression	  level	  for	  each	  gene	  in	  LTD4	  treated	  samples	  and	  the	  Y-­‐axis	  is	  the	  
mean	   gene	   expression	   level	   in	   untreated	   samples.	   Once	   again	   it	   is	   clear	   from	   this	  
representation	   that	   the	   genes	   identified	   as	   different	   due	   to	   LTD4	   treatment	   are	  
upregulated	   rather	   than	   downregulated.	   Interestingly	   however	   the	   scatter	   plot	   also	  
provides	  an	  estimate	  of	  the	  actual	   level	  of	  gene	  expression.	  Genes	  such	  as	  CD69	  and	  
MIR21	  are	  expressed	  at	  very	  high	  levels	  in	  comparison	  to	  most	  genes,	  whereas	  MIR24-­‐
2	   is	   expressed	   at	   very	   low	   levels	   and	   therefore	   less	   likely	   to	   be	   a	   biologically	  
meaningful	  change	  in	  expression.	  






	   	  
Figure	   5.7	   Volcano	   plot	   of	   gene	   expression	   at	   30	   min.	   X-­‐axis	   shows	   fold	  









	   	  
Figure	  5.8	  Scatter	  plot	  analysis	  of	  gene	  expression	  at	  30	  min	  time-­‐point.	  
Each	   gene	   is	   represented	   by	   a	   dot.	   Genes	   are	   colours	   by	   fold-­‐change	  
between	  Untreated	  and	  LTD4-­‐treated	  samples.	  Data	   is	  the	   log2	  of	  mean	  
signal	   intensity	   for	   each	   gene.	   Blue	   genes	   are	   higher	   in	   LTD4-­‐treated	  
samples,	  red	  are	  higher	  in	  untreated	  samples.	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Collectively	   these	   data	   suggest	   that	   LTD4	   functions	   to	   upregulate	   a	   small	   group	   of	  
immediate	  early	  genes,	  some	  microRNAs	  and	  markers	  of	  activation.	  
5.2.3 LTD4	  regulated	  genes 
The	  genes	  identified	  in	  the	  last	  section	  fall	  into	  several	  functional	  categories	  and	  have	  
different	  expression	  kinetics	  in	  a	  variety	  of	  other	  cell	  types.	  Figures	  5.9	  and	  5.10	  show	  
the	  individual	  expression	  profile	  of	  each	  gene	  identified	  as	  being	  regulated	  by	  LTD4.	  
Genes	   identified	   in	   our	   system	   are	   FOS,	   EGR1,	   EGR2,	   EGR3,	   FOSB,	   CD69,	   NR4A2,	  
DUSP1,	   TNF,	   PTGS2,	   Mir23A,	   Mir24-­‐2,	   Mir27A.	   Of	   these,	   we	   found	   a	   4-­‐	   to	   6-­‐fold	  
change	  for	  FOS,	  EGR1	  and	  EGR2;	  and	  a	  2-­‐	  to	  4-­‐	  fold	  change	  for	  the	  others.	  All	  of	  these	  
genes	  were	  found	  to	  be	  upregulated	  following	  30	  min	  treatment	  with	  LTD4.	  Here	  we	  
describe	  the	  effect	  of	  LTD4	  on	  the	  genes.	  	  
	   	  





	   	  
Figure	  5.9	  Expression	  profile	  of	  genes	  regulated	  by	  LTD4.	  X-­‐axis	  shows	  treatment	  
and	  time	  combinations.	  Y-­‐axis	  shows	  log2	  signal	  intensity. 














Figure	  5.10	  Expression	  profile	  of	  genes	  regulated	  by	  LTD4.	  X-­‐axis	  shows	  treatment	  
and	  time	  combinations.	  Y-­‐axis	  shows	  log2	  signal	  intensity.	  
 




EGR1	  was	  found	  to	  be	  differentially	  expressed	  following	  treatment	  with	  LTD4	  only	  at	  30	  
min	  time-­‐point.	   In	  comparison,	  4-­‐	  and	  24	  hour	  treatment	  of	  LTD4	  did	  not	   induce	  any	  
change	   in	  gene	  expression	  between	  LTD4-­‐treated	  cells	  and	  untreated.	  EGR2	  was	  also	  
differentially	   expressed	   at	   30	  min	   time-­‐point	  when	   treated	  with	   LTD4,	   and	  we	   could	  
still	  detect	  a	  very	  small	  change	  at	  4-­‐hour	  time-­‐point.	  However	  at	  24	  hours,	  no	  change	  
could	  be	  detected.	  EGR3	  followed	  a	  similar	  pattern	  to	  EGR1	  and	  the	  only	  difference	  in	  
expression	  was	  after	  30	  minutes	  of	  treatment.	  
EGRs	   are	   a	   family	  of	  Cys2His2-­‐type	   zinc	   finger	   transcription	   factors,	  which	   consist	   of	  
four	  members:	  EGR1,	  EGR2,	  EGR3	  and	  EGR4.	  In	  CD4+	  T	  cells,	  reports	  show	  that	  EGR2	  is	  
associated	  with	  the	  induction	  of	  anergy	  and	  may	  play	  a	  role	  in	  the	  anergic	  state	  of	  A.E7	  
T	   cells.	   The	  expression	  profile	   of	   EGR2	  was	   found	   to	  be	   initially	   upregulated	   in	   both	  
anergised	   and	   fully	   activated	   T	   cells	   before	   their	   proliferation.	   EGR2	   expression	  was	  
found	   to	   be	   inhibited	   by	   cyclosporin	   A	   and	   found	   to	   decrease	   more	   rapidly	   in	  
proliferating	  cells	  than	  anergized	  ones.	   Interestingly,	   IL-­‐2	  blocked	  the	  high	  expression	  
levels	   of	   EGR2	   in	   anergy,	   which	   therefore	   reversed	   the	   anergic	   state	   (Harris	   et	   al.	  
2004).	  
Using	  microarray	  analysis	  Safford	  et	  al.	  showed	  that	  EGR2	  and	  EGR3	  act	  as	  regulators	  
of	  T	  cell	  activation,	  as	  part	  of	  a	  negative	  feedback	  loop	  in	  order	  to	  dampen	  the	  immune	  
response.	   The	   group	   showed	   that	   in	   the	   presence	   of	   co-­‐stimulation	   and	   IL-­‐2	  
production,	   activation	   takes	   place	   and	   EGRs	   cannot	   act	   as	   negative	   regulators.	  
However	   in	   the	   absence	   of	   co-­‐stimulation,	   small	   amounts	   of	   IL-­‐2	   are	   produced,	   and	  
EGR2	   and	   EGR3	   are	   able	   to	   inhibit	   T	   cell	   activation	   and	   promote	   anergy.	   This	   data	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suggested	  that	  both	  EGR2	  and	  EGR3	  may	  be	  involved	  in	  promoting	  the	  upregulation	  of	  
certain	  inhibitory	  genes	  (Safford	  et	  al.	  2005).	  
EGR2	   has	   also	   been	   reported	   to	   play	   a	   critical	   role	   in	   the	   nervous	   system.	   Indeed,	  
mutations	  of	  the	  EGR2	  gene	  prevent	  Schwann	  cell	  development	  and	  peripheral	  nerve	  
myelination	   in	   mice	   and	   lead	   to	   the	   development	   of	   demyelinating	   neuropathy	  
(Topilko	  et	  al.	  1994).	   In	  humans,	  EGR2	  mutations	  have	  been	  linked	  to	  Charcot-­‐Marie-­‐
Tooth	   disease	   type	   1,	   Dejerine-­‐Sottas	   syndrome	   and	   congenital	   hypomyelination	  
neuropathy	  (Shy	  et	  al.	  2002).	  
Several	   recent	   genome-­‐wide	   association	   studies	   have	   identified	   new	   genetic	   links	  
between	  EGR2	  and	  human	  autoimmune	  diseases,	  such	  as	  Crohn’s	  disease	  (Consortium	  
2007;	   Rioux	   et	   al.	   2007).	   A	   candidate	   gene	   analysis	   study	   also	   reported	   that	   EGR2	  
polymorphisms	   could	   influence	   the	   susceptibility	   of	   developing	   systemic	   lupus	  
erythematosus	   (SLE)	   in	   humans.	   Mice	   with	   T	   cell-­‐specific	   EGR2	   cKO	   (conditional	  
knockout)	   have	   also	   been	   shown	   to	   develop	   lupus-­‐like	   autoimmunity	   (B.	   Zhu	   et	   al.	  
2008).	  
EGR1	   (also	   called	   Zif268,	   NGF1-­‐A,	   Krox24,	   or	   TIS8)	   is	   known	   as	   an	   immediate-­‐early	  
response	  gene,	  based	  on	  its	  very	  quick	  induction	  within	  minutes	  of	  a	  stimulus,	  and	  its	  
rapid	  downregulation,	  often	  within	  hours	  (Yan	  et	  al.	  2000a).	  Like	  the	  other	  members	  of	  
the	  EGR	   family,	   EGR1	   is	   a	   zinc	   finger	   transcription	   factor	  which	   can	  be	   induced	  by	   a	  
variety	  of	  stimuli.	  EGR1	  has	  been	  shown	  to	  regulate	  the	  expression	  of	  a	  large	  number	  
of	  genes,	  including	  repair	  enzyme	  systems,	  angiogenic	  factors,	  cytokines	  and	  apoptotic	  
factors	  (Yan	  et	  al.	  2000).	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In	  a	  study	  on	  COPD	  by	  Ning	  et	  al.,	  exposure	  to	  aqueous	  cigarette	  smoke	  extract	  (CSE)	  
treatment	  was	  seen	  to	  stimulate	  EGR1	  expression	  and	  transcriptional	  activity	  in	  human	  
lung	   fibroblasts.	   The	   group	   also	   showed	   that	   EGR1	   could	  modulate	   the	   activities	   of	  
matrix	   metalloproteases	   MMP-­‐2	   and	   MMP-­‐9	   in	   mouse	   lung	   fibroblasts	   (Ning	   et	   al.	  
2004).	   The	   group	   investigated	   gene	   expression	   profiling	   studies	   and	   identified	   a	  
number	   of	   inflammation-­‐related	   proteins	   that	   are	   modulated	   in	   COPD,	   including	  
adhesion	  molecules,	  and	  signaling	  molecules	  and	  transcription	  factors	  known	  for	  their	  
roles	   in	   regulating	   inflammatory	   processes.	   Among	   the	   thousands	   of	   genes	  
differentially	  expressed	  in	  COPD,	  EGR1	  mRNA	  was	  one	  of	  the	  significantly	  upregulated	  
transcripts	   identified	  by	  both	  SAGE	  and	  microarray	  analysis,	  with	  confirmation	  by	  RT-­‐
PCR	  and	  immunohistochemical	  approaches	  (Ning	  et	  al.	  2004).	  
In	   a	   study	   by	   McCaffrey,	   a	   sustained	   expression	   of	   EGR1	   was	   demonstrated	   in	  
atherosclerosis.	  Using	   RNA	   from	   fibrous	   cap	   of	   carotid	   endarterectomy	   samples	   and	  
cDNA	   expression	   arrays,	   they	   found	   a	   5-­‐fold	   increase	   in	   EGR1	   mRNA	   in	   lesions,	  
compared	  to	  media.	  Additionally,	  the	  lesions	  also	  showed	  an	  increase	  in	  known	  EGR1	  
target	  transcripts	  such	  as	  TNF-­‐α,	  ICAM-­‐1,	  and	  M-­‐CSF.	  They	  also	  found	  EGR1	  protein	  in	  
atherosclerosis	  lesions,	  particularly	  in	  smooth	  muscle	  cells	  (McCaffrey	  et	  al.	  2000).	  
EGR1	  has	   also	   been	   associated	  with	   ischemia	   as	   it	   can	   trigger	   the	   expression	   of	   key	  
regulators	   of	   inflammation,	   coagulation	   and	   vascular	   permeability.	   Chemokines	   such	  
as	   IP-­‐10	  and	  MIP-­‐2,	   and	  TF,	  PAI-­‐1,	   ICAM-­‐1	  and	  VEGF	  were	  upregulated	  and	   this	  was	  
correlated	  to	  rapid	  EGR1	  activation.	   In	  a	  murine	  model	  of	   lung	   ischemia/reperfusion,	  
deletion	   of	   the	   gene	   encoding	   EGR1	   led	   to	   a	   decrease	   in	   the	   expression	   of	   these	  
molecules,	  along	  with	  enhanced	  animal	  survival	  and	  organ	  function.	  This	  showed	  that	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EGR1	   regulates	   the	   activation	   of	   coagulation,	   leukocyte	   accumulation	   and	   vascular	  
permeability	   in	   the	   ischemia/reperfusion	   lung,	  which	  have	   important	  effects	  on	  end-­‐
organ	  function	  (Yan	  et	  al.	  2000b).	  
This	   suggests	   that	   the	   EGR	   family	   members	   may	   play	   a	   role	   in	   activating	   the	  
transcription	  of	  proinflammatory	  mediators	  in	  Th2	  cells	  in	  response	  to	  LTD4.	  
5.2.3.2 NR4A2/NR4A3	  
NR4A2	   followed	  a	   similar	  pattern	  of	   expression	   to	  EGR1.	  Differential	   expression	  was	  
observed	   at	   30	   min	   after	   LTD4	   treatment	   and	   no	   other	   difference	   was	   observed	   at	  
other	   time	   points,	   indicating	   that	   NRA42	   is	   rapidly	   upregulated	   and	   downregulated	  
before	  4	  hours.	  NR4A3	  followed	  a	  similar	  pattern	  of	  expression.	  
NR4A2	  and	  NR4A3	  are	  members	  of	  the	  orphan	  nuclear	  NR4A	  receptors	  superfamily	  of	  
transcription	  factors,	  which	  consists	  of	  NR4A1	  (also	  known	  as	  Nur77),	  NR4A2	  (Nurr1)	  
and	   NR4A3	   (NOR-­‐1),	   which	   all	   share	   high	   homology	   particularly	   around	   their	   DNA	  
binding	   domain.	   NR4A1,	   NR4A2	   and	   NR4A3	   have	   emerged	   as	   key	   transcription	  
regulators	  of	  cytokines	  and	  growth	  factor	  actions	  through	  regulating	  the	  inflammatory	  
response	   of	   several	   diseases	   such	   as	   rheumatoid	   arthritis	   and	   psoriatic	   arthritis.	   As	  
these	  receptors	  are	  ligand-­‐independent	  and	  constitutively	  active,	  they	  are	  also	  tightly	  
regulated	   at	   the	   level	   of	   expression,	   post-­‐translational	   modification	   and	   subcellular	  
localization	  (McMorrow	  and	  Murphy	  2011).	  
NRA4	  subfamily	  members	  are	  aberrantly	  expressed	  in	  inflamed	  human	  synovial	  tissue,	  
psoriatic	  skin,	  atherosclerotic	  lesions,	  lung	  and	  colorectal	  cancer	  cells	  (McMorrow	  and	  
Murphy	  2011).In	  activated	  cells,	  the	  NR4A	  receptor	  subfamily	  members	  are	  rapidly	  and	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potently	   induced,	   suggesting	   their	   importance	   as	   transcriptional	   mediators	   of	  
inflammatory	  signals	  and	  their	  function	  as	  immediate	  early	  response	  genes	  with	  a	  wide	  
variety	  of	  physiological	  and	  pathophysiological	  actions	  (Zhao	  and	  Bruemmer	  2010).	  
In	  a	  study	  by	  Doi	  et	  al,	  they	  identified	  NR4A2	  as	  a	  gene	  most	  significantly	  upregulated	  
by	   peripheral	   T	   cells	   in	   multiple	   sclerosis.	   The	   study	   involved	   the	   analysis	   of	   gene	  
expression	   profiles	   of	   peripheral	   blood	   T	   cells	   from	  MS	   and	   control	   subjects,	   which	  
revealed	   that	   286	   of	   1,263	   genes	   were	   differentially	   expressed	   between	   the	   two	  
groups.	  Among	  genes	  upregulated	  in	  MS,	  NR4A2	  was	  most	  significantly	  overexpressed	  
with	  an	  increase	  ratio	  of	  3.6-­‐fold.	  RT-­‐PCR	  confirmed	  the	  expression	  of	  NR4A2	  in	  T	  cells	  
from	  MS	  patients	  with	  an	  expression	  5-­‐fold	  higher	  than	  in	  healthy	  donors.	  The	  group	  
also	   investigated	   the	   role	  of	  NR4A2	   in	  T	   cell-­‐mediated	  autoimmune	  diseases	   such	  as	  
EAE.	  Using	  C57BL/6	  (B6)	  mice	  and	  isolating	  T	  cells	  after	  EAE	  induction,	  they	  measured	  
the	  expression	  levels	  of	  NR4A2	  gene	  RT-­‐PCR	  and	  detected	  NR4A2	  in	  T	  cells	  on	  days	  14,	  
21,	   28,	   showing	   a	  maximum	   value	   on	   day	   21,	  which	   correlated	  with	   the	   severity	   of	  
EAE.	   RT-­‐PCR	   also	   revealed	   expression	   of	   NR4A2	   in	   CNS-­‐derived	   T	   cells	   on	   day	   9,	  
correlating	   to	  early	   signs	  of	  EAE,	  and	  decreased	  gradually	   thereafter	  until	  day	  21.	  To	  
clarify	  whether	  Th1	  or	  Th17	  cells	  played	  a	  key	  role	  in	  EAE,	  the	  group	  analysed	  the	  CNS	  
T	   cells	   and	   their	   ability	   to	   produce	   IFN-­‐γ	   and	   IL-­‐17	   to	   find	   that	   an	   almost	   equal	  
percentage	  of	  T	  cells	  produced	  IFN-­‐γ	  and	  IL-­‐17	  respectively.	  Finally	  they	  demonstrated	  
that	  NR4A2	  could	  regulate	  T	  cell	  production	  of	  inflammatory	  cytokines	  IL-­‐17	  and	  IFN-­‐γ.	  
Silencing	  of	  NR4A2	  by	  siRNA	  was	  shown	  to	  prevent	  the	  expression	  of	  these	  cytokines.	  
Additionally,	   they	   found	   that	   siRNA	   reduced	   the	   ability	   of	   pathogenic	   T	   cells	   to	  
adoptively	  transfer	  EAE	  (Doi	  et	  al.	  2008).	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Ji	  et	  al.	   found	   that	  PGE2	   stimulation	  of	   the	  GPCR	  EP1	  upregulated	   the	  expression	  of	  
NR4A2.	  Using	  DNA	  microarray	  analysis,	  the	  group	  identified	  that	  treatment	  of	  HEK293	  
cells	   stably	  expressing	   the	   recombinant	  human	  EP1	  receptor	  with	  PGE2	  resulted	   in	  a	  
strong	  upregulation	  of	  NR4A2.	  	  Using	  qPCR	  and	  immunoblotting,	  they	  determined	  that	  
NR4A2	   expression	   following	   the	   treatment	   of	   PGE2	   on	   HEK-­‐EP1	   cells	   was	  
concentration-­‐dependent	  and	  that	  NR4A2	  mRNA	  expression	  was	  observed	  within	  1	  h	  
of	   treatment	   with	   PGE2	   and	   decreased	   but	   lasted	   over	   6	   hours.	   NR4A2	   protein	  
expression	  was	   induced	   after	   3	   and	   6	   hour	   of	   treatment	  with	   PGE2.	   The	   group	   also	  
found	   that	   PGE2	   stimulation	   of	   the	   human	   EP1	   receptor	   can	   activate	   NF-­‐kB	  
transcriptional	   activity	   by	   a	  mechanism	   involving	   the	  phosphorylation	  of	   IkB.	  Overall	  
the	   study	   found	   that	   the	   activation	   of	   EP1	   receptor	   by	   PGE2	   lead	   to	   a	   cAMP-­‐
independent	   activation	   of	   PKA,	   which	   resulted	   in	   transcriptional	   upregulation	   of	  
NR4A2,	  via	  CREB	  and	  NF-­‐kB	  signalling	  (Ji	  et	  al.	  2010).	  
Holla	  et	  al	  attempted	  to	  identify	  novel	  PGE2	  target	  genes	  in	  colorectal	  carcinoma	  cells	  
and	   reported	   that	   the	   immediate	   early	   gene	  NR4A2	   (Nurr1)	   was	   induced	   by	   PGE2,	  
which	   in	   turn	   regulates	   cell	   death.	   PGE2	   can	   be	   generated	   from	  arachidonic	   acid	   by	  
either	  COX1	  or	  COX2.	  In	  this	  study,	  the	  group	  showed	  that	  COX2-­‐derived	  PGE2	  rapidly	  
but	   transiently	   induced	   NR4A2	   in	   colorectal	   carcinoma	   cells	   via	   a	   cAMP/PKA-­‐
dependent	  pathway	  (Holla	  et	  al.	  2006).	  
NR4A2	  has	  been	   shown	   to	  play	   an	   important	   role	   in	  physiological	   processes	   such	  as	  
apoptosis	   in	   lymphocytes	   and	   other	   cell	   types,	   but	   also	   inflammation,	   and	   is	   highly	  
inducible	   in	   macrophages	   by	   inflammatory	   cytokines	   and	   oxidized	   lipids	   (Pei	   et	   al.	  
2006).	  Additionally,	   its	  gene	  expression	  has	  been	  shown	  to	  increase	  by	  enhanced	  NF-­‐
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κB	  and	  CREB-­‐1-­‐binding	  activity	  on	  the	  gene	  promoter	  and	  also	  by	  stimulation	  of	  IL-­‐1β	  
and	  TNFα,	  and	  PGE2	  (McEvoy	  et	  al.	  2002;	  E.	  P.	  Murphy	  et	  al.	  2001).	  
Interestingly,	   NR4A	   nuclear	   receptors	   have	   been	   linked	   to	   immune	   diseases	   and	  
inflammation	   through	   their	  modulation	  of	   leukocyte	   functions.	  Although	  not	  directly	  
related	   to	   NR4A2,	   a	   study	   by	   Kagava	   et	   al.	   reported	   that	   NR4A1	   AND	   NR4A3	   were	  
induced	   by	   CD30	   stimulation	   during	   eosinophil-­‐specific	   apoptosis.	   The	   results	   of	   the	  
study	   suggested	   that	   CD30-­‐activated	   NR4A	   receptors	   expression	   may	   regulate	  
eosinophil	   apoptosis	   in	   allergic	   conditions	   such	   as	   atopic	   dermatitis	   (Hashida	   et	   al.	  
2007;	  Kagaya	  et	  al.	  2005).	  
It	   is	   interesting	   that	   the	   members	   of	   the	   NR4A	   receptor	   family	   are	   expressed	   as	  
immediate	  early	  genes	   in	  different	  cell	  types	  following	  various	  stimuli	  and	  it	  suggests	  
that	  these	  genes	  must	  play	  multiple	  roles	  in	  biological	  functions.	  It	  is	  a	  possibility	  that	  
NR4	   genes	   may	   also	   play	   a	   role	   in	   activating	   transcription	   of	   proinflammatory	  
mediators	  in	  Th2	  cells	  in	  response	  to	  LTD4	  (Winoto	  and	  Littman	  2002).	  
  




Differential	   gene	   expression	   for	   CD69	   was	   observed	   at	   the	   30-­‐min	   time-­‐point.	   No	  
change	  was	  detected	  at	  4-­‐	  and	  24-­‐hour	  treatment.	  
CD69	   is	   a	   type	   II	   integral	  membrane	   protein	  with	   a	   C-­‐type	   lectin-­‐binding	   domain.	   It	  
belongs	   to	   the	   family	   of	   natural	   killer	   cell	   gene	   complex	   (or	   NKC)	   of	   cell	   surface	  
receptors.	   In	   humans,	   the	   molecule	   is	   a	   disulfide-­‐linked	   homodimer	   formed	   by	   the	  
association	   of	   two	   subunits	   of	   27	   and	   33	   kDa	   and	   it	   is	   the	   product	   of	   a	   single	   gene	  
located	  on	  chromosome	  12	  (Schnittger	  et	  al.	  1993).	  
CD69	  is	  known	  as	  an	  activation	  inducer	  molecule	  or	  very	  early	  activation	  antigen	  as	  it	  
was	   initially	  detected	  on	   the	   surface	  of	  activated	   lymphocytes.	  However	  CD69	   is	  not	  
restricted	   to	   activated	   lymphocytes	   and	   is	   constitutively	   expressed	   on	   human	  
monocytes,	  platelets	  and	  epidermal	  Langerhans	  cells	  (Atzeni	  et	  al.	  2002;	  Marzio	  et	  al.	  
1999).	   Reports	   also	   show	   that	   CD69	   can	   be	   induced	   in	   vitro	   on	   the	   surface	   of	  most	  
hematopoietic	  lineages,	  including	  recently	  activated	  T	  and	  B	  lymphocytes	  (Cosulich	  et	  
al.	   1987;	   Testi	   et	   al.	   1994)	   but	   also,	   amongst	   others,	   	   activated	   neutrophils	   and	  
eosinophils	   (Gavioli	   et	   al.	   1992;	   Nishikawa	   et	   al.	   1992),	   and	   human	   monocytes	   (De	  
Maria	  et	  al.	  1994).	  Moreover,	  CD69	  can	  be	  induced	  by	  PMA	  and	  fMLP	  in	  neutrophils,	  
while	  GM-­‐CSF,	  IL-­‐3,	  IL-­‐5,	  and	  IFN-­‐γ	  are	  appropriate	  stimuli	  for	  eosinophils	  (Nopp	  et	  al.	  
2000).	  
No	  physiological	  ligand	  has	  been	  identified	  for	  CD69	  yet.	  It	  has	  however	  been	  linked	  to	  
the	  biology	  of	  hematopoietic	  cells	  and	  the	  pathogenesis	  of	  some	  human	  diseases	  (Testi	  
et	  al.	  1994).	  CD69	  has	  also	  been	  reported	   to	   induce	  platelet	  aggregation	   (Testi	  et	  al.	  
1990),	   T	   cell	   proliferation	   and	   pro-­‐inflammatory	   cytokine	   production,	   neutrophil	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degranulation,	  and	  calcium	  flux	  (Gavioli	  et	  al.	  1992;	  Santis	  et	  al.	  1992;	  Testi	  et	  al.	  1989;	  
Testi	  et	  al.	  1990)	  via	  its	  crosslinking	  by	  monoclonal	  antibodies.	  	  
In	  a	  study	  by	  Atzeni	  et	  al.,	  CD69	  expression	  was	  nearly	  undetectable	  on	  neutrophils	  but	  
increased	  after	   a	  60-­‐min	  activation	  with	  PMA.	  When	  neutrophils	  were	   cultured	  with	  
cytokines	   GM-­‐CSF,	   IFN-­‐α,	   and	   IFN-­‐γ,	   the	   number	   of	   CD69-­‐positive	   neutrophils	  
significantly	   increased.	   Studies	   also	   confirmed	   that	   CD69	   crosslinking	   by	   anti-­‐CD69	  
mAb	   resulted	   in	   the	   induction	   of	   several	   cellular	   responses.	   In	   PMA-­‐activated	  
neutrophils,	   CD69	   crosslinking	   by	   mAb	   induced	   Ca2+	   influx,	   lysozyme	   release,	   and	  
CD11B	  expression	  (Atzeni	  et	  al.	  2002).	  
CD69	  crosslinking	  has	  also	  been	  shown	  on	  T	  lymphocytes,	  causing	  cellular	  effects	  such	  
as	   calcium	   signalling,	   but	  not	  PKC.	  When	  PKC	  was	   simultaneously	   activated	  by	  PMA,	  
CD69	   was	   seen	   to	   induce	   IL-­‐2	   and	   IFN-­‐γ	   gene	   expression,	   enhancement	   of	   CD25	  
expression	  and	  IL-­‐2-­‐dependent	  T	  cell	  proliferation	  (Testi	  et	  al.	  1989).	  
CD69	  has	  also	  been	  associated	  with	  allergic	   inflammation.	   Indeed,	  a	  CD69	  deficiency	  
inhibits	  the	  development	  of	  asthma,	  as	  shown	  in	  a	  study	  by	  Miki-­‐Hosokawa.	  The	  group	  
investigated	  the	  role	  of	  CD69	  in	  the	  pathogenesis	  of	  allergic	  airway	  inflammation	  using	  
a	  mouse	  model	  of	  allergic	  asthma.	  The	  results	  showed	  that	  CD69	  played	  a	  critical	  role	  
in	   the	   induction	  of	   both	   antigen-­‐induced	   eosinophilic	   airway	   inflammation	   and	  AHR.	  
Adding	   anti-­‐CD69	   antibody	   resulted	   in	   a	   dramatic	   reduction	   in	   the	   extent	   of	   airway	  
inflammation	  and	  AHR.	  Using	  CD69KO	  mice	  crossed	  with	  BALB/c	  mice,	  results	  showed	  
that	  OVA-­‐induced	  airway	  inflammation	  and	  AHR	  were	  reduced	  in	  CD69-­‐deficient	  mice	  
compared	   to	  wild	   type,	   as	  numbers	  of	   total	   infiltrated	   leukocytes	   and	  eosinophils	   in	  
the	  BAL	  fluid	  were	  significantly	  decreased.	  Analysis	  of	  mRNA	  expression	  levels	  showed	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that	  levels	  of	  IL-­‐5,	  IL-­‐13	  and	  eotaxin-­‐2	  were	  significantly	  lower	  in	  BAL	  fluid	  CD4+	  T	  cells	  
from	  CD69KO	  mice	   compared	   to	  normal.	   Further	   experiments	   also	   showed	   that	   Th2	  
cell	  numbers	  was	   lower	   in	  CD69-­‐deficient	  mice	  following	  OVA-­‐sensitisation	  and	  OVA-­‐
challenge.	  CD69-­‐deficient	  CD4	  T	  cells	  were	  also	  found	  to	  have	  impaired	  migration	  into	  
the	   asthmatic	   lung.	   The	   study	   suggested	   that	   CD69	   plays	   a	   critical	   role	   in	   the	  
development	  of	   allergen-­‐induced	  eosinophilic	   inflammation	   and	  AHR	  by	   allowing	   for	  
efficient	  migration	  of	  Th2	  cells	  into	  the	  asthmatic	  lung	  (Miki-­‐Hosokawa	  et	  al.	  2009).	  
In	  contrast,	  a	   study	  by	  Martin	  et	  al.	  used	   two	  models	  of	  allergic	  disease,	  ovalbumin-­‐
induced	   allergic	   airway	   inflammation	   (BALB/c	   genetic	   background)	   and	   contact	  
hypersensitivity	  to	  oxazolone	  (C57BL/6J	  genetic	  background)	  of	  CD69	  in	  knockout	  and	  
wild-­‐type	   mice	   and	   demonstrated	   that	   CD69	   negatively	   regulates	   the	   inflammatory	  
response	  in	  these	  models.	  Results	  showed	  that	  CD69	  deficiency	  dramatically	  enhanced	  
the	   inflammatory	   response	   in	   the	   ovalbumin-­‐induced	   asthma	   model	   of	   antigen-­‐
induced	   airway	   allergy.	   CD69	   knockout	   mice	   showed	   exacerbated	   pulmonary	  
eosinophil	  recruitment,	  high	  vascular	  cell	  adhesion	  molecule	  1	  expression	  levels	  in	  lung	  
vasculature,	  and	  enhanced	  Th2	  and	  Th17	  cytokines	   in	  the	  bronchoalveolar	  space	  and	  
lung	  tissue.	  In	  the	  contact	  hypersensitivity	  model,	  both	  CD69	  deficiency	  and	  treatment	  
with	   anti-­‐CD69	   mAb	   increased	   inflammation.	   Treatment	   with	   contact	   allergens	  
induced	   enhanced	   Th1	   and	   Th17	   responses	   in	   CD69-­‐deficient	  mice,	   and	   neutralizing	  
anti–IL-­‐17	   antibodies	   reduced	   skin	   inflammation.	   In	   both	   experimental	   systems,	  
adoptive	   transfer	   of	   lymph	   node	   cells	   from	   CD69	   knockout	   mice	   increased	   the	  
inflammatory	  response	  in	  recipient	  mice	  (P.	  Martin	  et	  al.	  2010).	  	  
Although	  contradictory,	  these	  studies	  strongly	  suggest	  that	  CD69	  plays	  a	  complex	  role	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in	  lymphocyte	  and	  other	  immune	  cell	  migration	  which	  is	  interesting	  in	  relation	  to	  our	  
evidence	  that	  LTD4	   is	  chemotactic	  for	  Th2	  cells.	  Further	   investigation	  will	  be	  required	  
to	  understand	   the	   role	  of	  CD69	  upregulation	   in	   response	   to	   LTD4	   treatment	  and	   the	  
effects	  on	  Th2	  cell	  migration.	  
5.2.3.4 FOS/FOSB 
FOSB	  and	  FOS	  were	  differentially	  expressed	  after	  30	  minutes	  of	  treatment	  with	  LTD4.	  
No	  change	  in	  gene	  expression	  was	  observed	  after	  4	  hours	  or	  24	  hours	  of	  treatment	  in	  
either	  of	  the	  genes.	  The	  pattern	  of	  expression	  of	  the	  two	  genes	  was	  very	  similar.	  
FOS	   and	   FOSB	   are	  members	   of	   the	   Fos	   family	   (c-­‐Fos,	   FOSB,	   Fra-­‐1,	   and	   Fra-­‐2),	  which	  
combine	  with	  Jun	  family	  members	  (c-­‐Jun,	  JunB,	  and	  Jun	  D)	  to	  form	  activator	  protein	  1	  
(AP-­‐1),	   a	   transcription	   factor	   with	   very	   potent	   proinflammatory	   effects,	   which	  
dimerizes	   in	   various	   combinations	   through	   a	   region	   known	   as	   a	   leucine	   zipper	   (P.	   J.	  
Barnes	  2006).	  AP-­‐1	  may	  be	  activated	  via	  PKC	  and	  by	  various	  cytokines,	  including	  TNF-­‐α	  
and	   interleukin	   IL-­‐1β,	   via	   several	   types	   of	   protein	   tyrosine	   kinase	   (PTK)	   and	   MAP	  
kinase,	  which	   in	   turn	   activate	   a	   cascade	  of	   intracellular	   kinases.	   Certain	   signals	   have	  
been	  found	  to	  rapidly	  increase	  the	  transcription	  of	  the	  FOS	  gene,	  resulting	  in	  increased	  
synthesis	  of	  Fos	  protein.	  Other	  signals	  lead	  to	  activation	  of	  kinases	  that	  phosphorylate	  
c-­‐Jun,	  resulting	  in	  increased	  activation.	  Once	  again	  these	  transcription	  factors	  are	  likely	  
involved	   in	  upregulating	  proinflammatory	  genes	   in	  response	  to	  LTD4	  such	  as	  CD69	  or	  
TNF-­‐α.	  
5.2.3.5 MicroRNAs 
MIR21	   was	   differentially	   expressed	   at	   30	   minutes	   of	   LTD4	   treatment	   compared	   to	  
untreated	   cells.	   After	   4	   hours	   of	   treatment,	   there	  was	   still	   a	   slight	   increase	   in	   gene	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expression	   in	   LTD4-­‐treated	   cells	   versus	   untreated.	   At	   24	   hours,	   treatment	   of	   LTD4	  
induced	  a	  decrease	   in	  MIR21	  gene	  expression.	  The	   same	  pattern	  of	   gene	  expression	  
was	  observed	  for	  MIR23A	  and	  MIR27A.	  However	  in	  MIR24-­‐2,	  the	  only	  gene	  expression	  
difference	  was	  after	  30	  mins	  of	  treatment	  with	  LTD4,	  after	  which	  the	  effect	  decreased	  
until	  24	  hours.	  
MicroRNAs	  (or	  MiRNAs)	  are	  short	  single	  stranded,	  non-­‐coding	  RNAs	  of	  approximately	  
21–23	  nucleotides	  in	  length	  that	  regulate	  gene	  expression	  by	  binding	  to	  specific	  mRNA	  
targets	  and	  promoting	  their	  degradation	  and/or	  translational	  inhibition	  (Pritchard	  et	  al.	  
2012).	  They	  are	  predicted	  to	  regulate	  almost	  one	  third	  of	  the	  human	  genome	  and	  are	  
essential	  for	  cellular	  and	  organism	  development	  (Mishra	  et	  al.	  2008).	  The	  discovery	  of	  
microRNAs	  as	  independent	  functional	  units	  of	  noncoding	  RNAs	  has	  changed	  our	  views	  
about	   these	   noncoding	   regions.	   Computational	   predictions	   suggest	   that	   the	   total	  
number	  of	  different	  miRNA	  sequences	  in	  humans	  may	  approach	  1000	  (Berezikov	  et	  al.	  
2005).	   In	  most	  organisms,	   there	  are	  a	   limited	  number	  of	  miRNAs	  compared	  with	  the	  
number	   of	   mRNAs	   and	   proteins;	   for	   example,	   the	   human	   genome	   is	   believed	   to	  
encode	   approximately	   1,000	   miRNAs,	   whereas	   the	   number	   of	   mRNAs	   is	   typically	  
estimated	  at	  approximately	  30,000	  (Pritchard	  et	  al.	  2012).	  Although	  little	  is	  still	  known	  
about	  MiRNAs,	   they	   are	   predicted	   to	   regulate	   genes	   involved	   in	   multiple	   pathways	  
such	   as	   cell	   death,	   cell	   proliferation,	   stress	   resistance	   and	   fat	   metabolism	   (Ambros	  
2003).	   As	   little	   is	   known	   about	   MIR21,	   MIR23,	   MIR24	   and	   MIR27,	   which	   we	   have	  
identified	  as	  being	  upregulated	  in	  our	  microarray	  studies,	  we	  focus	  here	  on	  reports	  of	  
miRNAs	  in	  general.	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Several	   studies	   have	   shown	   a	   central	   role	   of	  miRNAs	   in	   the	   pathogenesis	   of	   asthma	  
with	  a	  number	  of	  studies	  reporting	  changes	  in	  the	  expression	  of	  several	  miRNAs,	  which	  
have	   been	   shown	   to	   be	   associated	   with	   the	   development	   and/or	   improvement	   in	  
asthma	  (Ariel	  and	  Upadhyay	  2012;	  Oglesby	  et	  al.	  2010).	  
In	  a	  study	  by	  Williams	  et	  al.,	   they	  compared	  the	  microRNA	  profile	  of	  airway	  biopsies	  
from	   patients	   with	   mild	   asthma	   compared	   to	   those	   from	   healthy	   non-­‐asthmatic	  
volunteers.	   They	   then	   looked	   at	   the	   effect	   of	   treatment	   with	   inhaled	   corticosteroid	  
therapy	   over	   4	   weeks	   on	   the	   microRNA	   profile	   in	   patients	   with	   steroid-­‐naive	   mild	  
asthma.	   From	   their	   experiments	   they	   found	   a	   specific	   miRNA	   expression	   profile	   in	  
human	  airway	  biopsies	   from	  mild	  asthmatic	  patients	  and	   in	   the	  cell	   types	  commonly	  
associated	  with	  the	  airways	  and	  lung.	  Of	  these,	  Mir-­‐24	  was	  one	  of	  the	  28	  miRNAs	  to	  be	  
classified	   as	   highly	   expressed.	   Comparing	   airway	   biopsy	   samples	   from	   asthmatic	  
patients	   with	   those	   of	   healthy	   individuals,	   the	   group	   observed	   that	   this	   profile	   was	  
maintained	  in	  the	  mild	  asthmatic	  phenotype	  (Williams	  et	  al.	  2009).	  
In	  a	  review	  by	  Tomankova	  et	  al.,	  they	  report	  a	  role	  for	  miRNAs	  in	  the	  physiology	  and	  
pathology	   of	   the	   lung	   (mainly	   based	   on	   mouse	   studies)	   and	   a	   specific	   miRNA	  
expression	   profile	   in	   the	   lung	   (Tomankova	   et	   al.	   2010).	   Several	   miRNAs	   have	   been	  
shown	  to	  be	  involved	  in	  homeostasis	  and	  in	  the	  lung	  development.	  Of	  these,	  miR-­‐155	  
has	  been	  shown	  that	  to	  be	  involved	  in	  the	  differentiation	  of	  naive	  T	  cells	  into	  Th1	  and	  
Th2	  cells	   in	  mice	   (Banerjee	  et	  al.	  2010).	  Mice	  deficient	   in	  bic/miR-­‐155	  were	  found	  to	  
display	  increased	  lung	  remodelling,	  higher	  bronchoalveolar	  leukocytes	  and	  impaired	  T-­‐	  
and	  B-­‐cell	   responses	   to	   inflammatory	   stimuli	   (Rodriguez	  et	  al.	   2007).	  The	   role	  of	   the	  
miRNAs	  that	  we	  have	  identified	  in	  Th2	  cell	  function	  will	  require	  further	  investigation	  to	  
identify	  potential	  mRNA	  targets	  for	  these	  miRNAs.	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5.2.3.6 PTGS2	  (COX2) 
PTGS2,	  also	  known	  as	  COX-­‐2,	   followed	  a	   similar	  pattern	   to	  all	  other	  genes	  described	  
earlier,	   in	   that	   LTD4	   treatment	   was	   found	   to	   affect	   gene	   expression	   only	   after	   30	  
minutes	  of	  treatment.	  Expression	  of	  COX-­‐2	  had	  returned	  to	  baseline	  by	  the	  4-­‐	  and	  24-­‐
hour	  time-­‐points.	  
The	  COX	  enzymes	  are	  responsible	  for	  initiating	  the	  synthesis	  of	  prostaglandins,	  which	  
are	  involved	  in	  regulating	  inflammatory	  responses.	  COX	  enzymes	  are	  encoded	  by	  two	  
genes;	  COX-­‐1	  and	  COX-­‐2.	  Cyclooxygenase-­‐1	  and	  cyclooxygenase-­‐2	  (COX-­‐1	  and	  COX-­‐2),	  
also	  termed	  prostaglandin	  endoperoxide	  H	  synthase-­‐1	  and	  -­‐2	  (PGHS-­‐1	  and	  -­‐2)	  are	  key	  
enzymes	   that	   catalyse	   the	   first	   step	   in	   the	   synthesis	   of	   prostanoids	   from	   fatty	   acid	  
precursors	   like	  arachidonic	  acid.	  When	  arachidonic	  acid	   is	   released	  by	  phospholipase	  
A2	   following	   stimulus,	   it	   is	   converted	   to	   PGH2	   by	   COX-­‐1	   or	   COX-­‐2.	   PGH2	   is	   then	  
converted	   to	   PGE2	   by	   mPGES1	   and	   other	   prostanoids	   such	   as	   PGD2,	   PGF2,	   PGI2,	  
Thromboxane	  A2	  (Carey	  et	  al.	  2003).	  
The	  enzymes	  share	  60%	  homology	  (Smith	  et	  al,	  2000)	  and	  consist	  of	  three	  domains;	  an	  
EGF	  domain,	  a	  membrane-­‐binding	  domain	  and	  a	  catalytic	  domain	  that	  controls	  both	  its	  
COX	  and	  peroxidase	  activity.	  In	  humans	  COX-­‐1	  and	  COX-­‐2	  are	  homodimers	  of	  576	  and	  
581	   amino	   acids,	   respectively,	   and	   despite	   their	   homology,	   are	   regulated	  
independently	  by	  different	  systems.	  	  
COX-­‐1	  has	  been	  found	  to	  be	  constitutively	  expressed	  by	  most	  cell	  types.	  It	  serves	  as	  a	  
housekeeping	  enzyme	  responsible	   for	  producing	  basal	   levels	  of	  prostaglandins	   in	   the	  
endoplasmic	  reticulum,	  and	  also	  been	  suggested	  to	   function	  only	  at	  high	  arachidonic	  
concentrations,	  such	  as	  in	  inflammation.	  COX-­‐1	  is	  ubiquitously	  expressed	  and	  needed	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for	   homeostasis,	   for	   example	   in	   maintaining	   the	   epithelial	   barrier.	   COX-­‐2	   is	   an	  
inducible	   enzyme	   and	   its	   expression	   is	   generally	   undetectable	   in	  most	   tissues	   under	  
homeostatic	  conditions	  and	  upregulated	  in	  response	  to	  inflammatory	  stimuli	  (Carey	  et	  
al.	  2003).	  
COX-­‐2	  is	  expressed	  under	  the	  control	  of	  the	  pro-­‐inflammatory	  transcription	  factor	  NF-­‐
kB	   in	   response	   to	   a	   vast	   range	   of	   extracellular	   and	   intracellular	   stimuli.	   It	   is	   able	   to	  
function	  with	  much	  lower	  concentrations	  of	  arachidonic	  acid	  to	  COX-­‐1.	  Both	  enzymes	  
can	   be	   inhibited	   by	   non-­‐steroidal	   anti-­‐inflammatory	   drugs	   such	   as	   aspirin	   and	  
ibuprofen.	  Aspirin	   inhibits	  COX-­‐1	   completely,	  while	  COX-­‐2	  only	  partially	   (Smith	  et	   al.	  
2000).	  
As	  PGE2	  is	  generally	  associated	  with	  inflammatory	  responses	  and	  high	  levels	  are	  found	  
in	   the	   sputum	  of	   asthmatic	   subjects	   versus	   healthy	   individuals,	   the	   enhancement	   of	  
PGE2	   is	  generally	  positively	  correlated	   to	  disease	  severity.	  Although	  the	  evidence	   for	  
the	  role	  of	  COX	  enzymes	  in	  Th2-­‐mediated	  inflammation	  is	  still	  contradictive,	  COX-­‐2	  has	  
been	  linked	  to	  allergic	  lung	  inflammation	  and	  asthma	  due	  to	  its	  associated	  with	  PGE2.	  
Some	  reports	  have	  suggested	  that	  PGE2	  plays	  a	  role	  in	  Th2	  inflammation	  by	  inhibiting	  
the	  production	  of	  Th1-­‐specific	  cytokines	  IL-­‐2	  and	  IFN-­‐γ	  (Betz	  and	  Fox	  1991)(Betz	  et	  al,	  
1991).	  However	  other	   reports	  have	  also	  suggested	  that	  PGE2	  can	   inhibit	  Th2-­‐specific	  
cytokines	  secretion	  as	  well	  as	  the	  production	  of	  IgE	  on	  B	  cells	  (Khan	  1995;	  Pene	  et	  al.	  
1988).	  
COX-­‐2	   has	   also	   been	   involved	   in	   the	   regulation	   of	   Th17	   cell	   differentiation	   during	  
allergic	   lung	   inflammation.	   The	   study	  by	   Li	  et	  al.	   demonstrated	   that	   allergic	  COX-­‐2-­‐/-­‐	  
mice	   showed	   reduced	   Th17	   cells	   in	   the	   lung,	   BALF	   and	   lymph	   nodes	   during	   lung	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inflammation	  in	  vivo,	  as	  well	  as	  reduced	  levels	  of	  IL-­‐17A	  in	  blood	  and	  BALF.	  The	  group	  
also	   found	   that	   Th17	   differentiation	   of	   naïve	   CD4+	   T	   cells	   from	   COX-­‐2-­‐/-­‐	   mice	   was	  
impaired	   in	  vitro	  with	  decreased	  STAT3	  phosphorylation	  and	  RORγt	  expression.	  Th17	  
differentiation	  could	  also	  be	  inhibited	  by	  COX-­‐2	  inhibitors	  (H.	  Li	  et	  al.	  2011a).	  
COX-­‐2	   is	   likely	   to	   play	   an	   important	   role	   in	   upregulating	   proinflammatory	   lipid	  
production	  in	  response	  to	  LTD4.	  
5.2.3.7 TNF-­‐a 
TNF-­‐α	  is	  cytokine	  and	  member	  of	  the	  TNF	  superfamily,	  which	  plays	  an	  important	  role	  
in	   immediate	  host	   responses	  against	  pathogens.	  TNF-­‐α	   is	  generally	  produced	  by	  LPS-­‐
activated	  macrophages	  but	  also	  by	  other	  inflammatory	  cells	  such	  as	  T	  cells,	  monocytes,	  
dendritic	  cells,	  B	  cells,	  neutrophils,	  mast	  cells	  and	  eosinophils	  (Brightling	  et	  al.	  2008).	  
	  
TNF-­‐α	   has	   been	   implicated	   in	   the	   pathophysiology	   of	   several	   inflammatory	   diseases	  
such	  as	  rheumatoid	  arthritis	  and	  asthma	  (Brightling	  et	  al.	  2008).	  It	  has	  been	  shown	  to	  
play	  a	  role	   in	  the	  promotion	  of	  airway	  inflammation	  and	  airway	  hyperresponsiveness	  
in	  asthmatic	  patients	  (Berry	  et	  al.	  2006;	  Erzurum	  2006),	  but	  also	  in	  airway	  remodelling,	  
by	   stimulating	   the	   growth	   and	   maturation	   of	   fibroblasts	   into	   myofibroblasts	   by	  
promoting	   TGF-­‐β	   expression	   (Baluk	   et	   al.	   2009).	   Anti-­‐TNF-­‐α	   is	   a	   known	   efficacious	  
treatment	  for	  rheumatoid	  disease	  (Olsen	  and	  Stein	  2004)	  and	  has	  been	  suggested	  as	  a	  
potential	  treatment	  for	  severe	  (or	  refractory)	  asthma	  (Howarth	  et	  al.	  2005).	  
TNF-­‐α	   has	   been	   implicated	   in	   several	   asthma-­‐related	   studies.	   For	   example,	   it	   was	  
identified	   as	   a	   chemoattractant	   for	   neutrophils	   and	   eosinophils	   (Lukacs	   et	   al.	   1995),	  
but	  also	  as	  an	  enhancer	  of	  T	  cell	  responses	  (Scheurich	  et	  al.	  1987).	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In	  a	  study	  by	  Thomas	  et	  al.,	  they	  found	  that	   inhalation	  of	  recombinant	  human	  TNF-­‐α	  
by	  normal	   and	   asthmatic	   patients	   induced	   an	   increase	   in	   airway	   responsiveness	   and	  
neutrophil	   infiltration	   (Thomas	   et	   al.	   1995;	   Thomas	   and	   Heywood	   2002).	   Studies	  
looking	  at	  the	  effect	  of	  TNF-­‐α	  on	  airway	  hyperresponsiveness	  have	  revealed	  that	  AHR	  
could	   be	   caused	   by	   the	   release	   of	   cysteinyl	   leukotrienes	   (Huber	   et	   al.	   1988),	   as	  
evidenced	  by	   in	  vivo	   studies	   in	   rats.	   In	   this	  study,	  Huber	  et	  al.	   found	  that	   infusion	  of	  
TNF-­‐α	   increased	   the	   rate	   of	   cysteinyl	   leukotrienes	   production,	   as	   measured	   by	  
excreted	  LTE4.	  Anti-­‐TNF-­‐α	  prevented	  the	  increased	  synthesis	  of	  leukotrienes.	  
	  
In	   a	   study	   by	   Haneda	   et	   al.,	   they	   found	   that	   LTD4	   enhanced	   TNF-­‐α-­‐induced	   VEGF	  
production	  in	  human	  monocytic	  leukemia	  THP-­‐1	  cells	  (Haneda	  et	  al.	  2011).	  
TNF-­‐α	   has	   also	   been	   found	   to	   increase	   the	   levels	   of	   COX-­‐2	   in	   non-­‐transformed	  
epithelial	   cells	   and	   those	   of	   5-­‐LO	   in	   non-­‐transformed	   epithelial	   cells	   and	   cancer	   cell	  
lines.	   TNF-­‐α	   and	   LTD4	   were	   both	   observed	   to	   increase	   levels	   of	   the	   enzyme	   LTC4S,	  
which	   is	   involved	   in	   the	   leukotrienes	   biosynthesis	   pathway,	   in	   these	   types	   of	   cells.	  
These	  data	  suggested	  that	  inflammatory	  mediators	  such	  as	  TNF-­‐α	  and	  LTD4	  could	  play	  
an	   important	   role	   in	   upregulating	   the	   expression	   of	   enzymes	   involved	   in	   the	  
biosynthesis	   of	   eicosanoids	   during	   inflammation	   (Yudina	   et	   al.	   2008).	   This	   data	   was	  
supported	  by	  Serio	  et	  al.,	  who	  found	  that	  treatment	  of	  THP-­‐1	  cells	  and	  primary	  human	  
monocytes	  with	  TNF-­‐α	  decreased	  the	  capacity	  of	  these	  cells	  for	  CysLT	  release,	  as	  well	  
as	   LTC4S	   gene	   expression.	   This	   effect	   was	   also	   observed	   in	   primary	   bone	   marrow-­‐
derived	  macrophages	  and	  eosinophilic	  AML14.3D10	  cells	  (Serio	  et	  al.	  2007).	  
In	   a	   study	  by	   Ichiyama	  et	  al.,	   they	   found	   that	   cysteinyl	   leukotrienes	   alone	   could	  not	  
induce	  the	  expression	  of	  MMP-­‐9	  in	  THP-­‐1	  cells.	  However,	  CysLTs	  such	  as	  LTC4	  and	  LTD4	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were	   able	   to	   enhance	   the	   effect	   that	   TNF-­‐α	   has	   on	   inducing	   MMP-­‐9	   expression.	  
Interestingly,	  this	  enhancement	  of	  TNF-­‐α	  -­‐induced	  MMP-­‐9	  was	  completely	  inhibited	  by	  
CysLT1R	  antagonist	  pranlukast,	   suggesting	  a	   role	   for	   the	  CysLT1	   receptor	   (Ichiyama	  et	  
al.	  2007).	  
Overall,	   these	   data	   support	   the	   importance	   of	   TNF-­‐α	   in	   inflammatory	   responses,	  
particularly	  its	  close	  association	  with	  cysteinyl	  leukotrienes.	  	  
	  
	  
	   	  




Most	  genes	  described	  in	  this	  chapter	  show	  differential	  expression	  after	  30	  minutes	  of	  
treatment	  with	  LTD4,	  where	  LTD4	  is	  found	  to	  induce	  an	  upregulation	  in	  the	  genes.	  This	  
upregulation	  is	  generally	  already	  lost	  at	  4	  hours	  and	  24	  hours.	  
In	  contrast	  to	  the	  data	  by	  Woszczek	  and	  Uzonyi,	  our	  data	  suggest	  that	  human	  T	  cells	  
signal	   through	   CysLTR1,	   which	   is	   partially	   coupled	   to	   Gαi/Gαq,	   in	   response	   to	   LTD4	  
stimulation,	   unlike	   human	   monocytes	   (which	   couple	   via	   Gαi).	   Regardless	   of	   the	  
differences	  in	  G	  protein	  coupling,	  these	  data	  suggest	  that	  both	  signalling	  mechanisms	  
can	  induce	  the	  expression	  of	  immediate-­‐early	  genes.	  
There	   were	   also	   a	   few	   differences	   between	   our	   data	   and	   previous	   data	   by	   other	  
groups.	   In	  monocytes,	  Woszczek	  et	  al.	   observed	  an	   induction	  of	   FOSB	  and	  TSC22D3,	  
which	   were	   not	   found	   to	   be	   upregulated	   in	   HUVECs.	   Also,	   no	   change	   in	   EGR1	  
expression,	   a	   gene	   potently	   induced	   by	   CysLTR2	   signalling,	   was	   observed	   in	   human	  
monocytes	   (Woszczek	   et	   al.	   2008b).	   In	   our	   data	   EGR	   family	   members	   EGR1,	   EGR2,	  
EGR3,	   but	   also	   NR4A2	   and	   FOSB	   were	   found	   to	   be	   upregulated	   after	   30	   minutes.	  
However	  we	  also	  found	  that	  CD69	  and	  three	  microRNAs	  were	  also	  induced	  at	  that	  time	  
point.	   These	   differences	   observed	   between	   these	   studies	   could	   be	   a	   result	   of	  
differences	   in	   signalling	   in	   different	   cell	   types,	   as	   well	   as	   the	   potential	   existence	   of	  
divergent	  pathways	  that	  are	  used	  by	  CysLTR1	  and	  CysLTR2,	  which	  are	  yet	  to	  be	  found.	  
Collectively	  the	  microarray	  studies	  have	  indicated	  that	  LTD4	  does	  not	  have	  a	  profound	  
effect	  on	  transcriptional	  control	   in	  human	  Th2	  cells.	  However	   the	  genes	   identified	  at	  
the	  30	  min	  time-­‐point	  suggest	  that	  a	  cascade	  of	  transcription	  factors	  and	  miRNAs	  are	  
induced	   which	   may	   in	   turn	   regulate	   other	   genes	   and	   proteins.	   It	   is	   particularly	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interesting	  that	  increases	  in	  CD69	  and	  TNF-­‐α	  are	  observed	  and	  this	  will	  require	  further	  
investigation	  by	  real-­‐time	  RT-­‐PCR,	  flow	  cytometry	  (CD69)	  and	  ELISA	  (TNF-­‐α).	  Given	  the	  
roles	  of	  each	  molecule	  in	  inflammatory	  processes	  it	  will	  be	  interesting	  to	  further	  study	  
the	  effect	  of	  LTD4	  stimulation	  on	  their	  expression.	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Chapter	  6 Discussion	  
In	  the	  studies	  presented	  here,	  we	  have	  shown	  that	  CYSLTR1	  expression	  was	  detected	  
in	  Th1	  and	  Th2	  cells	  in	  microarrays	  and	  that	  Th2	  cells	  express	  significantly	  higher	  levels	  
of	  CYSLTR1	  mRNA.	  We	  then	  confirmed	  these	  observations	  using	  real-­‐time	  quantitative	  
RT-­‐PCR	   to	   find	   that	   Th2	   cells	   selectively	   express	  CYSLTR1	  mRNA	  with	  6.5-­‐fold	  higher	  
expression	   than	   human	   Th1	   cells,	   and	   that	   this	   expression	   increases	   with	  
differentiation.	   CYSLTR1	  was	   highly	   expressed	   in	   Th2	   resting	   cells	   and	   its	   expression	  
was	   significantly	   downregulated	   by	   acute	   cell	   activation,	   a	   GPCR	   profile	   commonly	  
identified	   in	   T	   cells,	   suggesting	   that	   activated	   T	   cells	   have	   an	   altered	   chemotactic	  
potential	  (Sallusto	  et	  al.	  1999).	  In	  our	  data,	  we	  found	  no	  evidence	  for	  the	  expression	  of	  
the	   other	   known	   CysLT	   receptors,	   CYSLTR2,	   GPR17,	   or	   P2RY12,	   in	   T	   cells.	   Following	  
confirmation	   that	   Th2	   cells	   do	   express	   CYSLTR1	   mRNA,	   we	   sought	   to	   determine	   a	  
functional	   role	   for	  CysLTR1	   in	  T	   cells.	  Using	  FLIPR	  calcium	   flux	  assays,	  we	   found	   that	  
cysteinyl	   leukotrienes	   induced	   a	   calcium	   flux	   in	   both	   Th1	   and	   Th2	   cells,	   in	   the	   rank	  
order	  of	  potency	  LTD4	  >	  LTC4	  >	  LTE4,	  with	  much	  stronger	  calcium	  response	  observed	  in	  
Th2	   cells	   consistent	   with	   the	   expression	   levels	   of	   CYSLTR1	   mRNA.	   This	   calcium	  
response	  was	   dose-­‐dependent	   and	  was	   fully	   inhibited	  with	   treatment	   using	   specific	  
CysLT1	   receptor	   antagonists	   MK571,	   montelukast	   and	   zafirlukast.	   These	   results	  
demonstrate	  that	  the	  selective	  expression	  of	  mRNA	  for	  CYSLTR1	  observed	  in	  Th2	  cells	  
results	   in	   functional	   CysLT1R	   expression.	   Activated	   Th2	   cells	   were	   unresponsive	   to	  
LTD4	  in	  calcium	  flux	  assays,	  suggesting	  that	  T	  cell	  activation	  might	  cause	  heterologous	  
desensitization	  of	  CysLT1	  in	  T	  cells,	  a	  common	  feature	  found	  in	  GPCR	  biology	  (Tan	  et	  al.	  
2004).	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Pre-­‐treatment	  of	  Th2	   cells	  with	  pertussis	   toxin,	   a	  Gαi	  protein	   inhibitor,	   led	   to	  a	  50%	  
decrease	   in	   calcium	  mobilization,	   suggesting	   a	   partial	   signaling	   pathway	   for	   CysLTR1	  
via	   Gαi.	   In	   order	   to	   support	   these	   results,	   we	   used	   cyclic	   AMP	   assays,	   as	   the	   Gαi	  
subunit	   GPCRs	   can	   inhibit	   increases	   in	   intracellular	   cAMP	   levels.	   LTD4	   was	   found	   to	  
induce	  a	  50%	  reduction	  in	  forskolin-­‐induced	  cAMP	  generation,	  and	  this	  response	  was	  
dose-­‐dependent.	  These	  data	  strongly	  suggest	  that	  CysLTR1	  is	  partially	  coupled	  to	  Gαi	  
and	  Gαq	  in	  human	  Th2	  cells.	  The	  cyclic	  AMP	  response	  was	  inhibited	  by	  the	  antagonist	  
MK571,	   demonstrating	   that	   it	   is	   CysLTR1-­‐dependent.	   Both	   intracellular	   and	  
extracellular	  calcium	  were	  required	  for	  calcium	  flux,	  as	  determined	  by	  the	  use	  of	  EDTA	  
and	   thapsigargin.	   Our	   finding	   that	   CysLTR1	   is	   partially	   coupled	   to	   Gαi	   and	   Gαq	   in	  
human	  Th2	  cells	  is	  consistent	  with	  results	  found	  in	  other	  cell	  types	  where	  endogenous	  
expression	   of	   CysLTR1	   has	   been	   examined.	   Intracellular	   calcium	   signaling	   was	  
identified	  in	  human	  monocytes	  in	  response	  to	  cysteinyl	  leukotrienes	  in	  the	  same	  rank	  
order	   of	   potency	   observed	   in	   our	   system,	   and	   this	  was	   fully	   inhibited	   using	  MK571.	  
However	  in	  the	  human	  monocytes	  system,	  pre-­‐treatment	  with	  Gαi	  inhibitor	  pertussis	  
toxin	   fully	   inhibited	   calcium	   flux,	   suggesting	   that	   CysLTR1	   was	   coupled	   to	   Gαi	   only	  
(Woszczek	  et	  al.	  2008b).	  
Although	  we	  were	  able	  to	  demonstrate	  functional	  expression	  of	  CYSLTR1	   in	  Th2	  cells	  
via	  mRNA	  and	  calcium	  flux	  measurements	  we	  were	  unable	  to	  detect	  CysLTR1	  protein	  
expression	   in	   Th2	   cells	   using	   the	   commercially	   available	   antibodies	   to	   CysLTR1.	  We	  
attempted	   both	  Western	   blotting	   and	   extracellular	   and	   intracellular	   flow	   cytometry	  
using	  antibodies	  from	  two	  manufacturers.	  GPCRs	  in	  general,	  and	  CysLTR1	  in	  particular,	  
have	   proven	   difficult	   to	   generate	   high	   quality	   antibodies	   against.	   There	   are	   several	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possible	   reasons	   for	   the	   limited	   availability	   of	   high	   quality	   antibodies	   for	   GPCRs	  
including	   low	   levels	   of	   expression,	   high	   turnover	   on	   the	   cell	   surface,	   limited	   surface	  
epitopes	  and	  structural	  instability.	  	  
We	  went	   on	   to	   examine	   the	   role	   of	   CysLTR1	   expression	   in	   Th2	   cell	  migration	   using	  
chemotaxis	   assays.	   LTD4	   induced	   migration	   of	   Th2	   cells,	   with	   a	   peak	   of	   migration	  
observed	   at	   3	   nM	   LTD4,	   with	   a	   classical	   bell-­‐shaped	   dose-­‐response	   curve.	   This	  
chemotaxis	   was	   dose-­‐dependent	   and	   was	   inhibited	   when	   cells	   were	   treated	   with	  
antagonist	  MK571	  suggesting	  that	  CysLTs	  may	  play	  a	  role	   in	  Th2	  cell	  recruitment	  and	  
that	  CysLT1	  receptor	  antagonists	  may	  function	  to	  suppress	  Th2	  cell	  recruitment	  in	  vivo.	  
Additionally,	  we	  investigated	  the	  effect	  of	  LTD4	  on	  Th2	  cells	  using	  LTD4	  during	  Th2	  cell	  
differentiation	  and	  found	  that	  LTD4	  did	  not	  seem	  to	  have	  any	  significant	  effect	  on	  the	  
expression	  of	  Th2-­‐specific	  cytokines	  by	  intracellular	  cytokine	  staining,	  and	  these	  results	  
were	  supported	  by	  mRNA	  expression	  studies.	  Finally,	  using	  LTD4-­‐treated	  and	  untreated	  
Th2	  cells	  at	  various	  time-­‐points	  on	  microarrays,	  we	  found	  that	  a	  series	  of	  genes	  were	  
significantly	  up-­‐regulated	  following	  30	  minutes	  of	  treatment	  with	  LTD4.	  Amongst	  those	  
genes,	   EGR	   family	   genes	   and	   NR4A2	   were	   also	   upregulated	   in	   previous	   expression	  
studies	  performed	  in	  human	  monocytes	  and	  HUVECs	  (Uzonyi	  et	  al.	  2006;	  Woszczek	  et	  
al.	   2008b).	   Collectively	   these	   results	   suggest	   that	  CysLT1R	   is	   selectively	   expressed	  on	  
human	  Th2	  cells	  and	  that	  its	  principal	  role	  identified	  to	  date	  is	  in	  Th2	  cell	  migration.	  
The	   CysLTs	   are	   potent	   pro-­‐inflammatory	   lipid	   mediators	   with	   a	   major	   role	   in	   the	  
pathogenesis	   of	   asthma,	   including	   bronchial	   constriction	   and	   cell	   trafficking,	   as	  
described	  in	  earlier	  chapters.	  Recent	  studies	  have	  shown	  that	  CysLTs	  also	  play	  a	  critical	  
role	   in	   the	   development	   and	   amplification	   of	   antigen-­‐specific	   Th2	   cell–mediated	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inflammation,	  although	  the	  mechanisms	  by	  which	  this	  occurs	  are	  not	  fully	  elucidated	  
(Kim	   et	   al.	   2006).	   Several	   studies	   have	   implicated	  myeloid	   cells	   in	   this	   process,	  with	  
both	  dendritic	  cells	   (Machida	  et	  al.	  2004;	  Okunishi	  et	  al.	  2004),	  monocytes	  (Thivierge	  
et	  al.	  2001;	  Woszczek	  et	  al.	  2008b),	  but	  also	  endothelial	  cells	  (Uzonyi	  et	  al.	  2006),	  mast	  
cells	   (Di	   Capite	   and	   Parekh	   2009),	   basophils	   (Gauvreau	   et	   al.	   2005)	   and	   peripheral	  
blood	  CD34+	  progenitor	  cells	  (Bautz	  et	  al.	  2001)	  recognized	  as	  CysLT	  target	  cells.	  	  
A	   limited	   number	   of	   previous	   studies	   have	   also	   suggested	   that	   CysLT1R	   may	   be	  
expressed	   by	   T	   cells	   (Early	   et	   al.	   2007;	   Prinz	   et	   al.	   2005;	   Sharma	   et	   al.	   2011).	   For	  
example,	   Prinz	  et	   al.	   showed	   that	  murine	  T	   cells	   expressing	   a	  mutant	   version	  of	   the	  
linker	   for	   activation	   of	   T	   cells	   (LAT),	   LatY136F	   CD4+	   T	   cells,	   responded	   to	   LTD4.	  
However	  this	  was	  not	  reported	  in	  wild	  type	  CD4+	  T	  cells	  (Prinz	  et	  al.	  2005).	  
To	  our	  knowledge,	  this	  is	  therefore	  the	  first	  report	  of	  T	  cell	  subset–specific	  expression	  
of	   CysLT1	   receptor,	   and	   our	   results	   strongly	   suggest	   that	   the	   Th2	   cell	   should	   be	  
considered	  a	  target	  cell	  for	  cysteinyl	  leukotrienes.	  
Because	   LTD4-­‐mediated	   effects	   on	   Th2	   cells	   are	   sensitive	   to	   inhibition	   by	   the	   CysLT1	  
receptor	   antagonists	   MK571,	   montelukast,	   and	   zafirlukast,	   Th2	   cells	   might	   be	   a	  
previously	   overlooked	   target	   of	   these	   clinically	   efficacious	   drugs.	   The	   importance	   of	  
CysLTs	  in	  the	  development	  of	  Th2	  inflammation	  in	  the	  lung	  has	  been	  demonstrated	  in	  
murine	  models	  of	   allergic	   airways	  disease	   through	  both	   genetic	   deletion	  of	   the	   LTC4	  
synthase	   gene	   (Kim	   et	   al.	   2006)	   and	   pharmacologic	   blockade	   with	   CysLT1	   receptor	  
antagonists	   (Henderson	   et	   al.	   2002).	   Although	   the	   mechanisms	   by	   which	   CysLTs	  
function	  in	  these	  systems	  are	  unclear,	  we	  could	  suggest	  that	  CysLTs	  may	  play	  a	  role	  in	  
Th2	  cell	  activation	  or	  Th2	  cell	  recruitment	  to	  sites	  of	  inflammation.	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Interestingly,	   since	   they	  were	   first	   introduced	   into	   the	   clinic,	   anti-­‐leukotriene	   agents	  
have	  been	   the	  subject	  of	   several	   studies	   that	  have	   investigated	   their	  effects.	  Studies	  
have	   revealed	   that	   CysLT1	   receptor	   antagonists	   are	   effective	   in	   only	   a	   subset	   of	  
patients,	   although	   no	   mechanistic	   explanation	   of	   this	   effect	   on	   efficacy	   has	   been	  
identified.	  However,	  a	  recent	  study	  has	  suggested	  that	  the	  ratio	  between	  urinary	  LTE4	  
and	  exhaled	  nitric	  oxide	  levels	  can	  have	  some	  predictive	  benefit	  in	  identifying	  children	  
who	  will	  respond	  to	  montelukast	  (Rabinovitch	  et	  al.	  2010).	  
Furthermore,	  novel	  approaches	   to	  endotyping	  and	  phenotyping	  have	  begun	   to	  allow	  
stratification	  of	  asthma	  patients	  into	  different	  groups	  (Lotvall	  et	  al.	  2011;	  Woodruff	  et	  
al.	   2009).	   Additionally,	   a	   study	   by	   Terashima	   et	   al.	   examined	   the	   factors	   correlated	  
with	  a	  clinical	  response	  to	  antagonist	  pranlukast	  in	  patients	  with	  asthma	  to	  understand	  
why	  not	  all	  patients	  show	  significant	  clinical	   improvements	  to	  anti-­‐leukotriene	  drugs.	  
The	   group	   found	   that	   the	   clinical	   response	   to	   pranlukast	   was	   correlated	   with	   an	  
elevated	   ex	   vivo	   release	   of	   cysteinyl	   leukotriene	   from	   leukocytes	   (Terashima	   et	   al.	  
2002).	   They	   also	   showed	   that	   age,	   total	   white	   blood	   cell	   counts,	   percentage	   of	  
eosinophils,	  percentage	  of	  basophils,	  and	  serum	  IgE	  showed	  no	  correlation,	  consistent	  
with	   reports	   from	  Reiss	  et	  al.	  on	  LTE4	  excretion	   levels	  after	  exercise-­‐induced	  asthma	  
(Reiss	   et	   al.	   1997).	   Terashima	  et	   al.	   also	   showed	   that	   a	   relatively	   low	  percentage	   of	  
patients	   responded	   to	   pranlukast	   (52%),	   which	   was	   similar	   to	   previously	   reported	  
studies	  (Manning	  et	  al.	  1990a).	  
As	  described	  in	  earlier	  chapters,	  several	  sub-­‐phenotypes	  of	  allergic	  asthma	  have	  been	  
identified	   in	   allergic	   asthmatic	   patients	   in	   the	   population	   (S.	   E.	   Wenzel	   2012b).	   Of	  
these,	  Th2-­‐associated	  asthma	  phenotypes	  such	  as	  late-­‐onset	  allergic	  asthma,	  exercise-­‐
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induced	   asthma	   and	   aspirin-­‐induced	   asthma	   can	   be	   controlled	   by	   anti-­‐leukotriene	  
agents	   (S.	   E.	   Wenzel	   2012b;	   S.	   Wenzel	   2012a)	   .	   The	   cysteinyl	   leukotriene	   pathway,	  
which	   is	   upregulated	   by	   Th2	   cytokines	   and	   present	   in	   cells	   associated	   with	   Th2	  
inflammation	   such	   as	   eosinophils,	   basophils	   and	   mast	   cells,	   (Christie	   et	   al.	   1991;	  
Cowburn	  et	  al.	  1998)	  is	  upregulated	  in	  AERD	  (aspirin-­‐exacerbated	  respiratory	  disease),	  
and	   some	   studies	   have	   suggested	   that	   the	   AERD	   phenotype	   is	   linked	   to	   leukotriene	  
pathway–related	   genes	   (Choi	   et	   al.	   2004).	   Anti-­‐leukotriene	   drugs	   have	   also	   been	  
shown	   to	   suppress	   exercise-­‐induced	  asthma	   (Finnerty	   et	   al.	   1992;	  Reiss	   et	   al.	   1997).	  
There	   is	   also	   evidence	   that	   leukotriene	   receptor	   antagonists	   (LTRAs)	   can	   be	   used	   as	  
add-­‐on	   therapy	   to	   control	   moderate	   to	   severe	   asthma	   (Capra	   et	   al.	   2006),	   as	  
corticosteroids	  have	  only	  negligible	  effects	  on	  LT	  synthesis,	  whereas	  LTRAs	  can	  provide	  
additional	  non-­‐steroidal	  anti-­‐inflammatory	  properties	  (Capra	  et	  al.	  2006).	  
Based	   on	   our	   results,	   we	   suggest	   that	   cysteinyl	   leukotrienes	  may	   play	   an	   important	  
role	   in	   the	   activation	   and	   recruitment	   via	   migration	   of	   Th2	   cells	   to	   sites	   of	  
inflammation	   during	   an	   asthmatic	   response	   and	   that	   LTRAs	   may	   be	   involved	   in	  
targeting	  Th2	  cells.	  This	  hypothesis	  could	  explain	  some	  of	  the	  reasons	  as	  to	  why	  anti-­‐
leukotriene	   agents	   are	   efficacious	   only	   on	   a	   certain	   subset	   of	   asthmatic	   patients.	   If	  
LTRAs	  do	  target	  Th2	  cells,	  then	  patients	  with	  a	  Th2-­‐associated	  asthma	  phenotype	  may	  
benefit	  from	  their	  clinical	  effects.	  
Novel	  approaches	  to	  endotyping	  and	  phenotyping	  have	  begun	  to	  allow	  stratification	  of	  
patients	  into	  different	  groups.	  For	  example,	  Woodruff	  et	  al.	  used	  microarrays	  analyses	  
of	   airway	   epithelial	   brushings	   from	   patients	   with	   mild-­‐to-­‐moderate	   asthma	   and	  
healthy	  control	  subjects,	  who	  were	  classified	  according	  to	  their	  high	  or	  low	  expression	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of	  IL-­‐13.	  The	  group	  identified	  two	  distinct	  subgroups,	  which	  they	  called	  ‘‘Th2-­‐high’’	  and	  
‘‘Th2-­‐low’’	  asthma	  (Woodruff	  et	  al.	  2009).	  Recently,	  it	  has	  been	  shown	  that	  asthmatic	  
patients	   may	   be	   divided	   into	   two	   groups	   based	   on	   their	   level	   of	   periostin	   in	   the	  
peripheral	   blood.	   Periostin	   has	   been	   identified	   as	   a	   gene	   expressed	   by	   bronchial	  
epithelial	   cells	   in	   response	   to	   IL-­‐13,	   and	   can	   play	   a	   role	   in	   bronchial	  
hyperresponsiveness	   and	   inflammation.	   It	   has	   been	   suggested	   that	   periostin	   level	   in	  
blood	  could	  potentially	  be	  a	  clinically	  useful	  method	  to	  discriminate	  patients	  who	  do	  
not	  have	  Th2-­‐specific	  inflammation.	  In	  a	  study	  by	  Corren	  et	  al.,	  they	  demonstrated	  that	  
treatment	   with	   anti-­‐IL-­‐13	   (Lebrikizumab),	   was	   more	   effective	   in	   patients	   with	   high	  
periostin	   levels	   than	   in	  patients	  with	   low	   levels,	   as	  evidenced	  by	  an	   increase	   in	  FEV1	  
and	  a	  decline	   in	  FeNO	   (Corren	  et	  al.	  2011).	   In	   light	  of	  our	   identification	  of	  a	   role	   for	  
CysLTR1	   in	   Th2	   cell	   function,	   it	   would	   be	   very	   interesting	   to	   examine	   the	   effect	   of	  
CysLT1	   receptor	   antagonists	   in	   a	   similarly	   stratified	   patient	   group.	   Further	   in	   vivo	  
studies	   in	   animal	   models	   with	   conditional	   deletion	   of	   CYSLTR1	   in	   T	   cells	   will	   be	  
required	  to	  fully	  characterize	  the	  relative	  importance	  of	  CysLTR1	  expression	  on	  Th2	  cell	  
function	  during	  asthma	  pathogenesis	  and	  the	  potential	  role	  of	  anti-­‐leukotriene	  agents	  
on	  these	  cells.	  
In	   conclusion,	  we	   have	   shown	   that	   human	   Th2	   cells	   express	   functional	   CysLTR1	   and	  
that	  LTD4	  causes	  migration	  of	  Th2	  cells.	  These	  findings	  suggest	  a	  possible	  explanation	  
for	   the	   role	   of	   CysLTs	   in	   the	   development	   or	   amplification	   of	   allergic	   disease	   and	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Human TH2 cells respond to cysteinyl leukotrienes through
selective expression of cysteinyl leukotriene receptor 1
Celine N. Parmentier, MSc,a,b Elisabeth Fuerst, PhD,a,b Joanne McDonald, PhD,a,b Holly Bowen, PhD,a,b Tak H. Lee, MD,
ScD,a,b James E. Pease, PhD,a,c Grzegorz Woszczek, MD, PhD,a,b and David J. Cousins, PhDa,b London, United Kingdom
Background: Allergic asthma is characterized by reversible
airway obstruction and bronchial hyperresponsiveness
associated with TH2 cell–mediated inflammation. Cysteinyl
leukotrienes (CysLTs) are potent lipid mediators involved in
bronchoconstriction, mucus secretion, and cell trafficking in
asthmatic patients. Recent data have implicated CysLTs in the
establishment and amplification of TH2 responses in murine
models, although the precise mechanisms are unresolved.
Objectives: Preliminary microarray studies suggested that
human TH2 cells might selectively express cysteinyl leukotriene
receptor 1 (CYSLTR1) mRNA. We sought to establish whether
human TH2 cells are indeed a CysLT target cell type.
Methods: We examined the expression of CYSLTR1 using real-
time PCR in human TH1 and TH2 cells. We functionally assessed
cysteinyl leukotriene receptor 1 protein (CysLT1) expression
using calcium flux, cyclic AMP, and chemotaxis assays.
Results: We show that human TH2 cells selectively express
CYSLTR1 mRNA at high levels compared with TH1 cells after
in vitro differentiation from naive precursors. Human TH2 cells
are selectively responsive to CysLTs in a calcium flux assay when
compared with TH1 cells with a rank order of potency similar to
that described for CysLT1 (leukotriene [LT] D4 > LTC4 > LTE4).
We also show that LTD4-induced signaling in TH2 cells is
mediated through CysLT1 coupled to Gaq and Gai proteins, and
both pathways can be completely inhibited by selective CysLT1
antagonists. LTD4 is also found to possess potent chemotactic
activity for TH2 cells at low nanomolar concentrations.
Conclusions: These findings suggest a novel mechanism of action
for CysLTs in the pathogenesis of asthma and provide a potential
explanation for the anti-inflammatory effects of CysLT1
antagonists. (J Allergy Clin Immunol 2012;nnn:nnn-nnn.)
Key words: Human, TH1, TH2, cysteinyl leukotrienes, chemotaxis,
CYSLTR1, cysteinyl leukotriene receptor 1 protein, LTD4
Allergic asthma is characterized by reversible airway obstruc-
tion and bronchial hyperresponsiveness to otherwise innocuous
environmental antigens and is associated with inflammation of
the airways involving numerous immune cell types and inflam-
matory mediators.1,2 In particular, the immune pathology ob-
served is dominated by a TH2-type response with increased
expression of the classical TH2 cytokines IL-4, IL-5, and IL-13,
which might cause many of the hallmark features of allergic air-
ways disease.3 Central to this TH2 immune pathology is the
allergen-specific TH2 cell, which is the predominant source of
TH2 cytokines in asthmatic subjects, although the precise mecha-
nisms by which the TH2 phenotype develops in asthmatic subjects
remain to be determined.4
Cysteinyl leukotrienes (CysLTs) are potent lipid mediators
involved in the pathogenesis of a wide range of chronic inflam-
matory and immune disorders, including asthma, allergic rhinitis,
atherosclerosis, and inflammatory bowel disease.5,6 The CysLT
leukotriene (LT) C4 is derived from arachidonic acid through cy-
tosolic phospholipase A2, 5-lipoxygenase, and LTC4 synthase.
LTC4 is transported out of the cell and converted sequentially to
LTD4 and LTE4 by the ubiquitous enzymes g-glutamyl transpep-
tidase and aminopeptidase, respectively. The biological activities
of the CysLTs are mediated through at least 4 G protein–coupled
receptors, cysteinyl leukotriene receptor 1 protein (CysLT1),
CysLT receptor 2 protein, G protein-coupled receptor 17
(GPR17), and purinergic receptor P2Y12 protein (P2Y12), al-
though the role of each of these receptors in CysLT action is in-
completely understood.6-8 In asthmatic subjects the CysLTs are
believed to be involved in bronchoconstriction, mucus secretion,
and cell trafficking and have been shown to be chemotactic agents
for eosinophils, hematopoietic progenitor cells, and mono-
cytes.9-11 In addition to their role in bronchoconstriction and in-
nate cell recruitment to the lungs of asthmatic subjects, CysLTs
play a role in the establishment and amplification of antigen-
specific TH2 cell–dependent immune responses in murine models
of allergic airways disease.12 Although the precise mechanistic
role of CysLTs in the development of the adaptive TH2 response
is unclear, prior studies have focused on the role of CysLTs in pul-
monary dendritic cell migration and maturation.13-15 Here we
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report that human TH2 cells selectively express functional CysLT1
and that LTD4 is a potent chemotactic agonist for TH2 cells. TH2
cells exhibit robust calcium signaling in response to all 3 CysLTs,
with the most potent response observed with LTD4 followed by
LTC4 and LTE4, which is consistent with previous studies on
CysLT1.
16,17 The calcium signaling in response to LTD4was com-
pletely blocked with the selective CysLT1 antagonists MK571,
montelukast, and zafirlukast. These findings suggest a novel
mechanism of action for CysLTs in the pathogenesis of asthma
and provide a potential explanation for the anti-inflammatory ef-
fects of CysLT1 antagonists.
METHODS
Reagents
Leukotrienes (LTC4, LTD4, and LTE4) and CysLT1 antagonists (MK571,
montelukast, and zafirlukast) were purchased from Cayman Chemical (Ann
Arbor, Mich). Recombinant chemokines (CXCL12 and CCL18) were pur-
chased from R&D Systems (Abingdon, United Kingdom). Pertussis toxin,
thapsigargin, and forskolin were purchased from Sigma-Aldrich (Dorset,
United Kingdom). EDTA was purchased from Life Technologies (Paisley,
United Kingdom).
Human T-cell isolation and differentiation
These studies were approved by the Research Ethics Committee of Guy’s
Hospital with informed consent. The donors used in this studywere nonatopic,
nonasthmatic male subjects (25-40 years) with no other chronic or acute ill-
nesses at the time of venipuncture. Naive CD41 T cells were isolated from pe-
ripheral blood by usingmagnetic positive selection of CD41 cells (Dynal CD4
Positive Isolation kit; Invitrogen, Paisley, United Kingdom) followed by de-
pletion of CD45RO1memory cells, as described in detail previously.18 Naive
T cells were stimulated with anti-CD3 (clone OKT3, ECACC, prepared in
house) and anti-CD28 (clone 15E8; Sanquin Reagents, Amsterdam, TheNeth-
erlands) in the presence of cocktails of cytokines and antibodies to generate
TH1 and TH2 cells, as described in detail previously.
18 Every 7 days, TH1/
TH2 differentiation was assessed by using intracellular cytokine staining, as
described previously.18
RNA isolation, microarrays, and real-time reverse
transcription PCR
Cells for RNA isolation were snap-frozen in liquid nitrogen and stored at
2808C. Total cellular RNAwas isolated with the miRNeasy mini kit (Qiagen,
Crawley, United Kingdom), according to the manufacturer’s instructions.
cRNA samples were prepared for microarray hybridization to GeneChip
U133 plus 2 arrays, according to the manufacturer’s instructions (Affymetrix,
Santa Clara, Calif). Fragmented cRNAwas hybridized to GeneChip arrays at
458C for 18 hours. Arrays were washed and stained with streptavidin-
phycoerythrin, according to the manufacturer’s instructions, on the GeneChip
fluidics station 450 (Affymetrix). Fluorescent signals were detected with the
GeneChip scanner 3000. Images were analyzed with the GeneChip operating
software (Affymetrix) to generate raw data as .cel files. Further analysis was
performed with the Partek Genomics Suite (Partek, St Louis, Mo) by using
thegene expressionworkflow to identify differentially expressed genes. Briefly,
robustmultichip averagepreprocessingwas performed, and genes differentially
expressed between TH1 and TH2 cells were identified by using the Partek AN-
OVAmodel. One thousand seven hundred ninety-four genes were identified as
differentially expressed with a P value of less than .05, including Benjamini-
Hochberg step-up for false discovery rate. Data shown in Table I are the
mean probe-set signals from 3 independent biological replicates for each con-
dition. cDNA synthesis and real-time PCRwere performedwith TaqManMGB
probes (Applied Biosystems, Invitrogen, Paisley, United Kingdom), as de-
scribed in detail previously.19 TaqMan probe sets used in this study were as fol-
lows: cysteinyl leukotriene receptor 1 (CYSLTR1), Hs00272624_s1; cysteinyl
leukotriene receptor 2 (CYSLTR2), Hs00272624_s1; IL5, Hs00174200_m1;
IFNG, Hs00174143_m1; and 18s rRNA, 4319413E. Statistical analyses were
performed by comparing gene expression levels relative to 18s rRNA levels
by using a 2-way repeated-measures ANOVA with Bonferroni post tests in
GraphPad Prism version 5.0a software (GraphPad, Inc, La Jolla, Calif).
Calcium-signaling assay
Cultured human TH1 and TH2 cells were tested for calcium signaling when
fully differentiated at days 21 and 28 in response to LTB4, LTC4, LTD4, and
LTE4. Cells were resuspended at 200,000 cells/well in 100 mL of RPMI
plus 20 mmol/L HEPES and plated onto a 96-well, black-wall, clear,
flat-bottom assay plate (Costar), and an equal volume of loading buffer (Com-
ponent Awith 1X HBSS Buffer; FLIPR Calcium 4 Assay Kit; Molecular De-
vices, Eugene, Ore) was added. The plate was incubated for 45 minutes at
378C and 5% CO2. After incubation, the plate was centrifuged at 200 g for
5 minutes and transferred directly to a FlexStation 3 Microplate Reader (Mo-
lecular Devices) at 378C. Varying concentrations of CysLTs were added as in-
dicated. Where indicated, the selective CysLT1 antagonist MK571 (100
nmol/L), montelukast (100 nmol/L), or zafirlukast (100 nmol/L) was added
5 minutes before adding ligand. In some experiments pertussis toxin (100
ng/mL) was added 16 hours before the assay was performed to inhibit Gai.
Where indicated, thapsigargin (1 mmol/L) or EDTA (2.5 mmol/L) was added
5minutes before adding ligand. Results were analyzed with SoftMax Pro Soft-
ware (Molecular Devices), and data are shown as a percentage of maximal re-
sponse. Controls included a negative medium control of RPMI plus 20
mmol/L HEPES and a positive control of stromal cell–derived factor
1/CXCL12, and all experiments were performed with triplicate wells.
Cyclic AMP assay
Intracellular cyclic AMP (cAMP) levels were measured by luminescence
with the HitHunter cAMP XS1 assay (DiscoverRX, Birmingham, United
Kingdom). The assaywas carried out according to themanufacturer’s protocol
for a 3-reagent addition. TH2 cells were suspended in PBS at a concentration of
10 3 106/mL and warmed to 378C, and 1 nmol/L 3-isobutyl-1-methylxanthine
(Sigma) was added to inhibit cAMP phosphodiesterases. The TH2 cell suspen-
sion (23 105 cells/well) was loaded into a 96-well plate, and 20mmol/L forsk-
olinwas added to stimulate cAMP induction alongwith varying concentrations
of LTD4, as indicated.Where indicated, 100 nmol/LMK571was added 5min-
utes before adding ligand. Plates were incubated at 378C for 15minutes before
cells were processed according to the kit’s instructions, and cAMP signal was
detected bymeans of luminescencemeasured 4 hours after cell lysis. Lumines-
cencewas detected by using a Flexstation 3 (Molecular Devices), and analysis
of cAMP concentrations was performed with SOFTMax Pro software
(Molecular Devices). Data are shown as a percentage of maximal response.
Chemotaxis assay
Chemotaxis assays were carried out by using a modification of a protocol20
obtained from Andrew Luster (Massachusetts General Hospital, Harvard,
Boston, Mass) by using 24-well 6.5-mm Transwell plates with a polycarbon-
ate membrane insert filter and a pore size of 5.0 mm (3421; Corning, Corning,
NY). In vitro cultured human TH2 cells were resuspended at 1 3 10
6/mL in
RPMI buffer; rested for 4 hours in a low rIL-2 concentration (25 U/mL;
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Novartis, Horsham, United Kingdom); and then harvested, washed in PBS,
and resuspended at 500,000 cells/100 mL in chemotaxis buffer (RPMI 1 20
mmol/L HEPES1 0.5% ultrapure BSA [Sigma, A7638]). Six hundred micro-
liters of chemotaxis buffer with or without the chemokine or leukotriene of in-
terest was loaded on the bottom of the Transwell. Each chemotactic agent
(LTD4, LTE4, and the positive control stromal cell–derived factor 1) was tested
in duplicate. By using tweezers, the Transwell filter was placed in the bottom
well, and 100 mL of cells was added and left to migrate for 2 hours in an in-
cubator at 378C 5%CO2. After 2 hours, the platewas placed at 48C for 15min-
utes. Migrated cells were counted by using flow cytometry, with polystyrene
beads as a reference (polystyrene 15-mm beads; Polysciences, Warrington,
Pa). A chemotactic index was calculated as the ratio of migration to chemoat-
tractant compared with the basal migration to buffer alone.
RESULTS
Human TH2 cells selectively express CYSLTR1
We have previously reported a method to generate highly
polarized human TH1 and TH2 cells from naive precursors in vitro
and have used this model extensively to investigate the lineage-
specific functions of these cells.18,19,21 To identify novel
lineage-specific molecules that might play a selective role in
TH2 cell function, we have previously performed a preliminary
microarray-based study comparing TH1 and TH2 cells. Analysis
of CysLT receptor mRNA expression in these samples revealed
that CYSLTR1 mRNA was highly and selectively expressed by
TH2 cells when compared with TH1 cells (P5 .000692, Table I).
Expression of other potential CysLT receptors, CYSLTR2,
GPR17, and P2RY12, was undetectable by means of microarray
in both TH1 and TH2 populations (Table I). Intracellular cytokine
staining of resting and activated TH1 and TH2 cells demonstrated
that highly polarized TH1/TH2 populations were generated (Fig 1,
A). On activation, at least 99% of the TH1 cells express IFN-gwith
minimal TH2 cytokine expression. In contrast, the TH2 cells ex-
press negligible IFN-g, and a very high proportion express TH2
cytokines (IL-4, 42%; IL-5, 46%; and IL-13, 85%). Quantitative
real-time RT-PCR of highly differentiated TH1 and TH2 samples
confirmed that the TH1 and TH2 cells express high levels of tran-
scripts for the hallmark cytokines IFN-g (TH1) and IL-4, IL-5, and
IL-13 (TH2) on acute activation (Fig 1, B, and data not shown).
Examination of CYSLTR1 mRNA expression by using real-time
RT-PCR confirmed that it is selectively expressed by resting
TH2 cells with 6.5-fold higher levels than seen in resting TH1 cells
(Fig 1, C). The selective expression of CYSLTR1 was predomi-
nantly observed in cells before activation, with a substantial de-
crease in mRNA expression after acute activation of TH2 cells
(Fig 1, C). Real-time PCR analysis also confirmed that CYSLTR2
mRNAwas not expressed at high levels in either TH1 or TH2 cells
(Fig 1, C). Examination of CYSLTR1 mRNA expression during
the time course of differentiation revealed that expression in-
creased substantially during TH2 differentiation (Fig 1, D),
suggesting that CYSLTR1 expression is acquired during TH2 dif-
ferentiation rather than being expressed on naive T cells and se-
lectively lost during TH1 differentiation. This also indicated that
expression of CYSLTR1 by TH2 cells is not merely caused by ex-
posure to IL-4 because it requires at least 3 weeks of in vitro cul-
ture before high levels of expression are observed (Fig 1, D). The
genes adjacent to CYSLTR1 (ie, PGK1, TAF9B, and ZCCHC5)
were not differentially expressed between TH1 and TH2 cells, sug-
gesting that the TH2-selective expression of CYSLTR1 is not
merely due to the gene being located in close proximity to other
TH2-specific genes (Table I).
TH2 cell–specific calcium flux in response to CysLTs
CysLT signaling through CysLT1 induces calcium flux in other
cell types known to express the receptor. In vitro differentiated
TH1 and TH2 cells were treated with LTD4 and intracellular cal-
cium responses were measured to determinewhether the selective
expression of CYSLTR1 mRNA observed in TH2 cells resulted in
functional expression of CysLT1 in these cells (Fig 2, A). LTD4
induced a substantial calciummobilization in TH2 cells at concen-
trations similar to those reported for CysLT1 in other systems (me-
dian effective concentration, approximately 1 nmol/L). A much
weaker response to LTD4was observed in TH1 cells at higher con-
centrations. This confirmed that human TH2 cells selectively ex-
press a functional receptor for LTD4. Treatment of TH2 cells with
LTC4, LTD4, and LTE4 showed that all 3 CysLTs induced calcium
mobilization, with LTD4 being the most potent, followed by LTC4
and LTE4 (Fig 2, B). This rank order of potency (LTD4 > LTC4 >
LTE4) resembles the results of previous studies on CysLT1 in
other cell types, suggesting that TH2 cells express functional
CysLT1.
16,17 Interestingly, in contrast to the original studies
with transfectants expressing CysLT1, the potency of LTC4 and
LTE4 is similar until higher concentrations of agonist are used
(10-100 nmol/L), where LTC4 induces more calcium flux. The
CysLT1 selective antagonists MK571 (100 nmol/L), montelukast
(100 nmol/L), and zafirlukast (100 nmol/L) were used to treat TH2
cells before treatment with 100 nmol/L LTD4 (Fig 2,C) to confirm
the identity of the CysLT-responsive receptor expressed by TH2
cells. All 3 CysLT1 antagonists almost completely inhibited cal-
cium mobilization, confirming that the calcium flux in response
to LTD4 by human TH2 cells is dependent on selective expression
of functional CysLT1.
CysLT1 is coupled to both Gai and Gaq G proteins in
human TH2 cells
TH2 cells were preincubated with the Gai inhibitor pertussis
toxin and treated with increasing concentrations of LTD4 to
further characterize the signaling mechanisms involved in
TABLE I. Expression of selected genes in preliminary microarray analysis
Gene name Probe set ID TH1, resting TH1, activated TH2, resting TH2, activated
CYSLTR1 231747_at 349.4 179.2 1053 101.1
CYSLTR2 220813_at 6.549 6.517 10.02 7.413
GPR17 215225_s_at 3.993 4.112 3.956 4.067
P2RY12 224102_at 4.214 4.363 4.16 4.279
PGK1 200737_at 1902 1669 1956 1605
TAF9B 221618_s_at 206.6 74.86 312.6 137.3
ZCCHC5 1552935_at 6.926 9.382 6.134 6.99
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CysLT-induced calcium flux (Fig 3, A). Pertussis toxin partially
inhibited calciummobilization in response to LTD4, with approx-
imately 50% inhibition of calcium flux at the highest LTD4 con-
centration, suggesting that CysLT1 is coupled to bothGai andGaq
G proteins in TH2 cells. To confirm a role for Gai in CysLT1 sig-
naling, we examinedwhether LTD4 could inhibit cAMP signaling
in TH2 cells. Treatment of TH2 cells with LTD4 alone did not in-
duce cAMP in a luminescence-based cAMP assay (Fig 3, B).
Treatment of TH2 cells with forskolin induced a robust increase
in cAMP levels, which was partially inhibited (approximately
50%) by LTD4 in a concentration-dependent manner (Fig 3, B).
Pretreatment of the cells with the CysLT1 selective antagonist
MK571 completely blocked the LTD4-dependent inhibition of
cAMP signaling, confirming that CysLT1 is partially coupled to
Gai in TH2 cells (Fig 3, C). Preincubation of TH2 cells with thap-
sigargin to deplete intracellular endoplasmic reticular calcium
stores completely inhibited calcium mobilization in response to
LTD4, and chelation of extracellular calciumwith EDTA partially
inhibited calcium flux (Fig 3, D). These data suggest that LTD4
signaling through CysLT1 activates store-operated calcium chan-
nels in TH2 cells.
LTD4 induces chemotaxis of human TH2 cells
CysLTshave previously been shown tobe chemotactic agents for
eosinophils, hematopoietic progenitor cells, andmonocytes.9-11 To
examinewhether LTD4 treatment causes chemotaxis of humanTH2
cells, we performed a Transwell-based chemotaxis assay.20 The
chemokine CXCL12 is strongly chemotactic for human lympho-
cytes22 and caused a robust chemotactic response in human TH2
cells (Fig 4). In contrast, CCL18, which has been reported to be se-
lectively chemotactic for human TH2 cells,
23 did not cause chemo-
taxis (Fig 4). This might be due to differences in polarization
protocols because in the previous study only a single round of
in vitro polarization was performed. LTD4 induced concentration-
dependent chemotaxis of human TH2 cells with a classical bell-
shaped curve (Fig 4). Maximal chemotaxis was observed at 3
nmol/LLTD4,which is very similar to themedian effective concen-
tration for LTD4 observed in the calcium mobilization studies.
DISCUSSION
The CysLTs are potent proinflammatory lipid mediators with a





























































































































































































































FIG 1. TH2 cells selectively express CYSLTR1. A, Intracellular cytokine staining of human TH1 and TH2 cells.
Cells were either resting or activated for 4 hours with phorbol 12-myristate 13-acetate (5 ng/mL) and iono-
mycin (500 ng/mL). B and C, Real-time RT-PCR analysis of TH1 and TH2 cells for IFN-g and IL-5 (Fig 1, B) and
CYSLTR1 and CYSLTR2 (Fig 1, C).D, Time-course analysis of gene expression during TH1/TH2 differentiation
by using real-time RT-PCR. Data shown are representative of 5 experiments with different donors except Fig
1, B, C, and D, which show means 6 SEMs of 5 experiments. *P < .05, **P < .01, and ***P < .001, 2-way
ANOVA with Bonferroni post test. A, Activated; R, resting.
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constriction and cell trafficking. Recent studies have shown that
CysLTs also play a critical role in the development and ampli-
fication of antigen-specific TH2 cell–mediated inflammation, al-
though the mechanisms by which this occurs are not fully
elucidated.12 Several studies have implicated myeloid cells in
this process, with both dendritic cells13,14 andmonocytes11 recog-
nized as CysLT target cells. CysLTs have been shown to potenti-
ate dendritic cell functions, such as antigen presentation and
cytokine production, in 2 murine models of allergic airway dis-
ease.13,14 Moreover, the CysLT1 receptor antagonist pranlukast
was shown to inhibit antigen-dependent eosinophilic airway in-
flammation, mucus production, and airway hyperresponsiveness
in an inhalation model of allergic airways disease.13We have pre-
viously shown that human monocytes are activated by LTD4,
which induces expression of several immediate early genes and
causes chemotaxis.11
Here we show, for the first time, that human TH2 cells selec-
tively express CYSLTR1 mRNA with 6.5-fold higher expres-
sion than human TH1 cells (Fig 1, C). We found no evidence
for expression of the other known CysLT receptors, CYSLTR2,
GPR17, or P2RY12, in T cells. TH2 cells selectively responded
to CysLTs through calcium signaling in a rank order that re-
sembled, to some extent, previous work on CysLT1, with


























































FIG 2. TH2 cells express functional CysLT1. A, Calcium flux in response to
increasing concentrations of LTD4 in TH1 and TH2 cells. B, Calcium flux in
TH2 cells in response to increasing concentrations of LTC4, LTD4, and
LTE4. C, Inhibition of calcium flux in TH2 cells in response to 100 nmol/L
LTD4 by 3 different CysLT1 antagonists: MK571, montelukast, and zafirlu-
kast. Data are presented as mean 6 SEM percentages of maximum
response to LTD4 from 3 experiments with different donors. ***P < .001,
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FIG 3. CysLT1 is partially Gi and Gq coupled in TH2 cells. A, Pertussis
toxin (PTX)–mediated inhibition of calcium response to LTD4 in TH2
cells. ***P < .001, 2-way ANOVA with Bonferroni post test. B, LTD4-me-
diated inhibition of cAMP signaling in TH2 cells. Cells were treated with
forskolin to induce cAMP, and increasing concentrations of LTD4 in-
hibited cAMP generation. C, The CysLT1 antagonist MK571 blocks the
LTD4-mediated inhibition of cAMP response. Cells were treated with
100 nmol/L LTD4. D, Thapsigargin (THP)–mediated inhibition and
EDTA-mediated partial inhibition of calcium flux response to LTD4 in
TH2 cells. All data are expressed as mean 6 SEM percentages of maxi-
mum response to LTD4 or forskolin from 3 experiments with different
donors. Fig 3, B and D: **P < .01 and ***P < .001, 1-way ANOVA with
Tukey post test.
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(Fig 2, B). Calcium flux in response to LTD4 was completely
inhibited by treatment with the CysLT1 selective receptor an-
tagonists MK571, montelukast, or zafirlukast (Fig 2, C). These
results demonstrate that the selective expression of mRNA for
CYSLTR1 observed in TH2 cells results in functional CysLT1
expression. CYSLTR1 mRNA was significantly downregulated
by acute activation of TH2 cells (Fig 1, C), and activated
TH2 cells were unresponsive to LTD4 in calcium flux assays
(data not shown), suggesting that T-cell activation might cause
heterologous desensitization of CysLT1 in T cells. This is a
common feature of several G protein–coupled receptor in T
cells, most notably the chemokine receptors, and it suggests
that activated T cells have an altered chemotactic potential.24
Treatment of TH2 cells with the Gai selective inhibitor pertus-
sis toxin resulted in a 50% inhibition of calcium mobilization,
suggesting that CysLT1 was partially coupled to Gai in TH2
cells (Fig 3, A). Gai G protein–coupled receptors can inhibit
increases in intracellular cAMP levels. Treatment of TH2 cells
with LTD4 partially (50%) inhibited forskolin-induced cAMP
generation (Fig 3, B). The LTD4-dependent inhibition of
cAMP signaling could be completely blocked by MK571,
demonstrating that it is CysLT1 dependent (Fig 3, C). Further-
more, LTD4-induced calcium mobilization is dependent on
store-operated calcium channels because it is completely in-
hibited by thapsigargin (Fig 3, D). Collectively, these data
suggest that CysLT1 is coupled to both Gai and Gaq G proteins
in TH2 cells. We have also shown that LTD4 is chemotactic
for human TH2 cells (Fig 4). The peak of migration was ob-
served at 3 nmol/L, with a classical bell-shaped dose-response
curve.
A limited number of previous studies have suggested that
CysLT1 might be expressed by T cells.
25-27 Prinz et al25 showed
that murine T cells expressing a mutant version of the linker for
activation of T-cells (LAT) adaptor molecule express Cysltr1
and chemotax in response to LTD4. Early et al
26 showed that
short-term treatment with IL-4 caused an increase in CYSLTR1
mRNA in T cells. Sharma et al27 recently found evidence for
upregulation of Cysltr1 mRNA in T cells in a compound mu-
rine mutant in which the IL2 gene was deleted in a forkhead
box protein 3 mutant strain. However, to our knowledge, the
data presented here are the first report of T cell subset–specific
expression of any CysLT receptor, and the results strongly sug-
gest that the TH2 cell should be considered a CysLT target cell.
Because LTD4-mediated effects on TH2 cells are sensitive to in-
hibition by the CysLT1 receptor antagonists MK571, montelu-
kast, and zafirlukast, TH2 cells might be a previously
overlooked target of these clinically efficacious drugs. The im-
portance of CysLTs in the development of TH2 inflammation in
the lung has been demonstrated in murine models of allergic
airways disease through both genetic deletion of the LTC4 syn-
thase gene12 and pharmacologic blockade with CysLT1 receptor
antagonists.28 Although the mechanisms by which CysLTs
function in these systems are unclear, it is tempting to speculate
that a direct role in TH2 cell activation or migration might be
involved. Further in vivo studies in animal models with condi-
tional deletion of CYSLTR1 in T cells will be required to fully
characterize the relative importance of CysLT1 expression on
TH2 cell function during asthma pathogenesis.
It has been clear for many years that there are several
subphenotypes of allergic asthmatic patients in the population.
Since they were first introduced into the clinic, it has been
recognized that the CysLT1 antagonists are effective in only a
subset of patients, although no mechanistic explanation of this
phenomenon has been identified.29 However, a recent study
has suggested that the ratio between urinary LTE4 and exhaled
nitric oxide levels can have some predictive benefit in identify-
ing children who will respond to montelukast.30 Furthermore,
novel approaches to endotyping and phenotyping have begun
to allow stratification of patients into different groups.31-33
A striking example of this is the recent demonstration that asth-
matic patients can be stratified into 2 groups based on the level
of periostin in the peripheral blood.34 Periostin has been identi-
fied as a gene expressed by bronchial epithelial cells in response
to IL-13.33 The authors contend that the periostin level in blood
is a clinically useful method to discriminate patients with clas-
sical TH2-driven allergic asthma and patients who do not have
such inflammation. In an elegant study they demonstrate that
anti–IL-13 might have some benefit in patients with high peri-
ostin levels.34 In light of our identification of a role for CysLT1
in TH2 cell function, it would be very interesting to examine the
effect of CysLT1 antagonists in a similarly stratified patient
group.
In conclusion, we have shown that human TH2 cells express
functional CysLT1 and that LTD4 causes chemotaxis of TH2 cells.
These findings suggest a possible explanation for the role of
CysLTs in the development or amplification of allergic disease
and provide insight into potential mechanisms of action of CysLT
receptor antagonists in asthmatic subjects.
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FIG 4. LTD4 is chemotactic for TH2 cells. Chemotactic agents were assessed
in a Transwell-based system. Cells were allowed to migrate for 2 hours.
Varying concentrations of LTD4 were used as shown. Control chemokines
CXCL12 and CCL18 were used at 10 nmol/L concentration. Data shown
are means 6 SEMs of 3 independent experiments with different donors.
***P < .001 and *P < .05, 2-way ANOVA with Bonferroni post test.
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Key messages
d Human TH2 cells selectively express CYSLTR1 mRNA.
d Functional analysis shows that TH2 cells respond to
CysLTs.
d LTD4 is chemotactic for TH2 cells.
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